

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 17:55:32 ; Search time 92.5 Seconds
(without alignments)
677.353 Million cell updates/sec

Title: NOLAN463-1A.SEQ

Perfect score: 140

Sequence: 1 GAATCAATCACTAGTGAAG.....ATATTAGCAGCTGTTAGCC 81

Scoring table:

```
BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1
```

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 4211384

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

```
-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2.1/USPTO.spool.p/NOLAN08728463-1/runat_04082005.125805.24527/app.query.fasta_1.5
-DB=A Geneseq -QFWT=fastan -SUFFIX=rag -MINMATCH=0.1 -LOOPEXT=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THRM SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-1.@CGN.1.1.308@runat_04082005.125805.24527 -NCPU=6
-ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1
```

Database :

```
A Geneseq 16Dec04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	113.1	80.8	249	5	ABP45310 Human Bly
2	113.1	80.8	249	7	ADG96137 Single ch
3	93.8	67.0	250	5	ABP44982 Human Bly
4	93.8	67.0	250	7	ADG95809 Single ch
5	93.8	67.0	253	5	ADG94943 Human Bly
6	93.8	67.0	253	7	ADG95770 Single ch
7	92.4	66.0	80	2	AAW62794 Amino aci
8	92.4	66.0	97	2	AAY05694 Multiple
9	92.4	66.0	97	5	ABG78212 Human Fv
10	92.4	66.0	97	5	ABG91903 Human ant

11	92.4	66.0	97	6	ABO27107	Human ger
12	92.4	66.0	97	7	ADB75646	Human pro
13	92.4	66.0	97	7	ADD28104	Lymphoma
14	92.4	66.0	97	7	ADF10048	VEGF anti
15	92.4	66.0	97	7	ADP10150	Antibody
16	92.4	66.0	97	7	ADF09942	Antibody
17	92.4	66.0	97	7	ADJ80323	VH gene 1
18	92.4	66.0	114	3	ABO19499	Anti-Id1
19	92.4	66.0	114	3	ABO1950	Anti-Id1
20	92.4	66.0	114	3	ABO1953	Anti-Id1
21	92.4	66.0	114	3	ABO1959	High affi
22	92.4	66.0	114	3	ABO1952	Anti-Id1
23	92.4	66.0	114	3	ABO1955	Streptativ
24	92.4	66.0	114	3	ABO1956	Streptativ
25	92.4	66.0	114	3	ABO1948	Wild-type
26	92.4	66.0	114	7	ADG70086	Diversifi
27	92.4	66.0	114	7	ADG70013	Diversifi
28	92.4	66.0	115	2	AAR66324	Human imm
29	92.4	66.0	117	4	AAW60904	Human bra
30	92.4	66.0	117	4	ABG55317	Human liv
31	92.4	66.0	117	5	ABG43454	Human pep
32	92.4	66.0	118	6	ADA89246	Human ant
33	92.4	66.0	122	7	ADK17418	Anti-huma
34	92.4	66.0	122	8	ADG42840	scFv Ab12
35	92.4	66.0	123	2	AAW03757	Anti-rhes
36	92.4	66.0	125	6	ADA89266	Human ant
37	92.4	66.0	125	6	ADA89274	Human ant
38	92.4	66.0	139	3	AAW99556	Human Lh1
39	92.4	66.0	139	6	ABR42859	Tumour-ep
40	92.4	66.0	139	7	ABW02445	Human mon
41	92.4	66.0	142	6	ABP96287	Anti-hTNF
42	92.4	66.0	154	6	ABP96293	Human ant
43	92.4	66.0	190	2	AAW34304	IGM antib
44	92.4	66.0	202	2	AAW34303	IGM antib
45	92.4	66.0	205	2	AAW34299	IGM antib

ALIGNMENTS

RESULT 1

ABP45310
ID ABP45310 standard; protein; 249 AA.

AC ABP45310;

XX 19-AUG-2002 (first entry)

DE Human BlyS binding scFv SEQ ID 1321.

XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunomodulatory; immunostimulant; immunomodulatory; antirheumatic;
anti-AIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

PN WO200202641-A1.

PD 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US019110.

XX 16-JUN-2000; 2000US-0212210P.

PR 17-OCT-2000; 2000US-0240816P.

PR 16-MAR-2001; 2001US-0276248P.

PR 21-MAR-2001; 2001US-0277379P.

PR 25-MAY-2001; 2001US-0293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

PA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX

```

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B lymphocyte stimulating polypeptides, useful for the
XX diagnosis and treatment of cancers and immune disorders.
XX Claim 1; Page 1979-1980; 3148pp; English.
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX and so may be used to detect and quantitate the presence of BlyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BlyS. They may also be
XX administered to treat diseases associated with aberrant BlyS expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method of
XX the invention
XX
SQ Sequence 249 AA;

Alignment Scores:
Pred. No.: 2.44e-05 Length: 249
Score: 113.10 Matches: 26
Percent Similarity: 20.63% Conservative: 0
Best Local Similarity: 20.63% Mismatches: 1
Query Match: 80.79% Indels: 99
DB: 5 Gaps: 1

NOLAN463-1A.SEQ (1-81) x ABP45310 (1-249)
QY 1 GAATCATCATAGTGGAGCAACCACTACACCGCTCCCTCAAGAGT----- 48
D50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrIle 69
QY 48 ----- 48
D70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
QY 48 ----- 48
D90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
QY 48 ----- 48
D110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGlyGly 129
QY 48 ----- 48
D130 GlySerGlyGlyGlyGlySerGlyGlyGlyGlySerAspIleValMetThrGlnSerPro 149
QY 49 -----CGGGCGAGTCAGCAT 63
D150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
QY 64 ATTAGCAGCTGGTAGCC 81
D170 IleSerSerTrpLeuAla 175

RESULT 2
ADG96137
ID ADG96137 standard; protein; 249 AA.
XX
AC ADG96137;
XX

```

```

DT 11-MAR-2004 (first entry)
XX Single chain antibody that immunospecifically binds BlyS SeqID 1321.
XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX B cell proliferation; differentiation; scFv; myasthenia gravis;
XX multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
XX antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX Unidentified.
XX WO2003055979-A2.
XX 10-JUL-2003.
XX 14-NOV-2002; 2002WO-US036496.
XX 16-NOV-2001; 2001US-0331469P.
XX 19-DEC-2001; 2001US-0340817P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (BlyS), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 1321; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey BlyS. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of BlyS or its receptors. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antirheumatic, antiarthritic, neuroprotective,
XX antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX polypeptide sequence is a single chain antibody that binds BlyS of the
XX invention. NOTE: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
SQ Sequence 249 AA;

Alignment Scores:
Pred. No.: 2.44e-05 Length: 249
Score: 113.10 Matches: 26
Percent Similarity: 20.63% Conservative: 0
Best Local Similarity: 20.63% Mismatches: 1
Query Match: 80.79% Indels: 99
DB: 7 Gaps: 1

NOLAN463-1A.SEQ (1-81) x ADG96137 (1-249)
QY 1 GAATCATCATAGTGGAGCAACCACTACACCGCTCCCTCAAGAGT----- 48
D50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrIle 69
QY 48 ----- 48
D70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
QY 48 ----- 48
D90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
QY 48 ----- 48
D110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGlyGly 129
QY 48 ----- 48
D130 GlySerGlyGlyGlyGlySerGlyGlyGlyGlySerAspIleValMetThrGlnSerPro 149
QY 49 -----CGGGCGAGTCAGCAT 63
D150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
QY 64 ATTAGCAGCTGGTAGCC 81
D170 IleSerSerTrpLeuAla 175

RESULT 2
ADG96137
ID ADG96137 standard; protein; 249 AA.
XX
AC ADG96137;
XX

```

Db 70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
 QY 48 ----- 48
 Db 90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
 QY 48 ----- 48
 Db 110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGly 129
 QY 48 ----- 48
 Db 130 GlySerGlyGlyGlySerGlyGlyGlyGlySerAspIleValMetThrGlnSerPro 149
 QY 49 -----CGGCGCAGTCAGGAT 63
 Db 150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
 QY 64 ATTACGACGCTGTTAGCC 81
 Db 170 IleSerSerTrpLeuAla 175
 RESULT 3
 ABP44982
 ID ABP44982 standard; protein; 250 AA.
 XX
 AC ABP44982;
 DT 19-AUG-2002 (first entry)
 XX
 DE Human BlyS binding scFv SEQ ID 993.
 KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX
 FN WO200202641-A1.
 XX
 PD 10-JAN-2002.
 XX
 PF 15-JUN-2001; 2001WO-US019110.
 XX
 PR 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX
 DR WPI; 2002-114799/15.
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 XX
 PS Claim 1; Page 1586-1587; 3148pp; English.
 XX
 CC This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS

CC and so may be used to detect and quantitate the presence of BlyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BlyS. They may also be
 CC administered to treat diseases associated with aberrant BlyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX
 SQ Sequence 250 AA;
 Alignment Scores:
 Pred. No.: 0.00726 Length: 250
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 5 Gaps: 1
 NOLAN463-1A.SEQ (1-81) x ABP44982 (1-250)
 QY 1 GAATCATCATGATGAGGACCACTACACCGCTCCCTCAAGATCGGCG----- 54
 Db 50 GluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
 QY 55 AGTCAGGATATTAGCAGC 72
 Db 70 SerGlnAspThrSerAsn 75
 RESULT 4
 ADG95809
 ID ADG95809 standard; protein; 250 AA.
 XX
 AC ADG95809;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Single chain antibody that immunospecifically binds BlyS SeqID 993.
 KW antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiallergic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
 XX
 OS Unidentified.
 XX
 FN WO2003055979-A2.
 XX
 PD 10-JUL-2003.
 XX
 PF 14-NOV-2002; 2002WO-US036496.
 XX
 PR 16-NOV-2001; 2001US-0331469P.
 PR 19-DEC-2001; 2001US-0340817P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 XX
 DR WPI; 2003-505530/47.
 XX
 PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (BlyS), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.
 PS Example 1; SEQ ID NO 993; 394pp; English.
 XX
 CC This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour

CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey BlyS. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of BlyS or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds BlyS of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.

XX
 SQ Sequence 250 AA;

Alignment Scores:
 Pred. No.: 0.00726 Length: 250
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 7 Gaps: 1

NOLAN463-1A.SEQ (1-81) x ADG95809 (1-250)

Qy 1 GAAATCAATCATGTGGAGCACCACACTACAAACCGTCCTCAAGATCGGGCG----- 54
 |||||
 Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
 Qy 55 AGTCAGGATATTAGCAGC 72
 |||||
 Db 70 SerGlnAspThrSerAsn 75

RESULT 5
 ABP44943

ID ABP44943 standard; protein; 253 AA.

XX AC ABP44943;

XX DT 19-AUG-2002 (first entry)

XX DE Human BlyS binding scFv SEQ ID 954.

XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX OS Homo sapiens.

XX PN WO200202641-A1.

XX PD 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US019110.

XX PR 16-JUN-2000; 2000US-0212210P.

XX PR 17-OCT-2000; 2000US-0240816P.

XX PR 16-MAR-2001; 2001US-0276248P.

XX PR 21-MAR-2001; 2001US-0277379P.

XX PR 25-MAY-2001; 2001US-0293499P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Baraah SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.

XX Antibodies against B lymphocyte stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.

XX Claim 1; Page 1540-1541; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
 CC and so may be used to detect and quantitate the presence of BlyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BlyS. They may also be
 CC administered to treat diseases associated with aberrant BlyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention

XX SQ Sequence 253 AA;

Alignment Scores:
 Pred. No.: 0.00728 Length: 253
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 5 Gaps: 1

NOLAN463-1A.SEQ (1-81) x ABP44943 (1-253)

Qy 1 GAAATCAATCATGTGGAGCACCACACTACAAACCGTCCTCAAGATCGGGCG----- 54
 |||||

Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69

Qy 55 AGTCAGGATATTAGCAGC 72

|||||

Db 70 SerGlnAspThrSerAsn 75

RESULT 6

ADG95770

ID ADG95770 standard; protein; 253 AA.

XX AC ADG95770;

XX DT 11-MAR-2004 (first entry)

XX Single chain antibody that immunospecifically binds BlyS SeqID 954.
 KW antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX OS Unidentified.

XX PN WO2003055979-A2.

XX PD 10-JUN-2003.

XX PF 14-NOV-2002; 2002WO-US036496.

XX PR 16-NOV-2001; 2001US-0331469P.


```

PR 19-DEC-2001; 2001US-0340817P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT (Blys), useful for detecting and treating diseases or disorders e.g.
PT rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 954; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey Blys. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of Blys or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antineoplastic, antiarthritic, neuroprotective,
XX antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX polypeptide sequence is a single chain antibody that binds Blys of the
XX invention. NOTE: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 253 AA;
SQ
Alignment Scores:
Pred. No.: 0.00728 Length: 253
Score: 93.80 Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00% Indels: 2
DB: 7 Gaps: 1
NOLAN463-1A.SEQ (1-81) x ADG95770 (1-253)
QY 1 GAAATCAATCATAGTGGAGCACCACCACTACACCCGTCCTCAAGAGTGGGCGG----- 54
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
QY 55 ACTCAGGATATAGCAGC 72
Db 70 SerGlnAspThrSerAsn 75
RESULT 7
AAW62794
XX AAW62794 standard; peptide; 80 AA.
XX
XX AC AAW62794;
XX
XX 23-SEP-1998 (first entry)
XX
XX Amino acid sequence of a human antibody fragment.
XX
XX Human; immunoglobulin; Ig; transgenic; non-human mammal;
XX inactivated endogenous Ig locus; B-cell development;
XX human heavy chain Ig locus; micro constant region; J-H; D-H; V-H gene;
XX kappa light chain Ig locus; kappa constant region; J-kappa gene; V-kappa;
XX production; antibody.
XX

```

```

OS Homo sapiens.
XX
XX WO9824893-A2.
XX
XX PD 11-JUN-1998.
XX
XX PF 03-DEC-1997; 97WO-US023091.
XX
XX PR 03-DEC-1996; 96US-00759620.
XX
XX PA (ABGE-) ABGENIX INC.
XX
XX PI Jakobovits A, Kucherlapati R, Klapholz S, Mendez M, Green L;
XX WPI; 1998-333314/29.
XX
XX New transgenic non-human mammals - having an inactivated immunoglobulin
XX locus and a near complete human immunoglobulin locus, used for production
XX of human antibodies.
XX
XX Disclosure; Page 71; 128pp; English.
XX
XX AAW62793-822 represent fragments of human antibodies produced by
XX transgenic Xenomice, created using the method of the invention. The
XX specification describes a transgenic non-human mammal which has genome
XX modifications that comprise an inactivated endogenous immunoglobulin (Ig)
XX locus, so that the mammal does not display normal B-cell development. The
XX modified genome also has an inserted human heavy chain Ig locus in
XX germline configuration, the human heavy chain Ig locus comprising a human
XX micro constant region and regulatory and switch sequences, human J-H
XX genes, human D-H genes, and human V-H genes and an inserted human kappa
XX light chain Ig locus in germline configuration, the human kappa light
XX chain Ig locus comprising a human kappa constant region, J-kappa genes,
XX and V-kappa genes, where the number of V-H and V-kappa genes inserted are
XX selected to restore normal B-cell development in the mammal. The
XX transgenic animals have a near complete human Ig locus, including both a
XX human heavy chain locus and a human kappa light chain locus. They can be
XX used for the production of human antibodies when exposed to particular
XX antigens e.g. when exposed to human IL-8, EGFR or TNF- alpha the mice
XX will produce antibodies to IL-8, EGFR or TNF- alpha respectively
XX
XX Sequence 80 AA;
SQ
Alignment Scores:
Pred. No.: 0.00804 Length: 80
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0
NOLAN463-1A.SEQ (1-81) x AAW62794 (1-80)
QY 1 GAAATCAATCATAGTGGAGCACCACCACTACACCCGTCCTCAAGAGTGGGCGGAGTCAG 60
Db 33 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThr--- 51
QY 61 GATATTAGC 69
Db 52 ---IleSer 53
RESULT 8
AAW62794
XX AAW62794 standard; protein; 97 AA.
XX
XX AC AAW62794;
XX
XX 19-JUL-1999 (first entry)
XX
XX Multiple sclerosis patient CSF B-cell VH region (clone 4d76).
XX
XX Multiple sclerosis; cerebrospinal fluid; CSF; B-cell;
XX heavy chain variable region; VH gene; somatic hypermutation;
XX

```

KW B-cell clonality; RA gene; diagnosis; human.

XX Homo sapiens.

PH Key Location/Qualifiers
FT Region 1. .30
FT /label= FR1

FT Misc-difference 8 /note= "encoded by GGC"

FT Misc-difference 13 /note= "replaces Glu of RA"

FT Misc-difference 14 /note= "encoded by CCT"

FT Misc-difference 23 /note= "replaces Gly of RA"

FT Misc-difference 25 /note= "replaces Phe of RA"

FT Misc-difference 30 /note= "replaces Gly of RA"

FT Region 31. .36

FT /label= CDR1

FT Misc-difference 31 /note= "replaces Gly of RA"

FT Misc-difference 32 /note= "replaces Phe of RA"

FT Region 37. .50

FT /label= FR2

FT Region 51. .66

FT /label= CDR2

FT Misc-difference 56 /note= "replaces Asn of RA"

FT Misc-difference 57 /note= "replaces Ser of RA"

FT Misc-difference 58 /note= "replaces Lys of RA"

FT Region 67. .97

FT /label= FR3

FT Misc-difference 71 /note= "replaces Leu of RA"

FT Misc-difference 81 /note= "replaces Arg of RA"

XX WO9915696-A1.

XX 01-APR-1999.

XX 17-SEP-1998; 98WO-CA000873.

XX 19-SEP-1997; 97CA-02216595.

XX 04-NOV-1997; 97CA-02220245.

XX (QINY/) QIN Y.

XX Qin Y;

XX WPI; 1999-276985/23.

XX N-PSDB; AAX25318.

XX Determination of B-cell clonality by amplification or enzymatic digestion.

XX Disclosure; Fig 9D; 67pp; English.

XX This sequence represents a heavy chain variable region (VH) as predicted from DNA of dominant clone 4d76 of B-cells taken from the cerebrospinal fluid (CSF) of a multiple sclerosis (MS) patient. Sequences of VH of CSF B-cells were obtained from 4 MS patients (see AAX25316-19). Differences in nucleotide and predicted amino acid (see AAX05691-94) sequences were compared with the closest known germline VH genes; for 4d76, this was RA. The results provided direct evidence that intrathecal clonally expanded B-cells from the CSF of MS patients are hypermutated postgerminal centre antibody-forming or memory lymphocytes that have undergone antigen selection. This finding implicates an important pathogenic pathway for

CC the development of demyelination in CNS of MS. The invention provides assay kits for determining B-cell or T-cell clonality. This technology allows the establishment of clonal specific RNA library from pathogenic cells in the CNS of patients, which is important for further understanding of the role of antigen(s) in the cause of B-cell clonal expansion, and towards developing antigen specific therapeutic strategy

XX SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.00847 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x AAY05694 (1-97)

Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileasnhisserGlyserThrAsnTyRAsnProserleuylsSerArgValThr--- 68

Qy 61 GATATTAGC 69

Db 69 ---IleSer 70

RESULT 9

ABG78212

ID ABG78212 standard; protein; 97 AA.

XX AC ABG78212;

XX DT 15-NOV-2002 (first entry)

XX Human Fv molecule hypervariable region related peptide #87.

XX Human: Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX Homo sapiens.

XX WO200259264-A2.

XX PD 01-AUG-2002.

XX 31-DEC-2001; 2001WO-US049440.

XX 29-DEC-2000; 2000US-00751181.

XX (BIOT-) BIO-TECHNOLOGY GEN CORP.

XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;

XX Plaksin D, Peretz T;

XX WPI; 2002-619166/66.

XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct or fragment, or construct of fragment with enhanced binding characteristics so as to selectively bind target cell in favor of other cells.

XX Claim 13; Page 193; 232pp; English.

XX The invention relates to a peptide or polypeptide comprising an Fv molecule, a construct or fragments or a construct of a fragment with enhanced binding characteristics which selectively and/or specifically binds to a target cell in favour of other cells, where binding is primarily determined by a first hypervariable region and Fv is a single chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in association with or attached, coupled, combined, linked or fused to a pharmaceutical agent, is useful in the manufacture of a medicament, where

CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 CC related peptide of the invention

XX Sequence 97 AA;

Alignment Scores:
 Pred. No.: 0.00847 Length: 97
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservatives: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 5 Gaps: 0

NOLAN463-1A.SEQ (1-81) x ABG78212 (1-97)

QY 1 GAAATCAATCATAGTGGAGGACCAACTACACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| : : :
 50 GlulleAenHisSerGlySerThrAsnTyxRhanProSerLeuLysSerArgValThr--- 68
 QY 61 GATATTAGC 69
 Db |||||
 69 ---IleSer 70

RESULT 10
 ABG91903
 ID ABG91903 standard; protein; 97 AA.
 XX AC ABG91903;
 DT 04-DEC-2002 (first entry)
 XX Human antibody fragment #87.
 DE Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
 KW metastasis; hypervariable region; autoimmune disease; thrombosis;
 KW retenosis; leukaemia; inflammatory disease; cardiovascular disease;
 KW myocardial infarction; retinopathic disease; abnormal platelet function;
 KW sulphated tyrosine-dependent protein-protein interaction.
 XX Homo sapiens.
 OS WO200253700-A2.
 PN 11-JUL-2002.
 PD 31-DEC-2001; 2001WO-US049442.
 PF 29-DEC-2000; 2000US-00751181.
 PR 29-DEC-2000; 2000US-0258948P.
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
 PI Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
 XX WPI; 2002-674776/72.
 DR Novel isolated epitope present on cancer cells and important in
 XX physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.
 XX Disclosure; Page 269; Opp; English.
 PS The invention relates to an isolated epitope present on cancer cells and
 CC important in physiological phenomena such as cell rolling, metastasis and
 CC inflammation, where the epitope is capable of being bound by an antibody,
 CC its antigen-binding fragment or its complex comprising at least one

CC antibody or its binding fragment having a first hypervariable region. The
 CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
 CC tumour or leukaemia cells, increase in number of tumour or leukaemia
 CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 CC platelet and/or cell-platelet adhesion or aggregation, for increasing
 CC mortality of tumour or leukaemia cells, for increasing the susceptibility
 CC of diseased cells to damage by anti-disease, anti-cancer or anti-
 CC leukaemia agents, or for decreasing the number of tumour or leukaemia
 CC cells in a patient, or in the manufacture of a medicament for the above
 CC mentioned purposes. The epitopes are useful for diagnosing and treating
 CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 CC diseases, cardiovascular diseases such as myocardial infarction,
 CC retinopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention

XX Sequence 97 AA;

Alignment Scores:
 Pred. No.: 0.00847 Length: 97
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservatives: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 5 Gaps: 0

NOLAN463-1A.SEQ (1-81) x ABG91903 (1-97)

QY 1 GAAATCAATCATAGTGGAGGACCAACTACACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| : : :
 50 GlulleAenHisSerGlySerThrAsnTyxRhanProSerLeuLysSerArgValThr--- 68
 QY 61 GATATTAGC 69
 Db |||||
 69 ---IleSer 70

RESULT 11
 ABO27107
 ID ABO27107 standard; protein; 97 AA.
 XX AC ABO27107;
 DT 10-SEP-2003 (first entry)
 XX Human germline heavy chain variable region gene segment #40.
 DE Human; heavy chain variable region; VH; humanised antibody;
 KW chimeric antibody; complementarity determining region; CDR;
 KW canonical CDR structure type.
 XX Homo sapiens.
 OS US2003039649-A1.
 PN 27-FEB-2003.
 PD 12-JUL-2001; 2001US-0305111P.
 PF 12-JUL-2002; 2002US-00194975.
 PR 12-JUL-2001; 2001US-0305111P.
 XX (FOOT/) FOOTE J.
 XX Foote J;
 XX WPI; 2003-492151/46.
 DR Making humanized antibody for converting antibody, by making chimeric
 PT antibodies containing complementarity determining region from non-human
 PT antibody and appropriate framework sequences of human antibodies.
 XX Example 1; Fig 1; 31pp; English.

XX The invention describes a method of making a humanised antibody,
CC comprising making chimeric antibodies containing a complementarity
CC determining region (CDR) from a non-human antibody and appropriate
CC framework sequences (I) of human antibodies. (I) is selected by using
CC canonical CDR structure types of non-human antibody in comparison to
CC germline canonical CDR structure types of human antibodies as the basis
CC for selection, for humanisation. The method is useful for making a
CC humanised antibody or a converted antibody. The method is applicable for
CC converting a subject antibody sequence of any subject species to a less
CC immunogenic form suitable for use in an object species. The method is
CC reliable for identifying suitable human framework sequences to support
CC non-human CDR regions and to provide humanised antibodies that retain
CC high antigen binding with low immunogenicity in humans, without the need
CC for direct comparison of framework sequences, without the need for
CC determining critically important amino acid residues in the framework,
CC and without the need for multiple iteration and construction to obtain
CC humanised antibodies with suitable therapeutic properties. The antibody
CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies

XX SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.00847 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 6 Gaps: 0

NOLAN463-1A.SEQ (1-81) x ABO27107 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGCTCCCTCAAGAGTCGGCGAGTCAG 60
Db |||||
50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68

Qy 61 GATATTAGC 69
Db |||||
69 ---IleSer 70

RESULT 12

ADB75646
ID ADB75646 standard; protein; 97 AA.

XX ADB75646;

XX AC

XX 04-DEC-2003 (first entry)

XX Human protein relating to the invention SEQ ID NO:55.

XX antibody library; CD1 region; CD2 region; VH region; VL region;

XX immunoglobulin; CD3 region; TM1 scFv; human.

XX Homo sapiens.

XX WO2003044198-A1.

XX 30-MAY-2003.

XX 22-NOV-2002; 2002WO-JP012236.

XX 22-NOV-2001; 2001JP-00358602.

XX (UYKE-) UNIV KEIO.

XX Shimizu N, Takayanagi A, Okui M;

XX WPI; 2003-449818/42.

XX Highly stable artificial antibody libraries with super-repository and

PT little contamination from unexpressible ones, useful as tool in
XX proteomics and e.g. for diagnosis and treating various diseases.
XX Disclosure; Page 101; 108pp; Japanese.

XX The invention relates to a novel artificial single-stranded antibody
CC library with super-repository. The library is created by using a cDNA
CC library as template for amplifying a fragment containing the CD1 and CD2
CC regions of the VH or VL region of immunoglobulin gene and a fragment
CC containing the CD3 region by PCR, respectively, producing VH and VL
CC libraries, transferring into a host, and displaying the single-stranded
CC antibody on a phage surface. An antibody library of the invention is
CC useful as a tool in proteomics and antibody chips and filters, for
CC screening ligands for antigens, and for studying protein-DNA interaction,
CC diagnosis and treating various diseases. The present sequence represents
CC a protein of the invention.

XX SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.00847 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 7 Gaps: 0

NOLAN463-1A.SEQ (1-81) x ADB75646 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGCTCCCTCAAGAGTCGGCGAGTCAG 60
Db |||||
50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68

Qy 61 GATATTAGC 69
Db |||||
69 ---IleSer 70

RESULT 13

ADD28104
ID ADD28104 standard; protein; 97 AA.

XX ADD28104;

XX AC

XX 15-JAN-2004 (first entry)

XX Lymphoma related immunoglobulin variable region F5.

XX B-cell; malignant; immunoglobulin; immunoglobulin variable region;
XX Ig variable region; glycosylation site; lymphoma; B cell receptor;
XX cytostatic; gene therapy; glycosylation inhibitor;

XX non-Hodgkin's lymphoma.

XX Synthetic.

XX Homo sapiens.

XX WO2003074059-A2.

XX 12-SEP-2003.

XX 24-FEB-2003; 2003WO-GB000783.

XX 07-MAR-2002; 2002GB-00005395.

XX (CANC-) CANCER RES TECHNOLOGY LTD.

XX Zhu D, Stevenson F;

XX WPI; 2003-902720/82.

XX Classifying a B-cell as malignant or normal by isolating a sequence

XX representing an Ig variable region from the B cell, detecting the

XX presence of a glycosylation site and classifying the cell as malignant or

XX normal.

XX Disclosure; Fig 4; 61pp; English.

XX The present invention describes a method for classifying a B-cell as

CC malignant or normal comprising: (a) isolating a sequence representing an

CC immunoglobulin (Ig) variable region from the B cell; (b) detecting the

CC presence of a glycosylation site; and (c) classifying the cell as

CC malignant or normal on the basis of the presence or absence of a

CC glycosylation site. Also described: (1) treating a patient suffering from

CC or at risk of having lymphoma; (2) screening for substances capable of

CC inhibiting glycosylation of the Ig variable region of the B cell receptor

CC ; and (3) screening for substances (S) capable of inhibiting the

CC interaction between lectins of the type found in the germinal centre and

CC N-glycans found on the surface of Ig of lymphoma cells. (S) has

CC cytosstatic activity, and can be used in gene therapy, and as a

CC glycosylation inhibitor. The method is useful in classifying a B-cell as

CC malignant or normal. The glycosylation inhibitor is useful in preparing a

CC medicament for treating non-Hodgkin's lymphoma. The present sequence

CC represents an Ig variable region sequence which is used in the

CC exemplification of the present invention.

XX

SQ Sequence 97 AA;

Alignment Scores:

Pred. No.:	0.00847	Length:	97
Score:	92.40	Matches:	19
Percent Similarity:	74.07%	Conservative:	1
Best Local Similarity:	70.37%	Mismatches:	1
Query Match:	66.00%	Indels:	6
DB:	7	Gaps:	0

NOLAN463-1A.SEQ (1-81) x ADD28104 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
|||
Db 50 GlulleasnHissSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
:::

Qy 61 GATATTAGC 69
|||

Db 69 ---IleSer 70

RESULT 14

ID ADF10048
ID ADF10048 standard; protein; 97 AA.

XX ADF10048;

XX 12-FEB-2004 (first entry)

XX VEGF antibody heavy chain variable region VH_4-34.

XX Antibody; stability; solubility; antigen binding affinity;

XX variable region; human; VEGF.

XX Homo sapiens.

XX WO2003074679-A2.

XX 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;

XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies

PT comprises analyzing the interactions of amino acids at variable

PT positions.

XX Example 6; Fig 16a; 135pp; English.

XX The present invention relates to a method for optimizing at least one

CC physico-chemical property of an antibody by a computational screening

CC method. The method comprises: receiving a template antibody structure;

CC selecting at least one variable position belonging to the antibody

CC structure; selecting at least one amino acid to be considered at the

CC variable position(s); analyzing the interaction of each selected amino

CC acid at each variable position with at least part of the remainder of the

CC antibody, including the selected amino acids at other variable positions;

CC and identifying a set of at least one antibody sequence with at least one

CC optimized physico-chemical property. The method is useful for optimizing

CC the physico-chemical properties of an antibody, especially the stability,

CC solubility, or antigen binding affinity. The optimized antibody may be

CC useful for treating a patient. The present sequence is an antibody

CC variable region sequence used to illustrate the invention.

XX Sequence 97 AA;

Alignment Scores:

Pred. No.:	0.00847	Length:	97
Score:	92.40	Matches:	19
Percent Similarity:	74.07%	Conservative:	1
Best Local Similarity:	70.37%	Mismatches:	1
Query Match:	66.00%	Indels:	6
DB:	7	Gaps:	0

NOLAN463-1A.SEQ (1-81) x ADF10048 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
|||
Db 50 GlulleasnHissSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
:::

Qy 61 GATATTAGC 69
|||

Db 69 ---IleSer 70

RESULT 15

ID ADF10150
ID ADF10150 standard; protein; 97 AA.

XX ADF10150;

XX 12-FEB-2004 (first entry)

XX Antibody heavy chain variable region VH_4-34.

XX Antibody; stability; solubility; antigen binding affinity;

XX variable region; human.

XX Homo sapiens.

XX WO2003074679-A2.

XX 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;

XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies

PT comprises analyzing the interactions of amino acids at variable

PT positions.

XX

PS Example 16; Fig 40a; 135pp; English.
XX
CC The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.00847 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 7 Gaps: 0

NOLAN463-1A.SEQ (1-81) x ADF10150 (1-97)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db |||||
50 GluileAenHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db |||||
69 ---IleSer 70

Search completed: August 4, 2005, 18:14:24
Job time : 97.5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:05:28 ; Search time 23.25 Seconds
(without alignments)
520.135 Million cell updates/sec

Title: NOLAN463-1A.SEQ

Perfect score: 140

Sequence: 1 GAATCATCATCATAGTGGAG.....ATATTAGAGCTGTTAGCC 81

Scoring table:

BLOSUM62
-Q= /cg2 1/USPTO spool p/NOLAN08728463-1/runat 04082005 125807 24557/app_query.fasta_1.5
-DB=Issued Patents AA -QFWT=fastan -SUFFIX=rai -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pco -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-1 @CGN 1.1 66 @runat 04082005 125807 24557 -NCPU=6 -ICPU=3
-NO MWAP -LARGQUERY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 1027090

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cg2 1/USPTO spool p/NOLAN08728463-1/runat 04082005 125807 24557/app_query.fasta_1.5
-DB=Issued Patents AA -QFWT=fastan -SUFFIX=rai -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pco -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-1 @CGN 1.1 66 @runat 04082005 125807 24557 -NCPU=6 -ICPU=3
-NO MWAP -LARGQUERY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

Issued Patents AA:*
1: /cg2 6/ptodata/1/iaa/5A COMB.pcp:*
2: /cg2 6/ptodata/1/iaa/5B COMB.pcp:*
3: /cg2 6/ptodata/1/iaa/6A COMB.pcp:*
4: /cg2 6/ptodata/1/iaa/6B COMB.pcp:*
5: /cg2 6/ptodata/1/iaa/PTCUS COMB.pcp:*
6: /cg2 6/ptodata/1/iaa/backfiles1.pcp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	92.4	66.0	116	3	US-08-545-809A-118
2	92.4	66.0	123	3	US-08-793-450-4
3	92.4	66.0	139	4	US-09-203-768A-2
4	92.4	66.0	472	3	US-08-793-450-8
5	87.4	62.4	429	4	US-09-372-425A-6
6	84.4	60.3	118	3	US-09-025-769B-25
7	84.4	60.3	118	4	US-09-490-070A-25
8	84.4	60.3	118	4	US-09-490-153-25
9	84.4	60.3	118	4	US-09-490-324-25
10	81	57.9	120	3	US-08-545-809A-137
11	80.7	57.6	130	3	US-08-466-151-5
12	80.7	57.6	130	3	US-08-466-163B-5

13	80.7	57.6	130	4	US-09-802-096-5
14	80.7	57.6	130	4	US-09-802-077-5
15	79.4	56.7	147	4	US-09-471-276-835
16	79.4	56.7	447	4	US-09-372-425A-2
17	77	55.0	119	2	US-08-428-197-16
18	77	55.0	119	5	PCT-US93-10555-16
19	76.4	54.6	112	3	US-09-344-587-14
20	75.9	54.2	118	2	US-08-652-816A-13
21	74.4	53.1	120	4	US-09-424-840B-20
22	73.4	52.4	21	3	US-08-918-148-45
23	73.4	52.4	21	4	US-09-138-091A-45
24	73.4	52.4	76	3	US-08-851-362D-22
25	73.4	52.4	96	3	US-08-851-362D-35
26	73.4	52.4	116	3	US-08-545-809A-140
27	73.4	52.4	117	3	US-08-851-362D-48
28	73.4	52.4	118	3	US-08-545-809A-142
29	73.4	52.4	119	3	US-09-025-769B-39
30	73.4	52.4	119	3	US-09-025-769B-65
31	73.4	52.4	119	4	US-09-490-070A-39
32	73.4	52.4	119	4	US-09-490-070A-65
33	73.4	52.4	119	4	US-09-490-153-39
34	73.4	52.4	119	4	US-09-490-153-65
35	73.4	52.4	119	4	US-09-490-324-39
36	73.4	52.4	119	4	US-09-490-324-65
37	73.4	52.4	139	4	US-09-471-276-837
38	73.4	52.4	244	3	US-08-918-148-79
39	73.4	52.4	244	4	US-09-138-091A-77
40	73	52.1	100	4	US-09-726-219A-169
41	72.4	51.7	140	4	US-09-471-276-850
42	72.4	51.7	240	2	US-07-956-399-2
43	72	51.4	95	4	US-09-471-276-882
44	72	51.4	116	3	US-08-545-809A-92
45	72	51.4	119	3	US-08-767-128-18

ALIGNMENTS

RESULT 1

US-08-545-809A-118
; Sequence 118, Application US/08545809A
; Patent No. 6096878

GENERAL INFORMATION:

APPLICANT: Honjo, Tasuku

APPLICANT: Matsuda, Fumihiko

TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE

TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME

NUMBER OF SEQUENCES: 145

CORRESPONDENCE ADDRESS:

ADDRESSES: Fish & Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/545,809A

FILING DATE: 27-MAR-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/JP93/00603

FILING DATE: 10-MAY-1993

ATTORNEY/AGENT INFORMATION:

NAME: Freeman, John W.

REGISTRATION NUMBER: 29,066

REFERENCE/DOCKET NUMBER: 06501/004001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-542-5070

TELEFAX: 617-542-8906

TELEX: 200154

Sequence 5, Appli
Sequence 5, Appli
Sequence 835, App
Sequence 2, Appli
Sequence 16, Appl
Sequence 16, Appl
Sequence 13, Appl
Sequence 14, Appl
Sequence 20, Appl
Sequence 45, Appl
Sequence 22, Appl
Sequence 35, Appl
Sequence 140, App
Sequence 48, Appl
Sequence 142, App
Sequence 39, Appl
Sequence 65, Appl
Sequence 39, Appl
Sequence 65, Appl
Sequence 65, Appl
Sequence 39, Appl
Sequence 837, App
Sequence 79, Appl
Sequence 77, Appl
Sequence 169, App
Sequence 850, App
Sequence 2, Appli
Sequence 882, App
Sequence 92, Appl
Sequence 18, Appl

```
; INFORMATION FOR SEQ ID NO: 118:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-118

Alignment Scores:
Pred. No.: 0.000752 Length: 116
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 3 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-08-545-809A-118 (1-116)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAACCCGTCCTCAAGAGTCGGCGGAGTCAG 60
Db 69 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 87
Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 2
US-08-793-450-4
; Sequence 4, Application US/08793450
; Patent No. 6312690
; GENERAL INFORMATION:
; APPLICANT: EDELMAN, LENA
; APPLICANT: MARGARITTE, CRISTEL
; APPLICANT: KACZOREK, MICHEL
; APPLICANT: CHAABIHI, HASSAN
; TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/793,450
; FILING DATE: 03-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 94/10566
; FILING DATE: 02-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 660-118-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-793-450-4
```

```
Alignment Scores:
Pred. No.: 0.000768 Length: 123
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 3 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-08-793-450-4 (1-123)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAACCCGTCCTCAAGAGTCGGCGGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 3
US-09-203-768A-2
; Sequence 2, Application US/09203768A
; Patent No. 6787638
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/09/203,768A
; CURRENT FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 139
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-203-768A-2

Alignment Scores:
Pred. No.: 0.000802 Length: 139
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 4 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-09-203-768A-2 (1-139)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAACCCGTCCTCAAGAGTCGGCGGAGTCAG 60
Db 69 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 87
Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 4
US-08-793-450-8
; Sequence 8, Application US/08793450
; Patent No. 6312690
; GENERAL INFORMATION:
; APPLICANT: EDELMAN, LENA
; APPLICANT: MARGARITTE, CRISTEL
; APPLICANT: KACZOREK, MICHEL
; APPLICANT: CHAABIHI, HASSAN
; TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
```


STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/793,450
FILING DATE: 03-MAR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 94/10566
FILING DATE: 02-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 680-118-0 PCT
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 472 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-793-450-8

Alignment Scores:
Pred. No.: 0.00124 Length: 472
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 3 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-08-793-450-8 (1-472)

Qy 1 GAATCATCATAGTGAAGCACCACCACTACACCGCTCCCTCAAGAGTCGGCGGAGTCAG 60
Db 69 GlulleAsnHisSerGlySerThrAsnTyAsnProSerLeuIysSerArgValThr--- 87
Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 5
US-09-372-425A-6
Sequence 6, Application US/09372425A
Patent No. 6475749
GENERAL INFORMATION:
APPLICANT: Sherie L. Morrison
APPLICANT: Ramon Montano
TITLE OF INVENTION: Improved Rh Antibody
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Oppenheimer Wolff & Donnelly LLP
STREET: 2029 Century Park East, Suite 3800
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90067
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 98
SOFTWARE: MS Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/372,425A
FILING DATE: August 11, 1999
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Oldenakmp, David J.
REGISTRATION NUMBER: 29,421
REFERENCE/DOCKET NUMBER: 510015-223
TELECOMMUNICATION INFORMATION:
TELEPHONE: (310) 788-5000
TELEFAX: (310) 788-5100
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 429 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Heavy chain without Tailpiece - AA
US-09-372-425A-6

Alignment Scores:
Pred. No.: 0.00554 Length: 429
Score: 87.40 Matches: 18
Percent Similarity: 74.07% Conservative: 2
Best Local Similarity: 66.67% Mismatches: 1
Query Match: 62.43% Indels: 6
DB: 4 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-09-372-425A-6 (1-429)

Qy 1 GAATCATCATAGTGAAGCACCACCACTACACCGCTCCCTCAAGAGTCGGCGGAGTCAG 60
Db 69 GlulleAsnHisSerGlySerThrAsnTyAsnProSerLeuIysSerArgValThr--- 87
Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 6
US-09-025-769B-25
Sequence 25, Application US/09025769B
Patent No. 6300064
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
APPLICANT: Pack, Peter
APPLICANT: Ilag, Vic
APPLICANT: Ge, Liming
APPLICANT: Moroney, Simon
APPLICANT: Plueckhuhn, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:

```
;
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-25
Alignment Scores:
Pred. No.: 0.00872 Length: 118
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservatives: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 3 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-09-025-769B-25 (1-118)
Qy 1 GAAATCAATCATGTGGAAGCACCACTACAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileTyHisSerGlySerThrAsnTyAsnProSerLeuLySerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---lleser 70

RESULT 7
US-09-490-070A-25
; Sequence 25, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>

;
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-490-070A-25
Alignment Scores:
Pred. No.: 0.00872 Length: 118
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservatives: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 4 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-09-490-070A-25 (1-118)
Qy 1 GAAATCAATCATGTGGAAGCACCACTACAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileTyHisSerGlySerThrAsnTyAsnProSerLeuLySerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---lleser 70

RESULT 8
US-09-490-153-25
; Sequence 25, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-153-25
```

Alignment Scores: 0.00872 Length: 118
Pred. No.: 84.40 Matches: 18
Score: 84.40
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 4 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-09-490-153-25 (1-118)

Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 50 GlulleTyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
|||

Qy 61 GATATTAGC 69
|||||
Db 69 ---IleSer 70
|||

RESULT 9
US-09-490-324-25
; Sequence 25, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9050
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-324-25

Alignment Scores: 0.00872 Length: 118
Pred. No.: 84.40 Matches: 18
Score: 84.40
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2

Query Match: 60.29% Indels: 6
DB: 4 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-09-490-324-25 (1-118)

Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 50 GlulleTyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
|||

Qy 61 GATATTAGC 69
|||||
Db 69 ---IleSer 70
|||

RESULT 10
US-08-545-809A-137
; Sequence 137, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiro
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 137:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-545-809A-137

Alignment Scores: 0.0248 Length: 120
Pred. No.: 81.00 Matches: 15
Score: 79.17% Conservative: 4
Percent Similarity: 79.17% Mismatches: 5
Best Local Similarity: 62.50% Indels: 0
Query Match: 57.86% Gaps: 0
DB: 3

NOLAN463-1A.SEQ (1-81) x US-08-545-809A-137 (1-120)

Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 69 GlulleHisSerGlySerThrTyrAsnProSerLeuLysSerArgIleThrMet 88
|||

Qy 61 GATATTAGCAGC 72
|||

Db 89 SerValAspThr 92

RESULT 11

US-08-466-151-5

; Sequence 5, Application US/08466151

; Patent No. 6037453

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Immunoglobulin Variants

; NUMBER OF SEQUENCES: 65

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 1 DNA Way

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatIn (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/466,151

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/466163

; FILING DATE: 06-Jun-1995

; APPLICATION NUMBER: 08/405617

; FILING DATE: 15-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/185899

; FILING DATE: 26-JAN-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/879495

; FILING DATE: 07-MAY-1992

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/744768

; FILING DATE: 14-AUG-1991

; ATTORNEY/AGENT INFORMATION:

; NAME: Svoboda, Craig G.

; REGISTRATION NUMBER: 39,044

; REFERENCE/DOCKET NUMBER: P0718P2C1D1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650/225-1489

; TELEFAX: 650/952-9881

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 130 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

US-08-466-151-5

Alignment Scores:

Pred. No.: 0.028 Length: 130

Score: 80.70 Matches: 18

Percent Similarity: 47.92% Conservative: 5

Best Local Similarity: 37.50% Mismatches: 2

Query Match: 57.64% Indels: 23

DB: 3 Gaps: 2

NOLAN463-1A.SEQ (1-81) x US-08-466-151-5 (1-130)

Qy 4 ATCAATCATAGTGGAGACCACTACAAACCGTCCCTCAAGAGTCGGCGAGT----- 57

Db 52 IleAsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSerArgIleSerIleThr 71

Qy 58 CAGGATATTAGC----- 69

Db 72 ArgAspThrSerLysAsnGlnPheLeuAenSerValThrThrGluAspThr 91

Db 89 SerValAspThr 92

US-08-466-151-5

; Sequence 5, Application US/08466151

; Patent No. 6037453

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Immunoglobulin Variants

; NUMBER OF SEQUENCES: 65

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 1 DNA Way

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatIn (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/466,151

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/466163

; FILING DATE: 06-Jun-1995

; APPLICATION NUMBER: 08/405617

; FILING DATE: 15-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/185899

; FILING DATE: 26-JAN-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/879495

; FILING DATE: 07-MAY-1992

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/744768

; FILING DATE: 14-AUG-1991

; ATTORNEY/AGENT INFORMATION:

; NAME: Svoboda, Craig G.

; REGISTRATION NUMBER: 39,044

; REFERENCE/DOCKET NUMBER: P0718P2C1D1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650/225-1489

; TELEFAX: 650/952-9881

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 130 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

US-08-466-151-5

Alignment Scores:

Pred. No.: 0.028 Length: 130

Score: 80.70 Matches: 18

Percent Similarity: 47.92% Conservative: 5

Best Local Similarity: 37.50% Mismatches: 2

Query Match: 57.64% Indels: 23

DB: 3 Gaps: 2

NOLAN463-1A.SEQ (1-81) x US-08-466-151-5 (1-130)

Qy 4 ATCAATCATAGTGGAGACCACTACAAACCGTCCCTCAAGAGTCGGCGAGT----- 57

Db 52 IleAsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSerArgIleSerIleThr 71

Qy 58 CAGGATATTAGC----- 69

Db 72 ArgAspThrSerLysAsnGlnPheLeuAenSerValThrThrGluAspThr 91

Qy 70 -----AGCTGGTTA 78

Db 92 AlaThrTyrTyrCysAlaIrrpVal 99

RESULT 12

US-08-466-163B-5

; Sequence 5, Application US/08466163B

; Patent No. 6329509

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Immunoglobulin Variants

; FILE REFERENCE: P0718P2C1D1

; CURRENT APPLICATION NUMBER: US/08/466,163B

; CURRENT FILING DATE: 1995-06-06

; PRIOR APPLICATION NUMBER: US 08/405,617

; PRIOR FILING DATE: 1995-03-15

; PRIOR APPLICATION NUMBER: US 08/185,899

; PRIOR FILING DATE: 1994-01-26

; PRIOR APPLICATION NUMBER: US 07/879,495

; PRIOR FILING DATE: 1992-05-07

; PRIOR APPLICATION NUMBER: US 07/744,768

; PRIOR FILING DATE: 1991-08-14

; NUMBER OF SEQ ID NOS: 64

; SEQ ID NO 5

; LENGTH: 130

; TYPE: PRT

; ORGANISM: Mus musculus

US-08-466-163B-5

Alignment Scores:

Pred. No.: 0.028 Length: 130

Score: 80.70 Matches: 18

Percent Similarity: 47.92% Conservative: 5

Best Local Similarity: 37.50% Mismatches: 2

Query Match: 57.64% Indels: 23

DB: 3 Gaps: 2

NOLAN463-1A.SEQ (1-81) x US-08-466-163B-5 (1-130)

Qy 4 ATCAATCATAGTGGAGACCACTACAAACCGTCCCTCAAGAGTCGGCGAGT----- 57

Db 52 IleAsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSerArgIleSerIleThr 71

Qy 58 CAGGATATTAGC----- 69

Db 72 ArgAspThrSerLysAsnGlnPheLeuAenSerValThrThrGluAspThr 91

Qy 70 -----AGCTGGTTA 78

Db 92 AlaThrTyrTyrCysAlaIrrpVal 99

RESULT 13

US-09-802-096-5

; Sequence 5, Application US/09802096

; Patent No. 6685939

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)

; FILE REFERENCE: P0718P2C3US

; CURRENT APPLICATION NUMBER: US/09/802,096

; CURRENT FILING DATE: 2001-03-08

; PRIOR APPLICATION NUMBER: US 08/405,617

; PRIOR FILING DATE: 1995-03-15

; PRIOR APPLICATION NUMBER: US 08/185,899

; PRIOR FILING DATE: 1994-01-26

; PRIOR APPLICATION NUMBER: PCT/US92/06860

; PRIOR FILING DATE: 1992-08-14

; PRIOR APPLICATION NUMBER: US 07/879,495

; PRIOR FILING DATE: 1992-05-07

; PRIOR APPLICATION NUMBER: US 07/744,768

; PRIOR FILING DATE: 1991-08-14

```

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

RESULT 14
US-09-802-077-5
; Sequence 5, Application US/09802077
; Patent No. 6699472
; GENERAL INFORMATION:
; APPLICANT: Prestea, Paula M.
; APPLICANT: Jardieu, Leonard G.
; TITLE OF INVENTION: Method of Treating Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C2US
; CURRENT APPLICATION NUMBER: US/09/802,077
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-077-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-077-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyTyCysAlaTrpVal 99

; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.028
Score: 80.70
Percent Similarity: 47.92%
Best Local Similarity: 37.50%
Query Match: 57.64%
DB: 4

NOLAN463-1A.SEQ (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGACCACTACACCGTCCCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrThrSerTyAsnProSerLeuLysSerArgIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGln
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:20:25 ; Search time 80.25 Seconds
(without alignments)
788.093 Million cell updates/sec

Title: NOLAN463-1A.SEQ

Perfect score: 140

Sequence: 1 GAATCATCATATGAG.....ATATTAGAGCTGTTAGCC 81

Scoring table:

BLOSUM62	Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1	
Fgapop 6.0 , Fgapext 0.1	
Delop 6.0 , Delext 0.1	

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 3505720

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/NOLAN08728463-1/runat_04082005_125809_24629/app_query.fasta_1.5
-DB=Published Applications AA -QFMT=faetan -SUFTX=rapb -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62
-TRANS=human40.cdi -LIST=45 -DOCALLIGN=200 -THR SCORE=pct -THR MAX=100
-THR MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0
-MAXLEN=2000000000
-USER=NOLAN08728463-1@cgn 1.1 260 @runat_04082005_125809_24629 -NCPU=6
-ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
- 18: /cgn2_6/ptodata/1/pubpaa/US10F_PUBCOMB.pep.*
- 19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
- 20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
- 21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
- 22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	113.1	80.8	249	10	US-09-880-748-1321
2	113.1	80.8	249	15	US-10-293-418-1321
3	96.4	68.9	115	17	US-10-898-408-12
4	93.8	67.0	250	10	US-09-880-748-993
5	93.8	67.0	250	15	US-10-293-418-993
6	93.8	67.0	253	10	US-09-880-748-954
7	93.8	67.0	253	15	US-10-293-418-954
8	92.4	66.0	80	14	US-10-078-958-2
9	92.4	66.0	97	14	US-10-194-875-40
10	92.4	66.0	97	15	US-10-308-817-83
11	92.4	66.0	97	15	US-10-032-037B-87
12	92.4	66.0	97	15	US-10-029-988B-87
13	92.4	66.0	97	15	US-10-032-423A-87
14	92.4	66.0	97	15	US-10-453-698-83
15	92.4	66.0	97	15	US-10-029-926B-87
16	92.4	66.0	97	16	US-10-379-392-47
17	92.4	66.0	114	17	US-10-733-532-128
18	92.4	66.0	117	9	US-09-864-761-44315
19	92.4	66.0	118	15	US-10-371-942-90
20	92.4	66.0	118	17	US-10-893-576-192
21	92.4	66.0	122	15	US-10-360-828-63
22	92.4	66.0	125	15	US-10-371-942-110
23	92.4	66.0	125	15	US-10-371-942-118
24	92.4	66.0	139	14	US-10-300-675-2
25	92.4	66.0	139	17	US-10-310-124-2
26	92.4	66.0	139	17	US-10-893-576-43
27	92.4	66.0	142	17	US-10-484-790A-10
28	92.4	66.0	223	10	US-09-972-656-66
29	92.4	66.0	229	10	US-09-972-656-82
30	92.4	66.0	230	10	US-09-972-656-72
31	92.4	66.0	249	10	US-09-880-748-957
32	92.4	66.0	249	15	US-10-293-418-957
33	92.4	66.0	250	10	US-09-880-748-1413
34	92.4	66.0	250	15	US-10-293-418-1413
35	92.4	66.0	253	10	US-09-880-748-1333
36	92.4	66.0	253	15	US-10-293-418-1333
37	92.4	66.0	254	10	US-09-880-748-1659
38	92.4	66.0	254	15	US-10-293-418-1659
39	92.4	66.0	450	17	US-10-484-790A-17
40	92.4	66.0	453	17	US-10-484-790A-18
41	90.4	64.6	246	10	US-09-880-748-1847
42	90.4	64.6	246	15	US-10-293-418-1847
43	90.3	64.5	123	14	US-10-269-805-31
44	90.3	64.5	123	14	US-10-269-805-55
45	88.4	63.1	255	10	US-09-880-748-1642

ALIGNMENTS

RESULT 1
US-09-880-748-1321
; Sequence 1321, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499

```
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1321
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1321

Alignment Scores:
Pred. No.: 3.33e-05 Length: 249
Score: 113.10 Matches: 26
Percent Similarity: 20.63% Conservative: 0
Best Local Similarity: 20.63% Mismatches: 1
Query Match: 80.79% Indels: 99
DB: 10 Gaps: 1

NOLAN463-1A.SEQ (1-81) x US-09-880-748-1321 (1-249)
Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCGTCCCTCAGAGT----- 48
Db 50 GluileasnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrIle 69
Qy 48 ----- 48
Db 70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
Qy 48 ----- 48
Db 90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
Qy 48 ----- 48
Db 110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGly 129
Qy 48 ----- 48
Db 130 GlySerGlyGlyGlySerGlyGlyGlyGlySerAspIleValMetThrGlnSerPro 149
Qy 49 -----CGGGCGAGTCAGGAT 63
Db 150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
Qy 64 ATTAGCAGCTGGTTAGCC 81
Db 170 IleSerSerTrpLeuAla 175

RESULT 2
US-10-293-418-1321
; Sequence 1321, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF52392
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16

; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1321
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1321

Alignment Scores:
Pred. No.: 3.33e-05 Length: 249
Score: 113.10 Matches: 26
Percent Similarity: 20.63% Conservative: 0
Best Local Similarity: 20.63% Mismatches: 1
Query Match: 80.79% Indels: 99
DB: 15 Gaps: 1

NOLAN463-1A.SEQ (1-81) x US-10-293-418-1321 (1-249)
Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCGTCCCTCAGAGT----- 48
Db 50 GluileasnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrIle 69
Qy 48 ----- 48
Db 70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
Qy 48 ----- 48
Db 90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
Qy 48 ----- 48
Db 110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGly 129
Qy 48 ----- 48
Db 130 GlySerGlyGlyGlySerGlyGlyGlyGlySerAspIleValMetThrGlnSerPro 149
Qy 49 -----CGGGCGAGTCAGGAT 63
Db 150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
Qy 64 ATTAGCAGCTGGTTAGCC 81
Db 170 IleSerSerTrpLeuAla 175

RESULT 3
US-10-898-408-12
; Sequence 12, Application US/10898408
; Publication No. US20050058642A1
; GENERAL INFORMATION:
; APPLICANT: GALIBERT, Laurent J.
; APPLICANT: YAN, Wei
; TITLE OF INVENTION: ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE
; FILE REFERENCE: 3467-A
; CURRENT APPLICATION NUMBER: US/10/898,408
; CURRENT FILING DATE: 2004-07-23
; PRIOR APPLICATION NUMBER: 60/490,027
; PRIOR FILING DATE: 2003-07-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 115
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-898-408-12

Alignment Scores:
Pred. No.: 0.00362 Length: 115
Score: 96.40 Matches: 19
Percent Similarity: 41.18% Conservative: 2
Best Local Similarity: 37.25% Mismatches: 4
Query Match: 68.86% Indels: 26
DB: 17 Gaps: 1
```



```
NOLAN463-1A.SEQ (1-81) x US-10-898-408-12 (1-115)
Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCGTCCTCAAGAGTCGGCGAGTCAG 60
    |||||
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrMet 69
    |||||
Qy 61 GATATTAGC-----
    |||||
Db 70 SerValAspThrSerLysAsnGlnPheSerLeuArgLeuAsnSerValThrAlaAlaAsp 89
    |||||
Qy 70 -----AGCTGG 75
    |||||
Db 90 ThrAlaValTyrTyrCysAlaArgValSerTrp 100
    |||||

RESULT 4
US-09-880-748-993
; Sequence 993, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR FILING DATE: 2001-06-15
; PRIOR FILING DATE: 2000-06-15
; PRIOR FILING DATE: 2000-10-17
; PRIOR FILING DATE: 2000-10-17
; PRIOR FILING DATE: 2001-03-16
; PRIOR FILING DATE: 2001-03-21
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 993
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-993

Alignment Scores:
Pred. No.: 0.00905          Length: 250
Score: 93.80              Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00%        Indels: 2
DB: 15                     Gaps: 1

NOLAN463-1A.SEQ (1-81) x US-10-293-418-993 (1-250)
Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCGTCCTCAAGAGTCGGCG----- 54
    |||||
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
    |||||
Qy 55 AGTCAGGATATTAGCAGC 72
    |||||
Db 70 SerGlnAspThrSerAsn 75
    |||||

RESULT 5
US-09-880-748-954
; Sequence 954, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR FILING DATE: 2001-06-15
; PRIOR FILING DATE: 2000-06-15
; PRIOR FILING DATE: 2000-10-17
; PRIOR FILING DATE: 2001-03-16
; PRIOR FILING DATE: 2001-03-21
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 954
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-954

Alignment Scores:
Pred. No.: 0.00908          Length: 253
Score: 93.80              Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00%        Indels: 2
```

```
DB: 10 Gaps: 1
NOLAN463-1A.SEQ (1-81) x US-09-880-748-954 (1-253)
Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGGCG----- 54
Db 50 GluileAenHisSerGlySerThrAsnTyAsnProSerLeuAenSerArgValThrIle 69
Qy 55 AGTCAGGATATTAGCAGC 72
Db 70 SerGlnAepThrSerAen 75
RESULT 7
US-10-293-418-954
; Sequence 954, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PFS23P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 954
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-954
Alignment Scores:
Pred. No.: 0.00908 Length: 253
Score: 93.80 Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00% Indels: 2
DB: 15 Gaps: 1
NOLAN463-1A.SEQ (1-81) x US-10-293-418-954 (1-253)
Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGGCG----- 54
Db 50 GluileAenHisSerGlySerThrAsnTyAsnProSerLeuAenSerArgValThrIle 69
Qy 55 AGTCAGGATATTAGCAGC 72
Db 70 SerGlnAepThrSerAen 75
RESULT 8
US-10-078-958-2
; Sequence 2, Application US/10078958
; Publication No. US20030070185A1
; GENERAL INFORMATION:
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: KLAPHOLZ, SUSAN
; APPLICANT: MENDEZ, MICHAEL J.
; APPLICANT: GREEN, LARRY
```

```
; TITLE OF INVENTION: TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING
; TITLE OF INVENTION: PLURAL Vh AND Vk REGIONS AND ANTIBODIES PRODUCED
; FILE REFERENCE: CELL 4.18 CON
; CURRENT APPLICATION NUMBER: US/10/078,958
; CURRENT FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: 08/759,620
; PRIOR FILING DATE: 1996-12-03
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-078-958-2
Alignment Scores:
Pred. No.: 0.0107 Length: 80
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 14 Gaps: 0
NOLAN463-1A.SEQ (1-81) x US-10-078-958-2 (1-80)
Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGGCGAGTCAG 60
Db 33 GluileAenHisSerGlySerThrAsnTyAsnProSerLeuAenSerArgValThr--- 51
Qy 61 GATATTAGC 69
Db 52 ---IleSer 53
RESULT 9
US-10-194-975-40
; Sequence 40, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-40
Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 14 Gaps: 0
NOLAN463-1A.SEQ (1-81) x US-10-194-975-40 (1-97)
Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGGCGAGTCAG 60
Db 50 GluileAenHisSerGlySerThrAsnTyAsnProSerLeuAenSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70
RESULT 10
```

```
US-10-308-817-83
; Sequence 83, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; PRIOR FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-308-817-83

Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-10-308-817-83 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyraProSerLeuLysSerArgValThr--- 68

Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 11
US-10-032-037B-87
; Sequence 87, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-87

Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-10-032-037B-87 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyraProSerLeuLysSerArgValThr--- 68

Qy 61 GATATTAGC 69
Db 69 ---IleSer 70
```

```
Db 69 ---IleSer 70

RESULT 12
US-10-029-988B-87
; Sequence 87, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-87

Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-10-029-988B-87 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyraProSerLeuLysSerArgValThr--- 68

Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 13
US-10-032-423A-87
; Sequence 87, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-87

Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-10-032-423A-87 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
```

Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 14
US-10-453-698-83
; Sequence 83, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-453-698-83

Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-10-453-698-83 (1-97)
Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 15
US-10-029-926B-87
; Sequence 87, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-87

Alignment Scores:
Pred. No.: 0.0112 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

NOLAN463-1A.SEQ (1-81) x US-10-029-926B-87 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

Search completed: August 4, 2005, 18:49:48
Job time : 87.25 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:04:24 ; Search time 18.25 Seconds
(without alignments)
854.089 Million cell updates/sec

Title: NOLAN463-1A.SEQ

Perfect score: 140

Sequence: 1 GAATCATCATAGTGAAG.....ATATTAGCAGCTGGTTAGCC 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 566832

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cgn2 1/USPTO.spool_P/NOLAN08728463-1/runat_04082005_125806_24544/app_query.fasta_1.5
-DB=PIR -OPMT=fastan -SUFFIX=rpr -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEADSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-1 @CGN 1 1 77 @runat_04082005_125806_24544 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAEXT=0.1 -FGAPOP=6
-FGAEXT=0.1 -YGAPOP=10 -YGAEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

PIR_79:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	94	67.1	97	2	S26806 Ig heavy chain V r
2	93.9	67.1	140	2	S78052 Ig heavy chain pre
3	92.4	66.0	97	2	S26898 Ig heavy chain V r
4	92.4	66.0	97	2	S26805 Ig heavy chain V r
5	92.4	66.0	106	2	S37454 Ig mu chain - huma
6	92.4	66.0	122	2	JL0047 Ig heavy chain V r
7	92.4	66.0	126	2	S47010 Ig heavy chain V4.
8	92.4	66.0	133	2	F50341 Ig heavy chain V-D
9	92.4	66.0	140	2	A49045 Ig heavy chain V r
10	92.4	66.0	143	2	B49028 Ig heavy chain V-I
11	92.4	66.0	231	2	B23746 Ig Fab region IV-J
12	88.4	63.1	97	2	G34964 Ig heavy chain V-I
13	84.4	60.3	98	2	S26905 Ig heavy chain V r
14	83.4	59.6	97	2	S14474 Ig heavy chain V r

ALIGNMENTS

RESULT 1

S26806

Ig heavy chain V region - human

C/Species: Homo sapiens (man)

C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000

C/Accession: S26806

R/Wang, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.

Eur. J. Immunol. 22, 1075-1082, 1992

A/Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.

A/Reference number: S26800; MUID:92201299; PMID:1348029

A/Accession: S26806

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-97 <WEN>

A/Cross-references: EMBL:Z14242; NID:g37716; PIDN:CAA78611.1; PID:g1335377

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:

Pred. No.: 0.000964 Length: 97

Score: 94.00 Matches: 17

Percent Similarity: 83.33% Conservative: 3

Best Local Similarity: 70.83% Mismatches: 4

Query Match: 67.14% Indels: 0

DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S26806 (1-97)

Qy 1 GAATCATCATAGTGAAGCACCACCTACACCCGTCCTCAAGAGTCGGCGAGTCAG 60

Db 50 GLUILCAASHISSErGlySerThrAsnProSerLeuLysSerArgIleThrMet 69

Qy 61 GATATTAGCAGC 72

Db 70 SerValAspThr 73

RESULT 2

S78052

Ig heavy chain precursor V-D-J region (clone mAb 63VH) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C/Accession: S78052; S23717
R/Harindranath, N.
Submitted to the EMBL Data Library, August 1990
A/Reference number: S78051
A/Accession: S78052
A/Molecule type: mRNA
A/Residues: 1-140 <HAR>
A/Cross-references: EMBL:X54441; NID:g37815; PIDN:CAA38308.1; PID:g930118
R/Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A/Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.

A/Reference number: S23716; MUID:92031262; PMID:1718404

A/Accession: S23717
A/Molecule type: mRNA
A/Residues: 15-111 <HAW>
A/Cross-references: EMBL:X54441
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: immunoglobulin
F/1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F/15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F/29-111/Domain: immunoglobulin homology <IMM>

Alignment Scores:

Pred. No.:	0.00102	Length:	140
Score:	93.90	Matches:	21
Percent Similarity:	33.85%	Conservative:	1
Best Local Similarity:	32.31%	Mismatches:	2
Query Match:	67.07%	Indels:	41
DB:	2	Gaps:	1

NOLAN463-1A.SEQ (1-81) x S78052 (1-140)

Qy 1 GAATCAATCATAGTGAAGACCACTACACCCGTCCTCAAGAGTCGGCGAGTCAG 60

Db 64 GluileAsnHisSerGlySerThrAsnTyAsnProSerLeuTySerArgValThr--- 82

Qy 61 GATATTAGC----- 69

Db 83 ---IleSerValAspThrSerLysAsnGlnPheSerLeuTySerValThrAla 101

Qy 70 -----AGCTGG 75

Db 102 AlaAspThrAlaValTyrTyrCysAlaArgGlyGlySerValLeuArgPheLeuGluTrp 121

Qy 76 TTA 78

Db 122 Leu 122

RESULT 3

S26898

Ig heavy chain V region (clone DP-63, V(H)4.2) - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C/Accession: S26898; S12420

R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V

A/Reference number: S26885; MUID:93021117; PMID:1404388

A/Accession: S26898

A/Molecule type: DNA

A/Residues: 1-97 <TOM>

A/Cross-references: EMBL:Z12363; NID:g32944; PIDN:CAA78233.1; PID:g32945

R/Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.

EMBO J. 8, 3741-3748, 1989

A/Title: The smaller human V(H) gene families display remarkably little polymorphism.

A/Reference number: S09421; MUID:90059975; PMID:2511001

A/Accession: S12420

A/Status: translation not shown

A/Molecule type: DNA

A/Residues: 1-97 <SAN>

A/Cross-references: EMBL:X56364

A/Experimental source: V(H)4.2

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F/15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:

Pred. No.:	0.00156	Length:	97
Score:	92.40	Matches:	19
Percent Similarity:	74.07%	Conservative:	1
Best Local Similarity:	70.37%	Mismatches:	1
Query Match:	66.00%	Indels:	6
DB:	2	Gaps:	0

NOLAN463-1A.SEQ (1-81) x S26898 (1-97)

Qy 1 GAATCAATCATAGTGAAGACCACTACACCCGTCCTCAAGAGTCGGCGAGTCAG 60

Db 50 GluileAsnHisSerGlySerThrAsnTyAsnProSerLeuTySerArgValThr--- 68

Qy 61 GATATTAGC 69

Db 69 ---IleSer 70

RESULT 4

S26805

Ig heavy chain V region - human

C/Species: Homo sapiens (man)

C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000

C/Accession: S26805

R/Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.

Eur. J. Immunol. 22, 1075-1082, 1992

A/Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.

A/Reference number: S26800; MUID:92201299; PMID:1348029

A/Accession: S26805

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-97 <WEN>

A/Cross-references: EMBL:Z14241; NID:g37714; PIDN:CAA78610.1; PID:g1335376

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F/15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:

Pred. No.:	0.00156	Length:	97
Score:	92.40	Matches:	19
Percent Similarity:	74.07%	Conservative:	1
Best Local Similarity:	70.37%	Mismatches:	1
Query Match:	66.00%	Indels:	6
DB:	2	Gaps:	0

NOLAN463-1A.SEQ (1-81) x S26805 (1-97)

Qy 1 GAATCAATCATAGTGAAGACCACTACACCCGTCCTCAAGAGTCGGCGAGTCAG 60

Db 50 GluileAsnHisSerGlySerThrAsnTyAsnProSerLeuTySerArgValThr--- 68

Qy 61 GATATTAGC 69

Db 69 ---IleSer 70

RESULT 5

S37454

Ig mu chain - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999

C/Accession: S37454

R/McIntosh, R.S.; Tandon, N.; Weetman, A.P.

submitted to the EMBL Data Library, September 1993

A/Description: Cloning and analysis of human IgM anti-Thyroglobulin autoantibodies from I

A:Reference number: S37453
 A:Accession: S37454
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-106 <MCi>
 A:Cross-references: EMBL:X75022; NID:q404311; PIDN:CAA52930.1; PID:g758093
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: immunoglobulin

Alignment Scores:
 Pred. No.: 0.00157 Length: 106
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S37454 (1-106)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 |||||
 Db 28 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLySerArgValThr--- 46
 |||||

Qy 61 GATATTAGC 69

Db 47 ---IleSer 48
 |||||

RESULT 6

JI0047

Ig heavy chain V region precursor (clone cR18) - human

C:Species: Homo sapiens (man)
 C:Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 16-Aug-1996
 C:Accession: JI0047

R:Baer, R.; Forster, A.; Lavenir, I.; Rabbitts, T.H.

J. Exp. Med. 167, 2011-2016, 1988

A:Title: Immunoglobulin V-H genes are transcribed by T cells in association with a new 5'

A:Reference number: JI0047; PMID:88258392; PMID:3133445

A:Accession: JI0047

A:Molecule type: mRNA

A:Residues: 1-122 <BAE>

A:Experimental source: T-cell line RPMI 8402

A:Note: the authors translated the reading frame which extends to the stop codon; the se

A:Note: this sequence belongs to the VH II subgroup

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:23-105/Domain: immunoglobulin homology <IMM>

Alignment Scores:
 Pred. No.: 0.00159 Length: 122
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x JI0047 (1-122)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 |||||
 Db 58 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLySerArgValThr--- 76
 |||||

Qy 61 GATATTAGC 69

Db 77 ---IleSer 78
 |||||

RESULT 7

S47010

Ig heavy chain V4.21-UniqueD-J5 region - human

C:Species: Homo sapiens (man)

C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999

C:Accession: S47010

R:Mamoudi, M.; Gasyna, E.; Denomme, G.; Edwards, J.; Bell, D.; Cairns, E.

submitted to the EMBL Data Library, July 1994

A:Description: The role of the immunoglobulin heavy chain in human anti-DNA antibody bin
 A:Reference number: S47009
 A:Accession: S47010
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-126 <MBH>
 A:Cross-references: EMBL:Z35492; NID:9517254; PIDN:CAA84625.1; PID:g517255
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
 Pred. No.: 0.00159 Length: 126
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S47010 (1-126)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 |||||
 Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLySerArgValThr--- 68
 |||||

Qy 61 GATATTAGC 69

Db 69 ---IleSer 70
 |||||

RESULT 8

PS0341

Ig heavy chain V-D-J region (RAMOS) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-May-1997

C:Accession: PS0341

R:Ratech, H.

Biochem. Biophys. Res. Commun. 182, 1260-1263, 1992

A:Title: Rapid cloning of rearranged immunoglobulin heavy chain genes from human B-cell

A:Reference number: PS0341; PMID:92171937; PMID:1540170

A:Accession: PS0341

A:Molecule type: mRNA

A:Residues: 1-133 <RAT>

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:9-38/Region: framework 1

F:39-43/Region: complementarity-determining 1

F:44-57/Region: framework 2

F:58-74/Region: complementarity-determining 2

F:75-106/Region: framework 3

Alignment Scores:
 Pred. No.: 0.0016 Length: 133
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x PS0341 (1-133)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 |||||
 Db 58 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLySerArgValThr--- 76
 |||||

Qy 61 GATATTAGC 69

Db 77 ---IleSer 78
 |||||

RESULT 9

A49045

Ig heavy chain V region (anti-B cell autoantibody) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999

C;Accession: A49045
R;Grillot-Courvalin, C.; Brouet, J.C.; Piller, F.; Rassenti, L.Z.; Labaume, S.; Silverma
Eur. J. Immunol. 22, 1781-1788, 1992
A;Title: An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i bl
A;Reference number: A49045; MUID:92324290; PMID:1623923
C;Accession: A49045
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-140 <RI>
A;Cross-references: GB:S39381; NID:9250899; PIDN:AAB2441.1; PID:9250900
A;Note: sequence extracted from NCBI backbone (NCBIN:108088, NCBI:P:108089)
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;34-116/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00161 Length: 140
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x A49045 (1-140)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 69 GluileAsnHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 87
:::

Qy 61 GATATTAGC 69
Db 88 ---IleSer 89
|||||

RESULT 10

B49028
Ig heavy chain V-IV region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999
C;Accession: B49028
R;Timmers, E.; Kenter, M.; Thompson, A.; Kraakman, M.E.; Berman, J.E.; Alt, F.W.; Schuur
Eur. J. Immunol. 21, 2355-2363, 1991
A;Title: Diversity of immunoglobulin heavy chain gene segment rearrangement in B lymphob
A;Reference number: A49028; MUID:92008140; PMID:1915549
C;Accession: B49028
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-143 <TIM>
A;Cross-references: GB:S64473; NID:g236906; PIDN:AAB20012.1; PID:g236907
A;Experimental source: X-linked agammaglobulinemia patients, B lymphoblastoid cell lines
A;Note: sequence extracted from NCBI backbone (NCBIN:64473, NCBI:P:64472)
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00161 Length: 143
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x B49028 (1-143)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileAsnHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
:::

Qy 61 GATATTAGC 69
Db 69 ---IleSer 70
|||||

RESULT 11

B23746

Ig Fab region IV-J(H4)-C (KAU cold agglutinin) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 21-Jan-2000
C;Accession: B23746
R;Leoni, J.; Ghiso, J.; Goni, F.; Frangione, B.
J. Biol. Chem. 266, 2836-2842, 1991
A;Title: The primary structure of the Fab fragment of protein KAU, a monoclonal immunogl
A;Reference number: A23746; MUID:9111575; PMID:1993660
A;Accession: B23746
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-231 <LEO>
C;Superfamily: immunoglobulin C region; immunoglobulin homology
F;140-209/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00167 Length: 231
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x B23746 (1-231)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 49 GluileAsnHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 67
:::

Qy 61 GATATTAGC 69
Db 68 ---IleSer 69
|||||

RESULT 12

G34964
Ig heavy chain V-IV region (Ab44) - human
C;Species: Homo sapiens (man)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
C;Accession: G34964
R;Sanz, I.; Casali, P.; Thomas, J.W.; Notkins, A.L.; Capra, J.D.
J. Immunol. 142, 4054-4061, 1989
A;Title: Nucleotide sequences of eight human natural autoantibody V-H regions reveals ap
A;Reference number: A92830; MUID:89235232; PMID:2497188
C;Accession: G34964
A;Molecule type: mRNA
A;Residues: 1-97 <SAN>
A;Cross-references: UNIPROT:Q8WUX4; GB:M26998
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00524 Length: 97
Score: 88.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 63.14% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x G34964 (1-97)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCCCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileAsnHisSerGlyThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
:::

Qy 61 GATATTAGC 69
Db 69 ---IleSer 70
|||||

RESULT 13

S26905
Ig heavy chain V region (DP-70 / 4.19) - human (fragment)


```
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26905; S1474
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26905
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: EMBL:Z12370; NID:g32960; PIDN:CAA78240.1; PID:g32961
A;Note: designated DP-70
R;Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A;Title: The smaller human V(H) gene families display remarkably little polymorphism.
A;Reference number: S09421; MUID:90059975; PMID:2511001
A;Accession: S12419
A;Status: preliminary; translation not shown
A;Molecule type: DNA
A;Residues: 1-98 <SAN>
A;Cross-references: EMBL:X56363
A;Note: designated 4.19
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0176 Length: 98
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservatives: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S26905 (1-98)

Qy 1 GAATCAATCATAGTGAAGACCAACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 51 GluileTyHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 69
Qy 61 GATATTAGC 69
Db 70 ---IleSer 71

RESULT 14
S14474
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C;Accession: S14474
R;van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derksen, R.H.
submitted to the EMBL Data Library, November 1990
A;Reference number: S14474
A;Accession: S14474
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <ESJ>
A;Cross-references: EMBL:X56591; NID:g37235; PIDN:CAA39929.1; PID:g1335354
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0238 Length: 97
Score: 83.40 Matches: 18
Percent Similarity: 70.37% Conservatives: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 59.57% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S14474 (1-97)

C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26905; S12419
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26905
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: EMBL:Z12370; NID:g32960; PIDN:CAA78240.1; PID:g32961
A;Note: designated DP-70
R;Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A;Title: The smaller human V(H) gene families display remarkably little polymorphism.
A;Reference number: S09421; MUID:90059975; PMID:2511001
A;Accession: S12419
A;Status: preliminary; translation not shown
A;Molecule type: DNA
A;Residues: 1-98 <SAN>
A;Cross-references: EMBL:X56363
A;Note: designated 4.19
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0176 Length: 98
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservatives: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S26905 (1-98)

Qy 1 GAATCAATCATAGTGAAGACCAACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 51 GluileTyHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 69
Qy 61 GATATTAGC 69
Db 70 ---IleSer 71

RESULT 15
S44114
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C;Accession: S44114
R;Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A;Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r
A;Reference number: S44105
A;Accession: S44114
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-129 <HAW>
A;Cross-references: EMBL:Z31579; NID:g472968; PIDN:CAA83451.1; PID:g940525
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0444 Length: 129
Score: 81.40 Matches: 17
Percent Similarity: 67.86% Conservatives: 2
Best Local Similarity: 60.71% Mismatches: 3
Query Match: 58.14% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x S44114 (1-129)

Qy 1 GAATCAATCATAGTGAAGACCAACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
Db 51 GluileTyHisSerGlySerThrAsnTyAsnProSerPheLysSerArgValThr--- 69
Qy 61 GATATTAGCAGC 72
Db 70 ---IleSerAla 72

Search completed: August 4, 2005, 18:21:23
Job time : 20:25 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 17:55:57 ; Search time 83.75 Seconds
(without alignments)
990.529 Million cell updates/sec

Title: NOLAN463-1A.SEQ

Perfect score: 140

Sequence: 1 GAAATCAATCATAGTGAAG.....ATATTAGCAGCTGGTAGCC 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 3224756

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODE=frame+n2p.model -DEV=xlp
-O=/cgn2.1/USPTO.spool_p/NOLAN08728463-1/runat_04082005_125806_24533/app_query.fasta_1.5
-DB=UniProt -QFMT=fastan -SUFFIX=rup -MINMATCH=0.1 -LOOFCU=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=-1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
-DOCALLIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN08728463-1@cgn.1.1.305 @runat_04082005_125806_24533 -NCPU=6
-ICPU=3 -NO MWAP -LARGEQUERY -NEG SCORES=0 -WAIT -DISPATCH=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : UniProt 03:.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	92.4	66.0	116	2 Q7Z3Y6	Q7Z3Y6 homo sapien
2	92.4	66.0	595	2 Q8WUX4	Q8WUX4 homo sapien
3	92.4	66.0	597	2 Q6GMX5	Q6GMX5 homo sapien
4	92.4	66.0	597	2 Q9BU10	Q9BU10 homo sapien
5	92.4	66.0	625	2 Q96AA6	Q96AA6 homo sapien
6	86.4	61.7	597	2 Q9BOB8	Q9BOB8 homo sapien
7	84.4	60.3	575	2 Q6P418	Q6P418 homo sapien
8	81.3	58.1	477	2 Q6GMX7	Q6GMX7 homo sapien
9	78.4	56.0	146	1 HV21 HUMAN	Q6GMX7 homo sapien
10	73.7	52.6	139	2 Q86SX2	P06331 homo sapien
11	72.6	51.9	479	2 Q9NM22	Q86SX2 homo sapien
12	72	51.4	465	2 Q6GMX6	Q9NM22 mus musculus
13	72	51.4	620	2 Q96EY0	Q6GMX6 homo sapien
14	70.6	50.4	262	2 Q65Z11	Q96EY0 homo sapien
15	69.3	49.5	119	2 Q9UL73	Q65Z11 mus musculus
16	69.1	49.4	113	1 HV47_MOUSE	Q9UL73 homo sapien
					P01823 mus musculus

17	69	49.3	116	1 HV61_MOUSE	P18532 mus musculus
18	67.4	48.1	2348	2 Q8Z027	Q8Z027 anabaena sp
19	66.9	47.8	476	2 Q6GMX1	Q6GMX1 homo sapien
20	65	46.4	116	1 HV60_MOUSE	P18531 mus musculus
21	65	46.4	478	2 Q6NVH3	Q6NVH3 homo sapien
22	64	45.7	478	2 Q7Z379	Q7Z379 homo sapien
23	60.8	43.4	3118	2 O17575	Q17575 caenorhabdi
24	59.5	42.5	1160	1 TFC3_YEAST	P34111 saccharomyc
25	59.4	42.4	150	2 Q95973	Q95973 homo sapien
26	59.1	39.7	274	2 Q9FL48	Q9FL48 arabidopsais
c	59	42.1	136	2 Q6LB05	Q6LB05 mus musculus
27	59	42.1	137	1 HV45_MOUSE	P01822 mus musculus
28	59	42.1	209	1 UPP_OCEIH	Q8EM74 oceanobacil
29	58.7	41.9	209	2 Q8XWU0	Q8XWU0 ralsstonia s
c	58.6	39.3	451	2 Q6NGD8	Q6NGD8 corynebacte
30	58.6	39.3	467	1 DPO4_CORGL	Q8NNP4 corynebacte
c	57.8	41.3	1083	1 KG88_HUMAN	Q9C0H5 homo sapien
32	57.5	41.1	393	2 Q7WZ77	Q7WZ77 nonomurea
33	57.5	41.1	963	2 Q8P5M2	Q8P5M2 xanthomonas
34	57.5	41.1	963	2 Q8P5M2	Q8P5M2 xanthomonas
35	57.4	41.0	496	2 Q96KX8	Q96KX8 homo sapien
c	57.2	40.9	729	1 DCMA_MOOTH	P27988 moorella th
37	57	38.3	337	2 Q6LOH3	Q6LOH3 picophilus
38	57	40.7	1916	2 Q9VKG8	Q9VKG8 drosophila
39	56.7	40.5	212	2 Q926K5	Q926K5 listeria in
40	56.6	40.4	360	2 Q92UL5	Q92UL5 rhizobium m
41	56.6	40.4	408	1 YBX0_ARATH	Q9ZQ34 arabidopsais
42	56.4	40.3	390	2 Q6HH60	Q6HH60 bacillus th
43	56.4	40.3	545	2 Q6HH58	Q6HH58 bacillus th
44	56.4	40.3	588	2 Q813F9	Q813F9 bacillus ce
45	56.4	40.3	588	2 Q813F9	Q813F9 bacillus ce

ALIGNMENTS

RESULT 1
Q7Z3Y6 PRELIMINARY; PRT; 116 AA.
ID Q7Z3Y6
AC Q7Z3Y6; (T-EMBLrel. 25, Created)
DT 01-OCT-2003 (T-EMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (T-EMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (T-EMBLrel. 26, Last annotation update)
DE Rearranged VH4-34 V gene segment (Fragment).
GN Names:VH4-34;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hodgkin lymphoma;
RA Tinguely M., Rosenquist R., Sundstroem C., Amini R.M., Kuppers R.,
RA Hansmann M.L., Brauning A.,
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ564425; CAD92032.1; .
DR HSSP; P18532; IKCV.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
SQ SEQUENCE 116 AA; 12902 MW; CE3D8A84616C908 CRC64;

Alignment Scores:
Pred. No.: 0.00339 Length: 116
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x Q7Z3Y6 (1-116)

QY 1 GAAATCAATCATAGTGAAGCACCACCACTACCAACCGTCCCTCAAGAGTCGGGCGAGTCAG 60


```
Db 69 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 87
|||
Qy 61 GATATTAGC 69
|||
Db 88 ---IleSer 89

RESULT 4
Q9BU10 PRELIMINARY; PRT; 597 AA.
AC Q9BU10;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE IGM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., McQuillan N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (FEB-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC002963; AAH02963.1; -
DR HSSP; P01861; IADQ.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65274 MW; 2DAFA8FB7E055851 CRC64;

Alignment Scores:
Pred. No.: 0.00427 Length: 597
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x Q9BU10 (1-597)
```

```
Qy 1 GAAATCAATCATAGTGGAGACCACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 69 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 87
|||
```

```
Qy 61 GATATTAGC 69
|||
Db 88 ---IleSer 89

RESULT 5
Q96AA6 PRELIMINARY; PRT; 625 AA.
AC Q96AA6;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., McQuillan N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (NOV-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC017356; AAH17356.2; -
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 625 AA; 68610 MW; F62FAB3ADE7ECBFE CRC64;

Alignment Scores:
Pred. No.: 0.00429 Length: 625
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x Q96AA6 (1-625)
```

```
Qy 1 GAAATCAATCATAGTGGAGACCACTACAAACCCGTCCTCAAGAGTCGGCGAGTCAG 60
```

```
|||||
76 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 94
:::
QY 61 GATATTAGC 69
|||||
Db 95 ---Ileser 96
|||||

RESULT 6
Q9BQB8 PRELIMINARY; PRT; 597 AA.
ID Q9BQB8
AC Q9BQB8
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC006180; AAH06180.1; -.
DR HSP; P01861; IADQ.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65300 MW; 2DAFAD50A6375851 CRC64;

Alignment Scores:
Pred. No.: 0.0281 Length: 597
Score: 86.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 61.71% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x Q9BQB8 (1-597)

QY 1 GAATCAATCATAGTGAAGCACCACCTACACCCCTCCCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 69 GluileAsnHisSerGlyIleThrAsnTyrAsnProSerLeuLysSerArgValThr--- 87
:::
```

```
QY 61 GATATTAGC 69
|||||
Db 88 ---Ileser 89
|||||

RESULT 7
Q6P4I8 PRELIMINARY; PRT; 576 AA.
ID Q6P4I8
AC Q6P4I8
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHM protein.
GN Name=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -.
DR HSP; P01820; IA7N.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00047; IGV; 1.
DR SMART; SM00409; IGV; 1.
DR SMART; SM00407; IGV; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63363 MW; FBB97C949D720F1E CRC64;

Alignment Scores:
Pred. No.: 0.0524 Length: 576
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 2 Gaps: 0

NOLAN463-1A.SEQ (1-81) x Q6P4I8 (1-576)
```

QY 1 GAATCAATCATAGTGAAGACCACTAGACACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 Db 77 GluileThyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 95
 QY 61 GATATTAGC 69
 Db 96 ---IleSer 97

RESULT 8
 Q6GMX7 PRELIMINARY; PRT; 477 AA.

AC Q6GMX7
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RX MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603999;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RA Strausberg R.;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC073765; AAH73765.1; -.
 DR InterPro; IPR003597; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig v.
 DR Pfam; PF07654; Cl-set; 2.
 DR Pfam; PF00047; Ig; 3.
 DR SMART; SM00409; Ig; 4.
 DR SMART; SM00407; IGcl; 3.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PSS0835; IG LIKE; 4.
 DR PROSITE; PSS0290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 477 AA; 51631 MW; 9FE59C09C50CF85 CRC64;

Alignment Scores:
 Pred. No.: 0.135 Length: 477
 Score: 81.30 Matches: 17
 Percent Similarity: 39.22% Conservative: 3
 Best Local Similarity: 33.33% Mismatches: 4
 Query Match: 58.07% Indels: 27
 DB: 2 Gaps: 1

NOLAN463-1A.SEQ (1-81) x Q6GMX7 (1-477)
 QY 4 ATCAATCATAGTGAAGACCACTAGACACCGTCCCTCAAGAGTCGGCGAGTCAG 63
 Db 70 IleSerHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrLeuSer 89
 QY 64 ATT----- 66
 Db 90 LeuAspThrSerLysAsnGlnPheSerLeuArgLeuAsnSerValThrAlaAlaAspThr 109
 QY 67 -----AGCAGCTGG 75
 Db 110 AlaValTyrTyrCysAlaHisGlySerSerTirp 120

RESULT 9
 HV2I_HUMAN STANDARD; PRT; 146 AA.
 ID HV2I_HUMAN
 AC P06331;
 DT 01-JAN-1988 (Rel. 06, Created)
 DT 01-JAN-1988 (Rel. 06, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Ig heavy chain V-II region ARH-77 precursor.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=85205332; PubMed=3922855; DOI=10.1016/0378-1119(85)90092-7;
 RA Kudo A., Ishihara T., Nishimura Y., Watanabe T.;
 RT "A cloned human immunoglobulin heavy chain gene with a novel direct-
 repeat sequence in 5' flanking region.";
 RL Gene 33:181-189 (1985).
 DR PIR; A02101; GIHUH2.
 DR HSP; P01825; 7FAB
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003823; F:antigen binding; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig v.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00406; IGv; 1.
 DR PROSITE; PSS0835; IG LIKE; 1.
 KW Immunoglobulin V region; Signal.
 RN SIGNAL 1 19
 FT CHAIN 20 146 Ig heavy chain V-II region ARH-77.
 FT DOMAIN 20 117 V segment.
 FT DOMAIN 118 127 D segment.
 FT DOMAIN 128 146 J segment.
 FT DISULFID 42 115 By similarity.
 FT NON TER 146 146
 SQ SEQUENCE 146 AA; 16228 MW; 8D7PD52BB218171F CRC64;

Alignment Scores:
 Pred. No.: 0.285 Length: 146
 Score: 78.40 Matches: 17
 Percent Similarity: 66.67% Conservative: 1
 Best Local Similarity: 62.96% Mismatches: 3
 Query Match: 56.00% Indels: 6
 DB: 1 Gaps: 0

NOLAN463-1A.SEQ (1-81) x HV2I_HUMAN (1-146)
 QY 1 GAATCAATCATAGTGAAGACCACTAGACACCGTCCCTCAAGAGTCGGCGAGTCAG 60
 Db 70 GluileAsnHisSerGlySerThrAsnTyrLysThrSerLeuLysSerArgValThr--- 88
 QY 61 GATATTAGC 69
 Db 89 ---IleSer 90

RESULT 10
 Q86SX2

```

ID Q86SX2 PRELIMINARY; PRT; 139 AA.
AC Q86SX2;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Full-length cDNA clone CSDDL004YM19 of B cells (Ramos cell line) of
DE Homo sapiens (human) (Fragment).
OS Homo sapiens (human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=B cells;
RA Li W.B., Gruber C., Jesse J., Polayes D.;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=B cells;
RA Genoscope;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX248300; CAD62627.1; -.
DR HSP; P01820; IG7J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
SQ SEQUENCE 139 AA; 15573 MW; 7D1E2302410E4F8C CRC64;

Alignment Scores:
Pred. No.: 1-24 Length: 139
Score: 73.70 Matches: 17
Percent Similarity: 35.71% Conservative: 3
Best Local Similarity: 30.36% Mismatches: 33
Query Match: 52.64% Indels: 33
DB: 2 Gaps: 1

NOLAN463-1A.SEQ (1-81) x Q86SX2 (1-139)
QY 4 ATCAATCATAGTGAAGACCAACTACACCGCTCCCTCAAGAGTCGGCGAGT----- 57
|||:::|||||
DB 83 IleTyrTyrSerGlySerThrAsnTyrAsnProSerSerLeuLysSerArgValThrIleSer 102
|||:::|||||
QY 57 ----- 57

DB 103 ValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAspThr 122
QY 58 -----CAGGATATTAGCAGC 72
|||:::|||||
DB 123 AlaValTyrTyrCysAlaArgAspThrValArgGlyAspValSerSer 138

RESULT 11
Q99M22 PRELIMINARY; PRT; 479 AA.
AC Q99M22;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=mix FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

```

```

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Arnason R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skaleka U., Smallus D.E., Schnerch A., Schein J.B.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=mix FVB/N; TISSUE=Mammary tumor;
RA Strausberg R.;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002091; AA02091.1; -.
DR HSP; P01820; IG7J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Alignment Scores:
Pred. No.: 2-08 Length: 479
Score: 72.60 Matches: 17
Percent Similarity: 33.93% Conservative: 2
Best Local Similarity: 30.36% Mismatches: 4
Query Match: 51.86% Indels: 34
DB: 2 Gaps: 1

NOLAN463-1A.SEQ (1-81) x Q99M22 (1-479)
QY 4 ATCAATCATAGTGAAGACCAACTACACCGCTCCCTCAAGAGTCGGCGAGTCA---- 59
|||:::|||||
DB 70 IleAsnTyrAspGlySerAsnTyrAsnProSerSerLeuLysAsnArgIleSerIleThr 89
|||:::|||||
QY 59 ----- 59

DB 90 ArgAspThrSerLysAsnGlnPhePheLeuLysLeuAsnSerValThrThrGluAspThr 109
QY 60 -----GGATATTAGCAGCTGG 75
|||:::|||||
DB 110 AlaThrTyrTyrCysAlaSerArgGlyTyr-----SerTrp 121

RESULT 12
Q6GMX6 PRELIMINARY; PRT; 465 AA.
AC Q6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

```


RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Touchman J.W., Green E.D., Dickson M.C.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: BC073766; AAH73766.1; -.
DR InterPro: IPR003599; Ig-like.
DR InterPro: IPR007110; Ig-cl.
DR InterPro: IPR003597; Ig-cl.
DR InterPro: IPR003006; Ig MHC.
DR InterPro: IPR003596; Ig v.
DR Pfam: PF07654; Cl-set; 3.
DR Pfam: PF00047; Ig; 4.
DR SMART: SM00409; IG; 2.
DR SMART: SM00407; IG1; 3.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 4.
DR PROSITE: PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;
Alignment Scores: 2.5 Length: 465
Pred. No.: 72.00 Matches: 13
Score: 80.00% Conservative: 3
Percent Similarity: 80.00%
Best Local Similarity: 65.00%
Query Match: 51.43%
Indels: 0
Gaps: 0
DB: 2

NOLAN463-1A.SEQ (1-81) x Q6GMX6 (1-465)

QY 13 AGTGAAGACCAACTACACCGCTCCCTCAAGAGTCGGCGAGTCAGGATATTAGCAGC 72
|||||
Db 73 SerGlySerThrAsnProSerLeuLysSerArgValThrMetSerValAspThr 92
|||||

RESULT 13
Q96EYO PRELIMINARY; PRT; 620 AA.
AC Q96EYO
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Touchman J.W., Green E.D., Dickson M.C.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: BC011857; AAH11857.2; -.
DR PIR: S15590; S15590.
DR HSP: P01820; IG7J
DR InterPro: IPR003599; Ig.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003597; Ig-cl.
DR InterPro: IPR003006; Ig MHC.
DR InterPro: IPR003596; Ig v.
DR Pfam: PF07654; Cl-set; 4.
DR SMART: SM00409; IG; 2.
DR SMART: SM00407; IG1; 4.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG LIKE; 5.
DR PROSITE: PS00290; IG_MHC; UNKNOWN_3.
SQ SEQUENCE 620 AA; 68125 MW; 990A1A4A6E8FF27B CRC64;
Alignment Scores: 2.61 Length: 620
Pred. No.: 72.00 Matches: 13
Score: 80.00% Conservative: 3
Percent Similarity: 80.00%
Best Local Similarity: 65.00%
Query Match: 51.43%
Indels: 0
Gaps: 0
DB: 2

NOLAN463-1A.SEQ (1-81) x Q96EYO (1-620)

QY 13 AGTGAAGACCAACTACACCGCTCCCTCAAGAGTCGGCGAGTCAGGATATTAGCAGC 72
|||||
Db 80 SerGlySerThrAsnProSerLeuLysSerArgValThrMetSerValAspThr 99
|||||

RESULT 14
Q65ZIL PRELIMINARY; PRT; 262 AA.
AC Q65ZIL
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Anti-HIV-1 reverse transcriptase single-chain variable.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hybridoma;
RX MEDLINE=96211469; PubMed=8648670;
RA Shaheen F., Duan L., Zhu M., Bagasra O., Pomerantz R.J.;
RT "Targeting human immunodeficiency virus type 1 reverse transcriptase
RT by intracellular expression of single-chain variable fragments to
RT inhibit early stages of the viral life cycle.";
RL J. Virol. 70:3392-3400(1996).
DR EMBL: U48716; AAB64342.1; -.

DR GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA.

DR InterPro; IPR003599; Ig-like.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003598; Ig_c2.

DR Pfam; PF00047; Ig; 2.

DR SMART; SM00409; IG; 2.

DR SMART; SM00408; IGC2; 2.

DR SMART; SM00406; IGV; 2.

DR PROSITE; PS50835; IG LIKE; 2.

KW RNA-directed DNA polymerase.

SQ SEQUENCE 262 AA; 27842 MW; 7DF20138E53865E4 CRC64;

Alignment Scores:

Pred. No.:	3.59	Length:	262
Score:	70.60	Matches:	16
Percent Similarity:	68.00%	Conservative:	1
Best Local Similarity:	64.00%	Mismatches:	4
Query Match:	50.43%	Indels:	4
DB:	2	Gaps:	0

NOLAN463-1A.SEQ (1-81) x Q65211 (1-262)

Qy	4	ATCAATCATAGTGGAGACCACTACAACCCGTCCTCAAGAGTCGGGCGAGTCAGGAT	63
Db	198	IleAsnTySerGlyAspThrTyTyrAsnProSerLeuLysSerArgIleSer----	216
Qy	64	ATTAGCA 70	
Db	216	eThrAla 218	

RESULT 15

Q9UL73	PRELIMINARY;	PRT;	119 AA.
AC Q9UL73;			
DT 01-MAY-2000	(TrEMBLrel. 13, Created)		
DT 01-MAY-2000	(TrEMBLrel. 13, Last sequence update)		
DT 01-MAR-2004	(TrEMBLrel. 26, Last annotation update)		
DE	Myosin-reactive immunoglobulin heavy chain variable region (Fragment).		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX	NCBI_TaxID=9606;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RX	MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;		
RA	Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,		
RA	Young D.C.;		
RT	"Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";		
RL	Clin. Immunol. Immunopathol. 87:184-192 (1998).		
DR	EMBL; AF035041; AAD56277.1; -.		
DR	PIR; PH0876; PH0876.		
DR	PIR; S12416; S12416.		
DR	HSP; P01820; I67J.		
DR	InterPro; IPR007110; Ig-like.		
DR	InterPro; IPR003596; IG_V.		
DR	SMART; SM00406; IGV; 1.		
DR	PROSITE; PS50835; IG LIKE; 1.		
FT	NON_TER 1		
FT	NON_TER 119		
SQ	SEQUENCE 119 AA; 13219 MW; 1BDB86B6420EA0BE CRC64;		

Alignment Scores:

Pred. No.:	4.84	Length:	119
Score:	69.30	Matches:	15
Percent Similarity:	37.25%	Conservative:	4
Best Local Similarity:	29.41%	Mismatches:	5
Query Match:	49.50%	Indels:	27
DB:	2	Gaps:	1

*, NOLAN463-1A.SEQ (1-81) x Q9UL73 (1-119)

Qy	4	ATCAATCATAGTGGAGACCACTACAACCCGTCCTCAAGAGTCGGGCGAGTCAGGAT	63
Db	51	IleTyTySerGlySerThrAsnTyThrProSerLeuLysSerArgValThrIleSer	70
Qy	64	ATT-----	66
Db	71	ValAspArgSerLysAsnGlnPheSerLeuLysLeuThrSerLeuThrAlaAlaAspThr	90
Qy	67	-----ACGAGCTGG	75
Db	91	AlaValTyPheCysAlaArgLeuSerAsnTrp	101

Search completed: August 4, 2005, 18:20:06

Job time : 89.75 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 17:55:32 ; Search time 92.5 Seconds
(without alignments)
677.353 Million cell updates/sec

Title: NOLAN463-1B.SEQ

Perfect score: 140

Sequence: 1 CGGCGAGTCAGGATATTAG.....ACAAACCGTCCTCTCAAGAGT 81

Scoring table:

BLOSUM62
Q=10.0, Xgapext 0.1
Ygapop 10.0, Ygapext 0.1
Fgapop 6.0, Fgapext 0.1
Delop 6.0, Delext 0.1

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 4211384

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2.1/USPTO.spool.p/NOLAN08728463-1/runat_04082005.125805.24527/app.query.fasta_1.5
-DB-A Geneseq -QFNT=fastan -SUFFIX=rag -MINMATCH=0.1 -LOOPEXT=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THRM SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-1 @CGN 1.1.308 @runat_04082005.125805.24527 -NCPUG=6
-ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

- 1: Geneseq16Dec04:*
- 2: Geneseq1980s:*
- 3: Geneseq1990s:*
- 4: Geneseq2000s:*
- 5: Geneseq2001s:*
- 6: Geneseq2002s:*
- 7: Geneseq2003as:*
- 8: Geneseq2003bs:*
- 9: Geneseq2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	100.1	71.5	253	5	ABP45322 Human Bly
2	100.1	71.5	253	7	Adg96149 Single ch
3	99.9	71.4	125	6	AdA89274 Human ant
4	98.2	70.1	80	2	AAW62794 Amino aci
5	98.2	70.1	97	2	AAy05694 Multiple
6	98.2	70.1	97	5	ABg78212 Human Fv
7	98.2	70.1	97	5	ABg91903 Human ant
8	98.2	70.1	97	6	ABO27107 Human ger
9	98.2	70.1	97	7	ABD75646 Human pro
10	98.2	70.1	97	7	ADD28104 Lymphoma

11	98.2	70.1	97	7	ADF10048	Adf10048 VEGF anti
12	98.2	70.1	97	7	ADF10150	Adf10150 Antitbody
13	98.2	70.1	97	7	ADF09942	Adf09942 Antitbody
14	98.2	70.1	97	7	ADJ80323	Adj80323 VH gene 1
15	98.2	70.1	114	3	AAB01949	Aab01949 Anti-Id1
16	98.2	70.1	114	3	AAB01950	Aab01950 Anti-Id1
17	98.2	70.1	114	3	AAB01953	Aab01953 Anti-Id1
18	98.2	70.1	114	3	AAB01959	Aab01959 High affi
19	98.2	70.1	114	3	AAB01952	Aab01952 Anti-Id1
20	98.2	70.1	114	3	AAB01955	Aab01955 Streptativ
21	98.2	70.1	114	3	AAB01956	Aab01956 Streptativ
22	98.2	70.1	114	3	AAB01948	Aab01948 Wild-type
23	98.2	70.1	114	3	AAB01954	Aab01954 Anti-Id1
24	98.2	70.1	114	7	ADG70086	Adg70086 Diversifi
25	98.2	70.1	114	7	ADG70013	Adg70013 Diversifi
26	98.2	70.1	116	2	AAR66324	Aar66324 Human imm
27	98.2	70.1	117	4	AAM60904	Aam60904 Human bra
28	98.2	70.1	117	4	ABG55317	Abg55317 Human liv
29	98.2	70.1	117	5	ABG43454	Abg43454 Human pep
30	98.2	70.1	118	6	ADA89246	Ada89246 Human ant
31	98.2	70.1	122	7	ADK17418	Adk17418 Anti-huma
32	98.2	70.1	122	8	ADG42840	Adg42840 scFv Ab12
33	98.2	70.1	123	2	AAW03757	Aaw03757 Anti-rhes
34	98.2	70.1	125	6	ADA89266	Ada89266 Human ant
35	98.2	70.1	139	3	AAy99556	Aay99556 Human LHL
36	98.2	70.1	139	6	ABR42859	AbR42859 Tumour-sp
37	98.2	70.1	139	7	ABW02445	Abw02445 Human mon
38	98.2	70.1	142	6	ABP96287	Abp96287 Anti-hTNF
39	98.2	70.1	154	6	ABP96293	Abp96293 Human ant
40	98.2	70.1	190	2	AAy34304	Aay34304 IGM antib
41	98.2	70.1	202	2	AAy34303	Aay34303 IGM antib
42	98.2	70.1	205	2	AAy34299	Aay34299 IGM antib
43	98.2	70.1	218	7	ADG70090	Adg70090 Diversifi
44	98.2	70.1	223	7	ADJ32112	Adj32112 Human int
45	98.2	70.1	224	7	ADG70088	Adg70088 Diversifi

ALIGNMENTS

RESULT 1

ABP45322
ID ABP45322 standard; protein; 253 AA.

XX ABP45322;

DT 19-AUG-2002 (first entry)

DE Human BlyS binding scFv SEQ ID 1333.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US019110.

XX 16-JUN-2000; 2000US-0212210P.

XX 17-OCT-2000; 2000US-0240816P.

XX 16-MAR-2001; 2001US-0276248P.

XX 21-MAR-2001; 2001US-0277379P.

XX 25-MAY-2001; 2001US-0293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX immunoglobulin; Ig; heavy chain variable domain;
KW light chain variable domain; major histocompatibility complex; MHC;
KW gp100; MUC1; TAX; hTERT; cytostatic; gene therapy; cancerous disorder;
KW cancer.
XX Synthetic.
OS Homo sapiens.
XX WO2003070752-A2.
XX 28-AUG-2003.
XX 20-FEB-2003; 2003WO-US005128.
XX 20-FEB-2002; 2002US-0358994P.
XX (DYAX-) DYAX CORP.
XX (TECR) TECHNION RES & DEV FOUND LTD.
XX Hoogenboom HRJM, Reiter Y;
XX WPI; 2003-663847/62.
XX N-PSDB; ADA89273.
XX New protein comprising an immunoglobulin heavy chain variable (VH) domain
PT and an immunoglobulin light chain variable (VL) domain, useful for
PT preparing a composition for treating or preventing a cancerous disorder.
XX Disclosure; Fig 28B; 224pp; English.

XX The present invention describes a protein comprising an immunoglobulin
CC (Ig) heavy chain variable (VH) domain and an Ig light chain variable (VL)
CC domain. The protein binds a complex comprising a major histocompatibility
CC complex (MHC) and a peptide, does not substantially bind the MHC in the
CC absence of the bound peptide, and does not substantially bind the peptide
CC in the absence of the MHC. The peptide is a peptide fragment of gp100,
CC MUC1, TAX or hTERT. Also described: (1) a pharmaceutical composition
CC comprising the novel protein and a carrier; (2) a cytotoxic T cell
CC comprising one or more nucleic acids for expressing the Ig that binds a
CC complex having an MHC and a peptide, does not substantially bind the MHC
CC in the absence of the bound peptide, and does not substantially bind the
CC peptide in the absence of the MHC; (3) an isolated nucleic acid
CC comprising a first segment that encodes the Ig variable domain; (4) a
CC host cell comprising heterologous nucleic acid sequences that encodes the
CC novel protein; (5) a transgenic animal whose genome includes heterologous
CC nucleic acid sequences that encode the protein; (6) identifying the
CC protein that specifically binds the MHC-peptide complex; (7) expressing
CC an antigen-binding protein; (8) ablating or killing a target cell that
CC displays a peptide on a surface MHC molecule; (9) treating or preventing
CC a cancerous disorder in a subject; and (10) detecting an MHC-peptide
CC complex in a sample. A protein of the invention has cytostatic activity,
CC and can be used in gene therapy. The protein is useful for preparing a
CC composition for treating or preventing a cancerous disorder. The present
CC sequence represents the heavy chain of an antibody which binds to an MHC-
CC peptide complex where the peptide component in as peptide fragment of
CC hTERT.

SQ Sequence 125 AA;

Alignment Scores:
Pred. No.: 0.000565 Length: 125
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 6 Gaps: 1

NOLAN463-1B.SEQ (1-81) x ADA89274 (1-125)

Qy 3 GGCGAGTCAGATATTACGAC-----
Db 26 GlyGlySer-----IleSerSerSerTyrTrpAlaTrpIleArgGlnProGln 44

Qy 25 -----TGTTAGCCGAAATCAATCATAGTGGAGGACCACTACACCCGTC 71
Db 44 YLysGlyLeuGlutTrpIleGlyGluIleAsnHisSerGlySerThrAenTyAsnProSe 64
Qy 72 CCTCAAGAGT 81
Db 64 rLeuLysSer 67
RESULT 4
AAW62794
ID AAW62794 standard; peptide; 80 AA.
XX AAW62794;
AC AAW62794;
DT 23-SEP-1998 (first entry)
XX Amino acid sequence of a human antibody fragment.
XX Human; immunoglobulin; Ig; transgenic; non-human mammal;
KW inactivated endogenous Ig locus; B-cell development;
KW human heavy chain Ig locus; micro constant region; J-H; D-H; V-H gene;
KW kappa light chain Ig locus; kappa constant region; J-kappa gene; V-kappa;
KW production; antibody.
XX Homo sapiens.
OS
XX WO9824893-A2.
XX 11-JUN-1998.
XX 03-DEC-1997; 97WO-US023091.
XX 03-DEC-1996; 96US-00759620.
XX (ABGE-) ABGENIX INC.
XX Jakobovits A, Kucheralapati R, Klapholz S, Mendez M, Green L;
XX WPI; 1998-333314/29.
XX New transgenic non-human mammals - having an inactivated immunoglobulin
PT locus and a near complete human immunoglobulin locus, used for production
PT of human antibodies.
XX Disclosure; Page 71; 128pp; English.

XX AAW62793-822 represent fragments of human antibodies produced by
CC transgenic xenomice, created using the method of the invention. The
CC specification describes a transgenic non-human mammal which has genome
CC modifications that comprise an inactivated endogenous immunoglobulin (Ig)
CC locus, so that the mammal does not display normal B-cell development. The
CC modified genome also has an inserted human heavy chain Ig locus in
CC germline configuration, the human heavy chain Ig locus comprising a human
CC micro constant region and regulatory and switch sequences, human J-H
CC genes, human D-H genes, and human V-H genes and an inserted human kappa
CC light chain Ig locus in germline configuration, the human kappa light
CC chain Ig locus comprising a human kappa constant region, J-kappa genes,
CC and V-kappa genes, where the number of V-H and V-kappa genes inserted are
CC selected to restore normal B-cell development in the mammal. The
CC transgenic animals have a near complete human Ig locus, including both a
CC human heavy chain locus and a human kappa light chain locus. They can be
CC used for the production of human antibodies when exposed to particular
CC antigens e.g. when exposed to human IL-8, EGFR or TNF- alpha the mice
CC will produce antibodies to IL-8, EGFR or TNF- alpha respectively

SQ Sequence 80 AA;

Alignment Scores:
Pred. No.: 0.000842 Length: 80
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3

```
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x AAW62794 (1-80)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGGAAGCACCAACT 61
   |||::: |||
Db 25 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 42
Qy 62 ACAACCCGTCCTCAAGAGT 81
Db 42 YrAsnProSerLeuLysSer 48

RESULT 5
AAY05694
ID AAY05694 standard; protein; 97 AA.
XX AC AAY05694;
XX DT 19-JUL-1999 (first entry)
XX DE Multiple sclerosis patient CSF B-cell VH region (clone 4d76).
XX KW Multiple sclerosis; cerebrospinal fluid; CSF; B-cell;
XX KW heavy chain variable region; VH gene; somatic hypermutation;
XX KW B-cell clonality; RA gene; diagnosis; human.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Region 1..30 /label= FR1
XX FT Misc-difference 8 /note= "encoded by GGC"
XX FT Misc-difference 13 /note= "replaces Glu of RA"
XX FT Misc-difference 14 /note= "encoded by CCT"
XX FT Misc-difference 23 /note= "replaces Gly of RA"
XX FT Misc-difference 25 /note= "replaces Phe of RA"
XX FT Misc-difference 30 /note= "replaces Gly of RA"
XX FT Region 31..36 /label= CDR1
XX FT Misc-difference 31 /note= "replaces Gly of RA"
XX FT Misc-difference 32 /note= "replaces Phe of RA"
XX FT Region 37..50 /label= FR2
XX FT Region 51..66 /label= CDR2
XX FT Misc-difference 56 /note= "replaces Asn of RA"
XX FT Misc-difference 57 /note= "replaces Ser of RA"
XX FT Misc-difference 58 /note= "replaces Lys of RA"
XX FT Region 67..97 /label= FR3
XX FT Misc-difference 71 /note= "replaces Leu of RA"
XX FT Misc-difference 81 /note= "replaces Arg of RA"
XX KW WO9915696-A1.
XX PD 01-APR-1999.
XX PF 17-SEP-1998; 98WO-CA000873.
XX
```

```
PR 19-SEP-1997; 97CA-02216595.
PR 04-NOV-1997; 97CA-02220245.
XX
PA (QIN)/ QIN Y.
XX QIN Y;
XX MPI; 1999-276985/23.
DR N-PSDB; AAX25318.
XX
XX Determination of B-cell clonality by amplification or enzymatic
XX digestion.
XX PS Disclosure; Fig 9D; 67pp; English.
XX
CC This sequence represents a heavy chain variable region (VH) as predicted
CC from DNA of dominant clone 4d76 of B-cells taken from the cerebrospinal
CC fluid (CSF) of a multiple sclerosis (MS) patient. Sequences of VH of CSF
CC B-cells were obtained from 4 MS patients (see AAX25316-19). Differences
CC in nucleotide and predicted amino acid (see AAY05691-94) sequences were
CC compared with the closest known germline VH genes; for 4d76, this was RA.
CC The results provided direct evidence that intrathecal clonally expanded B
CC -cells from the CSF of MS patients are hypermutated postgerminal centre
CC antibody-forming or memory lymphocytes that have undergone antigen
CC selection. This finding implicates an important pathogenic pathway for
CC the development of demyelination in CNS of MS. The invention provides
CC assay kits for determining B-cell or T-cell clonality. This technology
CC allows the establishment of clonal specific RNA library from pathogenic
CC cells in the CNS of patients, which is important for further
CC understanding of the role of antigen(s) in the cause of B-cell clonal
CC expansion, and towards developing antigen specific therapeutic strategy
XX
XX SQ Sequence 97 AA;
```

```
Alignment Scores:
Pred. No.: 0.000883 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x AAY05694 (1-97)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGGAAGCACCAACT 61
   |||::: |||
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGTCCTCAAGAGT 81
   |||
Db 59 YrAsnProSerLeuLysSer 65

RESULT 6
ABG78212
ID ABG78212 standard; protein; 97 AA.
XX AC ABG78212;
XX DT 15-NOV-2002 (first entry)
XX DE Human Fv molecule hypervariable region related peptide #87.
XX KW Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
XX KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
XX KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX OS Homo sapiens.
XX PN WO200259264-A2.
XX PD 01-AUG-2002.
XX PF 31-DEC-2001; 2001WO-US049440.
```

XX 29-DEC-2000; 2000US-00751181.
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
 XX Plaksin D, Peretz T;
 XX WPI; 2002-619166/66.
 XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
 PT or fragment, or construct of fragment with enhanced binding
 PT characteristics so as to selectively bind target cell in favor of other
 PT cells.
 XX Claim 13; Page 193; 232pp; English.
 XX The invention relates to a peptide or polypeptide comprising an Fv
 CC molecule, a construct or fragments or a construct of a fragment with
 CC enhanced binding characteristics which selectively and/or specifically
 CC binds to a target cell in favour of other cells, where binding is
 CC primarily determined by a first hypervariable region and Fv is a single
 CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
 CC association with or attached, coupled, combined, linked or fused to a
 CC pharmaceutical agent, is useful in the manufacture of a medicament, where
 CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 CC related peptide of the invention
 XX Sequence 97 AA;
 SQ
 Alignment Scores:
 Pred. No.: 0.000883 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 5 Gaps: 0
 NOLAN463-1B-SEQ (1-81) x ABG78212 (1-97)
 Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGAAGCACCACCT 61
 Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
 Qy 62 ACAACCCGTCCTCAAGAGT 81
 Db 59 yrAsnProSerLeuLysSer 65
 RESULT 7
 ABG91903
 ID ABG91903 standard; protein; 97 AA.
 XX AC ABG91903;
 XX 04-DEC-2002 (first entry)
 XX Human antibody fragment #87.
 XX Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
 KW metastasis; hypervariable region; autoimmune disease; thrombosis;
 KW reticentosis; leukaemia; inflammatory disease; cardiovascular disease;
 KW myocardial infarction; retinopathic disease; abnormal platelet function;
 KW sulphated tyrosine-dependent protein-protein interaction.
 XX OS Homo sapiens.
 XX WO200253700-A2.
 XX

PD 11-JUL-2002.
 XX 31-DEC-2001; 2001WO-US049442.
 XX 29-DEC-2000; 2000US-00751181.
 XX 29-DEC-2000; 2000US-0258948P.
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
 XX Szanton E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
 XX WPI; 2002-674776/72.
 XX Novel isolated epitope present on cancer cells and important in
 PT physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.
 XX Disclosure; Page 269; Opp; English.
 XX The invention relates to an isolated epitope present on cancer cells and
 CC important in physiological phenomena such as cell rolling, metastasis and
 CC inflammation, where the epitope is capable of being bound by an antibody,
 CC its antigen-binding fragment or its complex comprising at least one
 CC antibody or its binding fragment having a first hypervariable region. The
 CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
 CC tumour or leukaemia cells, increase in number of tumour or leukaemia
 CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 CC mortality and/or cell-platelet adhesion or aggregation, for increasing
 CC mortality of tumour or leukaemia cells, for increasing the susceptibility
 CC of diseased cells to damage by anti-disease, anti-cancer or anti-
 CC leukaemia agents, or for decreasing the number of tumour or leukaemia
 CC cells in a patient, or in the manufacture of a medicament for the above
 CC mentioned purposes. The epitopes are useful for diagnosing and treating
 CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 CC diseases, cardiovascular diseases such as myocardial infarction,
 CC retinopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention
 XX Sequence 97 AA;
 SQ
 Alignment Scores:
 Pred. No.: 0.000883 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 5 Gaps: 0
 NOLAN463-1B-SEQ (1-81) x ABG91903 (1-97)
 Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGAAGCACCACCT 61
 Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
 Qy 62 ACAACCCGTCCTCAAGAGT 81
 Db 59 yrAsnProSerLeuLysSer 65
 RESULT 8
 ABG27107
 ID ABG27107 standard; protein; 97 AA.
 XX AC ABG27107;
 XX 10-SEP-2003 (first entry)
 XX Human germline heavy chain variable region gene segment #40.
 XX

KW Ig variable region; glycosylation site; lymphoma; B cell receptor;
 KW cytostatic; gene therapy; glycosylation inhibitor;
 KW non-Hodgkin's lymphoma.
 OS Synthetic.
 OS Homo sapiens.
 XX
 FN WO2003074059-A2.
 XX
 PD 12-SEP-2003.
 XX
 XX 24-FEB-2003; 2003WO-GB000783.
 XX
 PF 07-MAR-2002; 2002GB-00005395.
 PR
 XX (CANC-) CANCER RES TECHNOLOGY LTD.
 XX
 PA Zhu D, Stevenson F;
 XX
 PI WPI; 2003-902720/82.
 DR
 XX
 XX
 PT Classifying a B-cell as malignant or normal by isolating a sequence
 PT representing an Ig variable region from the B cell, detecting the
 PT presence of a glycosylation site and classifying the cell as malignant or
 PT normal.
 XX
 PS Disclosure; Fig 4; 61pp; English.
 XX
 CC The present invention describes a method for classifying a B-cell as
 CC malignant or normal comprising: (a) isolating a sequence representing an
 CC immunoglobulin (Ig) variable region from the B cell; (b) detecting the
 CC presence of a glycosylation site; and (c) classifying the cell as
 CC malignant or normal on the basis of the presence or absence of a
 CC glycosylation site. Also described: (1) treating a patient suffering from
 CC or at risk of having lymphoma; (2) screening for substances capable of
 CC inhibiting glycosylation of the Ig variable region of the B cell receptor
 CC ; and (3) screening for substances (S) capable of inhibiting the
 CC interaction between lectins of the type found in the germinal centre and
 CC N-glycans found on the surface of Ig of lymphoma cells. (S) has
 CC cytosolic activity, and can be used in gene therapy, and as a
 CC glycosylation inhibitor. The method is useful in classifying a B-cell as
 CC malignant or normal. The glycosylation inhibitor is useful in preparing a
 CC medicament for treating non-Hodgkin's lymphoma. The present sequence
 CC represents an Ig variable region sequence which is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 97 AA;
 Alignment Scores:
 Pred. No.: 0.000883 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 7 Gaps: 0
 NOLAN463-1B-SEQ (1-81) x ADD28104 (1-97)
 QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAAGCACCRACT 61
 Db 42 GlyLys----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAenT 59
 QY 62 ACAACCCGCTCCCTCAAGAGT 81
 Db 59 yraenProSerLeuLysSer 65
 RESULT 11
 ADF10048
 ID ADF10048 standard; protein; 97 AA.
 XX
 AC ADF10048;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Antibody heavy chain variable region VH_4-34.

XX VEGF antibody heavy chain variable region VH_4-34.
 DE
 XX Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human; VEGF.
 KW
 XX Homo sapiens.
 OS
 XX WO2003074679-A2.
 FN
 XX 12-SEP-2003.
 PD
 XX 03-MAR-2003; 2003WO-US006598.
 PF
 XX 01-MAR-2002; 2002US-0360843P.
 PR
 XX 29-MAY-2002; 2002US-0384197P.
 PR
 XX (XENC-) XENCOR.
 PA
 XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 FI WPI; 2003-722066/68.
 PI
 XX Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.
 XX
 PS Example 6; Fig 16a; 135pp; English.
 XX
 CC The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.
 XX
 SQ Sequence 97 AA;
 Alignment Scores:
 Pred. No.: 0.000883 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 7 Gaps: 0
 NOLAN463-1B-SEQ (1-81) x ADF10048 (1-97)
 QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAAGCACCRACT 61
 Db 42 GlyLys----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAenT 59
 QY 62 ACAACCCGCTCCCTCAAGAGT 81
 Db 59 yraenProSerLeuLysSer 65
 RESULT 12
 ADF10150
 ID ADF10150 standard; protein; 97 AA.
 XX
 AC ADF10150;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Antibody heavy chain variable region VH_4-34.

XX Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX Homo sapiens.

OS

PN WO2003074679-A2.

XX

XX 12-SEP-2003.

XX

XX 03-MAR-2003; 2003WO-US006598.

XX

XX 01-MAR-2002; 2002US-0360843P.

XX

XX 29-MAY-2002; 2002US-0384197P.

XX

XX (XENC-) XENCOR.

XX

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;

XX WPI; 2003-722066/68.

XX

XX Computer optimization of physicochemical properties of antibodies

PT comprises analyzing the interactions of amino acids at variable

PT positions.

XX

XX Example 16; Fig 40a; 135pp; English.

XX

XX The present invention relates to a method for optimizing at least one

CC physico-chemical property of an antibody by a computational screening

CC method. The method comprises: receiving a template antibody structure;

CC selecting at least one variable position belonging to the antibody

CC structure; selecting at least one amino acid to be considered at the

CC variable position(s); analyzing the interaction of each selected amino

CC acid at each variable position with at least part of the remainder of the

CC antibody, including the selected amino acids at other variable positions;

CC and identifying a set of at least one antibody sequence with at least one

CC optimized physico-chemical property. The method is useful for optimizing

CC the physico-chemical properties of an antibody, especially the stability,

CC solubility, or antigen binding affinity. The optimized antibody may be

CC useful for treating a patient. The present sequence is an antibody

CC variable region sequence used to illustrate the invention.

XX

SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.000883 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: Gaps: 0

NOLAN463-1B.SEQ (1-81) x ADF10150 (1-97)

Qy 2 GGGCGAGTCAGTATTAGCAGCTGGTTAGCGGAAATCAATCATAGTGGAGCACCAACT 61

Db 42 GlyLys---GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81

Db 59 YrAsnProSerLeuLysSer 65

RESULT 13

ADFO9942

ID ADF09942 standard; protein; 97 AA.

XX

XX ADF09942;

XX

XX 12-FEB-2004 (first entry)

XX

XX Antibody heavy chain variable region VH_4-34.

DE

XX Antibody; stability; solubility; antigen binding affinity;

KW variable region; human.

XX Homo sapiens.

XX WO2003074679-A2.

XX

XX 12-SEP-2003.

XX

XX 03-MAR-2003; 2003WO-US006598.

XX

XX 01-MAR-2002; 2002US-0360843P.

XX

XX 29-MAY-2002; 2002US-0384197P.

XX

XX (XENC-) XENCOR.

XX

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;

XX WPI; 2003-722066/68.

XX

XX Computer optimization of physicochemical properties of antibodies

PT comprises analyzing the interactions of amino acids at variable

PT positions.

XX

XX Disclosure; Fig 2a; 135pp; English.

XX

XX The present invention relates to a method for optimizing at least one

CC physico-chemical property of an antibody by a computational screening

CC method. The method comprises: receiving a template antibody structure;

CC selecting at least one variable position belonging to the antibody

CC structure; selecting at least one amino acid to be considered at the

CC variable position(s); analyzing the interaction of each selected amino

CC acid at each variable position with at least part of the remainder of the

CC antibody, including the selected amino acids at other variable positions;

CC and identifying a set of at least one antibody sequence with at least one

CC optimized physico-chemical property. The method is useful for optimizing

CC the physico-chemical properties of an antibody, especially the stability,

CC solubility, or antigen binding affinity. The optimized antibody may be

CC useful for treating a patient. The present sequence is an antibody

CC variable region sequence used to illustrate the invention.

XX

SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.000883 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: Gaps: 0

NOLAN463-1B.SEQ (1-81) x ADF09942 (1-97)

Qy 2 GGGCGAGTCAGTATTAGCAGCTGGTTAGCGGAAATCAATCATAGTGGAGCACCAACT 61

Db 42 GlyLys---GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81

Db 59 YrAsnProSerLeuLysSer 65

RESULT 14

ADJ80323

ID ADJ80323 standard; protein; 97 AA.

XX

XX ADJ80323;

XX

XX 06-MAY-2004 (first entry)

XX

XX VH gene locus amino acid sequence #43.

DE

XX hybrid antibody; antibody; framework region; homology; immunogenicity.

XX Homo sapiens.

OS

XX PN WO2003048321-A2.
 XX PD 12-JUN-2003.
 XX PF 03-DEC-2002; 2002WO-US038450.
 XX PR 03-DEC-2001; 2001US-0336591P.
 XX PA (ALEX-) ALEXION PHARM INC.
 XX PI Rother R, Wu D;
 XX PW WPI; 2003-513753/48.
 XX PT Producing a hybrid antibody or hybrid antibody fragment by operatively
 XX PT linking the selected framework sequences to one or more complementarity
 XX PT determining regions of the initial antibody.
 XX PS Disclosure; SEQ ID NO 83; 77pp; English.
 XX CC The invention relates to a method of producing a hybrid antibody or
 XX CC hybrid antibody fragment by: (i) providing an initial antibody having
 XX CC specificity for a target; (ii) determining the sequence of a variable
 XX CC region of the initial antibody; (iii) selecting a first component of the
 XX CC variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
 XX CC sequence of the first component to sequencers contained in a reference
 XX CC database of antibody sequences or antibody fragment sequences from a
 XX CC target species; (v) selecting a sequence from an antibody in the database
 XX CC which demonstrates a high degree of homology to the first component; (vi)
 XX CC selecting a second component of the variable region which is different
 XX CC than the first component, the second component selected from the group
 XX CC consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
 XX CC second component to sequences contained in a reference database of
 XX CC antibody sequences or antibody fragment sequences from the target species
 XX CC; (viii) selecting a sequence from the database which demonstrates a high
 XX CC degree of homology to the second component and which is from a different
 XX CC antibody than the selected antibody; and (ix) operatively linking the
 XX CC selected framework sequences to one or more complementarity determining
 XX CC regions (CDRs) of the initial antibody to produce a hybrid antibody or
 XX CC hybrid antibody fragment. The method is useful for producing a hybrid
 XX CC antibody or hybrid antibody fragment (claimed). The antibody and
 XX CC fragments are useful for therapeutic and diagnostic purposes. The method
 XX CC uses entire framework regions from a single antibody variable heavy or
 XX CC variable light chain to receive the CDRs. This produces antibodies that
 XX CC are highly homologous and exhibit reduced immunogenicity while
 XX CC maintaining an optimum binding profile. This sequence represents the
 XX CC amino acid sequence of an antibody from the VH gene locus.
 XX SQ Sequence 97 AA;
 Alignment Scores:
 Pred. No.: 0.000883 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 7 Gaps: 0
 NOLAN463-1B.SEQ (1-81) x ADJ80323 (1-97)
 Qy 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGACCAACT 61
 Db 42 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAant 59
 Qy 62 ACACCCGTCCTCAAGAGT 81
 Db 59 YraenProSerLeuLysSer 65
 RESULT 15
 AAB01949
 ID AAB01949 standard; protein; 114 AA.
 XX

AC AAB01949;
 XX 18-SEP-2000 (first entry)
 DT DE Anti-Id1 Ab binding-defective mutant Ramos cell VH K70N/S77N.
 DE KW Lymphoid cell; antibody producing cell; Ramos cell; immunoglobulin M;
 KW IGM; V gene diversity; directed constitutive hypermutation;
 KW target sequence diversification; terminal deoxynucleotidyl transferase;
 KW Tdt; clonal expansion; selection; heavy chain variable region; VH;
 KW mutant; mutein.
 XX OS Homo sapiens.
 OS Synthetic.
 XX FH Key Location/Qualifiers
 FT Misc-difference 71
 FT /note= "Encoded by CAG"
 XX WO2000022111-A1.
 XX 20-APR-2000.
 XX 08-OCT-1999; 99WO-GB003358.
 XX 09-OCT-1998; 98GB-00022104.
 XX 19-JAN-1999; 99GB-00001141.
 XX 09-JUN-1999; 99GB-00013435.
 XX (MED1-) MEDICAL RES COUNCIL.
 XX Sale JBS, Neuberger MS, Cumbers SJ;
 WPI; 2000-317971/27.
 N-PSDB; AA52435.
 Lymphoid cell line preparation useful for producing gene products having
 desired activity, involves screening and selecting cells having ongoing
 target sequence diversification and higher mutation rates.
 Example 5; Page; 69pp; English.
 The invention relates to a method of preparing a lymphoid cell line
 capable of capable of directed constitutive hypermutation of a target
 nucleic acid region. The method comprises screening a cell population for
 ongoing target sequence diversification and selecting a cell in which the
 rate of target nucleic acid mutation exceeds that of other nucleic acid
 mutation by a factor of 100 or more. The invention also relates to a
 method for preparing a gene product with a desired activity, comprising
 expressing a nucleic acid encoding the target gene operably linked to a
 sequence which directs hypermutation e.g., terminal deoxynucleotidyl
 transferase (Tdt), in the lymphoid cell line, and identifying a cell or
 cells which express a mutated gene product with the desired activity. One
 or more clonal populations of the identified cells is established, and
 cells with an improved activity of interest are selected. These steps may
 be iteratively repeated until a gene product with a desired activity
 is obtained. The cell lines prepared according to the method of the
 invention are used for directed constitutive hypermutation of a nucleic
 acid region in the preparation of a gene product, preferably an enzyme or
 an immunoglobulin (Ig) with a desired activity. In the exemplifications
 of the invention, IGM-secreting Ramos cells were selected for use as they
 undergo hypermutation during clonal expansion. This was determined on the
 basis of the amount of diversity in the heavy chain variable region (VH).
 Sequences AAB01949-B01954 represent various mutant Ramos cell IGM VHS
 (AAB01949-B01954) which have lost the ability to bind anti-idiotypic
 antibodies (anti-Id1 Ab) relative to the wild-type VH (AAB01948). Note:
 The present sequence is not shown in the specification, but is derived
 from the wild-type Ramos cell VH shown in figure 7
 SQ Sequence 114 AA;
 Alignment Scores:
 Pred. No.: 0.00092 Length: 114

Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 3 Gaps: 0

NOLAN463-lb.SEQ (1-81) x AAB01949 (1-114)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGGAATCAATCATATAGTGGAGCACCACACT 61
Db 36 GlyLys----GlyLeu----GlutrpIleGlyGlutIleAsnHisSerGlySerThrAsnT 53
Qy 62 ACAACCGTCCTCAAGAGT 81
Db 53 YrAsnProSerLeuLysSer 59

Search completed: August 4, 2005, 18:14:25
Job time : 93.5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:05:28 ; Search time 23.25 Seconds
(without alignments)

520.135 Million cell updates/sec

Title: NOLAN463-1B.SEQ

Perfect score: 140

Sequence: 1 CGGGCAGTCAGATATTAG.....ACAAACCCGTCCTCAAGACT 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 1027090

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-Q/cgn2_1/USPTO.spool_p/NOLAN08728463-1/runat_04082005.125807.24557/app_query.fasta_1.5
-DB=Issued_PatentsAA -QFWT=fastan -SUFFIX=rai -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCLALIGN=200 -THR SCORE=spct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFWT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN08728463-1 @CGN 1.1.66 @runat_04082005.125807.24557 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Issued Patents AA.*
1: /cgn2_6/ptodata/1/iaa/5A COMB.pcp.*
2: /cgn2_6/ptodata/1/iaa/5B COMB.pcp.*
3: /cgn2_6/ptodata/1/iaa/6A COMB.pcp.*
4: /cgn2_6/ptodata/1/iaa/6B COMB.pcp.*
5: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pcp.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	98.2	70.1	116	3	US-08-545-809A-118
2	98.2	70.1	123	3	US-08-793-450-4
3	98.2	70.1	119	4	US-09-203-768A-2
4	98.2	70.1	472	3	US-08-793-450-8
5	93.2	66.6	429	4	US-09-372-425A-6
6	92.1	65.8	118	3	US-09-025-769B-25
7	92.1	65.8	118	4	US-09-490-070A-25
8	92.1	65.8	118	4	US-09-490-153-25
9	92.1	65.8	118	4	US-09-490-324-25
10	91.1	65.1	120	3	US-08-545-809A-137
11	87.2	62.3	147	4	US-09-471-276-835
12	86.3	61.6	130	3	US-08-466-151-5

13	86.3	61.6	130	3	US-08-466-163B-5	Sequence 5, Appli
14	86.3	61.6	130	4	US-09-802-096-5	Sequence 5, Appli
15	86.3	61.6	130	4	US-09-802-077-5	Sequence 5, Appli
16	85.2	60.9	447	4	US-09-372-425A-2	Sequence 2, Appli
17	83.1	59.4	118	2	US-08-652-816A-13	Sequence 13, Appli
18	83.1	59.4	139	4	US-09-471-276-837	Sequence 837, App
19	83.1	59.4	244	3	US-08-918-148-79	Sequence 79, Appl
20	83.1	59.4	244	4	US-09-138-091A-77	Sequence 77, Appl
21	81.2	58.0	119	2	US-08-428-197-16	Sequence 16, Appl
22	81.2	58.0	119	5	PCT-US93-10555-16	Sequence 16, Appl
23	80.1	57.2	100	4	US-09-726-219A-169	Sequence 169, App
24	80.1	57.2	117	4	US-09-720-493-2	Sequence 2, Appli
25	79.3	56.6	100	2	US-08-273-146-69	Sequence 69, Appl
26	79.3	56.6	137	3	US-08-466-151-7	Sequence 7, Appli
27	79.3	56.6	137	3	US-08-466-163B-7	Sequence 7, Appli
28	79.3	56.6	137	4	US-09-802-096-7	Sequence 7, Appli
29	79.3	56.6	137	4	US-09-802-077-7	Sequence 39, Appl
30	79.1	56.5	119	3	US-09-025-769B-39	Sequence 65, Appl
31	79.1	56.5	119	3	US-09-025-769B-65	Sequence 65, Appl
32	79.1	56.5	119	4	US-09-490-070A-39	Sequence 39, Appl
33	79.1	56.5	119	4	US-09-490-153-39	Sequence 39, Appl
34	79.1	56.5	119	4	US-09-490-153-65	Sequence 65, Appl
35	79.1	56.5	119	4	US-09-490-324-39	Sequence 39, Appl
36	79.1	56.5	119	4	US-09-490-324-65	Sequence 65, Appl
37	79.1	56.5	118	4	US-09-343-698-6	Sequence 6, Appli
38	78.3	55.9	118	4	US-08-325-955-6	Sequence 6, Appli
39	78.3	55.9	118	3	US-08-767-128-18	Sequence 18, Appl
40	78.3	55.9	119	3	US-09-170-769A-2	Sequence 2, Appli
41	78.3	55.9	213	4	US-09-630-820-7	Sequence 7, Appli
42	78.3	55.9	832	3	US-09-273-453-7	Sequence 140, App
43	78.3	55.9	832	4	US-08-545-809A-140	Sequence 22, Appl
44	78.1	55.8	116	3	US-08-851-362D-22	
45	77.9	55.6	76	3		

ALIGNMENTS

RESULT 1

US-08-545-809A-118
; Sequence 118, Application US/08545809A
; Patent No. 6096878

GENERAL INFORMATION:

APPLICANT: Honjo, Tasuku
APPLICANT: Matsuda, Fumihiko

TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE

TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME

NUMBER OF SEQUENCES: 145

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110-2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

OPERATING SYSTEM: Windows95

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/545,809A

FILING DATE: 27-MAR-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/JP93/00603

FILING DATE: 10-MAY-1993

ATTORNEY/AGENT INFORMATION:

NAME: Freeman, John W.

REGISTRATION NUMBER: 29,066

REFERENCE/DOCKET NUMBER: 06501/004001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-542-5070

TELEFAX: 617-542-8906

TELEX: 200154


```
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/793.450
  FILING DATE: 03-MAR-1997
  CLASSIFICATION: 536
PRIOR APPLICATION DATA:
  APPLICATION NUMBER: FR 94/10566
  FILING DATE: 02-SEP-1994
  ATTORNEY/AGENT INFORMATION:
    NAME: OBLON, NORMAN F.
    REGISTRATION NUMBER: 24,618
    REFERENCE/DOCKET NUMBER: 660-118-0 PCT
TELECOMMUNICATION INFORMATION:
  TELEPHONE: 703-413-3000
  TELEFAX: 703-413-2220
  INFORMATION FOR SEQ ID NO: 8:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 472 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-793-450-8

Alignment Scores:
Pred. No.: 0.00013          Length: 472
Score: 98.20              Matches: 19
Percent Similarity: 65.62%  Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14%        Indels: 8
DB: 3                      Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-08-793-450-8 (1-472)
QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAAGCACCACACT 61
Db 61 Glylys---GlyLeu---GluTrpIleGlyGluIleAsnHleSerGlySerThrAsnT 78
QY 62 ACAACCCGTCCTCAAGAGT 81
Db 78 yrasnProSerLeuLysSer 84

RESULT 5
US-09-372-425A-6
; Sequence 6, Application US/09372425A
; Patent No. 6475749
; GENERAL INFORMATION:
; APPLICANT: Sherie L. Morrison
; APPLICANT: Ramon Montano
; TITLE OF INVENTION: Improved Rh Antibody
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppenheimer Wolff & Donnelly LLP
; STREET: 2029 Century Park East, Suite 3800
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows 98
; SOFTWARE: MS Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/372.425A
; FILING DATE: August 11, 1999
; CLASSIFICATION: 435
```

```
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
  NAME: Oldenakmp, David J.
  REGISTRATION NUMBER: 29,421
  REFERENCE/DOCKET NUMBER: 510015-223
TELECOMMUNICATION INFORMATION:
  TELEPHONE: (310) 788-5000
  TELEFAX: (310) 788-5100
  INFORMATION FOR SEQ ID NO: 6:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 429 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: Heavy chain without Tailpiece - AA
US-09-372-425A-6

Alignment Scores:
Pred. No.: 0.000592          Length: 429
Score: 93.20              Matches: 18
Percent Similarity: 65.62%  Conservative: 3
Best Local Similarity: 56.25% Mismatches: 3
Query Match: 66.57%        Indels: 8
DB: 4                      Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-09-372-425A-6 (1-429)
QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAAGCACCACACT 61
Db 61 Glylys---GlyLeu---GluTrpIleGlyGluIleAsnHleSerGlySerThrAsnT 78
QY 62 ACAACCCGTCCTCAAGAGT 81
Db 78 yrasnProSerLeuLysSer 84

RESULT 6
US-09-025-769B-25
; Sequence 25, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckhuhn, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025.769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
```

```
;
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-025-769B-25

Alignment Scores:
Pred. No.: 0.000517 Length: 118
Score: 92.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 65.79% Indels: 19
DB: 3 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-09-025-769B-25 (1-118)

Qy 3 GCGAGTCAGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerTyrTyrTrpSerTrpIleArgGlnProProGlyLysG1 44
Qy 25 -----TGCTTAGCCGAATCAATCATAGTGGAGCACCACCACTACACCCGTCCTCAA 77
Db 44 yLeuGluTrpIleGlyGluIleTyrHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
Qy 78 GAGT 81
Db 64 sSer 65

RESULT 7
US-09-490-070A-25
; Sequence 25, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION NUMBER: EP 95 11 3021.0
; APPLICATION DATE: 18-AUG-1995
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2020
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-070A-25

Alignment Scores:
Pred. No.: 0.000517 Length: 118
Score: 92.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 65.79% Indels: 19
DB: 3 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-09-490-070A-25 (1-118)

Qy 3 GCGAGTCAGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerTyrTyrTrpSerTrpIleArgGlnProProGlyLysG1 44
Qy 25 -----TGCTTAGCCGAATCAATCATAGTGGAGCACCACCACTACACCCGTCCTCAA 77
Db 44 yLeuGluTrpIleGlyGluIleTyrHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
Qy 78 GAGT 81
Db 64 sSer 65

RESULT 8
US-09-490-153-25
; Sequence 25, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION NUMBER: US/09/025,769B
; APPLICATION DATE: 18-FEB-1998
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
```



```

;
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-324-25

Alignment Scores:
Pred. No.: 0.000517 Length: 118
Score: 92.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 65.79% Indels: 19
DB: 4 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-09-490-324-25 (1-118)

Qy 3 GCAGAGTCAGGATATTAGCAGC-----
Db 26 GlyGlySer-----lleserSerTyrTyrTrpSerTrpIleArgGlnProProGlyLys
Qy 25 -----TGGTTAGCCGAAATCAATCATAGTAGGGAAGACCAACTACACCCGTCCTC
Db 44 yLeuGluTrpIleGlyGluIleTyrHisSerGlySerThrAsnTyrAsnProSerLeu
Qy 78 GAGT 81
Db 64 sSer 65

RESULT 10
US-08-545-809A-137
; Sequence 137, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 137:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-137

```

```
Alignment Scores:
Pred. No.: 0.00071 Length: 120
Score: 91.10 Matches: 20
Percent Similarity: 52.27% Conservative: 3
Best Local Similarity: 45.45% Mismatches: 2
Query Match: 65.07% Indels: 19
DB: 3 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-08-545-809A-137 (1-120)
QY 3 GCGGAGTCAGATATTAGCAGC-----24
Db 45 GlyAspSer----IleSerSerGlyAsnTrpValArgGlnProProGlyLysG1 63
QY 25 -----TGGTTAGCCGAATCATCATAGTGGAGCACCACACTAGAACCGTCCCTCAA 77
Db 63 yLeuGluTrpIleGlyGluIleHisHisSerGlySerThrTyrTyrAsnProSerLeu 83
QY 78 GAGT 81
Db 83 sSer 84

RESULT 11
US-09-471-276-835
; Sequence 835, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CP1
; CURRENT APPLICATION NUMBER: US/09/471.276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 835
; LENGTH: 147
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -26...-1
US-09-471-276-835

Alignment Scores:
Pred. No.: 0.00257 Length: 147
Score: 87.20 Matches: 16
Percent Similarity: 65.62% Conservative: 5
Best Local Similarity: 50.00% Mismatches: 3
Query Match: 62.29% Indels: 8
DB: 4 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-09-471-276-835 (1-147)
QY 2 GCGGAGTCAGATATTAGCAGCTGGTTAGCCGNAATCAATCATAGTGGAGCACCACCT 61
Db 69 GlyLys----GlyLeu----GluTrpIleSerGluIleAspHisGlyGlyAsnThrAsn 86
QY 62 ACAACCGTCCCTCAAGAGT 81
Db 86 yAsnProSerLeuLysSer 92

RESULT 12
US-08-466-151-5
; Sequence 5, Application US/08466151
```

```
; Patent No. 6037453
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,151
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466163
; FILING DATE: 06-Jun-1995
; APPLICATION NUMBER: 08/405617
; FILING DATE: 15-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/185899
; FILING DATE: 26-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/879495
; FILING DATE: 07-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/744768
; FILING DATE: 14-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Svoboda, Craig G.
; REGISTRATION NUMBER: 39,044
; REFERENCE/DOCKET NUMBER: P0718P2C1D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1489
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 130 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-08-466-151-5

Alignment Scores:
Pred. No.: 0.00325 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: 3 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-08-466-151-5 (1-130)
QY 1 CGGCGAGTCAGCATATTAGC-----21
Db 13 LysProSerGlnSerLeuSerLeuThrCysThrValThrGlyTyrThrIleThrSerAsp 32
QY 22 -----AGCTGGTTAGCCGAAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrIle 52
QY 40 AATCATAGTGAAGCACCACCACTACACCGTCCCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSer 66

RESULT 13
```

```
US-08-466-163B-5
; Sequence 5, Application US/08466163B
; Patent No. 6329509
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; TITLE OF INVENTION: Immunoglobulin Variants
; FILE REFERENCE: P0718P2C1D1
; CURRENT APPLICATION NUMBER: US/08/466,163B
; CURRENT FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-08-466-163B-5

Alignment Scores:
Pred. No.: 0.00325 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-08-466-163B-5 (1-130)

QY 1 CGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuThrCysThrValThrGlyThrThrIleThrSerAsp 32
QY 22 -----AGCTGGTTAGCGGAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrIle 52
QY 40 AATCATAGTGGAGCACCACCACTACAACCGCTCCCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSer 66

RESULT 14
US-09-802-096-5
; Sequence 5, Application US/09802096
; Patent No. 6685939
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C3US
; CURRENT APPLICATION NUMBER: US/09/802,096
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.00325 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-08-466-163B-5 (1-130)

QY 1 CGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuThrCysThrValThrGlyThrThrIleThrSerAsp 32
QY 22 -----AGCTGGTTAGCGGAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrIle 52
QY 40 AATCATAGTGGAGCACCACCACTACAACCGCTCCCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSer 66

RESULT 15
US-09-802-077-5
; Sequence 5, Application US/09802077
; Patent No. 6699472
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; TITLE OF INVENTION: Method of Treating Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C2US
; CURRENT APPLICATION NUMBER: US/09/802,077
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-077-5

Alignment Scores:
Pred. No.: 0.00325 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-09-802-077-5 (1-130)

QY 1 CGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuThrCysThrValThrGlyThrThrIleThrSerAsp 32
QY 22 -----AGCTGGTTAGCGGAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrIle 52
QY 40 AATCATAGTGGAGCACCACCACTACAACCGCTCCCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyrAsnProSerLeuLysSer 66
```

Search completed: August 4, 2005, 18:23:04
Job time : 24.25 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:20:25 ; Search time 80.25 Seconds
(without alignments)
788.093 Million cell updates/sec

Title: NOLAN463-1B.SEQ

Perfect score: 140

Sequence: 1 CGGCGGAGTCAGGATATTAG.....ACAACCCGTCCTCAAGAGT 81

Scoring table:

BLOSUM62	
Xgapop 10.0 , Xgapext 0.1	
Ygapop 10.0 , Ygapext 0.1	
Fgapop 6.0 , Fgapext 0.1	
Delop 6.0 , Delext 0.1	

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 3505720

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/NOLAN08728463-1/runat_04082005_125809_24629/app_query.fasta_1.5
-DB=Published Applications AA_QFMT=fastan -SUFFIX=rapb -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNIT5=bits -START=1 -END=1 -MATRIX=Blodum62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100
-THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0
-MAXLEN=2000000000
-USER=NOLAN08728463-1@cgn2_1.1.260 @runat_04082005_125809_24629 -NCPU=6
-ICPU=3 -NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THRAUS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10F_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	100.1	71.5	253	10	US-09-880-748-1333	Sequence 1333, Ap
2	100.1	71.5	253	15	US-10-293-418-1333	Sequence 1333, Ap
3	99.9	71.4	125	15	US-10-371-942-118	Sequence 118, Ap
4	98.2	70.1	80	14	US-10-078-958-2	Sequence 2, Appli
5	98.2	70.1	97	14	US-10-194-975-40	Sequence 40, Appli
6	98.2	70.1	97	15	US-10-308-817-83	Sequence 83, Appli
7	98.2	70.1	97	15	US-10-032-037B-87	Sequence 87, Appli
8	98.2	70.1	97	15	US-10-029-988B-87	Sequence 87, Appli
9	98.2	70.1	97	15	US-10-032-423A-87	Sequence 87, Appli
10	98.2	70.1	97	15	US-10-453-698-83	Sequence 83, Appli
11	98.2	70.1	97	15	US-10-029-926B-87	Sequence 87, Appli
12	98.2	70.1	97	16	US-10-379-392-47	Sequence 47, Appli
13	98.2	70.1	114	17	US-10-733-532-128	Sequence 128, App
14	98.2	70.1	115	17	US-10-898-408-12	Sequence 12, Appli
15	98.2	70.1	117	9	US-09-864-761-44315	Sequence 44315, A
16	98.2	70.1	118	15	US-10-371-942-90	Sequence 90, Appl
17	98.2	70.1	118	17	US-10-893-576-192	Sequence 192, App
18	98.2	70.1	122	15	US-10-360-828-63	Sequence 63, Appli
19	98.2	70.1	125	15	US-10-371-942-110	Sequence 110, App
20	98.2	70.1	139	14	US-10-300-675-2	Sequence 2, Appli
21	98.2	70.1	139	17	US-10-910-124-2	Sequence 2, Appli
22	98.2	70.1	139	17	US-10-893-576-43	Sequence 43, Appli
23	98.2	70.1	142	17	US-10-484-790A-10	Sequence 10, Appli
24	98.2	70.1	223	10	US-09-972-656-66	Sequence 66, Appli
25	98.2	70.1	229	10	US-09-972-656-82	Sequence 82, Appli
26	98.2	70.1	230	10	US-09-972-656-72	Sequence 72, Appli
27	98.2	70.1	249	10	US-09-880-748-1321	Sequence 1321, Ap
28	98.2	70.1	249	15	US-10-293-418-1321	Sequence 1321, Ap
29	98.2	70.1	250	10	US-09-880-748-1413	Sequence 1413, Ap
30	98.2	70.1	250	15	US-10-293-418-1413	Sequence 1413, Ap
31	98.2	70.1	254	10	US-09-880-748-1659	Sequence 1659, Ap
32	98.2	70.1	254	15	US-10-293-418-1659	Sequence 1659, Ap
33	98.2	70.1	450	17	US-10-484-790A-17	Sequence 17, Appl
34	98.2	70.1	453	17	US-10-484-790A-18	Sequence 18, Appl
35	97.2	69.4	249	10	US-09-880-748-957	Sequence 957, App
36	97.2	69.4	249	15	US-10-293-418-957	Sequence 957, App
37	95	67.9	246	10	US-09-880-748-1847	Sequence 1847, Ap
38	95	67.9	246	15	US-10-293-418-1847	Sequence 1847, Ap
39	94.2	67.3	123	14	US-10-269-805-31	Sequence 31, Appl
40	94.2	67.3	123	14	US-10-269-805-55	Sequence 55, Appl
41	94.2	67.3	255	10	US-09-880-748-1642	Sequence 1642, Ap
42	94.2	67.3	255	15	US-10-293-418-1642	Sequence 1642, Ap
43	93.7	66.9	116	15	US-10-308-817-189	Sequence 189, App
44	93.7	66.9	116	15	US-10-453-698-189	Sequence 189, App
45	93.2	66.6	250	10	US-09-880-748-993	Sequence 993, App

ALIGNMENTS

RESULT 1
US-09-880-748-1333
; Sequence 1333, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499

```
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1333
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1333

Alignment Scores:
Pred. No.: 0.00155 Length: 253
Score: 100.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 71.50% Indels: 19
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-09-880-748-1333 (1-253)

QY 3 GCGAGTCA-----GGATAT 17
Db 26 GlycylserPheSerGlyTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
QY 18 TAGCAGCTGGTTAGCCGAATCAATAGTGGAAAGCACCAACTACAAACCGTCCCTCAA 77
Db 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
QY 78 GAGT 81
Db 64 sSer 65

RESULT 3
US-10-371-942-118
; Sequence 118, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-118

Alignment Scores:
Pred. No.: 0.00146 Length: 125
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-10-371-942-118 (1-125)

QY 3 GCGAGTCAAGATATTAGCAGC----- 24
Db 26 Glycylser-----IleSerSerSerSerTyrTrpAlaTrpIleArgGlnProProGl 44
QY 25 -----TGGTTAGCCGAATCAATCATAGTGGAAAGCACCAACTACAAACCGTC 71
Db 44 yLysGlyLeuGluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSe 64
QY 72 CCTCAAGAGT 81
Db 64 rLeuLysSer 67

RESULT 4
US-10-078-958-2
; Sequence 2, Application US/10078958
; Publication No. US20030070185A1
; GENERAL INFORMATION:
; APPLICANT: JAKOBOVITS, AVA
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: KLAPHOLZ, SUSAN
; APPLICANT: MENDEZ, MICHAEL J.
; APPLICANT: GREEN, LARRY
; TITLE OF INVENTION: TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING
; TITLE OF INVENTION: PLURAL Vh AND Vk REGIONS AND ANTIBODIES PRODUCED
; TITLE OF INVENTION: THEREFROM
; FILE REFERENCE: CELL 4.18 CON
; CURRENT APPLICATION NUMBER: US/10/078,958
; CURRENT FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: 08/759,620
```

```
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1333
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1333

Alignment Scores:
Pred. No.: 0.00155 Length: 253
Score: 100.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 71.50% Indels: 19
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-09-880-748-1333 (1-253)

QY 3 GCGAGTCA-----GGATAT 17
Db 26 GlycylserPheSerGlyTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
QY 18 TAGCAGCTGGTTAGCCGAATCAATAGTGGAAAGCACCAACTACAAACCGTCCCTCAA 77
Db 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
QY 78 GAGT 81
Db 64 sSer 65

RESULT 2
US-10-293-418-1333
; Sequence 1333, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1333
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1333

Alignment Scores:
Pred. No.: 0.00155 Length: 253
Score: 100.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 71.50% Indels: 19
DB: 1 Gaps: 1

NOLAN463-1B.SEQ (1-81) x US-10-293-418-1333 (1-253)
```

Db 59 yrAsnProSerLeuIySsr 65

RESULT 8

US-10-029-988B-87

; Sequence 87, Application US/10029988B

; Publication No. US20040001839A1

; GENERAL INFORMATION:

```
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-87

Alignment Scores:
Pred. No.: 0.00228 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-029-988B-87 (1-97)
QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGCACCACCACT 61
|||::: |||
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
QY 62 ACAACCCGTCCTCAAGAGT 81
||||| |||
Db 59 yrAsnProSerLeuLysSer 65

RESULT 9
US-10-032-423A-87
; Sequence 87, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-87

Alignment Scores:
Pred. No.: 0.00228 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-032-423A-87 (1-97)
QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGCACCACCACT 61
|||::: |||
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
QY 62 ACAACCCGTCCTCAAGAGT 81
||||| |||
Db 59 yrAsnProSerLeuLysSer 65
```

```
RESULT 10
US-10-453-698-83
; Sequence 83, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-453-698-83

Alignment Scores:
Pred. No.: 0.00228 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-453-698-83 (1-97)
QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGCACCACCACT 61
|||::: |||
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
QY 62 ACAACCCGTCCTCAAGAGT 81
||||| |||
Db 59 yrAsnProSerLeuLysSer 65

RESULT 11
US-10-029-926B-87
; Sequence 87, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-87

Alignment Scores:
Pred. No.: 0.00228 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-029-926B-87 (1-97)
QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGCACCACCACT 61
|||::: |||
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
QY 62 ACAACCCGTCCTCAAGAGT 81
||||| |||
Db 59 yrAsnProSerLeuLysSer 65
```



```
RESULT 12
US-10-379-392-47
; Sequence 47, Application US/10379392
; Publication No. US20040110226A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John Rudolf
; APPLICANT: Marshall, Shannon Alicia
; APPLICANT: Dahiyat, Bassil I.
; TITLE OF INVENTION: ANTIBODY OPTIMIZATION
; FILE REFERENCE: A-71386-3 463077-236
; CURRENT APPLICATION NUMBER: US/10/379,392
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/360,843
; PRIOR FILING DATE: 2002-03-01
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 47
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-379-392-47

Alignment Scores:
Pred. No.: 0.00228 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 16 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-379-392-47 (1-97)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61
Db 42 Glylys---GlyLeu---GlutrpIleGlyGlulleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 13
US-10-733-532-128
; Sequence 128, Application US/10733532
; Publication No. US20050026246A1
; GENERAL INFORMATION:
; APPLICANT: Sale, Julian E.
; APPLICANT: Neuberger, Michael S.
; APPLICANT: Cumbers, Sarah J.
; TITLE OF INVENTION: Method of Generating Diversity
; FILE REFERENCE: 18396/2002B
; CURRENT APPLICATION NUMBER: US/10/733,532
; CURRENT FILING DATE: 2003-12-11
; PRIOR APPLICATION NUMBER: PCT/GB02/02688
; PRIOR FILING DATE: 2002-06-11
; PRIOR APPLICATION NUMBER: 10/146,505
; PRIOR FILING DATE: 2002-05-15
; PRIOR APPLICATION NUMBER: 09/879,813
; PRIOR FILING DATE: 2001-06-11
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 128
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-733-532-128

Alignment Scores:
Pred. No.: 0.00235 Length: 114
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 16 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-733-532-128 (1-114)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61
Db 42 Glylys---GlyLeu---GlutrpIleGlyGlulleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 14
US-10-898-408-12
; Sequence 12, Application US/10898408
; Publication No. US20050058642A1
; GENERAL INFORMATION:
; APPLICANT: YAN, Wei
; APPLICANT: GALIBERT, Laurent J.
; TITLE OF INVENTION: ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE
; FILE REFERENCE: 3467-A
; CURRENT APPLICATION NUMBER: US/10/898,408
; CURRENT FILING DATE: 2004-07-23
; PRIOR APPLICATION NUMBER: 60/490,027
; PRIOR FILING DATE: 2003-07-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 115
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-898-408-12

Alignment Scores:
Pred. No.: 0.00235 Length: 115
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 17 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-898-408-12 (1-115)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61
Db 42 Glylys---GlyLeu---GlutrpIleGlyGlulleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 15
US-09-864-761-44315
; Sequence 44315, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeomica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
```

```
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 17 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-733-532-128 (1-114)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61
Db 36 Glylys---GlyLeu---GlutrpIleGlyGlulleAsnHisSerGlySerThrAsnT 53

Qy 62 ACAACCCGTCCTCAAGAGT 81
Db 53 yrAsnProSerLeuLysSer 59

RESULT 14
US-10-898-408-12
; Sequence 12, Application US/10898408
; Publication No. US20050058642A1
; GENERAL INFORMATION:
; APPLICANT: YAN, Wei
; APPLICANT: GALIBERT, Laurent J.
; TITLE OF INVENTION: ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE
; FILE REFERENCE: 3467-A
; CURRENT APPLICATION NUMBER: US/10/898,408
; CURRENT FILING DATE: 2004-07-23
; PRIOR APPLICATION NUMBER: 60/490,027
; PRIOR FILING DATE: 2003-07-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 115
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-898-408-12

Alignment Scores:
Pred. No.: 0.00235 Length: 115
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 17 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-10-898-408-12 (1-115)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61
Db 42 Glylys---GlyLeu---GlutrpIleGlyGlulleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 15
US-09-864-761-44315
; Sequence 44315, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeomica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
```

; PRIOR FILING DATE: 2000-08-03
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 09/608,408
 ; PRIOR FILING DATE: 2000-06-30
 ; PRIOR APPLICATION NUMBER: US 09/774,203
 ; PRIOR FILING DATE: 2001-01-29
 ; NUMBER OF SEQ ID NOS: 49117
 ; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
 ; SEQ ID NO 44315
 ; LENGTH: 117
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: MAP TO AB019439.1
 ; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.54
 ; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.57
 ; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 0.56
 ; OTHER INFORMATION: EST HUMAN HIT: BE672445.1, EVALUE 2.00e-57
 ; OTHER INFORMATION: SWISSPROT HIT: P06331, EVALUE 1.00e-53
 US-09-864-761-44315

Alignment Scores:
 Pred. No.: 0.00236 Length: 117
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 9 Gaps: 0

NOLAN463-1B.SEQ (1-81) x US-09-864-761-44315 (1-117)

Qy	2	GGCGAGTCAGGATATTAGCAGCTGGTAGCCGAAATCATCATAGTGGAGACCAACT	61
		:	
Db	45	Glylys---GluTrpIleGlyIleAsnHisSerGlySerThrAsnT	62
		:	
Qy	62	ACRACCGTCCCTCAAGAGT	81
		:	
Db	62	yrAsnProSerLeuLysSer	68
		:	

Search completed: August 4, 2005, 18:49:49
 Job time : 81.25 secs


```
RESULT 2
S26805
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C;Accession: S26805
R;Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A;Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A;Reference number: S26800; MUID:92201299; PMID:1348029
A;Accession: S26805
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <WEN>
A;Cross-references: EMBL:Z14241; NID:g37714; PIDN:CAA78610.1; PID:g1335376
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IM>

Alignment Scores:
Pred. No.: 0.000153 Length: 97
Score: 100.40 Matches: 20
Percent Similarity: 43.40% Conservative: 3
Best Local Similarity: 37.74% Mismatches: 4
Query Match: 71.71% Indels: 26
DB: 2 Gaps: 1

NOLAN463-1B.SEQ (1-81) x S26805 (1-97)
QY 1 CGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnThrLeuSerLeuThrCysAlaValTyrGlyGlySerPheSerGlyTyr 32
QY 22 -----AGCTGTTAGCCGAAATCAAT 42
Db 33 TyrTrpSerTrpLeuArgGlnProGlyGlyLeuGluTrpIleGlyGluIleAsn 52
QY 43 CATAGTGGAGACCAACTACACCCGTCCTCAAGAGT 81
Db 53 HisSerGlySerThrAsnTyrAsnProSerLeuLysSer 65

RESULT 3
S26898
Ig heavy chain V region (clone DP-63, V(H)4.2) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26898; S12420
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26898
A;Molecule type: DNA
A;Residues: 1-97 <TOW>
A;Cross-references: EMBL:Z12363; NID:g32944; PIDN:CAA78233.1; PID:g32945
A;Experimental source: clone DP-63
R;Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A;Title: The smaller human V(H) gene families display remarkably little polymorphism.
A;Reference number: S09421; MUID:90059975; PMID:2511001
A;Accession: S12420
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-97 <SAN>
A;Cross-references: EMBL:X56364
A;Experimental source: V(H)4.2
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IM>

Alignment Scores:
Pred. No.: 0.000295 Length: 97
```

```
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x S26898 (1-97)
QY 2 GGCGGAGTCAGGATATTAGCAGCTGTTAGCCGAAATCAATCATAGTGGAGCACCACACT 61
Db 42 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsn 59
QY 62 ACAACCCGTCCTCAAGAGT 81
Db 59 YrAsnProSerLeuLysSer 65

RESULT 4
S26806
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C;Accession: S26806
R;Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A;Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A;Reference number: S26800; MUID:92201299; PMID:1348029
A;Accession: S26806
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <WEN>
A;Cross-references: EMBL:Z14242; NID:g37716; PIDN:CAA78611.1; PID:g1335377
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IM>

Alignment Scores:
Pred. No.: 0.000295 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x S26806 (1-97)
QY 2 GGCGGAGTCAGGATATTAGCAGCTGTTAGCCGAAATCAATCATAGTGGAGCACCACACT 61
Db 42 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsn 59
QY 62 ACAACCCGTCCTCAAGAGT 81
Db 59 YrAsnProSerLeuLysSer 65

RESULT 5
S37454
Ig mu chain - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
C;Accession: S37454
R;McIntosh, R.S.; Tandon, N.; Weetman, A.P.
submitted to the EMBL Data Library, September 1993
A;Description: Cloning and analysis of human IGM anti-Thyroglobulin autoantibodies from
A;Reference number: S37453
A;Accession: S37454
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-106 <MCI>
A;Cross-references: EMBL:X75022; NID:g404311; PIDN:CAA52930.1; PID:g758093
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: immunoglobulin

Alignment Scores:
Pred. No.: 0.000297 Length: 106
```

```
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x S37454 (1-106)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCAACT 61
   |||:|:|
Db 20 Glylys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 37
   |||:|:|

Qy 62 ACAACCCGTCCTCAAGAGT 81
   |||:|:|
Db 37 yrAsnProSerLeuLysSer 43
   |||:|:|

RESULT 6
JL0047
Ig heavy chain V region precursor (clone cr18) - human
C:Species: Homo sapiens (man)
C:Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 16-Aug-1996
C:Accession: JL0047
R:Baer, R.; Forster, A.; Lavenir, I.; Rabbitts, T.H.
J. Exp. Med. 167, 2011-2016, 1988
A:Title: Immunoglobulin V-H genes are transcribed by T cells in association with a new 5'
A:Reference number: JL0047; MUID:88258392; PMID:3133445
A:Accession: JL0047
A:Molecule type: mRNA
A:Residues: 1-122 <BAE>
A:Experimental source: T-cell line RPMI 8402
A:Note: the authors translated the reading frame which extends to the stop codon; the se
A:Note: this sequence belongs to the VH II subgroup
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:23-105/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000299 Length: 122
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x JL0047 (1-122)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCAACT 61
   |||:|:|
Db 50 Glylys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 67
   |||:|:|

Qy 62 ACAACCCGTCCTCAAGAGT 81
   |||:|:|
Db 67 yrAsnProSerLeuLysSer 73
   |||:|:|

RESULT 7
S47010
Ig heavy chain V4.21-UniqueJ5 region - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S47010
R:Mahmoudi, M.; Gasyna, E.; Denomme, G.; Edwards, J.; Bell, D.; Cairns, E.
submitted to the EMBL Data Library, July 1994
A:Description: The role of the immunoglobulin heavy chain in human anti-DNA antibody bir
A:Reference number: S47009
A:Accession: S47010
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-126 <MAH>
A:Cross-references: EMBL:Z35492; NID:G517254; PIDN:CAA84625.1; PID:G517255
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>
```

```
Alignment Scores:
Pred. No.: 0.0003 Length: 126
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x S47010 (1-126)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCAACT 61
   |||:|:|
Db 42 Glylys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
   |||:|:|

Qy 62 ACAACCCGTCCTCAAGAGT 81
   |||:|:|
Db 59 yrAsnProSerLeuLysSer 65
   |||:|:|

RESULT 8
S78052
Ig heavy chain precursor V-D-J region (clone mAB 63VH) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78052; S23717
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78052
A:Molecule type: mRNA
A:Residues: 1-140 <HAR>
A:Cross-references: EMBL:X54441; NID:G37815; PIDN:CAA38308.1; PID:G930118
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and h
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23717
A:Molecule type: mRNA
A:Residues: 15-111 <HAW>
A:Cross-references: EMBL:X54441
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F:15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:29-111/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000301 Length: 140
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x S78052 (1-140)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCAACT 61
   |||:|:|
Db 56 Glylys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 73
   |||:|:|

Qy 62 ACAACCCGTCCTCAAGAGT 81
   |||:|:|
Db 73 yrAsnProSerLeuLysSer 79
   |||:|:|

RESULT 9
A49045
Ig heavy chain V region (anti-B cell autoantibody) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999
C:Accession: A49045
R:Gillot-Courvalin, C.; Brouet, J.C.; Pillier, F.; Rassenti, L.Z.; Labaume, S.; Silverma
Eur. J. Immunol. 22, 1781-1788, 1992
A:Title: An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes 1 b1
```

A;Reference number: A49045; MUID:92324290; PMID:1623923

A;Accession: A49045

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-140 <GRI>

A;Cross-references: GB:G39381; NID:G250899; PIDN:AAB2441.1; PID:G250900

A;Note: sequence extracted from NCBI backbone (NCBIN:108088, NCBIPI:108089)

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;34-116/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000301 Length: 140
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x A49045 (1-140)

Qy 2 GGCGGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGGACCAACT 61

Db 61 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78

Qy 62 ACAACCCGTCCTCAAGAGT 81

Db 78 yrAsnProSerLeuLysSer 84

RESULT 10

B23746

Ig Fab region IV-J(H4)-C (KAU cold agglutinin) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 21-Jan-2000

C;Accession: B23746

R;Leoni, J.; Chiso, J.; Frangione, B.

J. Biol. Chem. 266, 2836-2842, 1991

A;Title: The primary structure of the Fab fragment of protein KAU, a monoclonal immunoglobulin

A;Reference number: A23746; MUID:91131575; PMID:1993660

A;Accession: B23746

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-231 <LBO>

C;Superfamily: immunoglobulin C region; immunoglobulin homology

F;140-209/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00031 Length: 231
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x B23746 (1-231)

Qy 2 GGCGGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGGACCAACT 61

Db 41 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 58

Qy 62 ACAACCCGTCCTCAAGAGT 81

Db 58 yrAsnProSerLeuLysSer 64

RESULT 11

PS0341

Ig heavy chain V-D-J region (RAMOS) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-May-1997

C;Accession: PS0341

R;Ratech, H.

Biochem. Biophys. Res. Commun. 182, 1260-1263, 1992

A;Title: Rapid cloning of rearranged immunoglobulin heavy chain genes from human B-cell

A;Reference number: PS0341; MUID:92171937; PMID:1540170

A;Accession: PS0341

A;Molecule type: mRNA

A;Residues: 1-133 <RAT>

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;9-38/Region: framework 1

F;39-43/Region: complementarity-determining 1

F;44-57/Region: framework 2

F;58-74/Region: complementarity-determining 2

F;75-106/Region: framework 3

Alignment Scores:
Pred. No.: 0.000319 Length: 133
Score: 98.00 Matches: 17
Percent Similarity: 94.74% Conservative: 1
Best Local Similarity: 89.47% Mismatches: 1
Query Match: 70.00% Indels: 0
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x PS0341 (1-133)

Qy 25 TGGTTAGCCGAAATCAATCATATAGTGGAGGACCAACTACACCGTCCTCAAGAGT 81

Db 55 TrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSer 73

RESULT 12

G34964

Ig heavy chain V-IV region (Ab44) - human

C;Species: Homo sapiens (man)

C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004

C;Accession: G34964

R;Sanz, I.; Casali, P.; Thomas, J.W.; Notkins, A.L.; Capra, J.D.

J. Immunol. 142, 4034-4061, 1989

A;Title: Nucleotide sequences of eight human natural autoantibody V-H regions reveals ap

A;Reference number: A92830; MUID:89235232; PMID:2497188

A;Accession: G34964

A;Molecule type: mRNA

A;Residues: 1-97 <SAN>

A;Cross-references: UNIPROT:Q8WUX4; GB:M26998

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000978 Length: 97
Score: 94.20 Matches: 18
Percent Similarity: 62.50% Conservative: 2
Best Local Similarity: 56.25% Mismatches: 4
Query Match: 67.29% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x G34964 (1-97)

Qy 2 GGCGGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATATAGTGGAGGACCAACT 61

Db 42 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlyGlyThrAsnT 59

Qy 62 ACAACCCGTCCTCAAGAGT 81

Db 59 yrAsnProSerLeuLysSer 65

RESULT 13

S26905

Ig heavy chain V region (DP-70 / 4.19) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Accession: S26905; S12419

R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V

A;Reference number: S26885; MUID:93021117; PMID:1404388

A;Accession: S26905

A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-98 <TON>
A:Cross-references: EMBL:Z12370; NID:g32960; PIDN:CAA78240.1; PID:g32961
A>Note: designated DP-70
R:Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A>Title: The smaller human V(H) gene families display remarkably little polymorphism.
A:Reference number: S09421; MUID:90059975; PMID:2511001
A:Accession: S12419
A>Status: preliminary; translation not shown
A:Molecule type: DNA
A:Residues: 1-98 <SAN>
A:Cross-references: EMBL:X56363
A>Note: designated 4.19
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00189 Length: 98
Score: 92.00 Matches: 21
Percent Similarity: 48.89% Conservative: 1
Best Local Similarity: 46.67% Mismatches: 3
Query Match: 65.71% Indels: 20
DB: 2 Gaps: 1
NOLAN463-1B.SEQ (1-81) x S26905 (1-98)
QY 3 GGCAGTCAGGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerSerAenTrpTrpSerTrpValArgGlnProProGlyLy 44
QY 25 -----TGCTTAGCCGAAATCAATCATAGTGGAGCAGCAACTACCAACCGTCCCT 74
Db 44 sGlyLeuGluTrpIleGlyGluLeuTyRHisSerGlySerThraSnyrAenProSerLe 64

QY 75 CAAGAGT 81
Db 64 ulySer 66
RESULT 14
S78055
Ig heavy chain precursor V-D-J region (clone mAb 67VH) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78055; S23720
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78055
A:Molecule type: mRNA
A:Residues: 1-145 <HAR>
A:Cross-references: EMBL:X54445; NID:g37817; PIDN:CAA38312.1; PID:g37818
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A>Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and high-affinity Ig heavy chain (fragment) #status predicted <SIG>
F:18-145/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:32-115/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00193 Length: 145
Score: 92.00 Matches: 21

Percent Similarity: 48.89% Conservative: 1
Best Local Similarity: 46.67% Mismatches: 3
Query Match: 65.71% Indels: 20
DB: 2 Gaps: 1
NOLAN463-1B.SEQ (1-81) x S78055 (1-145)
QY 3 GGCAGTCAGGATATTAGCAGC----- 24
Db 43 GlyGlySer-----IleSerSerSerAenTrpTrpSerTrpValArgGlnProProGlyLy 61
QY 25 -----TGCTTAGCCGAAATCAATCATAGTGGAGCAGCAACTACCAACCGTCCCT 74
Db 61 sGlyLeuGluTrpIleGlyGluLeuTyRHisSerGlySerThraSnyrAenProSerLe 81
QY 75 CAAGAGT 81
Db 81 ulySer 83

RESULT 15
S14474
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C:Accession: S14474
R:van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derksen, R.H.
submitted to the EMBL Data Library, November 1990
A:Reference number: S14474
A:Accession: S14474
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-97 <ESJ>
A:Cross-references: EMBL:X56591; NID:g37235; PIDN:CAA39929.1; PID:g1335354
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00437 Length: 97
Score: 89.20 Matches: 18
Percent Similarity: 62.50% Conservative: 2
Best Local Similarity: 56.25% Mismatches: 4
Query Match: 63.71% Indels: 8
DB: 2 Gaps: 0
NOLAN463-1B.SEQ (1-81) x S14474 (1-97)

QY 2 GGCAGTCAGGATATTAGCAGCTGGTAGCCGAAATCAATCATAGTGGAGCAGCAACT 61
Db 42 GlyLys-----GlyLeu----GluTrpIleGlyGluIleHisSerGlySerThraSnt 59
QY 62 ACAACCGTCCTCAAGAGT 81
Db 59 yrAenProSerLeuLysSer 65

Search completed: August 4, 2005, 18:21:23
Job time : 18.25 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 17:55:57 ; Search time 83.75 Seconds
(without alignments)
990.529 Million cell updates/sec

Title: NOLAN463-LB.SEQ

Perfect score: 140

Sequence: 1 CGGCGAGTCAAGATATTAG.....ACAAACCCGTCCTCAAGAGT 81

Scoring table: BLOSUM62

Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 3224756

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=x1p
-O=/cgn2.1/USPTO.spool.p/NOLAN08728463-1/runat.04082005.125806.24533/app_query.fasta_1.5
-DB=UniProt -OPMT=fastan -SUFFIX=rup -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALLIGN=200 -THR SCORE=spect -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-1 @CGN 1.1 305 @runat.04082005.125806.24533 -NCPU=6
-ICPU=3 -NO MAP -LARGEQUERY -NEG SCORE=0 -WAIT -DSPBLOC=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : UniProt_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	98.2	70.1	116	2 Q7Z3Y6	Q7Z3Y6 homo sapien
2	98.2	70.1	595	2 Q8WUX4	Q8WUX4 homo sapien
3	98.2	70.1	597	2 Q8GMX5	Q8GMX5 homo sapien
4	98.2	70.1	597	2 Q8BU10	Q8BU10 homo sapien
5	98.2	70.1	625	2 Q96AA6	Q96AA6 homo sapien
6	92.2	65.9	597	2 Q9BQB8	Q9BQB8 homo sapien
7	92	65.7	576	2 Q6P4I8	Q6P4I8 homo sapien
8	87.2	62.3	146	1 HV2I1_HUMAN	P06331 homo sapien
9	82.1	58.6	477	2 Q8GMX7	Q8GMX7 homo sapien
10	79.1	56.5	139	2 Q86SX2	Q86SX2 homo sapien
11	77.1	55.1	620	2 Q96EY0	Q96EY0 homo sapien
12	76.3	54.5	479	2 Q99M22	Q99M22 mus musculus
13	75.7	54.1	116	1 HV6I1_MOUSE	P18532 mus musculus
14	75.2	53.7	465	2 Q8GMX6	Q8GMX6 homo sapien
15	72.8	52.0	262	2 Q85Z11	Q85Z11 mus musculus
16	71.3	50.9	116	1 HV60_MOUSE	P18531 mus musculus

17	71.2	50.9	119	2	Q9UL73	Q9UL73 homo sapien
18	71.2	50.9	476	2	Q6GMX1	Q6GMX1 homo sapien
19	69.1	49.4	478	2	Q6NYH3	Q6NYH3 homo sapien
20	68.6	49.0	150	2	Q95973	Q95973 homo sapien
21	68.2	48.7	478	2	Q7Z379	Q7Z379 homo sapien
22	67.4	48.1	113	1	HV47_MOUSE	P01823 mus musculus
23	66.4	47.4	104	2	Q99CA9	Q99CA9 human immun
24	66.4	47.4	106	2	Q6TJQ4	Q6TJQ4 human immun
25	66.4	47.4	133	2	Q90QV6	Q90QV6 human immun
26	65.9	47.1	496	2	Q96KX8	Q96KX8 homo sapien
27	65.5	46.8	523	2	Q6QJ60	Q6QJ60 paraphlegop
28	65.5	46.8	523	2	Q6QJ62	Q6QJ62 paraphlegop
29	65.4	46.7	104	2	Q99CH3	Q99CH3 human immun
30	65.4	46.7	130	2	Q9QL43	Q9QL43 human immun
31	65.4	46.7	202	2	Q9IUP1	Q9IUP1 human immun
32	65.4	46.7	202	2	Q9IUR6	Q9IUR6 human immun
33	65.4	46.7	206	2	Q7ZN97	Q7ZN97 human immun
34	65.4	46.7	207	2	Q9IUI5	Q9IUI5 human immun
35	65.4	46.7	212	2	Q9J783	Q9J783 human immun
36	65.4	46.7	220	2	Q9IUT6	Q9IUT6 human immun
37	65.4	46.7	231	2	Q9IQS9	Q9IQS9 human immun
38	65.4	46.7	489	2	Q80632	Q80632 human immun
39	65.3	46.6	136	2	Q6LBQ5	Q6LBQ5 mus musculus
40	65.3	46.6	137	1	HV45_MOUSE	P01822 mus musculus
41	64.4	46.0	130	2	Q7ZB82	Q7ZB82 human immun
42	64.4	46.0	131	2	Q90QT5	Q90QT5 human immun
43	64.4	46.0	131	2	Q9QKY2	Q9QKY2 human immun
44	64.4	46.0	131	2	Q9QKY3	Q9QKY3 human immun
45	64.4	46.0	140	2	Q698Z8	Q698Z8 human immun

ALIGNMENTS

RESULT 1
Q7Z3Y6
ID Q7Z3Y6 PRELIMINARY; PRT; 116 AA.
AC Q7Z3Y6;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Rearranged VH4-34 V gene segment (Fragment).
GN Name=VH4-34;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hodgkin lymphoma;
RA Tanguely M., Rosenquist R., Sundstroem C., Amini R.M., Kuppers R.,
RA Hansmann M.L., Brauning A.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ564425; CAD92032.1; -
DR HSSP; P18532; IKCV.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
SQ SEQUENCE 116 AA; 12902 MW; CE3DBA846616C908 CRC64;

Alignment Scores:
Pred. No.: 0.000788 Length: 116
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-LB.SEQ (1-81) x Q7Z3Y6 (1-116)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGTAGCCGGAATCAATCATAGTGTGGAAGCACT 61

Db 42 GlyLeu----GlyLeu-----GlutrpIleGlyLeuLeaHisSerGlySerThrAsnt 59

QY 62 ACAACCCGTCCTCAAGAGT 81

Db 59 yrAnProSerLeuIysSer 65

RESULT 2

ID	Q8WUX4	PRELIMINARY	PRT	595 AA
AC	Q8WUX4			
DT	01-MAR-2002	(TEMBLrel. 20, Created)		
DT	01-MAR-2004	(TEMBLrel. 26, Last sequence update)		
DE	01-MAR-2004	(TEMBLrel. 26, Last annotation update)		
DE		Hypotheetical protein.		
OS		Homo sapiens (human).		
OC		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX		NCBI_TaxID=9606;		
RN		[1]		
RP		SEQUENCE FROM N.A.		
RC		TISSUE=Lymph;		
RX		MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;		
RA		Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,		
RA		Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,		
RA		Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,		
RA		Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,		
RA		Diatchenko L., Marusina K., Farmer A., Rubin G.M., Hong L.,		
RA		Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,		
RA		Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,		
RA		Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,		
RA		Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,		
RA		Richards S., Worley K.C., Hale S.J., Garcia A.M., Gay L.J., Hulyk S.W.,		
RA		Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,		
RA		Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,		
RA		Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,		
RA		Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,		
RA		Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,		
RA		Krzywinski M.I., Skalka U., Smailus D.E., Schnerch A., Schein J.E.,		
RA		Jones S.J., Marra M.A.;		
RT		"generation and initial analysis of more than 15,000 full-length human		
RT		and mouse cDNA sequences."		
RL		Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).		
[2]				
RP		SEQUENCE FROM N.A.		
RC		TISSUE=Lymph;		
RA		Strausberg R.;		
RL		Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.		
DR		EMBL; BC019235; AAH19235.2; -.		
DR		PIR; G34964; G34964.		
DR		HSSP; P01861; 1ADO.		
DR		Pfam; PF07654; Cl-set; 4.		
DR		SMART; SM00409; IG; 2.		
DR		SMART; SM00407; IGcl; 4.		
DR		SMART; SM00406; IG; 1.		
DR		PROSITE; PS0835; IG LIKE; 5.		
DR		PROSITE; PS00290; IG_MHC; UNKNOWN_3.		
DR		Hypotheetical protein.		
QY		SEQUENCE 595 AA; 65290 MW; 0D4B50776545714E CRC64;		

Alignment Scores:	
Pred. No.:	0.000979
Score:	98.20
Percent Similarity:	65.62%
Best Local Similarity:	59.38%
Query Match:	70.14%
DB:	2

Length:	
Matches:	19
Conservative:	2
Mismatches:	3
Indels:	8
Gaps:	0

NOLAN463-1B.SEQ (1-81) x Q8WUX4 (1-595)

QY 2 GGCGGAGTCAGGATATTAGCAGCTGGTTACCGCAATCAATCATAGTGAAGCACAACT 61

Db 68 GlyLeu----GlyLeu-----GlutrpIleGlyLeuLeaHisSerGlySerThrAsnt 85

```
Db 61 Glylys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78
Qy 62 AACACCCGCTCCCTCAAGAGT 81
Db 78 yRAsnProSerLeuLySer 84

RESULT 4
Q9BU10 ID Q9BU10 PRELIMINARY; PRT; 597 AA.
AC Q9BU10;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RC SEQUENCE FROM N.A.
RS TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalón D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Richards S., Worley K.C., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalón D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
RC SEQUENCE FROM N.A.
RS TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002963; AAH02963.1; -
DR HSSP; P01861; 1ADQ.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65274 MW; 2DAFA8FB7E055851 CRC64;

Alignment Scores:
Pred. No.: 0.000979 Length: 597
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x Q9BU10 (1-597)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGACCAACT 61
Db 61 Glylys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78
```

```
Qy 62 AACACCCGCTCCCTCAAGAGT 81
Db 78 yRAsnProSerLeuLySer 84

RESULT 5
Q96AA6 ID Q96AA6 PRELIMINARY; PRT; 625 AA.
AC Q96AA6;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RC SEQUENCE FROM N.A.
RS TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalón D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Richards S., Worley K.C., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalón D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
RC SEQUENCE FROM N.A.
RS TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC017356; AAH17356.2; -
DR HSSP; P01861; 1ADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IG; 2.
DR SMART; SM00407; IGcl; 4.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 625 AA; 68610 MW; F62FAB3ADE7ECBFE CRC64;

Alignment Scores:
Pred. No.: 0.000985 Length: 625
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x Q96AA6 (1-625)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGACCAACT 61
```

```
||||:|
68 GlyLys----GlyLeu----GluTrpIleGlyGluIleAenHisSerGlySerThrAsnT 85
||||:|
62 ACAACCGCTCCCTCAAGAGT 81
||||:|
85 YrAenProSerLeuLysSer 91
||||:|

RESULT 6
Q9QB08 PRELIMINARY; PRT; 597 AA.
ID Q9QB08
AC Q9QB08
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC006180; AAH06180.1; -.
DR HSP; P01861; IADQ.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65300 MW; 2DAFAD50A6375851 CRC64;

Alignment Scores:
Pred. No.: 0.00622 Length: 597
Score: 92.20 Matches: 18
Percent Similarity: 62.50% Conservative: 2
Best Local Similarity: 56.25% Mismatches: 4
Query Match: 65.86% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B.SEQ (1-81) x Q9QB08 (1-597)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATGATGGAGCCACCAACT 61
Db ||||:|
61 GlyLys----GlyLeu----GluTrpIleGlyGluIleAenHisSerGlySerThrAsnT 78
||||:|
```

```
Qy 62 ACAACCGCTCCCTCAAGAGT 81
||||:|
Db 78 YrAenProSerLeuLysSer 84
||||:|

RESULT 7
Q6P418 PRELIMINARY; PRT; 576 AA.
ID Q6P418
AC Q6P418
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHM protein.
GN Name=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -.
DR HSP; P01820; IA7N.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR SMART; SM00407; IGcl; 3.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63363 MW; FBB97C949D720F1E CRC64;

Alignment Scores:
Pred. No.: 0.00658 Length: 576
Score: 92.00 Matches: 21
Percent Similarity: 48.89% Conservative: 1
Best Local Similarity: 46.67% Mismatches: 3
Query Match: 65.71% Indels: 20
DB: 2 Gaps: 1

NOLAN463-1B.SEQ (1-81) x Q6P418 (1-576)
```

```

QY 3 GCGGAGTCAGGATATTAGCAGC----- 24
DB 52 GlyGlySer-----IleSerSerSerAsnTrpTrpVala:rgInProProGlyly 70
QY 25 -----TGTTAGCCGAATCAATCATAGTGGAGCAACCACTACACCGTCCCT 74
DB 70 sclyleuGluTrpIleGlyGluIleTyHisSerGlySerThrAsnTyAsnProSerue 90
QY 75 CAAGAGT 81
DB 90 ulysSer 92

RESULT 8
ID HV2I_HUMAN STANDARD; PRT; 146 AA.
AC P06331;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig heavy chain V-II region ARH-77 precursor.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RP MEDLINE=85205332; PubMed=3922855; DOI=10.1016/0378-1119(85)90092-7;
RX Kudo A., Ishihara T., Nishimura Y., Watanabe T.;
RA "A cloned human immunoglobulin heavy chain gene with a novel direct-
RT repeat sequence in 5' flanking region.";
RL Gene 33:181-189(1985).
DR PIR; A02101; GIHUH2.
DR HSSP; P01825; 7FAB.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 146 Ig heavy chain V-II region ARH-77.
FT DOMAIN 20 117 V segment.
FT DOMAIN 118 127 D segment.
FT DOMAIN 128 146 J segment.
FT DISULFID 42 115 By similarity.
FT NON_TER 146 146
SQ SEQUENCE 146 AA; 16228 MW; 8D7FD52BB218171F CRC64;

Alignment Scores:
Pred. No.: 0.024 Length: 146
Score: 87.20 Matches: 18
Percent Similarity: 59.38% Conservative: 1
Best Local Similarity: 56.25% Mismatches: 5
Query Match: 62.29% Indels: 8
DB: 1 Gaps: 0

NOLAN463-1B_SEQ (1-81) x HV2I_HUMAN (1-146)

QY 2 GCGGAGTCAGGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGGAGCAACCACT 61
DB 62 GlyArg-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 79
QY 62 ACAACCCGTCCTCAAGACT 81
DB 79 yzLysThrSerLeuLysSer 85

RESULT 9
QSGMX7
ID Q6GMX7 PRELIMINARY; PRT; 477 AA.
AC Q6GMX7;

```

```

DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RP TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usslin T.B., Toshiyuki S., Carninci P., Frange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smalios D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
SEQUENCE FROM N.A.
RP TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073765; AAH73765.1; -.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR Pfam; PF00047; Ig; 3.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 477 AA; 51631 MW; 9PE59C09C50CFF85 CRC64;

Alignment Scores:
Pred. No.: 0.135 Length: 477
Score: 82.10 Matches: 19
Percent Similarity: 47.73% Conservative: 2
Best Local Similarity: 43.18% Mismatches: 4
Query Match: 58.64% Indels: 19
DB: 2 Gaps: 1

NOLAN463-1B_SEQ (1-81) x Q6GMX7 (1-477)

QY 3 GCGGAGTCAGGATATTAGCAGC----- 24
DB 45 GlyGlySer-----IleSerSerTyTrpSerTrpIleArgGlnThrAlaGlyLysGl 63
QY 25 -----TGTTAGCCGAATCAATCATAGTGGAGCAACCACTACACCGTCCCTCAA 77
DB 63 yLeuGluTrpIleGlyTyrlleSerHisSerGlySerThrThrTyAsnProSerleuly 83
QY 78 GAGT 81

```



```

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/cJ;
RX MEDLINE=89279149; PubMed=2499654;
RT Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
RT "Early onset of somatic mutation in immunoglobulin VH genes during the
RT primary immune response.";
RL J. Exp. Med. 169:2007-2019(1989).
CC 1- MISCELLANEOUS: This sequence belongs to the VH3660 subfamily.
DR PIR; JT0508; HVMS1B.
DR PDB; 1KGS; X-ray; H=19-116.
DR PDB; 1KCV; X-ray; H=19-116.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003396; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW 3D-structure; Immunoglobulin V region; Signal.
FT SIGNAL 1 18
FT CHAIN 19 116 Ig heavy chain V region 1B43.
FT DOMAIN 19 48 Framework-1.
FT DOMAIN 49 53 Complementarity-determining-1.
FT DOMAIN 54 67 Framework-2.
FT DOMAIN 68 84 Complementarity-determining-2.
FT DOMAIN 85 116 Framework-3.
FT DISULFID 40 114 By similarity.
FT STRAND 21 25
FT STRAND 29 30
FT TURN 32 33
FT STRAND 35 43
FT TURN 47 49
FT STRAND 52 58
FT TURN 60 61
FT STRAND 64 71
FT TURN 72 73
FT STRAND 76 78
FT TURN 80 85
FT STRAND 86 91
FT TURN 92 95
FT STRAND 96 101
FT HELIX 106 108
FT STRAND 110 116
FT NON_TER 116
SQ SEQUENCE 116 AA; 13158 MW; 1CB547253681FF74 CRC64;

Alignment Scores:
Pred. No.: 0.805 Length: 116
Score: 75.70 Matches: 16
Percent Similarity: 56.76% Conservative: 5
Best Local Similarity: 43.24% Mismatches: 3
Query Match: 54.07% Indels: 13
DB: 1 Gaps: 1

NOLAN463-1B_SEQ (1-81) x HV61_MOUSE (1-116)
QY 9 TCAGGATATTAGC-----AGCTGGTTAGC 32
Db 49 SerGlyTyr-SerTTPHisTTPleArgGlnPheProGlyAsnLysLeuGluTTPMetG1 68
QY 33 CGAATCATCATAGTAGGAGACCACTAGAACCCGTCCTCAGACT 81
Db 68 yTyrlleHisTyrSerGlyAsnThrSerTyrAsnProSerLeuLysSer 84

RESULT 14
Q6GMX6 PRELIMINARY; PRT; 465 AA.
ID Q6GMX6
AC Q6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)

```

```
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.W., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.B.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Boeak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Heltan E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krywinski M.I., Skalska U., Smaluk D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: BC073766; AAT73766.1; -.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.V.
DR Pfam: PF07654; Cl-set; 3.
DR Pfam: PF00047; Ig; 4.
DR SMART: SM00409; IG; 2.
DR SMART: SM00407; IGL; 3.
DR SMART: SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FDB1386E CRC64;

Alignment Scores:
Pred. No.: 1.13 Length: 465
Score: 75.20 Matches: 16
Percent Similarity: 56.25% Conservative: 2
Best Local Similarity: 50.00% Mismatches: 6
Query Match: 53.71% Indels: 8
DB: 2 Gaps: 0

NOLAN463-1B_SEQ (1-81) x Q6GMX6 (1-465)

QY 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAATCAATCATATAGTCGAGCACCACCACT 61
Db |||:||||| |||:|||||
QY 61 GlyLys----GlyLeu----GluTrpIleGlyArgIleYrThrSerGlySerThrAsnT 78
Db |||:||||| |||:|||||

QY 62 ACAACCCGCTCCTCAAGAGT 81
Db |||:||||| |||:|||||

QY 78 YrAsnProSerLeuLysSer 84
Db |||:||||| |||:|||||

RESULT 15
Q65Z11 PRELIMINARY; PRT; 262 AA.
ID Q65Z11
AC Q65Z11;
```

```
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Anti-HIV-1 reverse transcriptase single-chain variable.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hybridoma;
RX MEDLINE=96211469; PubMed=8648670;
RA Shaheen F., Duan L., Zhu M., Bagasra O., Pomerantz R.J.;
RT "targeting human immunodeficiency virus type 1 reverse transcriptase
by intracellular expression of single-chain variable fragments to
inhibit early stages of the viral life cycle.";
RL J. Virol. 70:3392-3400(1996).
DR EMBL: U48716; AAB64342.1; -.
DR GO; GO:0003964; P:RNA-directed DNA polymerase activity; IEA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003596; Ig_v.
DR Pfam: PF00047; Ig; 2.
DR SMART: SM00409; IG; 2.
DR SMART: SM00408; IGV; 2.
DR SMART: SM00406; IGV; 2.
DR PROSITE; PS50835; IG LIKE; 2.
KW RNA-directed DNA polymerase.
SQ SEQUENCE 262 AA; 27842 MW; 7DF20138E53865B4 CRC64;

Alignment Scores:
Pred. No.: 2.19 Length: 262
Score: 72.80 Matches: 16
Percent Similarity: 55.56% Conservative: 4
Best Local Similarity: 44.44% Mismatches: 4
Query Match: 52.00% Indels: 12
DB: 2 Gaps: 1

NOLAN463-1B_SEQ (1-81) x Q65Z11 (1-262)

QY 9 TCAGGATATTAGCAGCTGGTTAGCCGAA----- 36
Db |||:||||| |||:|||||
QY 178 SerGlyTyr-TrpAsnTrpIleArgLysPheProGlyAsnLysLeuAspTyrMetGlyTy 197
Db |||:||||| |||:|||||

QY 37 -ATCAATCATAGTCGAGCACCACCACTACACCCGCTCCTCAAGAGT 81
Db |||:||||| |||:|||||

QY 197 rIleAsnTyrSerGlyAspThrTyrTyrAsnProSerLeuLysSer 212
Db |||:||||| |||:|||||

Search completed: August 4, 2005, 18:20:08
Job time : 85.75 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:21:34 ; Search time 90 Seconds
(without alignments)
721.953 Million cell updates/sec

Title: NOLAN463-2A.SEQ

Perfect score: 148

Sequence: 1 ATCATCTATCTGCTGACTC.....GTATTAGCAGCTGGTTAGCC 84

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 4211384

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2.1/USPTO.spool.p/NOLAN08728463-2/runat_04082005_123943_22574/app.query.fasta_1.5
-DB=A_Geneseq -OFMT=fastan -SUFFIX=rag -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
-UNIT5=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.coi -LIST=45
-DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN08728463-2 @CGN 1 1 308 @runat_04082005_123943_22574 -NCPU=6
-ICPU=3 -NO MMAP -LARGQUERY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : A_Geneseq_16Dec04.*

1: Genesep1980s.*
2: Genesep1990s.*
3: Genesep2000s.*
4: Genesep2001s.*
5: Genesep2002s.*
6: Genesep2003as.*
7: Genesep2003bs.*
8: Genesep2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	114.1	77.1	240	AAV15128	AAV15128 Anti-muri
2	104.9	70.9	302	AAE70844	AAE70844 SNV-env 1
3	97.9	66.1	116	AAH48005	AAH48005 Human mon
4	97.9	66.1	116	ADR46821	ADR46821 Human ant
5	97.9	66.1	411	ADR46829	ADR46829 Human pB1
6	97.9	66.1	468	ADR46819	ADR46819 Human ant
7	97.9	66.1	613	ADR46827	ADR46827 Human bet
8	96.2	65.0	118	ADP47114	ADP47114 Human pho
9	95.4	64.5	129	ADK18605	ADK18605 Anti-huma
10	95.4	64.5	129	ADK18791	ADK18791 Anti-huma

11	95.4	64.5	129	7	ADK18895	Adk18895 Anti-huma
12	95.4	64.5	129	7	ADK18826	Adk18826 Anti-huma
13	95.4	64.5	129	8	ADL25428	Adl25428 Human mAb
14	94.9	64.1	116	8	ADP22194	Adp22194 Human ant
15	93.8	63.4	118	8	ADP47088	Adp47088 Human pho
16	93.5	63.2	118	8	ADP47090	Adp47090 Human pho
17	93.5	63.2	118	8	ADP47098	Adp47098 Human pho
18	93.5	63.2	118	8	ADP47224	Adp47224 Human pho
19	93.5	63.2	245	4	AAE67621	AAE67621 Human leu
20	93.2	63.0	123	5	ABG76561	Abg76561 HCV E1 an
21	92.4	62.4	225	6	ABR01521	AbR01521 Human ant
22	92.2	62.3	84	2	AAW62797	Aaw62797 Amino aci
23	92.2	62.3	98	5	ABG78233	Abg78233 Human Fv
24	92.2	62.3	98	5	ABG78231	Abg78231 Human Fv
25	92.2	62.3	98	5	ABG91924	Abg91924 Human ant
26	92.2	62.3	98	5	ABG91922	Abg91922 Human ant
27	92.2	62.3	98	6	ABP56508	Abp56508 Human ant
28	92.2	62.3	98	6	ABJ18687	Abj18687 Antibody
29	92.2	62.3	98	6	ABO27112	ABO27112 Human ger
30	92.2	62.3	98	7	ADD69247	Add69247 Human hea
31	92.2	62.3	98	7	ADF10156	Adf10156 Antibody
32	92.2	62.3	98	7	ADF09948	Adf09948 Antibody
33	92.2	62.3	98	7	ADF10053	Adf10053 VEGF anti
34	92.2	62.3	98	7	ADK18943	Adk18943 Anti-huma
35	92.2	62.3	98	7	ADK18888	Adk18888 Anti-huma
36	92.2	62.3	98	7	ADK18877	Adk18877 Anti-huma
37	92.2	62.3	98	7	ADK18878	Adk18878 Anti-huma
38	92.2	62.3	98	7	ADK18912	Adk18912 Anti-huma
39	92.2	62.3	98	7	ADK18582	Adk18582 Anti-huma
40	92.2	62.3	98	7	ADK18890	Adk18890 Anti-huma
41	92.2	62.3	98	7	ADK18896	Adk18896 Anti-huma
42	92.2	62.3	98	7	ADK18894	Adk18894 Anti-huma
43	92.2	62.3	98	7	ADK18914	Adk18914 Anti-huma
44	92.2	62.3	98	7	ADJ80328	Adj80328 VH gene 1
45	92.2	62.3	98	8	ADR46847	Adr46847 Human VH5

ALIGNMENTS

RESULT 1
AAV15128
ID AAV15128 standard; protein; 240 AA.
XX
AC AAV15128;

DT 07-FEB-2000 (first entry)

DE Anti-murine CTLA-4 M24 sFv.

XX
KW Anti-murine CTLA-4 sFv; M24 sFv; single chain antibody; murine CTLA4;
membrane-associated protein; chimeric construct; extracellular domain;
human CD8; ligand; activated T-cell; co-stimulatory signal; donor B7;
KW recipient CD28; T-cell proliferation;
KW xenograft-specific immunosuppression.

XX Mus sp.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 153 /note= "Corresponds to atc codon"

FT

XX WO9957266-A2.

XX PD 11-NOV-1999.

XX PF 30-APR-1999; 99WO-GB001350.

XX PR 30-APR-1998; 98GB-00009280.

XX PA (IMCO-) IMPERIAL COLLEGE INNOVATIONS LTD.

XX Lechler IR, Dorling A;

XX WPI; 2000-039815/03.
 DR N-PSDB; AAZ229000.
 XX
 PT Inhibiting T-cell mediated rejection of xenotransplanted organs.
 XX
 PS Claim 9; Fig 11; 43pp; English.
 XX
 CC The present sequence is the anti-murine CTLA-4 sFv (M24 sFv). This is a
 CC membrane-associated protein which binds to CTLA-4. Chimeric constructs
 CC comprising DNA sequences encoding the extracellular domain of murine
 CC CTLA4 and human CD8 were used for the study of anti-CTLA4-sFv protein.
 CC The anti-CTL4 sFv functions as a ligand binding to CTLA-4 on activated
 CC T-cells and antagonises the co-stimulatory signal provided by the
 CC interaction between donor B7 and recipient CD28. Cells expressing the
 CC anti-hCTLA4 sFv failed to stimulate T-cell proliferation. This is used in
 CC xenograft-specific immunosuppression
 XX
 SQ Sequence 240 AA;

Alignment Scores:
 Pred. No.: 0.000165 Length: 240
 Score: 114.10 Matches: 26
 Percent Similarity: 23.08% Conservative: 1
 Best Local Similarity: 22.22% Mismatches: 1
 Query Match: 77.09% Indels: 89
 DB: 3 Gaps: 1

NOLAN463-2A.SEQ (1-84) x AAY15128 (1-240)

Qy 1 ATCATCTATCTGGTGACTCTGATACACATACACCGCTCTTCCRAAGGC----- 51
 Db 50 lilellyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyValThr 69
 Qy 51 ----- 51
 Db 70 lIeSerAlaAspLySeriIeSerThrAlaTyrLeuGlnTrpSerSerLeuIysAlaSer 89
 Qy 51 ----- 51
 Db 90 AspThrAlaValTyrTyrCysAlaArgPheSerLeuGlyGlyPheAspTyrTrpGlyGln 109
 Qy 51 ----- 51
 Db 110 GlyThrLeuValThrValSerSerGlyGlyGlySerGlyGlyGlySerGlyGly 129
 Qy 51 ----- 51
 Db 130 SerAlaLeuAspIleGlnLeuThrGlnSerProSerPheLeuSerAlaSerValGlyAsp 149
 Qy 52 -----CGGCGAGTCAGGTATTACAGCTGTTAGCC 84
 Db 150 ArgValThrThrCysArgAlaSerGlnGlyIleSerSerTyrLeuAla 166

RESULT 2
 AAB70844
 ID AAB70844 standard; protein; 302 AA.
 XX
 AC AAB70844;

XX
 DT 11-SEP-2003 (revised)
 DT 25-JUN-2001 (first entry)
 DE SNV-env leader/human 6C3-scFv fusion construct.
 XX
 KW T lymphocyte; antibody; single chain variable antibody; scFv; human;
 KW cell-targeting vector; antiviral; cytostatic; immunostimulant; AIDS;
 KW gene therapy; immunization; diagnosis; T cell-associated disease; SCID;
 KW acquired immune deficiency syndrome; severe combined immune deficiency;
 KW T cell lymphoma; fusion construct.
 XX
 OS Homo sapiens.
 OS Spleen necrosis virus.

OS Chimeric.
 XX Key Location/Qualifiers
 FT Protein 1..45
 FT /label= SNV-env_leader
 FT Protein 46..302
 FT /label= 6C3-scFv
 XX
 PN DE19946142-A1.
 XX 29-MAR-2001.
 PD
 XX 27-SEP-1999; 99DE-01046142.
 XX 27-SEP-1999; 99DE-01046142.
 XX (BUND) BUNDESREPUBLIK DEUT PAUL-EHRLICH-INST.
 XX Cichutek K, Engelstaedter M;
 PI WPI; 2001-246140/26.
 DR N-PSDB; AAF61513.
 XX
 PT Cell-targeting vector selective for T lymphocytes, useful in gene therapy
 of e.g. acquired immune deficiency syndrome, encodes a single-chain
 PT variable antibody fragment.
 XX
 PS Claim 1; Fig 5; 18pp; German.
 XX
 CC This invention describes a novel cell-targeting vector (A) containing a
 CC DNA sequence (I) encoding a single-chain variable antibody fragment
 CC (scFv). The products of the invention have antiviral, cytostatic and
 CC immunostimulant activity and can be used in gene therapy, immunization
 CC and diagnosis particularly of T cell-associated diseases, specifically
 CC acquired immune deficiency syndrome (AIDS), severe combined immune
 CC deficiency (SCID) or T cell lymphoma. (A) target T cells, independently
 CC of the CD4 receptor, with high selectivity, 4-5 fold selectivity over
 CC human B cells, and 1000 fold selectivity over other human cells. A vector
 CC designated 7A5 encodes a 329 amino acid single-chain variable antibody
 CC fragment, fully defined in the specification. It was used to transform
 CC D17 (canine osteosarcoma cells susceptible to spleen necrosis virus
 CC (SNV)) cells, C8166 (human T lymphocyte) cells, and HeLa (human cervical
 CC carcinoma) cells. After 48 hours, the cells were stained with X-gal to
 CC determine transfection. The viral titer (infectious units/ml) was over
 CC 1 million for D17, 1 million for C8166 but less than 100 for HeLa,
 CC showing the high selectivity for human T cells. This sequence represents
 CC the SNV-env leader/human 6C3-scFv fusion construct used in the
 CC construction of novel cell targeting vectors described in the invention.
 CC (Updated on 11-SEP-2003 to standardise OS field)

SQ Sequence 302 AA;

Alignment Scores:
 Pred. No.: 0.00218 Length: 302
 Score: 104.90 Matches: 23
 Percent Similarity: 19.38% Conservative: 2
 Best Local Similarity: 17.83% Mismatches: 3
 Query Match: 70.88% Indels: 101
 DB: 4 Gaps: 1

NOLAN463-2A.SEQ (1-84) x AAB70844 (1-302)

Qy 1 ATCATCTATCTGGTGACTCTGATACACATACACCGCTCTTCCRAAGGC----- 51
 Db 97 LeuIleTyrProGlyAspSerAspThrLysTyrSerProSerPheGlnGlyValThr 116
 Qy 51 ----- 51
 Db 117 lIeSerAlaAspLySeriIeSerThrAlaTyrLeuGlnTrpSerSerLeuIysAlaSer 136
 Qy 51 ----- 51
 Db 137 AspThrAlaMetTyrTyrCysAlaArgValSerGlyTyrCysSerSerThrSerCysTyr 156

QY 51 ----- 51
 Db 157 AspTyrTyrTyrTyrMetAspValTrpGlyArgGlyThrLeuValThrValSerArg 176
 QY 51 ----- 51
 Db 177 GlyGlyGlyGlySerGlyGlyGlySerGlyGlyGlyGlySerAspIleValMetThr 196
 QY 52 -----CGGGGG 57
 Db 197 GlnSerProSerThrLeuSerAlaSerValGlyAspArgValThrMetThrCysArgAla 216
 QY 58 ACTCAGGTATTAGCAGCTGTTAGCC 84
 Db 217 SerGlnAsnIleAsnIleTrpLeuAla 225

RESULT 3

AAM48005

ID AAM48005 standard; protein; 116 AA.

XX AC

XX AAM48005;

XX DT 08-MAR-2002 (first entry)

XX DE Human monoclonal antibody B11 variable heavy chain protein.

XX KW Human; monoclonal antibody; B11; antigen binding portion; dendritic cell;
 KW mannose receptor; growth; cytolysis; pathogen; virus; bacterium;
 KW autoimmune disease; inflammatory disorder; rheumatoid arthritis;
 KW multiple sclerosis; diabetes mellitus; immunomodulatory;
 KW antiinflammatory; antirheumatic; antiarthritic; neuroprotective;
 KW antidiabetic; antianaemic; endocrine; dermatological; antithyroid;
 KW uropathic; ophthalmological; muscular.

XX OS Homo sapiens.

XX XX WO200185799-A2.

XX PN 15-NOV-2001.

XX PD 08-MAY-2001; 2001WO-US015114.

XX PF 08-MAY-2000; 2000US-0203126P.

XX PR 07-SEP-2000; 2000US-0230739P.

XX XX (MEDA-) MEDAREX INC.

XX PA Deo YM, Keler T;

XX PI WPI; 2002-089788/12.

XX DR N-PSDB; ABA05500.

XX XX New human monoclonal antibodies specific for dendritic cells, useful for
 PT inhibiting growth or inducing cytolysis of a dendritic cell and treating
 PT or preventing a dendritic cell mediated disease, e.g., autoimmune
 PT disorders.

XX PS Example 2; Fig 13; 95pp; English.

XX XX The invention relates to human monoclonal antibodies or their antigen
 CC binding portions that specifically bind to dendritic cells and has one or
 CC more of the following characteristics: (a) a binding affinity constant to
 CC a dendritic cell of at least about 10 to the power 7 M-1; (b) the ability
 CC to opsonise a dendritic cell; (c) the ability to internalise after
 CC binding to dendritic cells; or (d) the ability to activate dendritic
 CC cells. The isolated human monoclonal antibody or its antigen binding
 CC portion may also have any of the following characteristics: (a) mediates
 CC cytolysis of dendritic cells in the presence of human effector cells; or
 CC (b) inhibits growth of dendritic cells. The antibodies or its antigen
 CC binding portion, binds to and blocks the human mannose receptor on
 CC dendritic cells. The antibodies have immunomodulatory, antiinflammatory,
 CC antirheumatic, antiarthritic, neuroprotective, antidiabetic, antianaemic,

CC endocrine, dermatological, antithyroid, uropathic, ophthalmological and
 CC muscular activity. The antibodies or their antigen-binding fragments are
 CC useful for inhibiting growth of a dendritic cell, inducing cytolysis of a
 CC dendritic cell, treating or preventing a dendritic cell mediated disease,
 CC detecting the presence of a dendritic cell, targeting an antigen to a
 CC dendritic cell and preventing binding of a pathogen (a virus or a
 CC bacterium) to human mannose receptor on dendritic cells. In particular,
 CC the antibodies may be used to treat, autoimmune disease, graft versus
 CC host disease, immune system or inflammatory disorders (e.g. rheumatoid
 CC arthritis), multiple sclerosis, diabetes mellitus, myasthenia gravis,
 CC pernicious anaemia, Addison's disease, lupus erythematosus, Reiter's
 CC syndrome and Graves disease. The present sequence is that of the human
 CC monoclonal antibody B11 variable heavy chain, useful to the invention
 XX SQ Sequence 116 AA;

Alignment Scores:

Pred. No.: 0.0111 Length: 116
 Score: 97.90 Matches: 19
 Percent Similarity: 36.84% Conservative: 2
 Best Local Similarity: 33.33% Mismatches: 5
 Query Match: 66.15% Indels: 31
 DB: 5 Gaps: 1

NOLAN463-2A-SEQ (1-84) x AAM48005 (1-116)

QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTCCAAAGC----- 51

Db 50 llelleTyrProGlyAspSerAspThrIleTyrSerProSerPheGlnGlyGlnValThr 69

QY 51 ----- 51

Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89

QY 52 -----CGGGCGAGTCAGGGTATTAGCAGCTGG 78

Db 90 AspThrAlaMetTyrTyrCysThrArgGlyAspArgGlyValAspTyrTrp 106

RESULT 4

ADR46821

ID ADR46821 standard; protein; 116 AA.

XX AC ADR46821;

XX DT 18-NOV-2004 (first entry)

XX DE Human antibody B11 heavy chain variable region protein SEQ ID NO:4.

XX KW molecular conjugate; monoclonal antibody; human antigen presenting cell;
 KW antigen presenting cell; APC; human; beta human chorionic gonadotropin;
 KW betahCG; beta chorionic gonadotropin; antibody;
 KW T cell-mediated immune response; immunisation; cytostatic; antimicrobial;
 KW immunosuppressive; anti-HIV; hepatotropic; virucide; antimalarial;
 KW CD8 agonist; vaccine; autoimmune disorder; cancer; infectious disease;
 KW melanoma; fibrosarcoma; leukaemia; HIV; hepatitis; malaria; herpes;
 KW antibody B11; heavy chain variable region.

XX OS Homo sapiens.

XX XX WO2004074432-A2.

XX PN 02-SEP-2004.

XX PD 30-JAN-2004; 2004WO-US002725.

XX PF 31-JAN-2003; 2003US-0443979P.

XX PR (MEDA-) MEDAREX INC.

XX PA Keler T, Endres M, He L, Ramakrishna V;

XX PI WPI; 2004-635555/61.

XX DR N-PSDB; ADR46820.

XX New molecular conjugate having a monoclonal antibody that binds to human
PT APCs linked to a beta human chorionic gonadotropin, useful for inducing a
PT cytotoxic T cell response in cancers and infectious diseases.
XX
XX
XX Claim 11; SEQ ID NO 4; 82pp; English.
XX
XX The present invention describes a molecular conjugate comprising a
CC monoclonal antibody that binds to human antigen presenting cells (APCs)
CC linked to beta human chorionic gonadotropin (betahCG), where the antibody
CC comprises a heavy and/or light chain variable region derived from a human
CC VH5-51 or VK-L15 germline sequence with the 98 or 95 amino acid sequences
CC of SEQ ID NO:30 or 32 (ADR46847, or ADR46849), respectively. Also
CC described: (1) a molecular conjugate comprising a human antibody heavy
CC chain and a human antibody light chain, where either or both chains are
CC linked to betahCG; (2) a molecular conjugate comprising a human single
CC chain antibody that binds to human APCs linked to betahCG, where the
CC conjugate comprises the 411 amino acid sequence of SEQ ID NO:12
CC (ADR46829); (3) a composition comprising any of the molecular conjugates
CC as described above, and a carrier, optionally in combination with an
CC adjuvant; (4) inducing or enhancing a T cell-mediated immune response,
CC against betahCG, comprising contacting any of the molecular conjugates
CC described above with APCs such that the antigen is processed and
CC presented to T cells in a manner which induces or enhances a T cell-
CC mediated response against the antigen; (5) immunising a subject
CC comprising administering any of the molecular conjugates described above,
CC optionally in combination with an adjuvant, a cytokine which stimulates
CC proliferation of dendritic cells and/or an immunostimulatory agent; and
CC (6) inducing or enhancing a cytotoxic T cell response against an antigen,
CC comprising forming a conjugate of the antigen and a monoclonal antibody
CC which binds to APCs, and contacting the conjugate either in vivo or ex
CC vivo with APCs such that the antigen is internalised, processed and
CC presented to T cells in a manner which induces or enhances a cytotoxic T
CC cell response against the antigen. The molecular conjugate has
CC cytostatic, antimicrobial, immunosuppressive, anti-HIV, hepatotropic,
CC virucide and antimalarial activities, and can be used as a CD8 agonist,
CC and in vaccines. The methods and compositions of the present invention
CC are useful for inducing a cytotoxic T cell response, and in particular
CC for treating autoimmune disorders, cancers and infectious diseases by
CC eliciting a potent antigen-specific cytotoxic T lymphocyte response,
CC including melanoma, fibrosarcoma, leukaemia, HIV, hepatitis, malaria and
CC herpes. The present sequence represents a human antibody B11 heavy chain
CC variable region, which is used in the exemplification of the present
XX invention.

SQ Sequence 116 AA;

Alignment Scores:
Pred. No.: 0.0111 Length: 116
Score: 97.90 Matches: 19
Percent Similarity: 36.84% Conservatives: 2
Best Local Similarity: 33.33% Mismatches: 5
Query Match: 66.15% Indels: 31
DB: 8 Gaps: 1

NOLAN463-2A.SEQ (1-84) x ADR46821 (1-116)

QY 1 ATCATCTATCTGGTGAATCTGATACACATACACCGCTCTTCCAGGC----- 51
Db 50 IletleTyProGlyAspSerAspThrIleTySerProSerPheGlnGlycInValThr 69
QY 51 ----- 51
Db 70 IleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrpSerSerLeuLysAlaSer 89
QY 52 -----CGGCGAGTCAGGCTGATTCAGCTGG 78
Db 90 AspThrAlaMetTyTyTyThrArgGlyAspArgGlyValAspTyTrp 106
|||
|||

RESULT 5
ADR46829
ID ADR46829 standard; protein; 411 AA.

AC ADR46829;
XX
XX 18-NOV-2004 (first entry)
XX
XX Human pB11-betahCG molecular conjugate protein SEQ ID NO:12.
XX
XX
XX molecular conjugate; monoclonal antibody; human antigen presenting cell;
KW antigen presenting cell; APC; human; beta human chorionic gonadotropin;
KW betahCG; beta chorionic gonadotropin; antibody;
KW T cell-mediated immune response; immunisation; cytostatic; antimicrobial;
KW immunosuppressive; anti-HIV; hepatotropic; virucide; antimalarial;
KW CD8 agonist; vaccine; autoimmune disorder; cancer; infectious disease;
KW melanoma; fibrosarcoma; leukaemia; HIV; hepatitis; malaria; herpes;
KW antibody B11; pB11-betahCG molecular conjugate; fusion protein.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX WO2004074432-A2.
XX
XX 02-SEP-2004.
XX
XX 30-JAN-2004; 2004WO-US002725.
XX
XX 31-JAN-2003; 2003US-0443979P.
XX
XX (MEDA-) MEDAREX INC.
XX
XX Keler T, Endres M, He L, Ramakrishna V;
XX WPI; 2004-635555/61.
XX N-PSDB; ADR46828.
XX
XX New molecular conjugate having a monoclonal antibody that binds to human
PT APCs linked to a beta human chorionic gonadotropin, useful for inducing a
PT cytotoxic T cell response in cancers and infectious diseases.
XX
XX Claim 16; SEQ ID NO 12; 82pp; English.
XX
XX The present invention describes a molecular conjugate comprising a
CC monoclonal antibody that binds to human antigen presenting cells (APCs)
CC linked to beta human chorionic gonadotropin (betahCG), where the antibody
CC comprises a heavy and/or light chain variable region derived from a human
CC VH5-51 or VK-L15 germline sequence with the 98 or 95 amino acid sequences
CC of SEQ ID NO:30 or 32 (ADR46847, or ADR46849), respectively. Also
CC described: (1) a molecular conjugate comprising a human antibody heavy
CC chain and a human antibody light chain, where either or both chains are
CC linked to betahCG; (2) a molecular conjugate comprising a human single
CC chain antibody that binds to human APCs linked to betahCG, where the
CC conjugate comprises the 411 amino acid sequence of SEQ ID NO:12
CC (ADR46829); (3) a composition comprising any of the molecular conjugates
CC as described above, and a carrier, optionally in combination with an
CC adjuvant; (4) inducing or enhancing a T cell-mediated immune response,
CC against betahCG, comprising contacting any of the molecular conjugates
CC described above with APCs such that the antigen is processed and
CC presented to T cells in a manner which induces or enhances a T cell-
CC mediated response against the antigen; (5) immunising a subject
CC comprising administering any of the molecular conjugates described above,
CC optionally in combination with an adjuvant, a cytokine which stimulates
CC proliferation of dendritic cells and/or an immunostimulatory agent; and
CC (6) inducing or enhancing a cytotoxic T cell response against an antigen,
CC comprising forming a conjugate of the antigen and a monoclonal antibody
CC which binds to APCs, and contacting the conjugate either in vivo or ex
CC vivo with APCs such that the antigen is internalised, processed and
CC presented to T cells in a manner which induces or enhances a cytotoxic T
CC cell response against the antigen. The molecular conjugate has
CC cytostatic, antimicrobial, immunosuppressive, anti-HIV, hepatotropic,
CC virucide and antimalarial activities, and can be used as a CD8 agonist,
CC and in vaccines. The methods and compositions of the present invention
CC are useful for inducing a cytotoxic T cell response, and in particular
CC for treating autoimmune disorders, cancers and infectious diseases by
CC eliciting a potent antigen-specific cytotoxic T lymphocyte response,
CC including melanoma, fibrosarcoma, leukaemia, HIV, hepatitis, malaria and
CC herpes. The present sequence represents a human antibody B11 heavy chain
CC variable region, which is used in the exemplification of the present
XX invention.

CC herpes. The present sequence represents a human pB11-betahCG molecular
 CC conjugate, which is used in the exemplification of the present invention.

XX Sequence 411 AA;

Alignment Scores:
 Pred. No.: 0.0162 Length: 411
 Score: 97.90 Matches: 19
 Percent Similarity: 36.84% Conservative: 2
 Best Local Similarity: 33.33% Mismatches: 5
 Query Match: 66.15% Indels: 31
 DB: 8 Gaps: 1

NOLAN463-2A.SEQ (1-84) x ADR46829 (1-411)

QY 1 ATCATCTATCTGGTACTCTGATACACATACAGCCGCTCTTCCAGGC----- 51
 |||||
 Db 191 lleiletyrProGlyAspSerAspThrIleTyrSerProSerPheGlnGlyGlnValThr 210
 |||||
 QY 51 ----- 51
 |||||
 Db 211 lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 230
 |||||
 QY 52 -----CGGGCGAGTCAGGCTATTAGCAGCTGG 78
 |||||
 Db 231 AspThrAlaMetTyrTyrCysThrArgGlyAspArgGlyValAspTyrTrp 247
 |||||

RESULT 6

ADR46819

ID ADR46819 standard; protein; 468 AA.

XX ADR46819;

XX 18-NOV-2004 (first entry)

XX Human antibody B11 heavy chain variable region protein SEQ ID NO:2.

XX molecular conjugate; monoclonal antibody; human antigen presenting cell;
 KW antigen presenting cell; APC; human; beta human chorionic gonadotropin;
 KW betahCG; beta chorionic gonadotropin; antibody;
 KW T cell-mediated immune response; immunisation; cytostatic; antimicrobial;
 KW immunosuppressive; anti-HIV; hepatotropic; virucide; antimalarial;
 KW CD8 agonist; vaccine; autoimmune disorder; cancer; infectious disease;
 KW melanoma; fibrosarcoma; leukaemia; HIV; hepatitis; malaria; herpes;
 KW antibody B11; heavy chain variable region.

XX Homo sapiens.

XX WO2004074432-A2.

XX 02-SEP-2004.

XX 30-JAN-2004; 2004WO-US002725.

XX 31-JAN-2003; 2003US-0443979P.

XX (MEDA-) MEDAREX INC.

XX Keler T, Endres M, He L, Ramakrishna V;

XX WPI; 2004-635555/61.

XX N-PSDB; ADR46818.

XX New molecular conjugate having a monoclonal antibody that binds to human
 PT APCs linked to a beta human chorionic gonadotropin, useful for inducing a
 PT cytotoxic T cell response in cancers and infectious diseases.

XX Claim 13; SEQ ID NO 2; 82pp; English.

XX The present invention describes a molecular conjugate comprising a
 CC monoclonal antibody that binds to human antigen presenting cells (APCs)
 CC linked to beta human chorionic gonadotropin (betahCG), where the antibody
 CC comprises a heavy and/or light chain variable region derived from a human

CC VHS-51 or Vx-115 germline sequence with the 98 or 95 amino acid sequences
 CC of SEQ ID NO:30 or 32 (ADR46847, or ADR46849), respectively. Also
 CC described: (1) a molecular conjugate comprising a human antibody heavy
 CC chain and a human antibody light chain, where either or both chains are
 CC linked to betahCG; (2) a molecular conjugate comprising a human single
 CC chain antibody that binds to human APCs linked to betahCG, where the
 CC conjugate comprises the 411 amino acid sequence of SEQ ID NO:12
 CC (ADR46829); (3) a composition comprising any of the molecular conjugates
 CC as described above, and a carrier, optionally in combination with an
 CC adjuvant; (4) inducing or enhancing a T cell-mediated immune response,
 CC against betahCG, comprising contacting any of the molecular conjugates
 CC described above with APCs such that the antigen is processed and
 CC presented to T cells in a manner which induces or enhances a T cell-
 CC mediated response against the antigen; (5) immunising a subject
 CC comprising administering any of the molecular conjugates described above,
 CC optionally in combination with an adjuvant, a cytokine which stimulates
 CC proliferation of dendritic cells and/or an immunostimulatory agent; and
 CC (6) inducing or enhancing a cytotoxic T cell response against an antigen,
 CC comprising forming a conjugate of the antigen and a monoclonal antibody
 CC which binds to APCs, and contacting the conjugate either in vivo or ex
 CC vivo with APCs such that the antigen is internalised, processed and
 CC presented to T cells in a manner which induces or enhances a cytotoxic T
 CC cell response against the antigen. The molecular conjugate has
 CC cytostatic, antimicrobial, immunosuppressive, anti-HIV, hepatotropic,
 CC virucide and antimalarial activities, and can be used as a CD8 agonist,
 CC and in vaccines. The methods and compositions of the present invention
 CC are useful for inducing a cytotoxic T cell response, and in particular
 CC for treating autoimmune disorders, cancers and infectious diseases by
 CC eliciting a potent antigen-specific cytotoxic T lymphocyte response,
 CC including melanoma, fibrosarcoma, leukaemia, HIV, hepatitis, malaria and
 CC herpes. The present sequence represents a human antibody B11 heavy chain
 CC variable region, which is used in the exemplification of the present
 CC invention.

XX SQ Sequence 468 AA;

Alignment Scores:

Pred. No.: 0.0168 Length: 468
 Score: 97.90 Matches: 19
 Percent Similarity: 36.84% Conservative: 2
 Best Local Similarity: 33.33% Mismatches: 5
 Query Match: 66.15% Indels: 31
 DB: 8 Gaps: 1

NOLAN463-2A.SEQ (1-84) x ADR46819 (1-468)

QY 1 ATCATCTATCTGGTACTCTGATACACATACAGCCGCTCTTCCAGGC----- 51

Db 69 lleiletyrProGlyAspSerAspThrIleTyrSerProSerPheGlnGlyGlnValThr 88

QY 51 ----- 51

Db 89 lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 108

QY 52 -----CGGGCGAGTCAGGCTATTAGCAGCTGG 78

Db 109 AspThrAlaMetTyrTyrCysThrArgGlyAspArgGlyValAspTyrTrp 125

RESULT 7

ADR46827

ID ADR46827 standard; protein; 613 AA.

XX ADR46827;

XX 18-NOV-2004 (first entry)

XX Human betahCG-B11 molecular conjugate protein SEQ ID NO:10.

XX molecular conjugate; monoclonal antibody; human antigen presenting cell;
 KW antigen presenting cell; APC; human; beta human chorionic gonadotropin;
 KW betahCG; beta chorionic gonadotropin; antibody;
 KW T cell-mediated immune response; immunisation; cytostatic; antimicrobial;
 KW immunosuppressive; anti-HIV; hepatotropic; virucide; antimalarial;


```
DB: 8 Gaps: 2
NOLAN463-2A.SEQ (1-84) x ADP47114 (1-118)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGCGG----- 54
Db 50 llelleTyProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GCAGGTACAGGTATTAGCAGC-----TGG 78
Db 70 lleSerAlaAspGlnSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 9
ADK18605
ID ADK18605 standard; protein; 129 AA.
XX AC ADK18605;
XX DT 06-MAY-2004 (first entry)
XX DE Anti-human PDGF-D antibody heavy chain protein sequence.
XX KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX OS Homo sapiens.
XX PN WO2003057857-A2.
XX PD 17-JUL-2003.
XX PF 06-JAN-2003; 2003WO-US000398.
XX PR 07-JAN-2002; 2002US-00041860.
XX PA (ABGE-) ABGENIX INC.
XX PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX DR WPI; 2003-587119/55.
XX CC The invention relates to a human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D), useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer.
XX PS Disclosure; SEQ ID NO 29; 255pp; English.
XX CC The invention relates to a human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D). The antibodies are useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are useful for modulating collagen formation, and for staging various cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were generated using an active protein fragment of the gene product from the clone 30664188.0.99 arising in the conditioned medium obtained when HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This sequence corresponds to a protein used in the invention.
XX SQ Sequence 129 AA;
Alignment Scores:
Pred. No.: 0.0228 Length: 129
Score: 95.40 Matches: 20
Percent Similarity: 57.50% Conservative: 3
Best Local Similarity: 50.00% Mismatches: 1
Query Match: 64.46% Indels: 16
DB: Gaps: 1
NOLAN463-2A.SEQ (1-84) x ADK18605 (1-129)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGCGGCGAGT 60
Db 50 llelleTyProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnAlaThr 69
RESULT 11
ADK18895
```

```
QY 61 CAGGTATTAGCAGC-----TGG 78
Db 70 -----lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 10
ADK18791
ID ADK18791 standard; protein; 129 AA.
XX AC ADK18791;
XX DT 06-MAY-2004 (first entry)
XX DE Anti-human PDGF-D antibody protein related sequence #17.
XX KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX OS Homo sapiens.
XX PN WO2003057857-A2.
XX PD 17-JUL-2003.
XX PF 06-JAN-2003; 2003WO-US000398.
XX PR 07-JAN-2002; 2002US-00041860.
XX PA (ABGE-) ABGENIX INC.
XX PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX DR WPI; 2003-587119/55.
XX CC New human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D), useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer.
XX PS Disclosure; SEQ ID NO 215; 255pp; English.
XX CC The invention relates to a human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D). The antibodies are useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are useful for modulating collagen formation, and for staging various cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were generated using an active protein fragment of the gene product from the clone 30664188.0.99 arising in the conditioned medium obtained when HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This sequence corresponds to a protein used in the invention.
XX SQ Sequence 129 AA;
Alignment Scores:
Pred. No.: 0.0228 Length: 129
Score: 95.40 Matches: 20
Percent Similarity: 57.50% Conservative: 3
Best Local Similarity: 50.00% Mismatches: 1
Query Match: 64.46% Indels: 16
DB: Gaps: 1
NOLAN463-2A.SEQ (1-84) x ADK18791 (1-129)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGCGGCGAGT 60
Db 50 llelleTyProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnAlaThr 69
QY 61 CAGGTATTAGCAGC-----TGG 78
Db 70 -----lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 11
ADK18895
```


OS Homo sapiens.
 XX WO2004024098-A2.
 PN 25-MAR-2004.
 PD 16-SEP-2003; 2003WO-US029414.
 PF 16-SEP-2002; 2002US-0411137P.
 XX (ABGE-) ABGENIX INC.
 XX (CURA-) CURAGEN CORP.
 PI Floege J, Gazit-Bornstein G, Keyt B, Larochele WJ, Lichenstein H;
 XX WPI; 2004-269881/25.
 DR N-PSDB; ADL25427.
 XX Use of an antibody or its binding fragment that binds platelet derived
 PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
 PT nephritis.
 XX Disclosure; SEQ ID NO 38; 115pp; English.
 PS The present invention describes an antibody or its binding fragment that
 CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
 CC useful in preparing a medicament for treating nephritis. Also described:
 CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
 CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
 CC of treating mesangial proliferative glomerulonephritis. The antibody has
 CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
 CC antidiabetic activities, and can be used in gene therapy. The antibody or
 CC its binding fragment, that binds PDGF-DD, can be used in preparing a
 CC medicament for treating nephritis and related disorders, e.g., mesangial
 CC proliferative glomerulonephritis. The present sequence represents a human
 CC monoclonal antibody (mab) variable region sequence, which is used in the
 CC exemplification of the present invention.
 XX SQ Sequence 129 AA;
 Alignment Scores:
 Pred. No.: 0.0228 Length: 129
 Score: 95.40 Matches: 20
 Percent Similarity: 57.50% Conservative: 3
 Best Local Similarity: 50.00% Mismatches: 1
 Query Match: 64.46% Indels: 16
 DB: 8 Gaps: 1
 NOLAN463-2A-SEQ (1-84) x ADL25428 (1-129)
 Qy 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGTCCTTCCAGGCGGGCGAGT 60
 Db 50 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnAlaThr 69
 Qy 61 CAGGTTATAGCAGC-----TG 78
 Db 70 -----lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 83
 RESULT 14
 ADP22194
 ID ADP22194 standard; protein; 116 AA.
 XX AC ADP22194;
 XX 09-SEP-2004 (first entry)
 XX Human anti-TNFA antibody light chain variable region SEQ ID NO:100.
 XX human; monoclonal antibody; tumour necrosis factor-alpha; TNFA;
 KW anti-TNFA antibody; anabolic; antiarteriosclerotic; antiarthritic;
 KW antibacterial; antiinflammatory; antipsoriatic; antirheumatic;
 KW eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
 KW neuroprotective; vasotropic; antiapoptotic; TNFA antagonist;

KW TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
 KW bladder cancer; lung cancer; glioblastoma; stomach cancer;
 KW endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
 KW prostate cancer; immuno-mediated inflammatory disease;
 KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
 KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
 KW septic shock; cachexia; anorexia; multiple sclerosis.
 XX Homo sapiens.
 OS WO2004050683-A2.
 XX 17-JUN-2004.
 PD 02-DEC-2003; 2003WO-US038281.
 PF 02-DEC-2002; 2002US-0430729P.
 XX (ABGE-) ABGENIX INC.
 XX Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
 PI Haak-Frendscho M, Rathanaawami P, Pigott C, Liang ML, Lee R;
 PI Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
 XX WPI; 2004-480601/45.
 DR N-PSDB; ADP22193.
 XX New recombinant human monoclonal antibody that specifically binds to
 PT Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
 PT as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
 PT arthritis.
 XX Example 10; SEQ ID NO 100; 213pp; English.
 CC The present invention describes a human monoclonal antibody (I) that
 CC specifically binds to tumour necrosis factor-alpha (TNFA) and comprises:
 CC (a) a heavy chain complementarity determining region 1 (CDRI) having the
 CC two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
 CC and (b) a light chain CDRI having the two fully defined 11 amino acid
 CC sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
 CC (M1) the level of TNFA in a patient sample, comprising contacting with
 CC (I), and detecting the level of binding between the antibody and TNFA in
 CC the sample; (2) a composition comprising the antibody or its functional
 CC fragment and a carrier; (3) treating (M2) an animal suffering from a
 CC neoplastic, or an immuno-mediated inflammatory disease by selecting an
 CC animal in need of treatment for the disease by administering the human
 CC monoclonal antibody of (I); and (4) inhibiting (M3) TNFA induced
 CC apoptosis in an animal by selecting an animal in need of treatment for
 CC TNFA induced apoptosis by administering the human monoclonal antibody of
 CC (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
 CC antibacterial, antiinflammatory, antipsoriatic, antirheumatic, eating-
 CC disorders, immunomodulator, immunosuppressive, nephrotropic,
 CC neuroprotective, vasotropic and antiapoptotic activities, and can be used
 CC as a TNFA antagonist. The antibody (I) is useful in the preparation of
 CC medicament for treating TNF induced apoptosis, neoplastic disease such as
 CC breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
 CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
 CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
 CC diseases such as rheumatoid arthritis, glomerulonephritis,
 CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
 CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
 CC multiple sclerosis. The present sequence represents a human anti-TNFA
 CC antibody light chain variable region, which is used in the
 CC exemplification of the present invention.
 XX SQ Sequence 116 AA;
 Alignment Scores:
 Pred. No.: 0.0253 Length: 116
 Score: 94.90 Matches: 19
 Percent Similarity: 36.84% Conservative: 2
 Best Local Similarity: 33.33% Mismatches: 5
 Query Match: 64.12% Indels: 31

```

DB:          8      Gaps:          1
NOLAN463-2A.SEQ (1-84) x ADP22194 (1-116)
Qy  1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGC----- 51
    |||||
Db  50 IleIleTyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
    |||||
Qy  51 ----- 51
Db  70 IleSerAlaAspLysSerIleThrThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89
Qy  52 -----CGGCGAGTCAGGCTATTAGCAGCTGG 78
    |||||
Db  90 AspThrAlaMetTyrTyrCysAlaArgSerGlyTyrGlyMetAspValTrp 106
    |||||

RESULT 15
ADP47088
ID  ADP47088 standard; protein; 118 AA.
XX
AC  ADP47088;
XX
DT  09-SEP-2004 (first entry)
XX
DE  Human phospholipase A2-specific monoclonal antibody heavy chain #1.
XX
KW  human; monoclonal antibody; phospholipase A2; PLA2;
KW  inflammatory disorder; degenerative disorder;
KW  joint inflammatory reaction; skin inflammatory reaction;
KW  blood vessels inflammatory reaction; arthritis; psoriasis; asthma;
KW  Alzheimer's disease; atherosclerosis; restenosis; heavy chain.
XX
OS  Homo sapiens.
XX
PN  WO2004050850-A2.
XX
PD  17-JUN-2004.
XX
PF  02-DEC-2003; 2003WO-US038234.
XX
PR  02-DEC-2002; 2002US-0430724P.
XX
PA  (ABGE-) ARGENIX INC.
PA  (LEXI-) LEXICON GENETICS INC.
XX
PI  Landes GM, Haak-Frendscho M, Chen L, Lee YR, Liang ML, Feng X;
PI  Jia X, Nocerini MR;
XX
DR  WPI; 2004-461119/43.
XX
PT  New human monoclonal antibody that binds to phospholipase A2 (PLA2),
PT  useful for treating inflammatory conditions, e.g. arthritis, psoriasis,
PT  asthma, Alzheimer's disease, atherosclerosis, or restenosis.
XX
PS  Claim 1; SEQ ID NO 3; 128pp; English.
XX
CC  The invention comprises a human monoclonal antibody that binds to
CC  phospholipase A2 (PLA2). The monoclonal antibody of the invention is
CC  useful in the preparation of a medicament for the treatment of
CC  inflammatory and degenerative disorders stemming from inflammatory
CC  reactions in the joints, skin, and blood vessels, arthritis, psoriasis,
CC  asthma, Alzheimer's disease, atherosclerosis, and restenosis. The present
CC  amino acid sequence represents the heavy chain from a monoclonal antibody
CC  that is specific for the human phospholipase A2 (PLA2) enzyme.
XX
SQ  Sequence 118 AA;

```

Alignment Scores:

Pred. No.:	0.0343	Length:	118
Score:	93.80	Matches:	19
Percent Similarity:	36.21%	Conservative:	2
Best Local Similarity:	32.76%	Mismatches:	5
Query Match:	63.38%	Indels:	32

Search completed: August 4, 2005, 18:55:54
Job time : 96 secs

```

DB:          8      Gaps:          1
NOLAN463-2A.SEQ (1-84) x ADP47088 (1-118)
Qy  1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGC----- 57
    |||||
Db  50 IleIleTyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
    |||||
Qy  57 ----- 57
Db  70 IleSerAlaAspLysSerIleThrThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89
Qy  58 -----AGTCAGGCTATTAGCAGCTGG 78
    |||||
Db  90 AspThrAlaMetTyrTyrCysAlaArgHisTrpSerTyrGlyMetAspValTrp 107
    |||||

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:44:26 ; Search time 22.25 Seconds
(without alignments)
563.642 Million cell updates/sec

Title: NOLAN463-2A.SEQ

Perfect score: 148

Sequence: 1 ATCATCTATCTCTGGTGACTC.....GTATTAGCAGCTGGTTAGCC 84

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 1027090

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-O=/cgn2_1/USPTO spool p/NOLAN08728463-2/runat_04082005 123945 22604/app_query.fasta_1.5
-DB=Issued Patents AA -QFWT=faetan -SUFFIX=rai -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=prco -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-2 @CGN 1.1 66 @runat_04082005 123945 22604 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Issued Patents AA:*

1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/ECTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	92.2	62.3	98	2	US-08-665-202-33
2	92.2	62.3	98	4	US-09-315-574-33
3	92.2	62.3	111	4	US-09-726-219A-171
4	92.2	62.3	117	3	US-08-545-809A-133
5	92.2	62.3	119	3	US-09-025-769B-26
6	92.2	62.3	119	4	US-09-490-070A-26
7	92.2	62.3	119	4	US-09-490-153-26
8	92.2	62.3	119	4	US-09-490-324-26
9	92.2	62.3	120	3	US-09-025-769B-40
10	92.2	62.3	120	3	US-09-025-769B-67
11	92.2	62.3	120	4	US-09-490-070A-40
12	92.2	62.3	120	4	US-09-490-070A-67

13	92.2	62.3	120	4	US-09-490-153-40	Sequence 40, Appl
14	92.2	62.3	120	4	US-09-490-153-67	Sequence 67, Appl
15	92.2	62.3	120	4	US-09-490-324-40	Sequence 40, Appl
16	92.2	62.3	120	4	US-09-490-324-67	Sequence 67, Appl
17	91.2	61.6	98	1	US-08-478-039-81	Sequence 81, Appl
18	91.2	61.6	98	1	US-08-478-349A-81	Sequence 81, Appl
19	91.2	61.6	125	2	US-08-665-202-46	Sequence 46, Appl
20	91.2	61.6	125	2	US-08-665-202-53	Sequence 53, Appl
21	91.2	61.6	125	2	US-08-665-202-54	Sequence 54, Appl
22	91.2	61.6	125	4	US-09-315-574-46	Sequence 46, Appl
23	91.2	61.6	125	4	US-09-315-574-53	Sequence 53, Appl
24	91.2	61.6	125	4	US-09-315-574-54	Sequence 54, Appl
25	88.4	59.7	125	2	US-08-665-202-44	Sequence 44, Appl
26	88.4	59.7	125	2	US-08-665-202-45	Sequence 45, Appl
27	88.4	59.7	125	2	US-08-665-202-47	Sequence 47, Appl
28	88.4	59.7	125	2	US-08-665-202-48	Sequence 48, Appl
29	88.4	59.7	125	2	US-08-665-202-49	Sequence 49, Appl
30	88.4	59.7	125	2	US-08-665-202-50	Sequence 50, Appl
31	88.4	59.7	125	2	US-08-665-202-51	Sequence 51, Appl
32	88.4	59.7	125	2	US-08-665-202-52	Sequence 52, Appl
33	88.4	59.7	125	2	US-08-665-202-55	Sequence 55, Appl
34	88.4	59.7	125	2	US-08-665-202-57	Sequence 57, Appl
35	88.4	59.7	125	2	US-08-665-202-58	Sequence 58, Appl
36	88.4	59.7	125	4	US-09-315-574-44	Sequence 44, Appl
37	88.4	59.7	125	4	US-09-315-574-45	Sequence 45, Appl
38	88.4	59.7	125	4	US-09-315-574-47	Sequence 47, Appl
39	88.4	59.7	125	4	US-09-315-574-48	Sequence 48, Appl
40	88.4	59.7	125	4	US-09-315-574-49	Sequence 49, Appl
41	88.4	59.7	125	4	US-09-315-574-50	Sequence 50, Appl
42	88.4	59.7	125	4	US-09-315-574-51	Sequence 51, Appl
43	88.4	59.7	125	4	US-09-315-574-52	Sequence 52, Appl
44	88.4	59.7	125	4	US-09-315-574-55	Sequence 55, Appl
45	88.4	59.7	125	4	US-09-315-574-57	Sequence 57, Appl

ALIGNMENTS

RESULT 1

US-08-665-202-33
; Sequence 33, Application US/08665202
; Patent No. 5977322

; GENERAL INFORMATION:
; APPLICANT: Marks, James D.

; APPLICANT: Schier, Robert
; TITLE OF INVENTION: Tumor Antigens

; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94111-3834

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/665,202

; FILING DATE: 13-JUN-1996

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/000,238

; FILING DATE: 14-JUN-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/000,250

; FILING DATE: 15-JUN-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Hunter, Tom

; REGISTRATION NUMBER: 38,498

; REFERENCE/DOCKET NUMBER: 02307E-061410

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 98 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-665-202-33
Alignment Scores:
Pred. No.: 0.00843 Length: 98
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2
NOLAN463-2A.SEQ (1-84) x US-08-665-202-33 (1-98)
Qy 1 ATCATCTATCTGCTGACTCTGTATACACATACAGCCGCTCTTCCAAAGCGCG----- 54
Db 50 llllelyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
Qy 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 llsSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 2
US-09-315-574-33
; Sequence 33, Application US/09315574
; Patent No. 6512097
; GENERAL INFORMATION:
; APPLICANT: Marks, James D.
; APPLICANT: Schier, Robert
; TITLE OF INVENTION: No. 6512097el High Affinity Human Antibodies to
; TITLE OF INVENTION: Tumor Antigens
; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Majestic, Parsons, Siebert & Hsue P.C.
; STREET: Four Embarcadero Center, Suite 1100
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4106
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/315,574
; FILING DATE: 20-MAY-99
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,238
; FILING DATE: 14-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,250
; FILING DATE: 15-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/665,202
; FILING DATE: 13-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 02307E-061411
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 33:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 98 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-315-574-33
Alignment Scores:
Pred. No.: 0.00843 Length: 98
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2
NOLAN463-2A.SEQ (1-84) x US-09-315-574-33 (1-98)
Qy 1 ATCATCTATCTGCTGACTCTGTATACACATACAGCCGCTCTTCCAAAGCGCG----- 54
Db 50 llllelyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
Qy 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 llsSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 3
US-09-726-219A-171
; Sequence 171, Application US/09726219A
; Patent No. 6806079
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clarkson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00013
; CURRENT APPLICATION NUMBER: US/09/726,219A
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR FILING DATE: 1991-05-15
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 171
; LENGTH: 111
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-09-726-219A-171

Alignment Scores:
Pred. No.: 0.00879      Length: 111
Score: 92.20           Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30%      Indels: 8
DB: 4                  Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-726-219A-171 (1-111)
QY 1 ATCATCTATCTGGTACTCTGTATACACATACAGCCGCTCTTCAAGCGCG----- 54
Db 50 lleiletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GCCAGTCAGGTTATTAGCAGC-----TGG 78
Db 70 lleSerAlaAspLysSerIleSerThrAlaTyrLeuHisTrp 83

RESULT 4
US-08-545-809A-133
; Sequence 133, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 133:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-133

Alignment Scores:
Pred. No.: 0.00895      Length: 117
Score: 92.20           Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30%      Indels: 8
DB: 3                  Gaps: 2

; ORGANISM: Homo sapiens
US-09-025-769B-26

Alignment Scores:
Pred. No.: 0.009        Length: 119
Score: 92.20           Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30%      Indels: 8
DB: 3                  Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-025-769B-26 (1-119)
QY 1 ATCATCTATCTGGTACTCTGTATACACATACAGCCGCTCTTCAAGCGCG----- 54
Db 50 lleiletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GCCAGTCAGGTTATTAGCAGC-----TGG 78
Db 89 lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 102

RESULT 5
US-09-025-769B-26
; Sequence 26, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-26

Alignment Scores:
Pred. No.: 0.009        Length: 119
Score: 92.20           Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30%      Indels: 8
DB: 3                  Gaps: 2
```

Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83

RESULT 6
US-09-490-070A-26
; Sequence 26, Application US/09490070A
; Patent No. 6696248
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
White & McAuliffe
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRAINEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-490-070A-26

Alignment Scores:
Pred. No.: 0.009 Length: 119
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 4 Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-490-070A-26 (1-119)

QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAGGCGG----- 54
Db 50 IleIleTyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69

QY 55 -----GCCAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83

RESULT 7
US-09-490-153-26
; Sequence 26, Application US/09490153
; Patent No. 6706484

GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,153
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRAINEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-490-153-26

Alignment Scores:
Pred. No.: 0.009 Length: 119
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 4 Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-490-153-26 (1-119)

QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAGGCGG----- 54
Db 50 IleIleTyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69

QY 55 -----GCCAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83

RESULT 8
US-09-490-324-26
; Sequence 26, Application US/09490324
; Patent No. 6828422
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming


```
;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-67
;
; Alignment Scores:
; Pred. No.: 0.00902 Length: 120
; Score: 92.20 Matches: 20
; Percent Similarity: 67.65% Conservative: 3
; Best Local Similarity: 58.82% Mismatches: 3
; Query Match: 62.30% Indels: 8
; DB: 2 Gaps: 2
;
; NOLAN463-2A.SEQ (1-84) x US-09-025-769B-67 (1-120)
;
; QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGCGG----- 54
; ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
; Db 50 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 69
;
; QY 55 -----GCGAGTCAGGTTAGCAGC-----TGG 78
; ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
; Db 70 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 83
;
; RESULT 11
; US-09-490-070A-40
; Sequence 40, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
```

```
;
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 40:
; US-09-490-070A-40
;
; Alignment Scores:
; Pred. No.: 0.00902 Length: 120
; Score: 92.20 Matches: 20
; Percent Similarity: 67.65% Conservative: 3
; Best Local Similarity: 58.82% Mismatches: 3
; Query Match: 62.30% Indels: 8
; DB: 2 Gaps: 2
;
; NOLAN463-2A.SEQ (1-84) x US-09-490-070A-40 (1-120)
;
; QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAGGCGG----- 54
; ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
; Db 50 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 69
;
; QY 55 -----GCGAGTCAGGTTAGCAGC-----TGG 78
; ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
; Db 70 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 83
;
; RESULT 12
; US-09-490-070A-67
; Sequence 67, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
```



```
;
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 67:
US-09-490-070A-67

Alignment Scores:
Pred. No.: 0.00902 Length: 120
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 4 Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-490-070A-67 (1-120)
QY 1 ATCATCTATCTGGTGACTCTGATACCATACAGCCGCTCTTCCAAAGCGCGG----- 54
Db 50 lilellyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 lileSerAlaAspLyseSerIleSerThrAlaTyrLeuGlnTrrp 83

RESULT 13
US-09-490-153-40
; Sequence 40, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
```

```
;
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 40:
US-09-490-153-40

Alignment Scores:
Pred. No.: 0.00902 Length: 120
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 4 Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-490-153-40 (1-120)
QY 1 ATCATCTATCTGGTGACTCTGATACCATACAGCCGCTCTTCCAAAGCGCGG----- 54
Db 50 lilellyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 lileSerAlaAspLyseSerIleSerThrAlaTyrLeuGlnTrrp 83

RESULT 14
US-09-490-153-67
; Sequence 67, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 67:
US-09-490-153-67
```

Alignment Scores:
Pred. No.: 0.00902 Length: 120
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 4 Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-09-490-153-67 (1-120)

QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAAGGCCGG----- 54
|||||
Db 50 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 69
|||||
QY 55 -----GCGAGTCACGGTATTAGCAGC-----TGG 78
|||||
Db 70 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 83
|||||

RESULT 15

US-09-490-324-40
; Sequence 40, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA: US/09/490,324
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 40:
US-09-490-324-40

Alignment Scores:
Pred. No.: 0.00902 Length: 120
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3

Query Match: 62.30% Indels: 8
DB: 4 Gaps: 2
NOLAN463-2A.SEQ (1-84) x US-09-490-324-40 (1-120)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAAGGCCGG----- 54
|||||
Db 50 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 69
|||||
QY 55 -----GCGAGTCACGGTATTAGCAGC-----TGG 78
|||||
Db 70 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 83
|||||

Search completed: August 4, 2005, 19:04:14
Job time : 25.25 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model
Run on: August 4, 2005, 19:01:38 ; Search time 78.75 Seconds
(without alignments)
832.849 Million cell updates/sec

Title: NOLAN463-2A.SEQ
Perfect score: 148
Sequence: 1 ATCATCTATCTCGTGACTC.....GTATTAGCAGCTGGTTAGCC 84

Scoring table:
BLOSUMP62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1752860 seqs, 390397842 residues
Total number of hits satisfying chosen parameters: 3505720
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+n2p.model -DEV=xlp
-O=/cgn2_1/USPTO_spool_p/NOLAN08728463-2/runat_04082005_123947_22665/app_query.fasta_1.5
-DB=Published Applications AA -QWTF=fastan -SUFFIX=rapb -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=BLOSUM62
-TRANS=human40.cdi -LIST=45 -LOCALIGN=200 -THR SCORE=pct -THR MAX=100
-THR MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0
-MAXLEN=2000000000
-USER=NOLAN08728463-2@cgn 1 1 260 @runat_04082005_123947_22665 -NCPU=6
-ICPU=3 -NO MMAP -LARGQUEY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THRA=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0 -DELOP=6 -DELEXT=0.1

Database : Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	97.9	66.1	116	US-09-851-614-4	Sequence 4, Appli
2	97.9	66.1	116	US-10-035-637-4	Sequence 4, Appli
3	97.9	66.1	116	US-10-769-144-4	Sequence 4, Appli
4	97.9	66.1	411	US-10-769-144-12	Sequence 12, Appli
5	97.9	66.1	468	US-10-769-144-2	Sequence 2, Appli
6	97.9	66.1	613	US-10-769-144-10	Sequence 10, Appli
7	96.2	65.0	118	US-10-726-332-29	Sequence 29, Appli
8	95.4	64.5	129	US-10-041-860-29	Sequence 29, Appli
9	95.4	64.5	129	US-10-041-860-215	Sequence 215, App
10	95.4	64.5	129	US-10-041-860-250	Sequence 250, App
11	95.4	64.5	129	US-10-041-860-319	Sequence 319, App
12	95.4	64.5	129	US-10-665-383-38	Sequence 38, Appli
13	94.9	64.1	116	US-10-727-155-100	Sequence 100, App
14	93.8	63.4	118	US-10-726-332-3	Sequence 3, Appli
15	93.5	63.2	118	US-10-726-332-5	Sequence 5, Appli
16	93.5	63.2	118	US-10-726-332-13	Sequence 13, Appli
17	93.5	63.2	118	US-10-726-332-139	Sequence 139, App
18	93.5	63.2	120	US-10-638-265-62	Sequence 62, Appli
19	93.5	63.2	120	US-10-638-265-78	Sequence 78, Appli
20	93.2	63.0	123	US-10-466-242-49	Sequence 49, Appli
21	93.2	63.0	301	US-10-002-631C-114	Sequence 114, App
22	92.4	62.4	225	US-10-128-520-158	Sequence 158, App
23	92.2	62.3	82	US-10-078-958-5	Sequence 5, Appli
24	92.2	62.3	98	US-10-194-975-45	Sequence 45, Appli
25	92.2	62.3	98	US-10-125-687-16	Sequence 16, Appli
26	92.2	62.3	98	US-10-041-860-6	Sequence 6, Appli
27	92.2	62.3	98	US-10-041-860-301	Sequence 301, App
28	92.2	62.3	98	US-10-041-860-302	Sequence 302, App
29	92.2	62.3	98	US-10-041-860-312	Sequence 312, App
30	92.2	62.3	98	US-10-041-860-314	Sequence 314, App
31	92.2	62.3	98	US-10-041-860-318	Sequence 318, App
32	92.2	62.3	98	US-10-041-860-320	Sequence 320, App
33	92.2	62.3	98	US-10-041-860-336	Sequence 336, App
34	92.2	62.3	98	US-10-041-860-338	Sequence 338, App
35	92.2	62.3	98	US-10-041-860-367	Sequence 367, App
36	92.2	62.3	98	US-10-308-817-88	Sequence 88, Appli
37	92.2	62.3	98	US-10-032-037B-106	Sequence 106, App
38	92.2	62.3	98	US-10-032-037B-108	Sequence 108, App
39	92.2	62.3	98	US-10-029-988B-106	Sequence 106, App
40	92.2	62.3	98	US-10-029-988B-108	Sequence 108, App
41	92.2	62.3	98	US-10-032-423A-106	Sequence 106, App
42	92.2	62.3	98	US-10-032-423A-108	Sequence 108, App
43	92.2	62.3	98	US-10-453-698-88	Sequence 88, Appli
44	92.2	62.3	98	US-10-029-926B-106	Sequence 106, App
45	92.2	62.3	98	US-10-029-926B-108	Sequence 108, App

ALIGNMENTS

RESULT 1
US-09-851-614-4
; Sequence 4, Application US/09851614
; Publication No. US20030167502A1
; GENERAL INFORMATION:
; APPLICANT: Deo, Yashwant M.
; APPLICANT: Keler, Tibor
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC
; TITLE OF INVENTION: CELLS
; FILE REFERENCE: MXI-166
; CURRENT APPLICATION NUMBER: US/09/851,614
; CURRENT FILING DATE: 2001-05-08
; PRIOR APPLICATION NUMBER: USSN 60/203,126
; PRIOR FILING DATE: 2000-05-08
; PRIOR APPLICATION NUMBER: USSN 60/230,739
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4


```

Pred. No.: 0.0236 Length: 411
Score: 97.90 Matches: 19
Percent Similarity: 36.84% Conservative: 2
Best Local Similarity: 33.33% Mismatches: 5
Query Match: 66.15% Indels: 31
DB: 16 Gaps: 1

NOLAN463-2A.SEQ (1-84) x US-10-769-144-12 (1-411)

QY 1 ATCATCTATCTGGTGACTCTGATACCATACAGCCCGCTCTTCCAGGC----- 51
Db 191 lileltyrProGlyAspSerAspThrIleTyrSerProSerPheGlnGlyGlnValThr 210
QY 51 ----- 51
Db 211 lileSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 230
QY 52 -----CGGGCGAGTCAGGGTATTAGCAGCTGG 78
Db 231 AspThrAlaMetTyrTyrCysThrArgGlyAspArgGlyValAspTyrTrp 247

RESULT 5
US-10-769-144-2
; Sequence 2, Application US/10769144
; Publication No. US20040248215A1
; GENERAL INFORMATION:
; APPLICANT: Keler, Tibor
; APPLICANT: Endres, Michael
; APPLICANT: He, Lizhen
; APPLICANT: Ramakrishna, Venky
; TITLE OF INVENTION: ANTIBODY VACCINE CONJUGATES AND USES
; FILE REFERENCE: MXI-301
; CURRENT APPLICATION NUMBER: US/10/769,144
; PRIOR FILING DATE: 2004-01-30
; PRIOR APPLICATION NUMBER: 60/443979
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 468
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-769-144-2

Alignment Scores:
Pred. No.: 0.0244 Length: 468
Score: 97.90 Matches: 19
Percent Similarity: 36.84% Conservative: 2
Best Local Similarity: 33.33% Mismatches: 5
Query Match: 66.15% Indels: 31
DB: 16 Gaps: 1

NOLAN463-2A.SEQ (1-84) x US-10-769-144-2 (1-468)

QY 1 ATCATCTATCTGGTGACTCTGATACCATACAGCCCGCTCTTCCAGGC----- 51
Db 69 lileltyrProGlyAspSerAspThrIleTyrSerProSerPheGlnGlyGlnValThr 88
QY 51 ----- 51
Db 89 lileSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 108
QY 52 -----CGGGCGAGTCAGGGTATTAGCAGCTGG 78
Db 109 AspThrAlaMetTyrTyrCysThrArgGlyAspArgGlyValAspTyrTrp 125

RESULT 6
US-10-769-144-10
; Sequence 10, Application US/10769144
; Publication No. US20040248215A1
; GENERAL INFORMATION:
; APPLICANT: Keler, Tibor

```

```

; APPLICANT: Endres, Michael
; APPLICANT: He, Lizhen
; APPLICANT: Ramakrishna, Venky
; TITLE OF INVENTION: ANTIBODY VACCINE CONJUGATES AND USES
; FILE REFERENCE: MXI-301
; CURRENT APPLICATION NUMBER: US/10/769,144
; PRIOR FILING DATE: 2004-01-30
; PRIOR APPLICATION NUMBER: 60/443979
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 613
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-769-144-10

Alignment Scores:
Pred. No.: 0.026 Length: 613
Score: 97.90 Matches: 19
Percent Similarity: 36.84% Conservative: 2
Best Local Similarity: 33.33% Mismatches: 5
Query Match: 66.15% Indels: 31
DB: 16 Gaps: 1

NOLAN463-2A.SEQ (1-84) x US-10-769-144-10 (1-613)

QY 1 ATCATCTATCTGGTGACTCTGATACCATACAGCCCGCTCTTCCAGGC----- 51
Db 69 lileltyrProGlyAspSerAspThrIleTyrSerProSerPheGlnGlyGlnValThr 88
QY 51 ----- 51
Db 89 lileSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 108
QY 52 -----CGGGCGAGTCAGGGTATTAGCAGCTGG 78
Db 109 AspThrAlaMetTyrTyrCysThrArgGlyAspArgGlyValAspTyrTrp 125

RESULT 7
US-10-726-332-29
; Sequence 29, Application US/10726332
; Publication No. US20050058649A1
; GENERAL INFORMATION:
; APPLICANT: Gregory M. Landes
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Ling Chen
; APPLICANT: Yen-Wah R. Lee
; APPLICANT: Meina Liang
; APPLICANT: Xiao Feng
; APPLICANT: Xiao-Chi Jia
; APPLICANT: Mark R. Nocerini
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PHOSPHOLIPASE A2
; FILE REFERENCE: ABGENIX.072A
; CURRENT APPLICATION NUMBER: US/10/726,332
; PRIOR FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: n/a
; NUMBER OF SEQ ID NOS: 222
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-726-332-29

Alignment Scores:
Pred. No.: 0.0275 Length: 118
Score: 96.20 Matches: 21
Percent Similarity: 67.65% Conservative: 2
Best Local Similarity: 61.76% Mismatches: 3

```

```
Query Match: 65.00% Indels: 8
DB: 17 Gaps: 2
NOLAN463-2A.SEQ (1-84) x US-10-726-332-29 (1-118)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAAGCGCGGAGT 60
Db 50 lileltyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GGAGTCAGGGTATTAGCAGC-----TGG 78
Db 70 lileSerAlaAspGlnSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 8
US-10-041-860-29
; Sequence 29, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 129
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-29
Alignment Scores:
Pred. No.: 0.0348 Length: 129
Score: 95.40 Matches: 20
Percent Similarity: 57.50% Conservativeness: 3
Best Local Similarity: 50.00% Mismatches: 1
Query Match: 64.46% Indels: 16
DB: 14 Gaps: 1
NOLAN463-2A.SEQ (1-84) x US-10-041-860-29 (1-129)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAAGCGCGGAGT 60
Db 50 lileltyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnAlaThr 69
QY 61 CAGGGTATTAGCAGC-----TGG 78
Db 70 -----lileSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 10
US-10-041-860-250
; Sequence 250, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 250
; LENGTH: 129
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-250
Alignment Scores:
Pred. No.: 0.0348 Length: 129
Score: 95.40 Matches: 20
Percent Similarity: 57.50% Conservativeness: 3
Best Local Similarity: 50.00% Mismatches: 1
Query Match: 64.46% Indels: 16
DB: 14 Gaps: 1
NOLAN463-2A.SEQ (1-84) x US-10-041-860-250 (1-129)
QY 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCGCTCTTCCAAAGCGCGGAGT 60
Db 50 lileltyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnAlaThr 69
QY 61 CAGGGTATTAGCAGC-----TGG 78
Db 70 -----lileSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83
RESULT 11
```

US-10-041-860-319
; Sequence 319, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Peng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 319
; LENGTH: 129
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-319
Alignment Scores:
Pred. No.: 0.0348 Length: 129
Score: 95.40 Matches: 20
Percent Similarity: 57.50% Conservative: 3
Best Local Similarity: 50.00% Mismatches: 1
Query Match: 64.46% Indels: 16
DB: 14 Gaps: 1
NOLAN463-2A-SEQ (1-84) x US-10-041-860-319 (1-129)
QY 1 ATCATCTATCTGGTACTCTGATACCATACACCGCTCTTCCAGGCGGGCGAGT 60
|||
Db 50 lleiletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyAlaThr 69
QY 61 CAGGTATTAGCAGC-----TGG 78
|||
Db 70 -----lleSerAlaAspLysSerIleThrAlaTyrLeuGlnTrp 83
|||
RESULT 12
US-10-665-383-38
; Sequence 38, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRoche, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; FILE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: AGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 129
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-38
Alignment Scores:
Pred. No.: 0.0348 Length: 129
Score: 95.40 Matches: 20
Percent Similarity: 57.50% Conservative: 3
Best Local Similarity: 50.00% Mismatches: 1

Query Match: 64.46% Indels: 16
DB: 16 Gaps: 1
NOLAN463-2A-SEQ (1-84) x US-10-665-383-38 (1-129)
QY 1 ATCATCTATCTGGTACTCTGATACCATACACCGCTCTTCCAGGCGGGCGAGT 60
|||
Db 50 lleiletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyAlaThr 69
QY 61 CAGGTATTAGCAGC-----TGG 78
|||
Db 70 -----lleSerAlaAspLysSerIleThrAlaTyrLeuGlnTrp 83
|||
RESULT 13
US-10-727-155-100
; Sequence 100, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaapal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenko
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE OF INVENTION: FACTOR AND USES THEREOF
; FILE REFERENCE: AGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 100
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-727-155-100
Alignment Scores:
Pred. No.: 0.0388 Length: 116
Score: 94.90 Matches: 19
Percent Similarity: 36.84% Conservative: 2
Best Local Similarity: 33.33% Mismatches: 5
Query Match: 64.12% Indels: 31
DB: 17 Gaps: 1
NOLAN463-2A-SEQ (1-84) x US-10-727-155-100 (1-116)
QY 1 ATCATCTATCTGGTACTCTGATACCATACACCGCTCTTCCAGGCGGGCGAGT 51
|||
Db 50 lleiletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyAlaThr 69
QY 51 -----TGG 78
|||
Db 70 lleSerAlaAspLysSerIleThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89
QY 52 -----CGGCGGAGTCAGGGTATTAGCAGTGG 78
|||
Db 90 AspThrAlaMetTyrTyrCysAlaArgSerGlyTyrGlyMetAspValTrp 106
|||
RESULT 14
US-10-726-332-3
; Sequence 3, Application US/10726332

; Publication No. US20050058649A1
; GENERAL INFORMATION:
; APPLICANT: Gregory M. Landes
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Ling Chen
; APPLICANT: Yen-Wah R. Lee
; APPLICANT: Meina Liang
; APPLICANT: Xiao Feng
; APPLICANT: Xiao-Chi Jia
; APPLICANT: Mark R. Nocerini
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PHOSPHOLIPASE A2
; FILE REFERENCE: ABGENIX.072A
; CURRENT APPLICATION NUMBER: US/10/726,332
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: n/a
; PRIOR FILING DATE:
; NUMBER OF SEQ ID NOS: 222
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-726-332-3

Alignment Scores:
Pred. No.: 0.0523 Length: 118
Score: 93.80 Matches: 19
Percent Similarity: 36.21% Conservative: 2
Best Local Similarity: 32.76% Mismatches: 5
Query Match: 63.38% Indels: 32
DB: 17 Gaps: 1

NOLAN463-2A.SEQ (1-84) x US-10-726-332-3 (1-118)

```
Qy 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCCGCTTCCAGGCGGCGG--- 57
Db 50 llelleTyPrGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
Qy 57 -----
Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89
Qy 58 -----AGTCAGGCTATTAGCAGCTGG 78
Db 90 AspThrAlaMetTyrTyrCysAlaArgHisTrpSerTyrGlyMetAspValTrp 107
```

RESULT 15

US-10-726-332-5
; Sequence 5, Application US/10726332
; Publication No. US20050058649A1
; GENERAL INFORMATION:
; APPLICANT: Gregory M. Landes
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Ling Chen
; APPLICANT: Yen-Wah R. Lee
; APPLICANT: Meina Liang
; APPLICANT: Xiao Feng
; APPLICANT: Xiao-Chi Jia
; APPLICANT: Mark R. Nocerini
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PHOSPHOLIPASE A2
; FILE REFERENCE: ABGENIX.072A
; CURRENT APPLICATION NUMBER: US/10/726,332
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: n/a
; PRIOR FILING DATE:
; NUMBER OF SEQ ID NOS: 222
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens

US-10-726-332-5

Alignment Scores:
Pred. No.: 0.0567 Length: 118
Score: 93.50 Matches: 21
Percent Similarity: 45.10% Conservative: 2
Best Local Similarity: 41.18% Mismatches: 3
Query Match: 63.18% Indels: 25
DB: 17 Gaps: 2

NOLAN463-2A.SEQ (1-84) x US-10-726-332-5 (1-118)

```
Qy 1 ATCATCTATCTGGTGACTCTGATACACATACAGCCCGCTTCCAGGCGGCGG--- 54
Db 50 llelleTyPrGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
Qy 55 -----CCGAGTCAGGCTATTAGC----- 72
Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89
Qy 73 -----AGCTGG 78
Db 90 AspThrAlaMetTyrTyrCysAlaArgSerTrp 100
```

Search completed: August 4, 2005, 19:30:17
Job time : 80.75 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:42:17 ; Search time 17.75 Seconds

(without alignments)
910.671 Million cell updates/sec

Title: NOLAN463-2A.SEQ

Perfect score: 148

Sequence: 1 ATCATCTATCTGTGGTACTC.....GTATTAGCAGCTGGTTAGCC 84

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 566832

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-O=/cgn2.1/USPTO.spool_p/NOLAN08728463-2/runat_04082005_123944_22592/app_query.fasta_1.5
-DB=PIR -QFMT=fastan -SUFFIX=rxp -MINMATCH=0.1 -LOOPEL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN08728463-2 @CGN 1.1.77 @runat_04082005_123944_22592 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

PIR 79:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	95.6	64.6	102	2 PH1281	Ig heavy chain V r
2	95.6	64.6	102	2 PH1249	Ig heavy chain V r
3	93.3	63.0	127	2 PH1409	Ig heavy chain V r
4	93.2	63.0	127	2 PH1414	Ig heavy chain V r
5	92.7	62.6	123	2 C36006	Ig heavy chain V r
6	92.4	62.4	98	2 PH0877	Ig heavy chain V r
7	92.2	62.3	98	2 PH1274	Ig heavy chain V r
8	92.2	62.3	98	2 S26907	Ig heavy chain V r
9	92.2	62.3	101	2 S12424	Ig heavy chain V r
10	92.2	62.3	102	2 PH1266	Ig heavy chain V r
11	92.2	62.3	102	2 PH1279	Ig heavy chain V r
12	92.2	62.3	102	2 PH1277	Ig heavy chain V r
13	92.2	62.3	102	2 PH1244	Ig heavy chain V r
14	92.2	62.3	102	2 PH1272	Ig heavy chain V r

15	92.2	62.3	102	2 PH1282	Ig heavy chain V r
16	92.2	62.3	102	2 PH1248	Ig heavy chain V r
17	92.2	62.3	102	2 PH1280	Ig heavy chain V r
18	92.2	62.3	102	2 PH1258	Ig heavy chain V r
19	92.2	62.3	102	2 PH1264	Ig heavy chain V r
20	92.2	62.3	102	2 PH1273	Ig heavy chain V r
21	92.2	62.3	102	2 PH1271	Ig heavy chain V r
22	92.2	62.3	102	2 PH1278	Ig heavy chain V r
23	92.2	62.3	104	2 B36006	Ig heavy chain V r
24	92.2	62.3	113	2 PH1428	Ig heavy chain V r
25	92.2	62.3	115	2 PH1557	Ig heavy chain V r
26	92.2	62.3	117	2 A28846	Ig heavy chain pre
27	92.2	62.3	117	2 S19670	Ig heavy chain V r
28	92.2	62.3	123	2 PH1423	Ig heavy chain V r
29	92.2	62.3	123	2 S38492	Ig heavy chain - h
30	92.2	62.3	127	2 PH1411	Ig heavy chain V r
31	92.2	62.3	128	2 S16685	Ig heavy chain V r
32	92.2	62.3	136	2 A49047	Ig heavy chain V r
33	92.2	62.3	136	2 PH1559	Ig heavy chain V r
34	92.2	62.3	139	2 PH1558	Ig heavy chain V r
35	91.4	61.8	101	2 S12428	Ig heavy chain V r
36	90.4	61.1	102	2 PH1267	Ig heavy chain V r
37	90.4	61.1	102	2 PH1259	Ig heavy chain V r
38	90.4	61.1	134	2 PH1422	Ig heavy chain V r
39	90.2	60.9	119	2 S36257	Ig heavy chain V r
40	89.6	60.5	127	2 PH1420	Ig heavy chain V r
41	89.2	60.3	102	2 PH1252	Ig heavy chain V r
42	88.4	59.7	123	2 PH1413	Ig heavy chain V r
43	88.2	59.6	102	2 PH1247	Ig heavy chain V r
44	87.2	58.9	86	2 S12580	Ig heavy chain V r
45	87.2	58.9	102	2 PH1265	Ig heavy chain V r

ALIGNMENTS

RESULT 1

PH1281
Ig heavy chain V region (clone PBL12) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1281
R:Cal, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chro
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1281
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
P:19-103/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00273 Length: 102
Score: 95.60 Matches: 19
Percent Similarity: 77.78% Conservative: 2
Best Local Similarity: 70.37% Mismatches: 2
Query Match: 64.59% Indels: 4
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x PH1281 (1-102)

Qy 1 ATCATCTATCTGTGGTACTCTGATACCACATACAGCCGCTCTTCCAGGCGCGGCGAGT 60

Db 54 lIleIleYrProGlyAspSerAspThrArgYrSerProSerPheGln----GlyGlnVa 72

Qy 61 CAGGCTATTAGCA 73

Db 72 lThrIleIeuAla 76

RESULT 2

PH1249

Ig heavy chain V region (clone CORD7) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1249

R:Cal, J.; Humphries, C.; Richardson, A.; Tucker, P.W.

J. Exp. Med. 176, 1073-1081, 1992

A:Title: Extensive and selective mutation of a rearranged VHS gene in human B cell chronic dermatitis.

A:Reference number: PH1232; MUID:93018822; PMID:1402653

A:Accession: PH1249

A:Molecule type: DNA

A:Residues: 1-102 <CAI>

A:Experimental source: cord blood B cell

A:Note: the authors translated the stop codon for residue 5 as X

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00273 Length: 102
Score: 95.60 Matches: 19
Percent Similarity: 77.78% Conservative: 2
Best Local Similarity: 70.37% Mismatches: 2
Query Match: 64.59% Indels: 4
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x PH1249 (1-102)

Qy 1 ATCATCTATCTGGTACTCTGATACACATACACCGCGTCTTCCAAAGCGCGGCGAGT 60

Db 54 lilelletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnVa 72

Qy 61 CAGGGTATTAGCA 73

Db 72 lthrileuAla 76

RESULT 3

PH1409

Ig heavy chain V region (clone P1-51) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 17-Mar-1999

C:Accession: PH1409

R:van der Stoep, N.; van der Linden, J.; Logtenberg, T.

J. Exp. Med. 177, 99-107, 1993

A:Title: Molecular evolution of the human immunoglobulin E response: High incidence of E dermatitis.

A:Reference number: PH1409; MUID:93115676; PMID:8418213

A:Accession: PH1409

A:Molecule type: mRNA

A:Residues: 1-127 <VAN>

A:Experimental source: PBMC

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00533 Length: 127
Score: 93.30 Matches: 18
Percent Similarity: 70.00% Conservative: 3
Best Local Similarity: 60.00% Mismatches: 2
Query Match: 63.04% Indels: 7
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x PH1409 (1-127)

Qy 1 ATCATCTATCTGGTACTCTGATACACATACACCGCGTCTTCCAAAGCGCGGCGAGT 60

Db 50 lilelletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyArgValThr 69

Qy 61 CAGGGTATTAGCAGT 76

Db 70 -----MetSerAla 72

RESULT 4

PH1414

Ig heavy chain V region (clone P1-54) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 17-Mar-1999

C:Accession: PH1414

R:van der Stoep, N.; van der Linden, J.; Logtenberg, T.

J. Exp. Med. 177, 99-107, 1993

A:Title: Molecular evolution of the human immunoglobulin E response: High incidence of E dermatitis.

A:Reference number: PH1409; MUID:93115676; PMID:8418213

A:Accession: PH1414

A:Molecule type: mRNA

A:Residues: 1-127 <VAN>

A:Experimental source: PBMC

A:Note: the authors translated the codon TTG for residue 119 as Met

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00548 Length: 127
Score: 93.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.97% Indels: 8
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1414 (1-127)

Qy 1 ATCATCTATCTGGTACTCTGATACACATACACCGCGTCTTCCAAAGCGCGG----- 54

Db 50 lilelletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69

Qy 55 -----GCGAGTCACGGGTATTAGCAGC-----TCG 78

Db 70 lileSerAlaAspGluSerIleSerThrAlaTyrLeuGlnTrp 83

RESULT 5

C36006

Ig heavy chain V region (83p2) - human

C:Species: Homo sapiens (man)

C:Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998

C:Accession: C36006

R:Schroeder Jr., H.W.; Wang, J.Y.

Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990

A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene A:Reference number: A36005; MUID:90349571; PMID:2117273

A:Accession: C36006

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-123 <SCH>

A:Cross-references: GB:M34022

C:Genetics:

A:Gene: GDB:IGH@; IGHDIY1

A:Cross-references: GDB:118731; OMIM:146910

A:Map position: 14q32.33-14q32.33

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00632 Length: 123
Score: 92.70 Matches: 19
Percent Similarity: 35.59% Conservative: 2
Best Local Similarity: 32.20% Mismatches: 5
Query Match: 62.64% Indels: 33
DB: 2 Gaps: 1

NOLAN463-2A.SEQ (1-84) x C36006 (1-123)

Qy 1 ATCATCTATCTGGTACTCTGATACACATACACCGCGTCTTCCAAAGCGCGG----- 54

Db 50 lilelletyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69

```
QY 54 ----- 54
Db 70 IleSerAlaAspLysSerThrAlaTyrLeuGlnTrpSerSerLeuLysAlaSer 89
QY 55 -----GCCAGTCACGGTATTAGCAGCTGG 78
Db 90 AspThrAlaMetTyrTyrCysAlaArgHisAenSerGlnThrGlyAlaSerLeuTrp 108

RESULT 6
PH0877
IG heavy chain V region (anti-DNA, II-1) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 16-Aug-1996
C:Accession: PH0877
R:Manheimer-Lory, A.; Katz, J.B.; Pillinger, M.; Ghossein, C.; Smith, A.; Diamond, B.
J. Exp. Med. 174, 1639-1652, 1991
A:Title: Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype
A:Reference number: PH0862; MUID:92078875; PMID:1660528
A:Accession: PH0877
A:Molecule type: DNA
A:Residues: 1-98 <MAN>
C:Comment: This antibody is produced by Epstein-Barr virus-transformed B cell that bears
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:50-66/Region: complementarity-determining 2

Alignment Scores:
Pred. No.: 0.00692 Length: 98
Score: 92.40 Matches: 18
Percent Similarity: 56.41% Conservative: 4
Best Local Similarity: 46.15% Mismatches: 1
Query Match: 62.43% Indels: 16
DB: 2 Gaps: 1

NOLAN463-2A.SEQ (1-84) x PH0877 (1-98)

QY 4 ATCTATCTCTGGTACTCTGATACCATACAGCCGCTCTTCCAGGCGGCGAGTCAG 63
Db 51 ValTyrProGlyAspSerAspThrTyrSerProSerPheGlnGlyGlnValThr 69
QY 64 GTATTAGCAGC-----TGG 78
Db 70 ---IleSerAlaAspLysCysIleSerThrAlaTyrLeuGlnTrp 83

RESULT 7
PH1274
IG heavy chain V region (clone PBL5) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1274
R:Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chronic
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1274
A:Molecule type: DNA
A:Residues: 1-98 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

Alignment Scores:
Pred. No.: 0.00722 Length: 98
Score: 92.20 Matches: 18
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1274 (1-98)
```

```
QY 1 ATCATCTATCTGGTACTCTGATACCATACAGCCGCTCTTCCAGGCGCGG----- 54
Db 54 IleIleTyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 73
QY 55 -----GCCAGTCACGGTATTAGCAGC-----TGG 78
Db 74 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 87

RESULT 8
S26907
IG heavy chain V region (DP-73) - human
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S26907
R:Tominson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26907
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-98 <TOM>
A:Cross-references: EMBL:Z12373; NID:G32965; PIDN:CAA78243.1; PID:G32966
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00722 Length: 98
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x S26907 (1-98)

QY 1 ATCATCTATCTGGTACTCTGATACCATACAGCCGCTCTTCCAGGCGCGG----- 54
Db 50 IleIleTyrProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 69
QY 55 -----GCCAGTCACGGTATTAGCAGC-----TGG 78
Db 70 IleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 83

RESULT 9
S12424
IG heavy chain V region (5) - human
C:Species: Homo sapiens (man)
C>Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 03-Aug-1998
C:Accession: S12424; S12425; S12426; S12427; S12429; S12432
R:Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A:Title: The smaller human V(H) gene families display remarkably little polymorphism.
A:Reference number: S09421; MUID:90059975; PMID:2511001
A:Accession: S12424
A:Status: preliminary; translation not shown
A:Molecule type: DNA
A:Residues: 1-101 <SAN>
A:Cross-references: EMBL:X56372
A:Experimental source: clones 5AU; 5BLK; 5CH; 5CW; 5LB; 5TT
A:Accession: S12425
A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-101 <SA2>
A:Cross-references: EMBL:X56373
A:Accession: S12426
A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-101 <SAJ>
A:Cross-references: EMBL:X56370
A:Accession: S12427
```

A>Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA4>
 A:Cross-references: EMBL:X56368
 A:Accession: S12429
 A>Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA5>
 A:Cross-references: EMBL:X56369
 A:Accession: S12432
 A>Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA6>
 A:Cross-references: EMBL:X56371
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:18-101/Domain: immunoglobulin homology <IMM>

Alignment Scores:
 Pred. No.: 0.00723 Length: 101
 Score: 92.20 Matches: 20
 Percent Similarity: 67.65% Conservative: 3
 Best Local Similarity: 58.82% Mismatches: 3
 Query Match: 62.30% Indels: 8
 DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x S12424 (1-101)

QY 1 ATCATCTATCTCGTGACTCTGATACCATACAGCCGCTCTTCCAGGCGG----- 54

Db 53 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 72

QY 55 -----GCGAGTCACGGGTATTAGCAGC-----TGG 78

Db 73 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 86

RESULT 10

PH1266
 Ig heavy chain V region (clone VERGS) - human (fragment)
 C:Species: Homo sapiens (man)
 C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
 C:Accession: PH1266
 R:Cal, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
 J. Exp. Med. 176, 1073-1081, 1992
 A>Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
 A:Reference number: PH1232; MUID:93018822; PMID:1402653
 A:Accession: PH1266
 A:Molecule type: mRNA
 A:Residues: 1-102 <CAI>
 A:Experimental source: EBV-transformed CD5+ B cell [from adult PBL]
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
 Pred. No.: 0.00723 Length: 102
 Score: 92.20 Matches: 20
 Percent Similarity: 67.65% Conservative: 3
 Best Local Similarity: 58.82% Mismatches: 3
 Query Match: 62.30% Indels: 8
 DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1266 (1-102)

QY 1 ATCATCTATCTCGTGACTCTGATACCATACAGCCGCTCTTCCAGGCGG----- 54

Db 54 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 73

QY 55 -----GCGAGTCACGGGTATTAGCAGC-----TGG 78

Db 74 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 87

RESULT 11

PH1279

Ig heavy chain V region (clones CLL11, CORD3, CORD4, CORD8, CORD9, CD+1, CD+3, CD+4, CD-
 C:Species: Homo sapiens (man)
 C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
 C:Accession: PH1279
 R:Cal, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
 J. Exp. Med. 176, 1073-1081, 1992
 A>Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
 A:Reference number: PH1232; MUID:93018822; PMID:1402653
 A:Accession: PH1279
 A:Molecule type: DNA
 A:Residues: 1-102 <CAI>
 A:Experimental source: adult PBL
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
 Pred. No.: 0.00723 Length: 102
 Score: 92.20 Matches: 20
 Percent Similarity: 67.65% Conservative: 3
 Best Local Similarity: 58.82% Mismatches: 3
 Query Match: 62.30% Indels: 8
 DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1279 (1-102)

QY 1 ATCATCTATCTCGTGACTCTGATACCATACAGCCGCTCTTCCAGGCGG----- 54

Db 54 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 73

QY 55 -----GCGAGTCACGGGTATTAGCAGC-----TGG 78

Db 74 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 87

RESULT 12

PH1277
 Ig heavy chain V region (clone PBL8) - human (fragment)
 C:Species: Homo sapiens (man)
 C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jan-2000
 C:Accession: PH1277
 R:Cal, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
 J. Exp. Med. 176, 1073-1081, 1992
 A>Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
 A:Reference number: PH1232; MUID:93018822; PMID:1402653
 A:Accession: PH1277
 A:Molecule type: DNA
 A:Residues: 1-102 <CAI>
 A:Experimental source: adult PBL
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
 Pred. No.: 0.00723 Length: 102
 Score: 92.20 Matches: 20
 Percent Similarity: 67.65% Conservative: 3
 Best Local Similarity: 58.82% Mismatches: 3
 Query Match: 62.30% Indels: 8
 DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1277 (1-102)

QY 1 ATCATCTATCTCGTGACTCTGATACCATACAGCCGCTCTTCCAGGCGG----- 54

Db 54 llelleTyProGlyAspSerAspThrArgTySerProSerPheGlnGlyGlnValThr 73

QY 55 -----GCGAGTCACGGGTATTAGCAGC-----TGG 78

Db 74 lleSerAlaAspLysSerIleSerThrAlaTyLeuGlnTrp 87

RESULT 13

PH1244

IG heavy chain V region (clone CORD2) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1244
R:Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chromosomal translocation
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1244
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: cord blood B cell
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00723 Length: 102
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1244 (1-102)

QY 1 ATCATCTATCTGGTACTCTGATACACATACAGCCGCTCTTCCAGGCGG----- 54
|||||
Db 54 llelleTyProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 73
QY 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
|||||
Db 74 lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 87

RESULT 14

PH1272

IG heavy chain V region (clone PBL3) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1272
R:Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chromosomal translocation
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1272
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00723 Length: 102
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1272 (1-102)

QY 1 ATCATCTATCTGGTACTCTGATACACATACAGCCGCTCTTCCAGGCGG----- 54
|||||
Db 54 llelleTyProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 73
QY 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
|||||
Db 74 lleSerAlaAspLysSerIleSerThrAlaTyrLeuGlnTrp 87

RESULT 15

PH1282

IG heavy chain V region (clone PBL13) - human (fragment)

C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1282
R:Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chromosomal translocation
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1282
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00723 Length: 102
Score: 92.20 Matches: 20
Percent Similarity: 67.65% Conservative: 3
Best Local Similarity: 58.82% Mismatches: 3
Query Match: 62.30% Indels: 8
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x PH1282 (1-102)

QY 1 ATCATCTATCTGGTACTCTGATACACATACAGCCGCTCTTCCAGGCGG----- 54
|||||
Db 54 llelleTyProGlyAspSerAspThrArgTyrSerProSerPheGlnGlyGlnValThr 73
QY 55 -----GCGAGTCAGGGTATTAGCAGC-----TGG 78
|||||
Db 74 lleSerAlaAspLysSerIleSerThrThrTyrLeuGlnTrp 87

Search completed: August 4, 2005, 19:02:36
Job time : 18.75 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:23:15 ; Search time 80.75 Seconds
 (without alignments)
 1065.378 Million cell updates/sec

Title: NOLAN463-2A.SEQ
 Perfect score: 148
 Sequence: 1 ARCATCTACTCTGGTGACTC.....GTATTAGCAGCTGGTTAGCC 84

Scoring table: BLOSUM62
 Xgapop 10.0 , Xgapext 0.1
 Ygapop 10.0 , Ygapext 0.1
 Fgapop 6.0 , Fgapext 0.1
 Delop 6.0 , Delext 0.1

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 3224756

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Command line parameters:
 -MODEL=frame+ n2p.model -DEV=xlp
 -O=/cgn2.1/USPTO.spool.p/NOLAN08728463-2/runat.04082005.123944.22581/app_query.fasta_1.5
 -DB=Uniprot -QFWT=fastan -SUFFIX=rup -MINMATCH=0.1 -LOOFC=0 -LOOPEXT=0
 -UNITS=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
 -DOCALIGN=200 -THRM SCORE=pt -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
 -OUTFWT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
 -USERS=NOLAN08728463-2 @CGN 1.1 305 @runat.04082005.123944.22581 -NCPU=6
 -ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
 -DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
 -FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DSELEXT=0.1

Database : Uniprot 03.*
 1: uniprot_sprot.*
 2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	70.3	47.5	118	Q921C4	Q921C4 mus musculus
2	68.3	46.1	111	Q9D9B8	Q9D9B8 mus musculus
3	68.3	46.1	474	Q8R3H6	Q8R3H6 mus musculus
4	67.6	45.7	236	Q6GMX8	Q6GMX8 homo sapien
5	67.3	45.5	614	Q7TMT6	Q7TMT6 mus musculus
6	64.4	42.4	302	Q9I9C3	Q9I9C3 anguilla an
7	63.6	43.0	117	KV11 HUMAN	P01601 homo sapien
8	63.6	43.0	236	Q6PIH7	Q6PIH7 homo sapien
9	63.5	42.9	473	Q7Q1B6	Q7Q1B6 anopheles g
10	62.3	42.1	117	HV52 MOUSE	P06327 mus musculus
11	62.2	42.0	436	Q6TL49	Q6TL49 glycemia fl
12	62	40.8	138	Q72WG5	Q72WG5 desulfovibr
13	61.8	40.7	984	Q8MT62	Q8MT62 drosophila
14	61.8	40.7	1043	Q9VYS8	Q9VYS8 drosophila
15	61.8	40.7	1059	Q76NS2	Q76NS2 drosophila
16	61.7	40.6	427	Q9AYR4	Q9AYR4 chaetoceros

c	17	61.7	40.6	427	2	Q9AYR6	Q9AYR6 chaetoceros
	18	61.3	41.4	110	2	Q9JL83	Q9JL83 mus musculus
	19	61	41.2	117	1	HV06 MOUSE	P01750 mus musculus
	20	60.8	41.1	293	2	Q73WB2	Q73WB2 mycobacteri
	21	60.6	40.9	324	2	Q7V9E2	Q7V9E2 prochloroco
	22	60.5	39.8	517	2	Q9Y781	Q9Y781 coprinus ci
	23	60.3	39.7	660	1	Y839_PSESM	Q8860 pseudomonas
	24	60	39.5	624	2	Q9ARZ1	Q9ARZ1 oryza sativ
	25	60	39.5	929	2	Q9FMN8	Q9FMN8 arabidopsis
	26	60	39.5	929	2	Q7F8S7	Q7F8S7 oryza sativ
	27	59.9	40.5	240	2	Q7PKV0	Q7PKV0 anopheles g
	28	59.9	40.5	882	2	Q7EUM0	Q7EUM0 anopheles g
	29	59.9	40.5	930	2	Q7PY03	Q7PY03 anopheles g
	30	59.8	40.4	244	2	Q65ZC8	Q65ZC8 homo sapien
	31	59.7	39.3	270	1	VMT1_DHV11	Q01479 dhori virus
	32	59.7	39.3	189	2	Q6Z8R9	Q6Z8R9 homo sapien
	33	59.7	40.3	354	2	Q27328	Q27328 methanobact
	34	59.6	40.3	323	2	Q8LDS8	Q8LDS8 arabidopsis
	35	59.6	40.3	323	2	Q94909	Q94909 arabidopsis
	36	59.6	40.3	353	2	Q9LFW2	Q9LFW2 arabidopsis
	37	59.3	40.1	481	2	Q91WT1	Q91WT1 mus musculus
	38	59.3	40.1	724	2	Q41384	Q41384 spinacia ol
	39	59	39.9	460	2	Q66IF9	Q66IF9 xenopus tro
	40	58.8	39.7	161	2	Q6JH66	Q6JH66 ambystoma t
	41	58.7	39.7	596	2	Q74C03	Q74C03 geobacter s
	42	58.7	39.7	777	2	Q6EP64	Q6EP64 oryza sativ
	43	58.7	39.7	793	2	Q7QXY1	Q7QXY1 giardia lam
	44	58.6	39.6	117	1	KV1J HUMAN	P01602 homo sapien
	45	58.4	39.5	477	2	Q89HMI	Q89HMI bradyrhizob

ALIGNMENTS

RESULT 1

Q921C4 PRELIMINARY; PRT; 118 AA.

ID Q921C4;
 AC Q921C4;
 DT 01-MAY-1999 (TREMBLrel. 10, Created)
 DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)
 DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
 DE Anti-porcine VCAM mab 3F4 heavy chain variable region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 ON NCBI TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Balb/C;
 RX MEDLINE=97450619; PubMed=9307060; DOI=10.1016/S0161-5890(97)00042-4;
 RA Mueller J.P., Giannoni M.A., Hartman S.L., Elliott E.A., Squinto S.P.,
 RA Matis L.A., Evans M.J.;
 RT "Humanized porcine VCAM-specific monoclonal antibodies with chimeric
 RT IgG2/G4 constant regions block human leukocyte binding to porcine
 RT endothelial cells.";
 RL Mol. Immunol. 34:441-452(1997).
 DR EMBL; U78801; AAD00293.1; -;
 DR HSSP; P01751; INQB.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR003596; IG_v.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG_LIKE; 1.
 FT NON TER 118
 FT NON TER 118
 SQ SEQUENCE 118 AA; 13036 MW; 90BEC559D31EC4FC CRC64;

Alignment Scores:
 Pred. No.: 12.1 Length: 118
 Score: 70.30 Matches: 13
 Percent Similarity: 62.07% Conserved: 5
 Best Local Similarity: 44.83% Mismatches: 4
 Query Match: 47.50% Indels: 7
 DB: 2 Gaps: 0


```

RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RN   SEQUENCE FROM N.A.
RP   STRAIN=CZECH II; TISSUE=Mammary tumor;
RA   Strausberg R.;
RL   Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR   EMBL; BC025447; AAH25447.1; -.
DR   HSPF; P01869; ICL7.
DR   MGD; MG1:2144967; AU044919.
DR   InterPro; IPR000345; CytC heme_BS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003597; Ig cl.
DR   InterPro; IPR003006; IG_MHC.
DR   InterPro; IPR003596; Ig v.
DR   Pfam; PF07654; Cl-set; 3.
DR   SMART; SM00406; IGV; 1.
DR   PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
DR   PROSITE; PS00835; IG_LIKE; 4.
DR   PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ   SEQUENCE      474 AA;  51748 MW;  8608B57C6CD2874A CRC64;

Alignment Scores:
Pred. No.:          27.1             Length:        474
Score:              68.30            Matches:         14
Percent Similarity: 55.17%           Conservative:     2
Best Local Similarity: 48.28%       Mismatches:      6
Query Match:        46.15%          Indels:          7
DB:                  2               Gaps:            0

NOLAN463-2A.SEQ (1-84) x QBR3H6 (1-474)

Qy    4 ATCTATCTGGTGACCTGTGATACCACATAGCCCGTCTTCGAAGCGCGGCAGTCAG 63
Db    70 IlleppheproglyaspGlyAspthrHisTySerGlyLysPheGIndgIlysalalys--- 88
Qy    64 GGTTATTAGCACGCT 76
Db    89 ----LeuThrAla 91

RESULT 4
O6GMX8 PRELIMINARY;      PRT;   236 AA.

ID O6GMX8                                PRELIMINARY;
AC O6GMX8;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A.
TISSUE=Primary B-Cells;
MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B.B., Buetow K.H., Schaefer C.J., Shah N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diachenko L., Marasina K., Farmer A.C., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Donaldson M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., ToShiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
RA Villalon D.K., Munzy D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahay J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skaleck U., Smalley D.E., Schermer A., Schein J.E.,
RA Jones S.-J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
```

RA Jones S.J., Marxa M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.",
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6NCr; TISSUE=Hematopoietic Stem Cell;
RA Strauberg R.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC053409; AAHS3409.1; -;
DR HSSP; P01820; 1G7J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; CI-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 614 AA; 67746 MW; 839BAF3B8D124F89 CRC64;

Alignment Scores:
Pred. No.: 37.8 Length: 614
Score: 67.30 Matches: 12
Percent Similarity: 58.62% Conservative: 5
Best Local Similarity: 41.38% Mismatches: 5
Query Match: 45.47% Indels: 7
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x Q7TWT6 (1-614)

QY 4 ATCTATCTGCTGACTCTGATACCATACAGCCGCTCTCCAGGCGCGGAGTCAG 63
DB 70 ValTyrProGlyAspGlyAspThrAsnTyrAsnGlyLysPheLysGlyLysAlaThr--- 88

QY 64 GGTATTAGCAGCT 76
DB 89 ----LeuThrAla 91

RESULT 6
QY919C3
ID QY919C3 PRELIMINARY; PRT; 302 AA.
AC QY919C3;
DT 01-OCT-2000 (TRENBLrel. 15, Created)
DT 01-OCT-2000 (TRENBLrel. 15, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE Sodium/potassium-transferring ATPase beta-233 chain (sodium/potassium-
DE dependent ATPase beta-233 subunit).
GN Name=atnb233;
OS Anguilla anguilla (European freshwater eel).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Anguilliformes; Anguillidae;
OC Anguilla.
OX NCBI_TaxID=7936;
RN [1]_TaxID=7936;
RP SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RC TISSUE=Gill;
RX PubMed=10896885;
RA Cutler C.P., Brezillon S., Bekir S., Sanders I.L., Hazon N., Cramb G.;
RT "Expression of a duplicate Na,K-ATPase beta(1)-isoform in the European
RT eel (Anguilla anguilla).";
RL Am. J. Physiol. 279:R222-R229(2000).
CC -!- FUNCTION: This is the non-catalytic component of the active
CC enzyme, which catalyzes the hydrolysis of ATP coupled with the
CC exchange of Na(+) and K(+) ions across the plasma membrane.
CC -!- SUBUNIT: Composed of three subunits: alpha (catalytic), beta and
CC gamma.
CC -!- SUBCELLULAR LOCATION: Type II membrane protein.
CC -!- TISSUE SPECIFICITY: Expressed mainly in epithelial tissues.
CC -!- SIMILARITY: Belongs to the Na+/K+ and H+/K+ ATPases beta chain
CC family.
DR EMBL; AJ239317; CAB85586.1; -;
DR GO; GO:0005890; C:sodium:potassium-exchanging ATPase complex; NAS.

DR GO; GO:0005391; F:sodium:potassium-exchanging ATPase activity; NAS.
DR GO; GO:0006813; P:potassium ion transport; NAS.
DR GO; GO:0006814; P:sodium ion transport; NAS.
DR InterPro; IPR004042; Na/K-ATPase_beta.
DR Pfam; PF00287; Na_K-ATPase; 1.
DR TIGRFAMS; TIGR01107; Na_K-ATPase bet; 1.
DR PROSITE; PS00390; ATPASE_NA_K_BETA_1; 1.
DR PROSITE; PS00391; ATPASE_NA_K_BETA_2; 1.
KW Glycoprotein; Signal-anchor; Sodium/potassium transport;
KW Transmembrane.
FT DOMAIN 1 33 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 34 54 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
(POTENTIAL).
FT DOMAIN 55 302 EXTRACELLULAR (POTENTIAL).
FT DISULFID 125 148 By similarity.
FT DISULFID 158 174 By similarity.
FT DISULFID 213 274 By similarity.
FT CARBOHYD 193 193 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 263 263 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 302 AA; 34706 MW; 721E056F04274D0D CRC64;

Alignment Scores:
Pred. No.: 79.1 Length: 302
Score: 64.40 Matches: 14
Percent Similarity: 26.15% Conservative: 3
Best Local Similarity: 21.54% Mismatches: 2
Query Match: 42.37% Indels: 46
DB: 2 Gaps: 2

NOLAN463-2A.SEQ (1-84) x Q9I9C3 (1-302)

QY 61 GACTCGCCGCGC-----CTTGA 44
DB 6 AspSerAspGlyGlyTyrLysThrPheLeuTrpAsnSerGluLysLysGluLeuGly 25

QY 43 AGGAGCGGCTGTGTGTGTATCATCAG----- 20
DB 26 ArgThrGlyCysSerTrpPheLysLeuLeuPheTyrValIlePheTyrGlyCysLeu 45

QY 20 ----- 20
DB 46 AlaAlaValPheValGlyThrIleGlnAlaLeuLeuThrLeuSerAsnTyrLysPro 65

QY 19 AGTCACCATGATAGA 5
DB 66 ThrHisGlnAspArg 70

RESULT 7
KV11_HUMAN
ID KV11_HUMAN STANDARD; PRT; 117 AA.
AC P01601.
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE IG kappa chain V-I region HK101 precursor (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=81098966; PubMed=6779204;
RA Bentley D.L., Rabbitts T.H.;
RT "Human immunoglobulin variable region genes -- DNA sequences of two V
RT kappa genes and a pseudogene.";
RL Nature 288:730-733(1980).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=8129397; PubMed=6402305; DOI=10.1016/0092-8674(83)90508-1;
RA Bentley D.L., Rabbitts T.H.;
RT "Evolution of immunoglobulin V genes: evidence indicating that
RT recently duplicated human V kappa sequences have diverged by gene
RT conversion.";

```

RL Cell 32:181-189(1983).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; K01322; AAA58930.1; -
DR EMBL; K01324; AAA58932.1; -
DR EMBL; V00558; CAA23824.1; -
DR PIR; A01881; KIHU11.
DR HSP; P01607; LBWV.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
DR Immunoglobulin V region; Signal.
KW SIGNAL 1
FT CHAIN 1
FT DOMAIN 23 >117
FT DOMAIN 23 45
FT DOMAIN 46 56
FT DOMAIN 57 71
FT DOMAIN 72 78
FT DOMAIN 79 110
FT DOMAIN 111 >117
FT DISULFID 45 110
FT NON_TER 117
SQ SEQUENCE 117 AA; 12799 MW; D7D0FF3718CFE587 CRC64;

Alignment Scores:
Pred. No.: 86 Length: 117
Score: 63.60 Matches: 17
Percent Similarity: 45.24% Conservative: 2
Best Local Similarity: 40.48% Mismatches: 9
Query Match: 42.97% Indels: 14
DB: 1 Gaps: 2

NOLAN463-2A-SEQ (1-84) x KV1I_HUMAN (1-117)
QY 1 ATCATCTATCTCGGT-----CACTCTGATACACATACAGCCGCTCC----- 42
Db 15 LeuCysPheProGlyAlaArgCysAspIleGlnMetThrGlnSerProSerSerLeuSer 34
QY 43 -----TTCCAAGCCGCGGAGTCAGGGTATTAGCAGCTGG 78
Db 35 AlaSerValGlyAspArgValThrIleThrCysArgAlaArgGlnGlyIleSerSerTrp 54
QY 79 TTAGCC 84
Db 55 LeuAla 56

RESULT 8
Q6PIH7
ID Q6PIH7 PRELIMINARY; PRT; 236 AA.
AC Q6PIH7;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RT TISSUE=Lung;

```

```

RX MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalón D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Pahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywicki M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RA Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034141; AAH34141.1; -
DR HSP; P01607; IAR2.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG.cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 236 AA; 25603 MW; 8BC561106861213F CRC64;

Alignment Scores:
Pred. No.: 96.2 Length: 236
Score: 63.60 Matches: 18
Percent Similarity: 48.72% Conservative: 1
Best Local Similarity: 46.15% Mismatches: 6
Query Match: 42.97% Indels: 14
DB: 2 Gaps: 2

NOLAN463-2A-SEQ (1-84) x Q6PIH7 (1-236)
QY 10 CCTGCT-----GACTCTGATACACATACAGCCGCTCCAGGC----- 51
Db 18 ProGlyAlaArgCysAspIleGlnLeuThrGlnSerProSerPheLeuSerAlaSerVal 37
QY 52 -----CGGCGGAGTCAGGGTATTAGCAGCTGGTAGCC 84
Db 38 GlyAspArgValThrIleThrCysArgAlaSerGlnGlyIleSerSerTrpLeuAla 56

RESULT 9
Q7Q1B6
ID Q7Q1B6 PRELIMINARY; PRT; 473 AA.
AC Q7Q1B6;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE AgCP8180 (Fragment).
GN Name=agCG51167; ORFNames=ENSANGG00000012318;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae; Anopheles.
OX NCBI_TaxID=180454;

```

```

RN [1]
RP SEQUENCE FROM N.A.
RC STRAINS-PEST;
RA Anopheles Genome Sequencing Consortium;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01008980; EAAL4419.1; -.
DR InterPro; IPR005654; AFG1_ATPase.
DR Pfam; PF03969; AFG1_ATPase; 1.
FT NON_TER 1
SQ SEQUENCE 473 AA; 53210 MW; 6F8197395A1C7F79 CRC64;

Alignment Scores:
Pred. No.: 111 Length: 473
Score: 63.50 Matches: 13
Percent Similarity: 44.74% Conservative: 4
Best Local Similarity: 34.21% Mismatches: 6
Query Match: 42.91% Indels: 15
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x Q7Q1B6 (1-473)

QY 1 ATCTATCTCTGGTGACTCTGATACCATACATACAGCCGCTCTCCAAAGCGCGGCGAGT 60
Db 84 ValValTyr-----AspSerIleGlyLysTrpPheSerPro-----ProLysPro-----Ser 98

QY 61 CAGGGTATTAGCAGCTGGTTAGCC 84
Db 99 ThrGlyIleGlyLysTrpPheSer 106

RESULT 10
ID HV52_MOUSE STANDARD; PRT; 117 AA.
AC P06327;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig heavy chain V region VH58 A1/A4 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85099340; Pubmed=2578321; DOI=10.1016/0092-8674(85)90141-2;
RA Yancopoulos G.D., Alt F.W.;
RT "Developmentally controlled and tissue-specific expression of
RT unarranged VH gene segments.";
RL Cell 40:271-281 (1985).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M13787; AAA38499.1; -.
DR PIR; A02029; HVMSA1.
DR HSSP; P01820; IG70.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V region VH58 A1/A4.
FT DOMAIN 20 49 Framework-1.
FT DOMAIN 50 54 Complementarity-determining-1.

```

```

FT DOMAIN 55 68 Framework-2.
FT DOMAIN 69 85 Complementarity-determining-2.
FT DOMAIN 86 117 Framework-3.
FT DISULFID 41 115 By similarity.
FT NON_TER 117
SQ SEQUENCE 117 AA; 12971 MW; 8B0BC138856DFC9D CRC64;

Alignment Scores:
Pred. No.: 126 Length: 117
Score: 62.30 Matches: 12
Percent Similarity: 55.17% Conservative: 4
Best Local Similarity: 41.38% Mismatches: 6
Query Match: 42.09% Indels: 7
DB: 1 Gaps: 0

NOLAN463-2A.SEQ (1-84) x HV52_MOUSE (1-117)

QY 4 ATCTATCTCTGGTGACTCTGATACCATACATACAGCCGCTCTCCAAAGCGCGGCGAGT 63
Db 70 IleTyrProGlyAspGlySerThrLysTyrAsnGluLysPheLysGlyLysAlaThr---- 88

QY 64 GGTATTAGCAGCT 76
Db 89 ----LeuThrAla 91

RESULT 11
ID Q6TL49 PRELIMINARY; PRT; 436 AA.
AC Q6TL49;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit
DE (Fragment).
GN Name=rbcl;
OS Glycemia fluitans.
OG Chloroplast.
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae;
OC Melicaceae; Glyceria.
OX NCBI_TaxID=254778;
RN [1]
RP SEQUENCE FROM N.A.
RA Dolphin K.P., Joseph J.A., Fay M.F., Purvis A., Gowing D.,
RA Crawley M.J., Cowan R.S.;
RL Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Rubisco catalyzes two reactions: the carboxylation of D-
CC ribulose 1,5-bisphosphate, the primary event in photosynthesis
CC carbon dioxide fixation, as well as the oxidative fragmentation of
CC the pentose substrate in the photorespiration process. Both
CC reactions occur simultaneously and in competition at the same
CC active site (By similarity).
CC -!- CATALYTIC ACTIVITY: D-ribulose 1,5-bisphosphate + CO(2) + H(2)O =
CC 2 3-phospho-D-glycerate.
CC -!- CATALYTIC ACTIVITY: D-ribulose 1,5-bisphosphate + O(2) = 3-
CC phospho-D-glycerate + 2-phosphoglycolate.
CC -!- SUBUNIT: 8 large chains + 8 small chains (By similarity).
CC -!- SUBCELLULAR LOCATION: Chloroplast (By similarity).
CC -!- SIMILARITY: Belongs to the Rubisco large chain family.
DR EMBL; AY395539; AAR38681.1; -.
DR GO; GO:0009507; C:chloroplast; IEA.
DR GO; GO:0009573; C:ribulose biphosphate carboxylase complex (. . .); IEA.
DR GO; GO:0016829; F:lyase activity; IEA.
DR GO; GO:0004497; F:monooxygenase activity; IEA.
DR GO; GO:0016984; F:ribulose-bisphosphate carboxylase activity; IEA.
DR GO; GO:0015977; P:carbon utilization by fixation of carbon di. . .; IEA.
DR GO; GO:0009853; P:photorespiration; IEA.
DR GO; GO:0015979; P:photosynthesis; IEA.
DR InterPro; IPR000685; RUBISCO_large.
DR Pfam; PF00016; RUBISCO_large; 1.
DR Pfam; PF02788; RUBISCO_large; 1.
DR PROSITE; PS00157; RUBISCO_LARGE; 1.
KW Carbon dioxide fixation; Chloroplast; Lyase; Monooxygenase;

```

KW Oxidoreductase; Photorespiration; Photosynthesis.

FT NON_TER 1
FT NON_TER 436
SQ SEQUENCE 436 AA; 48417 MW; 229C3E9FFCE4420B CRC64;

Alignment Scores:

Pred. No.: 160 Length: 436
Score: 62.20 Matches: 13
Percent Similarity: 39.47% Conservative: 2
Best Local Similarity: 34.21% Mismatches: 5
Query Match: 42.03% Indels: 18
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x Q6T149 (1-436)

QY 7 TATCTGCTGACTCTGATACACATACAGCCGCTCTTCCAGGCGCGCAGTCAGGCT 66
Db 61 TyrLysGlyArgCys--TyrHisIleGluProVal-----ProGlyGluGluGly- 76
QY 67 ATTACAGCTGTTAGCC 84
Db 77 -----GlnTrpIleAla 80

RESULT 12

Q72WG5 PRELIMINARY; PRT; 138 AA.

AC Q72WG5;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Sigma factor serine-protein kinase.
GN OrderedLocustNames=DVUA0124;
OS Desulfovibrio vulgaris (strain Hildenborough / ATCC 29579 / NCIMB 8303).
CG Plasmid pdv
OC Bacteria; Proteobacteria; Deltaproteobacteria; Desulfovibrionales;
OC Desulfovibrionaceae; Desulfovibrio.
OX NCBI_TaxID=882;
RN [1]

SEQUENCE FROM N.A.

RP PubMed=15077118; DOI=10.1038/nbr959;
RA Heidelberg J.F., Seshadri R., Haveman S.A., Hemme C.L., Paulsen I.T.,
RA Kolonay J.F., Eisen J.A., Ward N.L., Methe B.A., Brinkac L.M.,
RA Daugherty S.C., DeBoy R.T., Dodson R.J., Durkin A.S., Madupu R.,
RA Nelson W.C., Sullivan S.A., Fouts D.E., Haft D.H., Selengut J.,
RA Peterson J.D., Davidgen T.M., Zafar N., Zhou L., Radune D.,
RA Dimitrov G., Hance M., Tran K., Khouri H.M., Gill J., Utterback T.R.,
RA Feldblyum T.V., Wall J.D., Voordouw G., Fraser C.M.;
RT "The genome sequence of the anaerobic, sulfate-reducing bacterium
Desulfovibrio vulgaris Hildenborough.";
RL Nat. Biotechnol. 22:554-559 (2004).
DR EMBL; AB017286; AAS94340.1; -.
DR TIGR; DVUA0124; -.

KW Complete proteome.

SQ SEQUENCE 138 AA; 15178 MW; 0878CD5858774397 CRC64;

Alignment Scores:

Pred. No.: 141 Length: 138
Score: 62.00 Matches: 12
Percent Similarity: 41.38% Conservative: 0
Best Local Similarity: 41.38% Mismatches: 7
Query Match: 40.79% Indels: 10
DB: 2 Gaps: 0

NOLAN463-2A.SEQ (1-84) x Q72WG5 (1-138)

QY 67 TACCTGACTCCCGCGCTTGGAGGACGGGCTGTATGTGTATGATCAGATCACCAGGAT 8
Db 51 TyrProAspSerProGlyLysAlaGluValGlyCys-----ArgValValLeuPh 67
QY 7 AGATGAT 1
Db 67 eAspSep 69

RESULT 13

Q8MT62 PRELIMINARY; PRT; 984 AA.

AC Q8MT62;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE RE04357P.
GN ORFNames=CG10353;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]

SEQUENCE FROM N.A.

RC STRAIN=Berkley;
RA Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA Champagne M., Chavez C., Dorsett V., Dresnek D., Farfan D., Frise E.,
RA George R., Gonzalez M., Guarin H., Krommiller B., Li P., Liao G.,
RA Miranda A., Mungall C.J., Nuncio J., Pacleb J., Paragas V., Park S.,
RA Patel S., Phouanavong S., Wan K., Yu C., Lewis S.E., Rubin G.M.,
RA Ceiniker S.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY118358; AAM48387.1; -.
DR FLYBase; FBgn0030349; CG10353.
DR InterPro; IPR007632; DUF590.
DR Pfam; PF04547; DUF590; 1.

SQ SEQUENCE 984 AA; 112356 MW; 233EFCAAD0405E8 CRC64;

Alignment Scores:

Pred. No.: 205 Length: 984
Score: 61.80 Matches: 13
Percent Similarity: 55.88% Conservative: 6
Best Local Similarity: 38.24% Mismatches: 3
Query Match: 40.66% Indels: 12
DB: 2 Gaps: 1

NOLAN463-2A.SEQ (1-84) x Q8MT62 (1-984)

QY 77 CAGCTGCTATACCTGACTGCTCCCGCGCTTGGAGGAC-----GGGCTG 33
Db 685 GluMetLeuIleProTyrLeuMetArgThrPheLysGluLeuSerTyrArgHisGly--- 703
QY 32 TATGTGGTATCAGAGTCACAGGATAGA 5
Db 704 ---TriPtyrLysSerHisGlnAspGln 711

RESULT 14

Q9VYS8 PRELIMINARY; PRT; 1043 AA.

AC Q9VYS8;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE CG10353-PA.
GN ORFNames=CG10353;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]

SEQUENCE FROM N.A.

RP MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RX Adams M.D., Celnik S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scher S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Vandeil M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers J.H., Blazek R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkuch C., Baldwin D.,

Search completed: August 4, 2005, 19:01:24
Job time : 87.75 secs

```

RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA Williams S.M., Woodage, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426065; PubMed=12537568;
RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Laverty T., Muzny D.M., Nelson C.R.,
RA Pacleeb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskas R., Taber P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun. Release 3 of the Drosophila
RT melanogaster euchromatic genome sequence.";
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426070; PubMed=12537573;
RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA Ashburner M., Celniker S.E.;
RT "The transposable elements of the Drosophila melanogaster euchromatin:
RT a genomics perspective.";
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426069; PubMed=12537572;
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
RT systematic review.";
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).
RN [5]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AE003487; AAN09305.2; -.
DR InterPro; IPR007632; DUF590.
DR Pfam; PF04547; DUF590; 1.
SQ SEQUENCE 1059 AA; 120767 MW; 676365606C1CA98A CRC64;

Alignment Scores:
Pred. No.: 207 Length: 1059
Score: 61.80 Matches: 13
Percent Similarity: 55.88% Conservative: 6
Best Local Similarity: 38.24% Mismatches: 3
Query Match: 40.66% Indels: 12
DB: 2 Gaps: 1

NOLAN463-2A.SEQ (1-84) x Q76NS2 (1-1059)
QY 77 CAGCTGCTATACCTGACTCCCGCTTGAGAGAC-----GGGCTG 33
Db 760 GluMetLeuIleProTyrLeuMetArgThrPheLysGluLeuSerTyrArgHisGly--- 778
QY 32 TATGTGGTATCAGAGTCACCGAGATAGA 5
Db 779 ----trpTyrLysSerHisGlnAspGln 786

```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:21:34 ; Search time 90 Seconds
(without alignments)
721.953 Million cell updates/sec

Title: NOLAN463-2B.SEQ

Perfect score: 148

Sequence: 1 CGGGCGAGTCAGGTATTAG.....ACAGCCCGTCCTTCCAGGC 84

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 4211384

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-O=/cgn2.1/USPTO.spool.p/NOLAN08728463-2/runat_04082005_123943_22574/app.query.fasta_1.5
-DB=A_Geneseq -QFMT=fastan -SUFFIX=rag -MINMATCH=0.1 -LOOPEXT=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : A_Geneseq_16Dec04:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	115	77.7	123	5	ABG76561
2	113.3	76.6	411	8	ADr46829 Human p81
3	106.2	71.8	122	4	Aau02582 Anti-adip
4	104.4	70.5	474	4	Aau14177 Human nov
5	103.4	69.9	98	2	Aaw54008 Human Ant
6	103.4	69.9	98	5	ABG78233 Human Fv
7	103.4	69.9	98	5	ABG78231 Human Fv
8	103.4	69.9	98	5	ABG78232 Human Fv
9	103.4	69.9	98	5	ABG91924 Human ant
10	103.4	69.9	98	5	ABG91922 Human ant

11	103.4	69.9	98	5	ABG91923	Human ant
12	103.4	69.9	98	6	ABU56809	Human Imm
13	103.4	69.9	98	6	ABP56508	Human ant
14	103.4	69.9	98	6	ABJ18687	Antibody
15	103.4	69.9	98	6	ABO27112	Human ger
16	103.4	69.9	98	7	ADG69247	Human hea
17	103.4	69.9	98	7	ADF10156	Antibody
18	103.4	69.9	98	7	ADF09948	Antibody
19	103.4	69.9	98	7	ADF10053	VEGF anti
20	103.4	69.9	98	7	ADK18943	Anti-huma
21	103.4	69.9	98	7	ADK18888	Anti-huma
22	103.4	69.9	98	7	ADK18877	Anti-huma
23	103.4	69.9	98	7	ADK18878	Anti-huma
24	103.4	69.9	98	7	ADK18912	Anti-huma
25	103.4	69.9	98	7	ADK18582	Anti-huma
26	103.4	69.9	98	7	ADK18896	Anti-huma
27	103.4	69.9	98	7	ADK18894	Anti-huma
28	103.4	69.9	98	7	ADJ80328	VH gene 1
29	103.4	69.9	98	8	ADr46847	Human VH5
30	103.4	69.9	109	8	AD105782	Human mon
31	103.4	69.9	109	8	ADP22377	Human ant
32	103.4	69.9	109	8	ADP22385	Human ant
33	103.4	69.9	109	8	ADS12513	Human VH5
34	103.4	69.9	109	8	ADS12515	Human VH5
35	103.4	69.9	109	8	ADS12514	Human VH5
36	103.4	69.9	110	8	ADP47302	Human pho
37	103.4	69.9	113	6	ABU08149	Human Erb
38	103.4	69.9	113	7	ADD69211	Human ant
39	103.4	69.9	116	8	ADP22194	Human ant
40	103.4	69.9	117	2	AAR66339	Human Imm
41	103.4	69.9	117	4	AAG62966	Amino aci
42	103.4	69.9	117	5	AAO15186	Digi anti
43	103.4	69.9	117	6	ABP97450	Human ant
44	103.4	69.9	117	8	ADL70771	Anti-TNFA
45	103.4	69.9	117	8	ADP47229	Human pho

ALIGNMENTS

RESULT 1

ABG76561
ID ABG76561 standard; protein; 123 AA.

XX AC ABG76561;

XX DT 05-NOV-2002 (first entry)

XX DE HCV E1 antigen monoclonal antibody #49.

XX KW Human; HCV; hepatitis C virus; E1 antigen; monoclonal antibody; vaccine; hepatotropic; Fab; hypervariable region; E2 antigen; antibody.

XX OS Homo sapiens.

XX FN WO200260954-A1.

XX PD 08-AUG-2002.

XX PF 14-JAN-2002; 2002WO-SE000044.

XX PR 12-JAN-2001; 2001US-0260889P.

XX PA (KARO-) KAROLINSKA INNOVATIONS AB.

XX PI Drakenberg K, Persson MAA;

XX DR WPI; 2002-608502/65.

XX PT Vaccine comprising a human monoclonal antibody against hepatitis C virus (HCV) E1 or E2 antigen, useful for treating or preventing HCV infection.

XX PS Disclosure; Page 54; 64pp; English.

XX XX

CC The invention relates to a human monoclonal antibody or its antigen
CC binding fragments, which exhibit immunological binding affinity for a
CC hepatitis C virus (HCV) E1 antigen, comprising an amino acid sequence
CC homologous to the binding portion of a human antibody Fab molecule from a
CC combinatorial antibody library. The vaccine composition comprising the
CC antibodies or antigen binding fragments against HCV E1 or E2 antigen or
CC its hypervariable region is useful in treating or preventing HCV
CC infection in a subject. Sequences ABG76513-ABG76568 represent human
CC monoclonal antibodies against HCV E1 antigen
XX
SQ Sequence 123 AA;

Alignment Scores:
Pred. No.: 7,058-05 Length: 123
Score: 115.00 Matches: 23
Percent Similarity: 55.32% Conservative: 3
Best Local Similarity: 48.94% Mismatches: 1
Query Match: 77.70% Indels: 20
DB: 5 Gaps: 1

NOLAN463-2B-SEQ (1-84) x ABG76561 (1-123)

QY 1 CGGGCGAGT----- 9
DB 25 ArgAlaSerGlyTyrSerPheSerLeuPheTrpValAlaTrpValArgGlnMetProGly 44
QY 10 CAGGGTATTAGCAGCTGGTTAGCCATCATCTATCTCTGGTGACTCTGTATACCATACAGC 69
DB 45 GlnGlyLeu---GluTrpMetAlaIleIleTyrProGlyAspSerAspThrThrTyrSer 63
QY 70 CGGCTCTCCAGGC 84
DB 64 ProSerPheGluGly 68

RESULT 2

ADR46829

ID ADR46829 standard; protein; 411 AA.

XX ADR46829;

XX 18-NOV-2004 (first entry)

XX Human pB11-betahCG molecular conjugate protein SEQ ID NO:12.

XX molecular conjugate; monoclonal antibody; human antigen presenting cell;
XX antigen presenting cell; APC; human; beta human chorionic gonadotropin;
XX betahCG; beta chorionic gonadotropin; antibody;
XX T cell-mediated immune response; immunisation; cytostatic; antimicrobial;
XX immunosuppressive; anti-HIV; hepatotropic; virucide; antimalarial;
XX CD8 agonist; vaccine; autoimmune disorder; cancer; infectious disease;
XX melanoma; fibrosarcoma; leukaemia; HIV; hepatitis; malaria; herpes;
XX antibody B11; pB11-betahCG molecular conjugate; fusion protein.

XX Homo sapiens.

XX Synthetic.

XX WO2004074432-A2.

XX 02-SEP-2004.

XX 30-JAN-2004; 2004WO-US002725.

XX 31-JAN-2003; 2003US-0443979P.

XX (MEDA-) MEDAREX INC.

XX Keler T, Endres M, He L, Ramakrishna V;

XX WPI; 2004-635555/61.

XX N-PSDB; ADR46828.

XX New molecular conjugate having a monoclonal antibody that binds to human
XX APCs linked to a beta human chorionic gonadotropin, useful for inducing a

PT cytotoxic T cell response in cancers and infectious diseases.
XX Claim 16; SEQ ID NO 12; 82pp; English.

XX The present invention describes a molecular conjugate comprising a
CC monoclonal antibody that binds to human antigen presenting cells (APCs)
CC linked to beta human chorionic gonadotropin (betahCG), where the antibody
CC comprises a heavy and/or light chain variable region derived from a human
CC VHS-51 or Vh-125 germline sequence with the 98 or 95 amino acid sequences
CC of SEQ ID NO:30 or 32 (ADR46847, or ADR46849), respectively. Also
CC described: (1) a molecular conjugate comprising a human antibody heavy
CC chain and a human antibody light chain, where either or both chains are
CC linked to betahCG; (2) a molecular conjugate comprising a human single
CC chain antibody that binds to human APCs linked to betahCG, where the
CC conjugate comprises the 411 amino acid sequence of SEQ ID NO:12
CC (ADR46829); (3) a composition comprising any of the molecular conjugates
CC as described above, and a carrier, optionally in combination with an
CC adjuvant; (4) inducing or enhancing a T cell-mediated immune response,
CC against betahCG, comprising contacting any of the molecular conjugates
CC described above with APCs such that the antigen is processed and
CC presented to T cells in a manner which induces or enhances a T cell-
CC mediated response against the antigen; (5) immunising a subject
CC comprising administering any of the molecular conjugates described above,
CC optionally in combination with an adjuvant, a cytokine which stimulates
CC proliferation of dendritic cells and/or an immunostimulatory agent; and
CC (6) inducing or enhancing a cytotoxic T cell response against an antigen,
CC comprising forming a conjugate of the antigen and a monoclonal antibody
CC which binds to APCs, and contacting the conjugate either in vivo or ex
CC vivo with APCs such that the antigen is internalised, processed and
CC presented to T cells in a manner which induces or enhances a cytotoxic T
CC cell response against the antigen. The molecular conjugate has
CC cytostatic, antimicrobial, immunosuppressive, anti-HIV, hepatotropic,
CC virucide and antimalarial activities, and can be used as a CD8 agonist,
CC and in vaccines. The methods and compositions of the present invention
CC are useful for inducing a cytotoxic T cell response, and in particular
CC for treating autoimmune disorders, cancers and infectious diseases by
CC eliciting a potent antigen-specific cytotoxic T lymphocyte response,
CC including melanoma, fibrosarcoma, leukaemia, HIV, hepatitis, malaria and
CC herpes. The present sequence represents a human pB11-betahCG molecular
CC conjugate, which is used in the exemplification of the present invention.
XX
SQ Sequence 411 AA;

Alignment Scores:

Pred. No.: 0,000163 Length: 411
Score: 113.30 Matches: 26
Percent Similarity: 15.76% Conservative: 0
Best Local Similarity: 15.76% Mismatches: 2
Query Match: 76.55% Indels: 137
DB: 8 Gaps: 1

NOLAN463-2B-SEQ (1-84) x ADR46829 (1-411)

QY 1 CGGGCGAGTACGGGTATTAGCAGCTGGTTAGCC----- 33
DB 43 ArgAlaSerGlnGlyIleSerArgTrpLeuAlaTrpTyrGlnGlnLysProGlnLysAla 62
QY 33 ----- 33
DB 63 ProLysSerLeuIleTyrAlaAlaSerSerLeuGlnSerGlyValProSerArgPheSer 82
QY 33 ----- 33
DB 83 GlySerGlySerGlyThrAspPheThrLeuThrIleSerGlyLeuGlnProGlnAspPhe 102
QY 33 ----- 33
DB 103 AlaThrTyrTyrCysGlnGlnTyrAsnSerTyrProArgThrPheGlyGlnGlyThrLys 122
QY 33 ----- 33
DB 123 ValGluIleLysGlyGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlu 142

QY 33 ----- 33
 Db 143 ValGlnLeuValGlnSerGlyAlaGluValLysLysProGlyGluSerLeuArgIleSer 162
 QY 33 ----- 33
 Db 163 CysLysGlySerGlyAspSerPheThrThrTyrTrpIleGlyTrpValArgGlnMetPro 182
 QY 34 -----ATCATCTATPCTGGTGACTCTGATACCATACAGC 69
 Db 183 GlyLysGlyLeuGluTrpMetGlyIleIleTyrProGlyAspSerAspThrIleTyrSer 202
 QY 70 CCGTCTCTCCAAAGC 84
 Db 203 ProSerPheGlnGly 207
 RESULT 3
 AAU02582
 ID AAU02582 standard; protein; 122 AA.
 XX
 AC AAU02582;
 DT 29-AUG-2001 (first entry)
 XX
 DE Anti-adipocyte monoclonal antibody heavy chain, FAT 69.
 XX
 KW Antibody; adipocyte; heavy chain; light chain; obesity; fat;
 KW heart disease; complementarity determining region; CDR.
 XX
 OS Homo sapiens.
 XX
 PN WO200127279-A1.
 XX
 PD 19-APR-2001.
 XX
 PF 11-OCT-2000; 2000WO-GB003900.
 XX
 PR 12-OCT-1999; 99US-0158812P.
 XX
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 PI Edwards BM, Main SH, Vaughan TJ;
 XX
 DR WPI; 2001-282031/29.
 XX
 DR N-PSDB; AAS03482.
 XX
 PT Panel of specific binding members of antibody molecules which bind to
 PT whole adipocytes is used in the treatment of obesity and obesity related
 PT diseases.
 XX
 PS Claim 1; Page 144; 182pp; English.
 XX
 CC AAU02501-AAU02635, and AAU02641-AAU02748 represent the amino acid
 CC sequences of anti-adipocyte monoclonal antibody heavy chain, light chain,
 CC and heavy chain complementarity determining regions (CDR) of the
 CC invention. The antibodies can be used in the treatment of obesity and
 CC obesity related diseases. The antibodies can be used to deliver drugs or
 CC pro-drugs directly to the fat mass of an obese patient or the antibody
 CC can be used as a therapeutic itself. Antibodies binding specifically to
 CC adipocytes can be used to activate the immune system to destroy the cells
 CC by complement mediated lysis. The antibodies may be labeled with a
 CC detectable label such as radiolabel, fluorescent or chemical group and
 CC used in methods of diagnosis in human subjects e.g. to determine the
 CC presence of adipocyte antigen on the surface of an adipocyte to detect or
 CC determine the presence or level of adipocytes in a cell or tissue sample.
 CC The antibodies can be used as an alternative means of treatment for obese
 CC patients other than undergoing surgery to remove excess fat. Antibodies
 CC for different types of fat deposits can also be produced e.g. intra-
 CC abdominal fat associated with heart disease
 XX
 SQ Sequence 122 AA;
 Alignment Scores:

Pred. No.: 0.000801 Length: 122
 Score: 106.20 Matches: 20
 Percent Similarity: 66.67% Conservative: 2
 Best Local Similarity: 60.61% Mismatches: 3
 Query Match: 71.76% Indels: 8
 DB: 4 Gaps: 0
 NOLAN463-2B-SEQ (1-84) x AAU02582 (1-122)
 QY 2 GGGCAGTGCAGGCTATTAGCAGCTGGTTAGCCATCATCTATCTGGTGAATCATCA 61
 Db 42 GlyArg-----GlyLeu---GluTrpMetGlyIleIleTyrProGlyAspSerAspThrA 59
 QY 62 CATACAGCCGCTCTTCCAAAGC 84
 Db 59 rgTyrSerProSerPheGlnGly 66
 RESULT 4
 AAU14177
 ID AAU14177 standard; protein; 474 AA.
 XX
 AC AAU14177;
 DT 24-OCT-2001 (first entry)
 XX
 DE Human novel protein #48.
 XX
 KW Human; novel protein; Antianaemic; osteopathic; antiinflammatory;
 KW immunomodulatory; cytostatic; neuroprotective; vulnerable; nontropic;
 KW anticonvulsant; antiarthritic; cerebroprotective; antifungal; antiviral;
 KW antibacterial; antiallergic; dermatological; haemostatic; antiasthmatic;
 KW thrombolytic; immunogen; antibody; gene therapy; neurological disorder;
 KW Parkinson's disease; inflammatory disorder; cancer; asthma; osteoporosis;
 KW tissue regeneration; immune disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO200155437-A2.
 XX
 PD 02-AUG-2001.
 XX
 PF 25-JAN-2001; 2001WO-US002623.
 XX
 PR 25-JAN-2000; 2000US-00491404.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Drmanac RT;
 XX
 DR WPI; 2001-451939/48.
 DR N-PSDB; AAS22482.
 XX
 PT Isolated polypeptides useful for treating anti-inflammatory diseases,
 PT nervous system disorders, and for regenerating bone and cartilage.
 XX
 PS Example 4; Page 554-555; 894pp; English.
 XX
 CC The invention relates to polynucleotides encoding novel human proteins or
 CC their active domains. The polypeptides, polynucleotides and antibodies
 CC raised against the polypeptides are used in a method of treatment of a
 CC mammal and prevention of disorders caused by the aberrant protein
 CC expression or activity. The polypeptides can be used as molecular weight
 CC markers, food supplements, and in antibody production. The polypeptides
 CC are used to identify compounds which bind to the polypeptides.
 CC Polynucleotides of the invention are used as probes and primers, for
 CC sequencing, for chromosome or gene mapping, in the production of
 CC recombinant proteins, and in generating anti-sense DNA or RNA and in gene
 CC therapy. Polypeptides of the invention can be used to target drugs to a
 CC tumour, in assays to determine biological activity, to raise
 CC antibodies/elicit an immune response, to determine quantitative protein
 CC levels, as tissue markers, and to isolate receptors or ligands.
 CC Polypeptides of the invention may also be useful in treating platelet
 CC disorders, stem cell disorders, regenerating bone, cartilage, tendon,

CC ligament and/or nerve tissue, wound healing, treating burns, promoting
 CC the proliferation, differentiation and survival of stem cells, as a
 CC contraceptive, treating osteoporosis and osteoarthritis, anaemia, as a
 CC Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral
 CC sclerosis, stroke, immune deficiencies resulting from bacterial, viral or
 CC fungal infection or from autoimmunity, cancer, allergy, asthma, graft-
 CC versus-host disease, eczema, haemophilia, thrombosis, anti-inflammatory
 CC diseases, nervous system disorders, and infection. The present sequence
 CC represents a protein of the invention
 XX
 SQ Sequence 474 AA;

Alignment Scores:
 Pred. No.: 0.00199 Length: 474
 Score: 104.40 Matches: 23
 Percent Similarity: 47.17% Conservative: 2
 Best Local Similarity: 43.40% Mismatches: 2
 Query Match: 70.54% Indels: 26
 DB: 4 Gaps: 2

NOLAN463-2B-SEQ (1-84) x AAU14177 (1-474)

QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 DB 34 GlyGluSerValLysIleSerCysLysGlySerGlyTyr-SerPheSerAspTyrTrpVa 53
 QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
 DB 53 lAlaTrpValArgGlnSerProAspLysGlyLeuAlaTrpMetGlyIleIleTyrProGl 73
 QY 48 TGACTCTGATACCATACAGCCGCTCTTCCAAAGGC 84
 DB 73 yAspSerAspThrArgTyrSerProSerPheGlnGly 85

RESULT 5

AAW54008
 ID AAW54008 standard; protein; 98 AA.

XX
 AC AAW54008;
 XX
 DT 25-MAR-2003 (revised)
 DT 29-JUL-1998 (first entry)
 XX
 DE Human Anti-CD4 antibody VH5 consensus sequence.

XX Anti-CD4 antibody; monkey; human; therapy; variable heavy domain;
 KW Old World monkey; constant domain; eczema; immuno-modulated disease;
 KW rheumatoid arthritis.

XX Homo sapiens.

XX US5750105-A.

XX 12-MAY-1998.

XX 07-JUN-1995; 95US-00476349.

XX 25-JUL-1991; 91US-00735064.

PR 23-MAR-1992; 92US-00856281.

PR 10-JUL-1992; 92US-00912292.

PR 25-JAN-1995; 95US-00379072.

XX (IDEC-) IDEC PHARM CORP.

XX Raab RW, Newman RA, Hanna N;

XX WPI; 1998-296690/26.

XX Improved method for antibody treatment - uses an antibody comprising an
 PT Old World monkey variable region and a human constant domain.

PS Example 1; Fig 9e; 84pp; English.

CC This sequence is the consensus VH5 domain of an anti-CD4 antibody (Ab).
 CC This sequence can be used in the method of the invention for treating a
 CC subject, where the treatment comprises administration of an Ab. The
 CC method comprises the administration of an antibody which has an Old World
 CC monkey (e.g. baboon or macaque) variable region which binds to an antigen
 CC (Ag) for Ag binding portion, and a human constant domain. The method is
 CC useful for the treatment of eczema and immuno-modulated diseases and
 CC especially rheumatoid arthritis. The recombinant antibodies used are
 CC sufficiently different from native monkey antibodies to allow human
 CC antigens to raise these antibodies, but similar enough to human antibody
 CC so there is no immune response to the antibodies in humans. Compared to
 CC human anti-antibodies on repeated administration. They also have longer
 CC half-lives and do not have a lack of effector function with human cells.
 CC (Updated on 25-MAR-2003 to correct PR field.)
 XX

SQ Sequence 98 AA;

Alignment Scores:
 Pred. No.: 0.00163 Length: 98
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 2 Gaps: 2

NOLAN463-2B-SEQ (1-84) x AAW54008 (1-98)

QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
 QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
 DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
 QY 48 TGACTCTGATACCATACAGCCGCTCTTCCAAAGGC 84
 DB 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 6

ABG78233
 ID ABG78233 standard; protein; 98 AA.

AC ABG78233;

DT 15-NOV-2002 (first entry)

DE Human Fv molecule hypervariable region related peptide #108.

XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
 KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
 KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.

XX Homo sapiens.

XX WO200259264-A2.

PD 01-AUG-2002.

PF 31-DEC-2001; 2001WO-US049440.

XX 29-DEC-2000; 2000US-00751181.

XX (BIOT-) BIO-TECHNOLOGY GEN CORP.

XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;

PI Plaksin D, Peretz T;

XX WPI; 2002-619166/66.

XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
 PT or fragment, or construct of fragment with enhanced binding

PT characteristics so as to selectively bind target cell in favor of other
 XX cells.
 XX
 XX
 XX Claim 13; Page 205; 232pp; English.
 XX
 XX The invention relates to a peptide or polypeptide comprising an Fv
 CC molecule, a construct or fragments of a construct of a fragment with
 CC enhanced binding characteristics which selectively and/or specifically
 CC binds to a target cell in favor of other cells, where binding is
 CC primarily determined by a first hypervariable region and Fv is a single
 CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
 CC association with or attached, coupled, combined, linked or fused to a
 CC pharmaceutical agent, is useful in the manufacture of a medicament, where
 CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 XX related peptide of the invention
 XX
 XX Sequence 98 AA;
 SQ

Alignment Scores:
 Pred. No.: 0.00163 Length: 98
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 5 Gaps: 2

NOLAN463-2B.SEQ (1-84) x ABG78233 (1-98)

QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
 QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
 Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProgl 54
 QY 48 TGACTCTGTATACCATACAGCCGCTCTTCCAGGC 84
 Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 7

ABG78231
 ID ABG78231 standard; protein; 98 AA.

XX
 XX ABG78231;
 XX
 XX 15-NOV-2002 (first entry)
 XX
 XX Human Fv molecule hypervariable region related peptide #106.

XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
 KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
 KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.

XX Homo sapiens.

XX WO200259264-A2.

XX 01-AUG-2002.

XX 31-DEC-2001; 2001WO-US049440.

XX 29-DEC-2000; 2000US-00751181.

XX (BIOT-) BIO-TECHNOLOGY GEN CORP.

XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
 PI Plaksin D, Peretz T;

XX WPI; 2002-619166/66.

XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
 PT or fragment, or construct of fragment with enhanced binding
 PT characteristics so as to selectively bind target cell in favor of other
 XX cells.

XX Claim 13; Page 204; 232pp; English.

XX The invention relates to a peptide or polypeptide comprising an Fv
 CC molecule, a construct or fragments of a construct of a fragment with
 CC enhanced binding characteristics which selectively and/or specifically
 CC binds to a target cell in favour of other cells, where binding is
 CC primarily determined by a first hypervariable region and Fv is a single
 CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
 CC association with or attached, coupled, combined, linked or fused to a
 CC pharmaceutical agent, is useful in the manufacture of a medicament, where
 CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 CC related peptide of the invention
 XX

SQ Sequence 98 AA;

Alignment Scores:
 Pred. No.: 0.00163 Length: 98
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 5 Gaps: 2

NOLAN463-2B.SEQ (1-84) x ABG78231 (1-98)

QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
 QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
 Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProgl 54
 QY 48 TGACTCTGTATACCATACAGCCGCTCTTCCAGGC 84
 Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 8

ABG78232

ID ABG78232 standard; protein; 98 AA.

XX ABG78232;

XX 15-NOV-2002 (first entry)

XX Human Fv molecule hypervariable region related peptide #107.

XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
 KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
 KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.

XX Homo sapiens.

XX WO200259264-A2.

XX 01-AUG-2002.

XX 31-DEC-2001; 2001WO-US049440.

XX 29-DEC-2000; 2000US-00751181.

```
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
PA
XX
XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
PI Plaksin D, Peretz T;
XX
XX WPI; 2002-619166/66.
XX
XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
PT or fragment, or construct of fragment with enhanced binding
PT characteristics so as to selectively bind target cell in favor of other
PT cells.
XX
XX Claim 13; Page 204-205; 232pp; English.
XX
XX The invention relates to a peptide or polypeptide comprising an Fv
CC molecule, a construct or fragments or a construct of a fragment with
CC enhanced binding characteristics which selectively and/or specifically
CC binds to a target cell in favour of other cells, where binding is
CC primarily determined by a first hypervariable region and Fv is a single
CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
CC association with or attached, coupled, combined, linked or fused to a
CC pharmaceutical agent, is useful in the manufacture of a medicament, where
CC the medicament has activity against a diseased cell, preferably a cancer
CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
CC composition for use in inhibiting the growth of a diseased or cancer
CC cell. This sequence represents a human Fv molecule hypervariable region
CC related peptide of the invention
XX
XX Sequence 98 AA;
SQ
Alignment Scores:
Pred. No.: 0.00163 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 5 Gaps: 2
NOLAN463-2B.SEQ (1-84) x ABG78232 (1-98)
QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIlelleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGC 84
Db 54 yAspSerAepThrArgTyrSerProSerPheGlnGly 66
RESULT 9
ABG91924
ID ABG91924 standard; protein; 98 AA.
XX
XX ABG91924;
XX
XX 04-DEC-2002 (first entry)
XX
XX Human antibody fragment #108.
XX
XX Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
KW metastasis; hypervariable region; autoimmune disease; thrombosis;
KW retencoid; leukaemia; inflammatory disease; cardiovascular disease;
KW myocardial infarction; retinopathic disease; abnormal platelet function;
KW sulphated tyrosine-dependent protein-protein interaction.
XX
XX Homo sapiens.
XX
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
PA
XX
XX W0200253700-A2.
XX
XX 11-JUL-2002.
XX
XX 31-DEC-2001; 2001WO-US049442.
XX
XX 29-DEC-2000; 2000US-00751181.
XX
XX 29-DEC-2000; 2000US-0258948P.
XX
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
PA
XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
PI Szanton E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
XX
XX WPI; 2002-674776/72.
XX
XX Novel isolated epitope present on cancer cells and important in
PT physiological phenomena such as cell rolling, metastasis and
PT inflammation, for treating autoimmune, inflammatory or cardiovascular
PT diseases, and cancer.
XX
XX Disclosure; Page 281; Opp; English.
XX
XX The invention relates to an isolated epitope present on cancer cells and
CC important in physiological phenomena such as cell rolling, metastasis and
CC inflammation, where the epitope is capable of being bound by an antibody,
CC its antigen-binding fragment or its complex comprising at least one
CC antibody or its binding fragment having a first hypervariable region. The
CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
CC tumour or leukaemia cells, increase in number of tumour or leukaemia
CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
CC platelet and/or cell-platelet adhesion or aggregation, for increasing
CC mortality of tumour or leukaemia cells, for increasing the susceptibility
CC of diseased cells to damage by anti-disease, anti-cancer or anti-
CC leukaemia agents, or for decreasing the number of tumour or leukaemia
CC cells in a patient, or in the manufacture of a medicament for the above
CC mentioned purposes. The epitopes are useful for diagnosing and treating
CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
CC diseases, cardiovascular diseases such as myocardial infarction,
CC retinopathic diseases and other diseases mediated by abnormal platelet
CC function and diseases caused by sulphated tyrosine-dependent protein-
CC protein interactions. This sequence represents a human antibody fragment
CC of the invention
XX
XX Sequence 98 AA;
SQ
Alignment Scores:
Pred. No.: 0.00163 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 5 Gaps: 2
NOLAN463-2B.SEQ (1-84) x ABG91924 (1-98)
QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIlelleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGC 84
Db 54 yAspSerAepThrArgTyrSerProSerPheGlnGly 66
RESULT 10
ABG91922
ID ABG91922 standard; protein; 98 AA.
XX
XX
```

AC ABG91922;
 XX 04-DEC-2002 (first entry)
 XX Human antibody fragment #106.
 DE
 KW Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
 KW metastasis; hypervariable region; autoimmune disease; thrombosis;
 KW restenosis; leukaemia; inflammatory disease; cardiovascular disease;
 KW myocardial infarction; retinopathic disease; abnormal platelet function;
 KW sulphated tyrosine-dependent protein-protein interaction.
 XX
 OS Homo sapiens.
 XX
 XX WO200253700-A2.
 PN
 XX 11-JUL-2002.
 PD
 XX 31-DEC-2001; 2001WO-US049442.
 XX
 XX 29-DEC-2000; 2000US-00751181.
 PR
 XX 29-DEC-2000; 2000US-0258948P.
 XX
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 PA
 XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
 PI Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
 XX WPI; 2002-674776/72.
 DR
 XX Novel isolated epitope present on cancer cells and important in
 PT physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.
 XX
 XX Disclosure; Page 280; Opp; English.
 PS
 XX The invention relates to an isolated epitope present on cancer cells and
 CC important in physiological phenomena such as cell rolling, metastasis and
 CC inflammation, where the epitope is capable of being bound by an antibody,
 CC its antigen-binding fragment or its complex comprising at least one
 CC antibody or its binding fragment having a first hypervariable region. The
 CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
 CC tumour or leukaemia cells, increase in number of tumour or leukaemia
 CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 CC platelet and/or cell-platelet adhesion or aggregation, for increasing
 CC mortality of tumour or leukaemia cells, for increasing the susceptibility
 CC of diseased cells to damage by anti-disease, anti-cancer or anti-
 CC leukaemia agents, or for decreasing the number of tumour or leukaemia
 CC cells in a patient, or in the manufacture of a medicament for the above
 CC mentioned purposes. The epitopes are useful for diagnosing and treating
 CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 CC diseases, cardiovascular diseases such as myocardial infarction,
 CC retinopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention
 XX
 XX Sequence 98 AA;
 SQ

Alignment Scores:
 Pred. No.: 0.00163 Length: 98
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 5 Gaps: 2

NOLAN463-2B.SEQ (1-84) x ABG91922 (1-98)

QY 3 GCGAGTGCA-----GGGTATTAGC----- 21
 |||||||
 |||||||

Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 34
 QY 22 -----AGCTGGTTAGCCATCATCATCTATCTCGG 47
 |||||
 Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 54
 |||||
 QY 48 TGACTCTGATACCATACATACAGCCCTCTTCAAGGC 84
 |||||
 Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66
 |||||
 RESULT 11
 ABG91923
 ID ABG91923 standard; protein; 98 AA.
 XX
 XX AC ABG91923;
 XX
 XX 04-DEC-2002 (first entry)
 DT
 XX Human antibody fragment #107.
 DE
 XX Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
 KW metastasis; hypervariable region; autoimmune disease; thrombosis;
 KW restenosis; leukaemia; inflammatory disease; cardiovascular disease;
 KW myocardial infarction; retinopathic disease; abnormal platelet function;
 KW sulphated tyrosine-dependent protein-protein interaction.
 XX
 OS Homo sapiens.
 XX
 XX WO200253700-A2.
 PN
 XX 11-JUL-2002.
 PD
 XX 31-DEC-2001; 2001WO-US049442.
 XX
 XX 29-DEC-2000; 2000US-00751181.
 PR
 XX 29-DEC-2000; 2000US-0258948P.
 XX
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 PA
 XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
 PI Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
 XX WPI; 2002-674776/72.
 DR
 XX Novel isolated epitope present on cancer cells and important in
 PT physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.
 XX
 XX Disclosure; Page 280-281; Opp; English.
 PS
 XX The invention relates to an isolated epitope present on cancer cells and
 CC important in physiological phenomena such as cell rolling, metastasis and
 CC inflammation, where the epitope is capable of being bound by an antibody,
 CC its antigen-binding fragment or its complex comprising at least one
 CC antibody or its binding fragment having a first hypervariable region. The
 CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
 CC tumour or leukaemia cells, increase in number of tumour or leukaemia
 CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 CC platelet and/or cell-platelet adhesion or aggregation, for increasing
 CC mortality of tumour or leukaemia cells, for increasing the susceptibility
 CC of diseased cells to damage by anti-disease, anti-cancer or anti-
 CC leukaemia agents, or for decreasing the number of tumour or leukaemia
 CC cells in a patient, or in the manufacture of a medicament for the above
 CC mentioned purposes. The epitopes are useful for diagnosing and treating
 CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 CC diseases, cardiovascular diseases such as myocardial infarction,
 CC retinopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention
 XX

SQ Sequence 98 AA;

Alignment Scores:

Pred. No.:	0.00163	Length:	98
Score:	103.40	Matches:	23
Percent Similarity:	45.28%	Conservative:	1
Best Local Similarity:	43.40%	Mismatches:	3
Query Match:	69.86%	Indels:	26
DB:	5	Gaps:	2

NOLAN463-2B.SEQ (1-84) x ABG91923 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21

Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47

Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGC 84

Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 12

ABU56809

ID ABU56809 standard; protein; 98 AA.

AC ABU56809;

DT 03-APR-2003 (first entry)

XX Human Immunoglobulin heavy variable chain polypeptide #5.

DE Human; tumour; cancer; systemic lupus erythematosus;

KW immunoglobulin constant region; immunoglobulin variable region;

KW autoimmune response; rheumatoid arthritis; eczema; lymphoma;

KW immunomodulatory disease; leukaemia; Hashimoto's thyroiditis;

KW autoimmune carditis; Addison's disease; type I-diabetes mellitus;

KW multiple sclerosis; male infertility; autoimmune hemolytic anaemia;

KW inflammatory bowel disease; Sjogren's syndrome; psoriasis.

OS Homo sapiens.

XX US2002150580-A1.

PN 17-OCT-2002.

XX 08-MAY-2001; 2001US-00850165.

XX 25-JUL-1991; 91US-00735064.

PR 23-MAR-1992; 92US-00856281.

PR 10-JUL-1992; 92US-00912291.

PR 25-JAN-1995; 95US-00379072.

PR 07-JUN-1995; 95US-00476237.

PR 21-MAY-1998; 98US-00082472.

XX (IDEC-) IDEC PHARM CORP.

XX Newman RA, Hanna N, Raab RW;

XX WPI; 2003-182483/18.

XX New recombinant chimeric antibodies comprising human, chimpanzee and Old World monkey portions, useful for treating e.g. cancer, eczema, leukemia, lymphoma, Hashimoto's thyroiditis, multiple sclerosis or male infertility.

XX Disclosure; Fig 9E; 101pp; English.

XX The invention describes a recombinant antibody comprising a human, chimpanzee or a first Old World monkey immunoglobulin constant region, and an antigen-binding portion of a second Old World monkey

immunoglobulin variable region. The first and second Old World monkey can be the same or different. The recombinant antibody is useful for treating a human having a tumour antigen, or for treating a human suffering from an autoimmune response (where the antigen is involved in an autoimmune disease). In particular, the recombinant antibody is useful for treating rheumatoid arthritis, eczema, or an immunomodulatory disease. The recombinant antibody is also useful for treating tumours, leukaemia, lymphoma, Hashimoto's thyroiditis, autoimmune carditis, Addison's disease, type I-diabetes mellitus, multiple sclerosis, male infertility, autoimmune hemolytic anaemia, inflammatory bowel disease, Sjogren's syndrome, psoriasis, or systemic lupus erythematosus. This is the amino acid sequence of a human immunoglobulin heavy variable chain polypeptide for creation of the recombinant antibody

SQ Sequence 98 AA;

Alignment Scores:

Pred. No.:	0.00163	Length:	98
Score:	103.40	Matches:	23
Percent Similarity:	45.28%	Conservative:	1
Best Local Similarity:	43.40%	Mismatches:	3
Query Match:	69.86%	Indels:	26
DB:	6	Gaps:	2

NOLAN463-2B.SEQ (1-84) x ABU56809 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21

Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47

Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGC 84

Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 13

ABP56508

ID ABP56508 standard; protein; 98 AA.

AC ABP56508;

XX 20-MAR-2003 (first entry)

XX Human anti-Fc-epsilon-R1 alpha autoantibody heavy chain VHVCW.

DE Autoantibody; Fc-epsilon-R1 receptor alpha-chain; immunosuppressive;

KW allergic disease; urticaria; late phase allergic reaction; malignancy;

KW intrinsic asthma; drug intolerance; food intolerance; immunoglobulin E;

XX conditional autoimmunity; IgE mediated disease.

OS Homo sapiens.

XX Synthetic.

XX WO200282085-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-EP003660.

XX 04-APR-2001; 2001US-0281024P.

XX (ZLBB-) ZLB BIOPLASMA AG.

XX Miescher S;

XX WPI; 2003-103348/09.

XX Identifying and obtaining inhibitor of a pathological process for treating e.g. autoimmunity comprises determining if a compound is capable

PT of modulating the binding of the Fc-epsilon-R1 receptor and an
 XX autoantibody against its alpha-chain.
 PS Claim 20; Page 22; 29pp; English.

CC The present invention describes a method for identifying and obtaining an
 CC inhibitor of a pathological process. The method comprises determining if
 CC a compound is capable of modulating the binding of the Fc-epsilon-R1
 CC receptor alpha-chain and an autoantibody against its alpha-chain. Also
 CC described: (1) use of the autoantibody against the Fc-epsilon-R1 receptor
 CC alpha-chain for identifying and obtaining an inhibitor of a pathological
 CC process; (2) use of the identified inhibitor for inhibiting activity of
 CC the autoantibody against the Fc-epsilon-R1 receptor alpha-chain; and (3)
 CC a compound identified by the method, which binds but does not activate
 CC the receptor; and (4) a polypeptide capable of specific binding to the Fc
 CC -epsilon-R1 receptor alpha-chain. The method is useful for obtaining an
 CC inhibitor of a pathological process e.g. imbalance between cell-bound and
 CC free IGE e.g. allergic disease (urticaria, late phase allergic reactions,
 CC intrinsic asthma, drug intolerance and food intolerance), IGE mediated
 CC disease or malignancy. The compound is useful for treating a pathological
 CC process, particularly conditional autoimmunity. The present sequence
 CC represents a human recombinant anti-Fc-epsilon-R1 alpha autoantibody
 CC heavy chain protein sequence from the present invention
 XX Sequence 98 AA;

Alignment Scores:
 Pred. No.: 0.00163 Length: 98
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 6 Gaps: 2

NOLAN463-2B.SEQ (1-84) x ABP56508 (1-98)

QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
 QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
 DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
 QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGGC 84
 DB 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 14
 ABJ18687
 ID ABJ18687 standard; protein; 98 AA.

XX AC ABJ18687;

XX DT 06-MAR-2003 (first entry)

XX DE Antibody library related human protein sequence SEQ ID No 16.

XX KW Library; recombinant antibody; clustering variable region; in silico;
 KW immunogenecity; antibody therapeutic; human.

XX OS Homo sapiens.

XX PN WO200284277-A1.

XX PD 24-OCT-2002.

XX PF 17-APR-2002; 2002WO-US012202.

XX PR 17-APR-2001; 2001US-0284407P.

XX PA (ABMA-) ABMAXIS INC.

XX XX

PI Luo P;
 XX DR WPI; 2003-093043/08.

XX PT Constructing a library of recombinant antibodies useful as source of
 PT antibody candidates for screening antigens comprises clustering variable
 PT regions of antibodies having known 3-dimensional structures into
 PT structural ensembles.

XX PS Disclosure; Page 109-110; 119pp; English.

XX CC The invention relates to a novel method for the construction of a library
 CC of recombinant antibodies. The novel method comprises clustering variable
 CC regions of a collection of antibodies having known 3D structures into at
 CC least two families of structural ensembles, each comprising at least two
 CC different antibody sequences but with substantially identical main chain
 CC conformations. The method is useful for constructing a library of
 CC artificial antibodies in silico which provides a structurally diverse and
 CC yet functionally more relevant source of antibody candidates which can
 CC then be screened for binding a wide variety of target molecules,
 CC including small molecules, and biomacromolecules such as proteins,
 CC peptides and nucleic acids. The libraries constructed are useful as a
 CC source of antibody candidates for further screening for novel antibodies
 CC with high affinity against a wide range of antigens and having no or
 CC minimum immunogenecity to human subjects treated with antibody
 CC therapeutics. This sequence represents a human peptide region of an
 CC antibody relating to the novel antibody library construction method of
 CC the invention

XX SQ Sequence 98 AA;

Alignment Scores:
 Pred. No.: 0.00163 Length: 98
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 6 Gaps: 2

NOLAN463-2B.SEQ (1-84) x ABJ18687 (1-98)

QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
 QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
 DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
 QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGGC 84
 DB 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 15

ABO27112

ID ABO27112 standard; protein; 98 AA.

XX AC ABO27112;

XX DT 10-SEP-2003 (first entry)

XX DE Human germline heavy chain variable region gene segment #45.

XX KW Human; heavy chain variable region; VH; humanised antibody;

XX KW chimeric antibody; complementarity determining region; CDR;

XX KW canonical CDR structure type.

XX OS Homo sapiens.

XX PN US2003039649-A1.

XX PD 27-FEB-2003.

XX XX

```

PF 12-JUL-2002; 2002US-00194975.
XX
PR 12-JUL-2001; 2001US-0305111P.
XX
PA (FOOT/) FOOTE J.
XX
PI Foote J;
XX
XX WPI; 2003-492151/46.
DR
XX
XX Making humanized antibody for converting antibody, by making chimeric
PT antibodies containing complementarity determining region from non-human
PT antibody and appropriate framework sequences of human antibodies.
XX
XX Example 1; Fig 1; 31pp; English.
XX
XX The invention describes a method of making a humanised antibody,
CC comprising making chimeric antibodies containing a complementarity
CC determining region (CDR) from a non-human antibody and appropriate
CC framework sequences (I) of human antibodies. (I) is selected by using
CC canonical CDR structure types of non-human antibody in comparison to
CC germline canonical CDR structure types of human antibodies as the basis
CC for selection, for humanisation. The method is useful for making a
CC humanised antibody or a converted antibody. The method is applicable for
CC converting a subject antibody sequence of any subject species to a less
CC immunogenic form suitable for use in an object species. The method is
CC reliable for identifying suitable human framework sequences to support
CC non-human CDR regions and to provide humanised antibodies that retain
CC high antigen binding with low immunogenicity in humans, without the need
CC for direct comparison of framework sequences, without the need for
CC determining critically important amino acid residues in the framework,
CC and without the need for multiple iteration and construction to obtain
CC humanised antibodies with suitable therapeutic properties. The antibody
CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies
XX
SQ Sequence 98 AA;

Alignment Scores:
Pred. No.: 0.00163 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 6 Gaps: 2

NOLAN463-2B.SEQ (1-84) x ABO27112 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuIleSerCysIysGlySerGlyTyr-SerPheThrSerTyrTrpI 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGTCCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

Search completed: August 4, 2005, 18:55:57
Job time : 93 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:44:26 ; Search time 22.25 Seconds
(without alignments)
563.642 Million cell updates/sec

Title: NOLAN463-2B.SEQ

Perfect score: 148

Sequence: 1 CGGGGAGTCAAGGTATTAG.....ACAGCCCGTCTTCAAGGC 84

Scoring table:

BLOSUM62	Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1	
Fgapop 6.0 , Fgapext 0.1	
Delop 6.0 , Delext 0.1	

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 1027090

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-O=/cgn2_1/USPTO spool_p/NOLAN08728463-2/runat_04082005_123945_22604/app_query.fasta_1.5
-DB=Issued Patents AA -QWTF=fastan -SUFFIX=rai -MINMATCH=0.1 -LOOPCT=0
-LOOPEXT=0 -UNITS=Dits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -LOCAL=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pco -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN08728463-2 @CNG 1.1.66 @runat_04082005_123945_22604 -NCPU=6 -ICPU=3
-NO.MMAP -LARGESQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Issued Patents AA:*

1:	/cgn2_6/ptodata/1/iaa/5A.COMB.pap:*
2:	/cgn2_6/ptodata/1/iaa/5B.COMB.pap:*
3:	/cgn2_6/ptodata/1/iaa/6A.COMB.pap:*
4:	/cgn2_6/ptodata/1/iaa/6B.COMB.pap:*
5:	/cgn2_6/ptodata/1/iaa/PCTUS.COMB.pap:*
6:	/cgn2_6/ptodata/1/iaa/backfiles1.pap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	103.4	69.9	98	1	US-08-478-039-81
2	103.4	69.9	98	1	Sequence 81, Appl
3	103.4	69.9	98	2	US-08-476-349A-81
4	103.4	69.9	98	2	Sequence 33, Appl
5	103.4	69.9	117	3	US-09-315-574-33
6	103.4	69.9	119	3	US-08-545-809A-133
7	103.4	69.9	119	3	US-09-025-769B-26
8	103.4	69.9	119	4	US-09-025-769B-26
9	103.4	69.9	119	4	US-09-490-153-26
10	103.4	69.9	120	3	US-09-025-769B-40
11	103.4	69.9	120	3	US-09-025-769B-67
12	103.4	69.9	120	4	US-09-490-070A-40

13	103.4	69.9	120	4	US-09-490-070A-67	Sequence 67, Appl
14	103.4	69.9	120	4	US-09-490-153-40	Sequence 40, Appl
15	103.4	69.9	120	4	US-09-490-153-67	Sequence 67, Appl
16	103.4	69.9	120	4	US-09-490-324-40	Sequence 40, Appl
17	103.4	69.9	120	4	US-09-490-324-67	Sequence 67, Appl
18	103.2	69.7	111	4	US-09-726-219A-171	Sequence 171, Appl
19	99.2	66.4	122	3	US-08-983-607-30	Sequence 30, Appl
20	95	64.2	125	3	US-08-665-202-44	Sequence 44, Appl
21	95	64.2	125	4	US-09-315-574-44	Sequence 44, Appl
22	95	64.2	129	2	US-08-665-202-32	Sequence 32, Appl
23	95	64.2	129	4	US-09-315-574-32	Sequence 32, Appl
24	95	64.2	258	2	US-08-665-202-5	Sequence 5, Appl
25	95	64.2	258	4	US-09-315-574-5	Sequence 5, Appl
26	95	64.2	262	3	US-09-069-821-4	Sequence 4, Appl
27	95	64.2	262	4	US-09-956-086-4	Sequence 4, Appl
28	95	64.2	262	4	US-09-956-086-4	Sequence 4, Appl
29	95	64.2	282	3	US-09-430-592A-7	Sequence 7, Appl
30	95	64.2	282	4	US-09-985-442-7	Sequence 7, Appl
31	95	64.2	282	4	US-09-983-580-7	Sequence 7, Appl
32	93.6	63.2	125	2	US-08-665-202-48	Sequence 48, Appl
33	93.6	63.2	125	2	US-08-665-202-49	Sequence 49, Appl
34	93.6	63.2	125	2	US-08-665-202-50	Sequence 50, Appl
35	93.6	63.2	125	2	US-08-665-202-51	Sequence 51, Appl
36	93.6	63.2	125	2	US-08-665-202-52	Sequence 52, Appl
37	93.6	63.2	125	2	US-08-665-202-57	Sequence 57, Appl
38	93.6	63.2	125	4	US-09-315-574-48	Sequence 48, Appl
39	93.6	63.2	125	4	US-09-315-574-49	Sequence 49, Appl
40	93.6	63.2	125	4	US-09-315-574-50	Sequence 50, Appl
41	93.6	63.2	125	4	US-09-315-574-51	Sequence 51, Appl
42	93.6	63.2	125	4	US-09-315-574-52	Sequence 52, Appl
43	93.6	63.2	125	4	US-09-315-574-57	Sequence 57, Appl
44	93.2	63.0	88	4	US-09-726-219A-172	Sequence 172, Appl
45	92.9	62.8	125	2	US-08-665-202-47	Sequence 47, Appl

ALIGNMENTS

RESULT 1

US-08-478-039-81
; Sequence 81, Application US/08478039
; Patent No. 5681722
; GENERAL INFORMATION:
; APPLICANT: Newman, Roland A.
; APPLICANT: Hanna, Nabil
; APPLICANT: Raab, Ronald W.
; TITLE OF INVENTION: Recombinant Antibodies for Human Therapy
; NUMBER OF SEQUENCES: 114
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince St.
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/478,039
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/379,072
; FILING DATE: 25-JAN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/912,292
; FILING DATE: 10-JUL-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/856,281
; FILING DATE: 23-MAR-1992
; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US 07/735,064
; FILING DATE: 25-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin Esq., Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-160
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 98 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: not relevant
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: VHS consensus
US-08-478-039-81

Alignment Scores:
Pred. No.: 0.000271 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 1 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-08-478-039-81 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 2
US-08-476-349A-81
; Sequence 81, Application US/08476349A
; Patent No. 5750105
; GENERAL INFORMATION:
; APPLICANT: Newman, Roland A.
; APPLICANT: Hanna, Nabil
; APPLICANT: Raab, Ronald W.
; TITLE OF INVENTION: Recombinant Antibodies for Human Therapy
; NUMBER OF SEQUENCES: 114
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince St.
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/476,349A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/379,072
; FILING DATE: 25-JAN-1995

; APPLICATION NUMBER: US 07/735,064
; FILING DATE: 25-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin Esq., Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-161
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 98 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: not relevant
; MOLECULE TYPE: peptide
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: VHS consensus
US-08-476-349A-81

Alignment Scores:
Pred. No.: 0.000271 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 1 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-08-476-349A-81 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 3
US-08-665-202-33
; Sequence 33, Application US/0865202
; Patent No. 5977322
; GENERAL INFORMATION:
; APPLICANT: Marks, James D.
; APPLICANT: Schier, Robert
; TITLE OF INVENTION: No. 5977322el High Affinity Human Antibodies to
; TITLE OF INVENTION: Tumor Antigens
; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
```

;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/665,202
;; FILING DATE: 13-JUN-1996
;; CLASSIFICATION: 424
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 60/000,238
;; FILING DATE: 14-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 60/000,250
;; FILING DATE: 15-JUN-1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Hunter, Tom
;; REGISTRATION NUMBER: 38,498
;; REFERENCE/DOCKET NUMBER: 02307E-061410
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 576-0200
;; TELEFAX: (415) 576-0300
;; INFORMATION FOR SEQ ID NO: 33:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 98 amino acids
;; TYPE: amino acid
;; STRANDEDNESS:
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
US-08-665-202-33

Alignment Scores:
Pred. No.: 0.000271 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-08-665-202-33 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCATCATCTATCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 4
US-09-315-574-33
; Sequence 33, Application US/09315574
; Patent No. 6512097
; GENERAL INFORMATION:
; APPLICANT: Marks, James D.
; APPLICANT: Schier, Robert
; TITLE OF INVENTION: No. 6512097el High Affinity Human Antibodies to
; TITLE OF INVENTION: Tumor Antigens
; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Majestic, Parsons, Siebert & Hsue P.C.
; STREET: Four Embarcadero Center, Suite 1100
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4106
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/315,574
; FILING DATE: 20-MAY-99

;; CLASSIFICATION: 530
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 60/000,238
;; FILING DATE: 14-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 60/000,250
;; FILING DATE: 15-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/665,202
;; FILING DATE: 13-JUN-1996
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Hunter, Tom
;; REGISTRATION NUMBER: 38,498
;; REFERENCE/DOCKET NUMBER: 02307E-061411
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 576-0200
;; TELEFAX: (415) 576-0300
;; INFORMATION FOR SEQ ID NO: 33:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 98 amino acids
;; TYPE: amino acid
;; STRANDEDNESS:
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
US-09-315-574-33

Alignment Scores:
Pred. No.: 0.000271 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-09-315-574-33 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCATCATCTATCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 5
US-08-545-809A-133
; Sequence 133, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 133:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-133

Alignment Scores:
Pred. No.: 0.00288 Length: 117
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 3 Gaps: 2

NOLAN463-2B_SEQ (1-84) x US-08-545-809A-133 (1-117)

Qy 3 GCGAGTCA-----GGGTATTAG----- 21
Db 34 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 53
Qy 22 -----AGCTGGTTAGCCATCTATCTCTGG 47
Db 53 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 73
Qy 48 TGACTCTGATACCATACAGCCGCTCTCCAGGC 84
Db 73 YAspSerAspThrArgTyrSerProSerPheGlnGly 85

RESULT 6
US-09-025-769B-26
; Sequence 26, Application US/09025769B
; Patent No. 6300084
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-26

Alignment Scores:
Pred. No.: 0.00029 Length: 119
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 3 Gaps: 2

NOLAN463-2B_SEQ (1-84) x US-09-025-769B-26 (1-119)

Qy 3 GCGAGTCA-----GGGTATTAG----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
Qy 22 -----AGCTGGTTAGCCATCTATCTCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
Qy 48 TGACTCTGATACCATACAGCCGCTCTCCAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 7
US-09-490-070A-26
; Sequence 26, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-490-070A-26

Alignment Scores:
Pred. No.: 0.00029 Length: 119
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 4 Gaps: 2

NOLAN463-2B-SEQ (1-84) x US-09-490-070A-26 (1-119)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
DB 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 8

US-09-490-153-26
; Sequence 26, Application US/09490153
; Patent No. 6706484

GENERAL INFORMATION:

APPLICANT: Knappik, Achim

Pack, Peter

Ilag, Vic

Ge, Liming

Moroney, Simon

Plueckthun, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries

NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:

ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave

STREET: 1251 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10021

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/490,153

FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/025,769B

FILING DATE: 18-FEB-1998

APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: James F. Haley, Jr., Esq.

REGISTRATION NUMBER: 27,794

REFERENCE/DOCKET NUMBER: MORPHO/5

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 596-9000
TELEFAX: (212) 596-9090
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-490-153-26

Alignment Scores:
Pred. No.: 0.00029 Length: 119
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 4 Gaps: 2

NOLAN463-2B-SEQ (1-84) x US-09-490-153-26 (1-119)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
DB 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 9

US-09-490-324-26
; Sequence 26, Application US/09490324
; Patent No. 6828422

GENERAL INFORMATION:

APPLICANT: Knappik, Achim

Pack, Peter

Ilag, Vic

Ge, Liming

Moroney, Simon

Plueckthun, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries

NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:

ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave

STREET: 1251 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10021

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/490,324

FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/025,769

FILING DATE: 18-FEB-1998

APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: James F. Haley, Jr., Esq.

REGISTRATION NUMBER: 27,794

REFERENCE/DOCKET NUMBER: MORPHO/5

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 596-9000

```
;
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 119 amino acids
;   TYPE: amino acid
;   STRANDEDNESS:
;   TOPOLOGY: linear
; MOLECULE TYPE: <Unknown>
;
; Alignment Scores:
;   Pred. No.: 0.00029
;   Score: 103.40
;   Percent Similarity: 45.28%
;   Best Local Similarity: 43.40%
;   Query Match: 69.86%
;   DB: 4
;
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-490-324-26

Alignment Scores:
Pred. No.: 0.00029
Score: 103.40
Percent Similarity: 45.28%
Best Local Similarity: 43.40%
Query Match: 69.86%
DB: 4

NOLAN463-2B.SEQ (1-84) x US-09-490-324-26 (1-119)

Qy 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSeryTyrTrpIl 34
Qy 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleIleTyrProGl 54
Qy 48 TGACTCTGATACCATACATACAGCCGCTCTTCCAAAGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 10
US-09-025-769B-40
; Sequence 40, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9090
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-40

Alignment Scores:
Pred. No.: 0.00029
Score: 103.40
Percent Similarity: 45.28%
Best Local Similarity: 43.40%
Query Match: 69.86%
DB: 3

NOLAN463-2B.SEQ (1-84) x US-09-025-769B-40 (1-120)

Qy 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSeryTyrTrpIl 34
Qy 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleIleTyrProGl 54
Qy 48 TGACTCTGATACCATACATACAGCCGCTCTTCCAAAGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 11
US-09-025-769B-67
; Sequence 67, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
```


US-09-025-769B-67

Alignment Scores:

Pred. No.: 0.00029 Length: 120
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 3 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-09-025-769B-67 (1-120)

QY 3 GGCGAGTCA-----GGGTATTAGC----- 21
DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSertYrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCGG 47
DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACCATACATACAGCCGCTCTTCCAAGGC 84
DB 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 12

US-09-490-070A-40
; Sequence 40, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
FILING DATE: 24-Jan-2000

PRIOR APPLICATION NUMBER: US/09/490,070A
APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.

REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020

INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:

LENGTH: 120 amino acids
TYPE: amino acid

STRANDEDNESS: <Unknown>
TOPOLOGY: linear

MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 40:

US-09-490-070A-40

Alignment Scores:

Pred. No.: 0.00029 Length: 120
Score: 103.40 Matches: 23

Alignment Scores:

Pred. No.: 0.00029 Length: 120
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 4 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-09-490-070A-40 (1-120)

QY 3 GGCGAGTCA-----GGGTATTAGC----- 21
DB 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSertYrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCGG 47
DB 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACCATACATACAGCCGCTCTTCCAAGGC 84
DB 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 13

US-09-490-070A-67
; Sequence 67, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.

REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020

INFORMATION FOR SEQ ID NO: 67:
SEQUENCE CHARACTERISTICS:

LENGTH: 120 amino acids
TYPE: amino acid

TOPOLOGY: linear
MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 67:
US-09-490-070A-67

Alignment Scores:

Pred. No.: 0.00029 Length: 120
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 4 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-09-490-070A-67 (1-120)

```
Oy 3 GCGAGTCA-----GGGTATTAGC----- 21
|||||
Db 15 GlyGlusSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 34
Oy 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 54
Oy 48 TGACTCTGATACACATACACAGCCGCTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66
```

RESULT 14

US-09-490-153-40
; Sequence 40, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 40:

US-09-490-153-40

Alignment Scores:
Pred. No.: 0.00029 Length: 120
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1

Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 4 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-09-490-153-40 (1-120)

```
Oy 3 GCGAGTCA-----GGGTATTAGC----- 21
|||||
Db 15 GlyGlusSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 34
Oy 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 54
Oy 48 TGACTCTGATACACATACACAGCCGCTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66
```

RESULT 15

US-09-490-153-67
; Sequence 67, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 67:

US-09-490-153-67

Alignment Scores:
Pred. No.: 0.00029 Length: 120
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26

```

DB:          4          Gaps:          2
NOLAN463-2B.SEQ (1-84) x US-09-490-153-67 (1-120)
QY   3  GCGAGTCA-----GGGTATTAGC----- 21
Db   15  GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 34
QY   22  -----AGCTGGTTAGCCCATCATCTATCCTGG 47
Db   34  eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG 54
QY   48  TGACTCTGATACACATACAGCCGCTCTCCAGGC 84
Db   54  yAspSerAspThrArgTyrSerProSerPheGlnGly 66

```

Search completed: August 4, 2005, 19:04:16
Job time : 24.25 sec

THIS PAGE BLANK (USP10)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model
Run on: August 4, 2005, 19:01:38 ; Search time 78.75 Seconds
(without alignments)
832.849 Million cell updates/sec
Title: NOLAN463-2B.SEQ
Perfect score: 148
Sequence: 1 CGGGCGAGTCAGGTTATAG.....ACAGCCGCTCTTCCAGGC 84

Scoring table:
BLOSUM62
Xgapop 10.0, Xgapext 0.1
Ygapop 10.0, Ygapext 0.1
Fgapop 6.0, Fgapext 0.1
Delop 6.0, Delext 0.1

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 3505720

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/NOLAN08728463-2/runat_04082005_123947_22665/app_query.fasta_1.5
-DB=Published Applications AA -OPMT=faetan -SUFFIX=rapb -MINMATCH=0.1
-LOOPEXT=0 -LOOPEXT=0 -UNIT8=bits -START=1 -END=1 -HAIRIX=blosum62
-TRANS=human40.cdi -LIST=45 -DOCCALIGN=200 -THR SCORE=pct -THR MAX=100
-THR MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0
-MAXLEN=200000000
-USER=NOLAN08728463-2@cgn 1.1 260 @runat_04082005_123947_22665 -NCPU=6
-ICPU=3 -NO MMAP -LARGOQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREDS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	115	77.7	123	16	US-10-466-242-49 Sequence 49, Appl
2	113.3	76.6	411	16	US-10-769-144-12 Sequence 12, Appl
3	104.4	70.5	474	15	US-10-291-265-284 Sequence 284, App
4	104.2	70.4	301	14	US-10-002-631C-114 Sequence 114, App
5	103.4	69.9	98	9	US-09-850-165-89 Sequence 89, Appl
6	103.4	69.9	98	14	US-10-194-975-45 Sequence 45, Appl
7	103.4	69.9	98	14	US-10-125-687-16 Sequence 16, Appl
8	103.4	69.9	98	14	US-10-041-860-6 Sequence 6, Appl
9	103.4	69.9	98	14	US-10-041-860-301 Sequence 301, App
10	103.4	69.9	98	14	US-10-041-860-312 Sequence 302, App
11	103.4	69.9	98	14	US-10-041-860-318 Sequence 312, App
12	103.4	69.9	98	14	US-10-041-860-318 Sequence 318, App
13	103.4	69.9	98	14	US-10-041-860-320 Sequence 320, App
14	103.4	69.9	98	14	US-10-041-860-336 Sequence 336, App
15	103.4	69.9	98	14	US-10-041-860-367 Sequence 367, App
16	103.4	69.9	98	15	US-10-308-817-88 Sequence 88, Appl
17	103.4	69.9	98	15	US-10-032-037B-106 Sequence 106, App
18	103.4	69.9	98	15	US-10-032-037B-107 Sequence 107, App
19	103.4	69.9	98	15	US-10-032-037B-108 Sequence 108, App
20	103.4	69.9	98	15	US-10-029-988B-106 Sequence 106, App
21	103.4	69.9	98	15	US-10-029-988B-107 Sequence 107, App
22	103.4	69.9	98	15	US-10-029-988B-108 Sequence 108, App
23	103.4	69.9	98	15	US-10-032-423A-106 Sequence 106, App
24	103.4	69.9	98	15	US-10-032-423A-107 Sequence 107, App
25	103.4	69.9	98	15	US-10-032-423A-108 Sequence 108, App
26	103.4	69.9	98	15	US-10-453-698-88 Sequence 88, Appl
27	103.4	69.9	98	15	US-10-029-926B-106 Sequence 106, App
28	103.4	69.9	98	15	US-10-029-926B-107 Sequence 107, App
29	103.4	69.9	98	15	US-10-029-926B-108 Sequence 108, App
30	103.4	69.9	98	16	US-10-379-392-53 Sequence 53, Appl
31	103.4	69.9	98	16	US-10-769-144-30 Sequence 30, Appl
32	103.4	69.9	98	18	US-10-996-191-16 Sequence 16, Appl
33	103.4	69.9	109	16	US-10-800-197-145 Sequence 145, App
34	103.4	69.9	109	16	US-10-800-197-145 Sequence 145, App
35	103.4	69.9	109	16	US-10-800-197-146 Sequence 146, App
36	103.4	69.9	109	17	US-10-727-155-283 Sequence 283, App
37	103.4	69.9	109	17	US-10-727-155-291 Sequence 291, App
38	103.4	69.9	110	17	US-10-726-332-217 Sequence 217, App
39	103.4	69.9	116	17	US-10-727-155-100 Sequence 100, App
40	103.4	69.9	117	17	US-10-684-957-30 Sequence 30, Appl
41	103.4	69.9	117	17	US-10-684-957-30 Sequence 30, Appl
42	103.4	69.9	117	17	US-10-726-332-9 Sequence 9, Appl
43	103.4	69.9	117	17	US-10-726-332-138 Sequence 138, App
44	103.4	69.9	117	17	US-10-726-332-144 Sequence 144, App
45	103.4	69.9	118	17	US-10-726-332-3 Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-10-466-242-49
; Sequence 49, Application US/10466242
; Publication No. US20040208887A1
; GENERAL INFORMATION:
; APPLICANT: Drakenberg, Katarina
; APPLICANT: Persson, Mats
; TITLE OF INVENTION: Materials and methods for treatment of hepatitis C
; FILE REFERENCE: 0380-P03248US00
; CURRENT APPLICATION NUMBER: US/10/466.242
; CURRENT FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: PCT/SE02/00044
; PRIOR FILING DATE: 2002-01-14
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 49
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens

```
; FEATURE:
; NAME/KEY: PEPTIDE
; LOCATION: (1)-(123)
; OTHER INFORMATION: Clone 2b.7 VH
US-10-466-242-49

Alignment Scores:
Pred. No.: 0.000145 Length: 123
Score: 115.00 Matches: 23
Percent Similarity: 55.32% Conservative: 3
Best Local Similarity: 48.94% Mismatches: 1
Query Match: 77.70% Indels: 20
DB: 16 Gaps: 1

NOLAN463-2B.SEQ (1-84) x US-10-466-242-49 (1-123)

QY 1 CGGCGAGT----- 9
Db 25 ArgAlaSerGlyTyrSerPheSerLeuPheTrpValAlaTrpValArgGlnMetProGly 44
QY 10 CAGGTATTAGCAGCTGTTAGCCATCATCTCTCTGCTGACTCTGTATACCATACAGC 69
Db 45 GlnGlyLeu---GluTrpMetAlaIleIleTyrProGlyAspSerAspThrThrTyrSer 63
QY 70 CCGTCTTCCAAAGC 84
Db 64 ProSerPheGluGly 68

RESULT 2
US-10-144-12
; Sequence 12, Application US/10769144
; Publication No. US20040248215A1
; GENERAL INFORMATION:
; APPLICANT: Keler, Tibor
; APPLICANT: Endres, Michael
; APPLICANT: He, Lizhen
; APPLICANT: Ramakrishna, Venky
; TITLE OF INVENTION: ANTIBODY VACCINE CONJUGATES AND USES
; FILE REFERENCE: MX1-301
; CURRENT APPLICATION NUMBER: US/10/769,144
; PRIOR FILING DATE: 2004-01-30
; PRIOR APPLICATION NUMBER: 60/443979
; PRIOR FILING DATE: 2003-01-31
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-769-144-12

Alignment Scores:
Pred. No.: 0.000293 Length: 411
Score: 113.30 Matches: 26
Percent Similarity: 15.78% Conservative: 0
Best Local Similarity: 15.78% Mismatches: 2
Query Match: 76.55% Indels: 137
DB: 16 Gaps: 1

NOLAN463-2B.SEQ (1-84) x US-10-769-144-12 (1-411)

QY 1 CGGCGAGTCAGGTATTAGCAGCTGGTTAGCC----- 33
Db 43 ArgAlaSerGlnGlyIleSerArgTrpLeuAlaTrpTyrGlnGlnLysProGluLysAla 62
QY 33 ----- 33
Db 63 ProLysSerLeuIleTyrAlaAlaSerSerLeuGlnSerGlyValProSerArgPheSer 82
QY 33 ----- 33
Db 83 GlySerGlySerGlyThrAspPheThrLeuThrIleSerGlyLeuGlnProGluAspPhe 102

; RESULT 3
US-10-291-265-284
; Sequence 284, Application US/10291265
; Publication No. US20030232054A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; APPLICANT: Tang et al
; TITLE OF INVENTION: No. US20030232054A1el Nucleic Acids and Polypeptides
; FILE REFERENCE: 21272-017 (785)
; CURRENT APPLICATION NUMBER: US/10/291,265
; CURRENT FILING DATE: 2000-01-25
; PRIOR FILING DATE: 09/491,404
; PRIOR APPLICATION NUMBER: 09/617,746
; PRIOR FILING DATE: 2000-07-17
; PRIOR APPLICATION NUMBER: 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/633,870
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 944
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 284
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-291-265-284

Alignment Scores:
Pred. No.: 0.00333 Length: 474
Score: 104.40 Matches: 23
Percent Similarity: 47.17% Conservative: 2
Best Local Similarity: 43.40% Mismatches: 2
Query Match: 70.54% Indels: 26
DB: 15 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-291-265-284 (1-474)

QY 3 GCGCAGTCA-----GGGTATTAGC----- 21
Db 34 GlyGluSerValLysIleSerCysLysGlySerGlyTyr-SerPheSerAspTyrTrpVa 53
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
Db 53 LalaTrpValArgGlnSerProAspLysGlyLeuAlaTrpMetGlyIleIleTyrProGl 73
QY 48 TGACTCTCATACCATACAGCCGCTCTCTCCAGGC 84
Db 73 yAspSerAspThrArgTyrSerProSerPheGlnGly 85
```

```
RESULT 4
US-10-002-631C-114
; Sequence 114, Application US/10002631C
; Publication No. US20030157486A1
; GENERAL INFORMATION:
; APPLICANT: Graff, Jonathon M.
; APPLICANT: Muenster, Matthew
; TITLE OF INVENTION: METHODS TO IDENTIFY SIGNAL SEQUENCES
; FILE REFERENCE: A34943 090495.0243
; CURRENT APPLICATION NUMBER: US/10/002,631C
; CURRENT FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: 60/300,309
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 114
; LENGTH: 301
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: (2)...(66)
; OTHER INFORMATION: Xaa = any amino acid
US-10-002-631C-114

Alignment Scores:
Pred. No.: 0.0032 Length: 301
Score: 104.20 Matches: 19
Percent Similarity: 66.67% Conservative: 3
Best Local Similarity: 57.58% Mismatches: 3
Query Match: 70.41% Indels: 8
DB: 14 Gaps: 0

NOLAN463-2B-SEQ (1-84) x US-10-002-631C-114 (1-301)
QY 2 GGGCAGTACGGTATTAGCAGCTGGTTAGCCATCATCTCTGGTACTCTGTATACA 61
Db 92 GlyLys-----GlyLeu---GluTrpMetGlyLeuGlyLeuGlyLeuGlyLeu 109
QY 62 CATACAGCCGCTCTTCCAAAGC 84
Db 109 hrrtyrSerProSerPheGlnGly 116

RESULT 5
US-09-850-165-89
; Sequence 89, Application US/09850165
; Patent No. US20020150580A1
; GENERAL INFORMATION:
; APPLICANT: NEWMAN, ROLAND A.
; APPLICANT: HANNA, NABIL
; APPLICANT: RAAB, RONALD W.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY
; FILE REFERENCE: 037003-0280614
; CURRENT APPLICATION NUMBER: US/09/850,165
; CURRENT FILING DATE: 2001-05-08
; PRIOR APPLICATION NUMBER: 09/082,472
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 08/476,237
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/397,072
; PRIOR FILING DATE: 1995-04-17
; PRIOR APPLICATION NUMBER: 07/912,292
; PRIOR FILING DATE: 1992-07-10
; PRIOR APPLICATION NUMBER: 07/856,281
; PRIOR FILING DATE: 1992-03-23
; PRIOR APPLICATION NUMBER: 07/735,064
; PRIOR FILING DATE: 1991-07-25
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 89
; LENGTH: 98
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (19)
; OTHER INFORMATION: Arg or Lys
US-09-850-165-89

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 9 Gaps: 2

NOLAN463-2B-SEQ (1-84) x US-09-850-165-89 (1-98)
QY 3 GGGCAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeu***IleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyLeuGlyLeu 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 6
US-10-194-975-45
; Sequence 45, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 45
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-45

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B-SEQ (1-84) x US-10-194-975-45 (1-98)
QY 3 GGGCAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 34
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyLeuGlyLeu 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 7
US-10-125-687-16
```

```
; Sequence 16, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-125-687-16

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservatives: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-125-687-16 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuylsIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlylleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 8
US-10-041-860-6
; Sequence 6, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-6

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservatives: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-6 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuylsIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlylleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 9
US-10-041-860-301
; Sequence 301, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 301
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-301

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservatives: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-301 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuylsIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlylleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 10
US-10-041-860-302
; Sequence 302, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
```

```
; Sequence 16, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-125-687-16

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservatives: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-125-687-16 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuylsIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlylleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 8
US-10-041-860-6
; Sequence 6, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-6

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservatives: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-6 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuylsIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlylleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 9
US-10-041-860-301
; Sequence 301, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 301
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-301

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservatives: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-301 (1-98)

QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluserLeuylsIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlylleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 10
US-10-041-860-302
; Sequence 302, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
```


APPLICANT: Bezabeh, Binyam
TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
FILE REFERENCE: ABGENIX.051A
CURRENT APPLICATION NUMBER: US/10/041,860
CURRENT FILING DATE: 2002-01-07
NUMBER OF SEQ ID NOS: 377
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 302

LENGTH: 98
TYPE: PRT
ORGANISM: homo sapiens
FEATURE:
NAME/KEY: VARIANT
LOCATION: 23
OTHER INFORMATION: Xaa = Any Amino Acid
FEATURE:
NAME/KEY: VARIANT
LOCATION: 23
OTHER INFORMATION: Xaa = Any Amino Acid
US-10-041-860-302

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-302 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCys**GlySerGlyTyr-SerPheThrSerTyrTrpIl 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyr-ProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 11
US-10-041-860-312
Sequence 312, Application US/10041860
Publication No. US20030157109A1
GENERAL INFORMATION:
APPLICANT: Corvalan, Jose R.F.
APPLICANT: Jia, Xiao-Chi
APPLICANT: Feng, Xiao
APPLICANT: Yang, Xiao-Dong
APPLICANT: Chen, Francine
APPLICANT: Gazit, Gadi
APPLICANT: Weber, Richard
APPLICANT: Bezabeh, Binyam
TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
FILE REFERENCE: ABGENIX.051A
CURRENT APPLICATION NUMBER: US/10/041,860
CURRENT FILING DATE: 2002-01-07
NUMBER OF SEQ ID NOS: 377
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 312
LENGTH: 98
TYPE: PRT
ORGANISM: homo sapiens
US-10-041-860-312

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-302 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCys**GlySerGlyTyr-SerPheThrSerTyrTrpIl 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyr-ProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 11
US-10-041-860-312
Sequence 312, Application US/10041860
Publication No. US20030157109A1
GENERAL INFORMATION:
APPLICANT: Corvalan, Jose R.F.
APPLICANT: Jia, Xiao-Chi
APPLICANT: Feng, Xiao
APPLICANT: Yang, Xiao-Dong
APPLICANT: Chen, Francine
APPLICANT: Gazit, Gadi
APPLICANT: Weber, Richard
APPLICANT: Bezabeh, Binyam
TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
FILE REFERENCE: ABGENIX.051A
CURRENT APPLICATION NUMBER: US/10/041,860
CURRENT FILING DATE: 2002-01-07
NUMBER OF SEQ ID NOS: 377
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 312
LENGTH: 98
TYPE: PRT
ORGANISM: homo sapiens
US-10-041-860-312

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-312 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyr-ProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 13
US-10-041-860-320
Sequence 320, Application US/10041860
Publication No. US20030157109A1
GENERAL INFORMATION:
APPLICANT: Corvalan, Jose R.F.
US-10-041-860-320

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-312 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyr-ProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 13
US-10-041-860-320
Sequence 320, Application US/10041860
Publication No. US20030157109A1
GENERAL INFORMATION:
APPLICANT: Corvalan, Jose R.F.
US-10-041-860-320

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-312 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34

QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyr-ProGl 54

QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
Db 54 yAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 13
US-10-041-860-320
Sequence 320, Application US/10041860
Publication No. US20030157109A1
GENERAL INFORMATION:
APPLICANT: Corvalan, Jose R.F.
US-10-041-860-320

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23

Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-312 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34

```
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 320
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 68
; OTHER INFORMATION: Xaa = Any Amino Acid
; NAME/KEY: VARIANT
; LOCATION: 68
; OTHER INFORMATION: Xaa = Any Amino Acid
; US-10-041-860-320

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-320 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 14
US-10-041-860-336
; Sequence 336, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 367
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
; US-10-041-860-367

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-367 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 15
US-10-041-860-336
; Sequence 367, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 367
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
; US-10-041-860-367

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-336 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66
```

```
; ORGANISM: homo sapiens
US-10-041-860-336

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-336 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66

RESULT 15
US-10-041-860-367
; Sequence 367, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 367
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
; US-10-041-860-367

Alignment Scores:
Pred. No.: 0.00316 Length: 98
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 14 Gaps: 2

NOLAN463-2B.SEQ (1-84) x US-10-041-860-367 (1-98)
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
Db 15 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpIl 34
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 34 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGl 54
QY 48 TGACTCTGATACACATACAGCCCGTCTTCCAAGGC 84
Db 54 YAspSerAspThrArgTyrSerProSerPheGlnGly 66
```

Search completed: August 4, 2005, 19:30:18
Job time : 79.75 secs

THIS PAGE BLANK (USPTO)


```

Alignment Scores:
Pred. No.:      0.000145      Length:      101
Score:          103.40      Matches:      23
Percent Similarity: 45.28%      Conservative: 1
Best Local Similarity: 43.40%      Mismatches:  3
Query Match:      69.86%      Indels:      26
DB:               2          Gaps:          2

NOLAN463-2B.SEQ (1-84) x S12428 (1-101)

Qy      3 GGGGACTCA-----GGGTATTAGC-----
      |||||

```

Db 18 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 37
 QY 22 -----ACGTGGTTAGCCATCATCTATCTCTGG 47
 Db 37 eGlyTrrpValArgInMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 57
 QY 48 TGACTCTGATACCATACAGCCCGTCTTCCAGGC 84
 Db 57 yAspSerAspThrArgTyrSerProSerPheGlnGly 69
 RESULT 6
 S12424
 Ig heavy chain V region (S) - human
 C:Species: Homo sapiens (man)
 C:Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text change 03-Aug-1998
 C:Accession: S12424; S12425; S12426; S12427; S12429; S12432
 R:Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
 EMBL J. 8, 3741-3748, 1989
 A:Title: The smaller human V(H) gene families display remarkably little polymorphism.
 A:Reference number: S09421; MUID:90059975; PMID:2511001
 A:Accession: S12424
 A:Status: preliminary; translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA2>
 A:Cross-references: EMBL:X56372
 A:Experimental source: clones 5AU; 5BLK; 5CH; 5CW; 5LB; 5TT
 A:Accession: S12425
 A:Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA3>
 A:Cross-references: EMBL:X56370
 A:Accession: S12427
 A:Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA4>
 A:Cross-references: EMBL:X56368
 A:Accession: S12429
 A:Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA5>
 A:Cross-references: EMBL:X56369
 A:Accession: S12432
 A:Status: translation not shown
 A:Molecule type: DNA
 A:Residues: 1-101 <SA6>
 A:Cross-references: EMBL:X56371
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:18-101/Domain: immunoglobulin homology <IMM>
 Alignment Scores:
 Pred. No.: 0.000145 Length: 101
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 2 Gaps: 2
 NOLAN463-2B.SEQ (1-84) x S12424 (1-101)
 QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 Db 18 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 37
 QY 22 -----ACGTGGTTAGCCATCATCTATCTCTGG 47
 Db 37 eGlyTrrpValArgInMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 57
 RESULT 7
 S12426
 Ig heavy chain V region (clone VERGS) - human (fragment)
 C:Species: Homo sapiens (man)
 C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text change 16-Aug-1996
 C:Accession: PH1266
 R:Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
 J. Exp. Med. 176, 1073-1081, 1992
 A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chro
 A:Reference number: PH1232; MUID:93018822; PMID:1402653
 A:Accession: PH1266
 A:Molecule type: mRNA
 A:Residues: 1-102 <CAI>
 A:Experimental source: EBV-transformed CD5+ B cell [from adult PBL]
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:19-102/Domain: immunoglobulin homology <IMM>
 Alignment Scores:
 Pred. No.: 0.000145 Length: 102
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 2 Gaps: 2
 NOLAN463-2B.SEQ (1-84) x PH1266 (1-102)
 QY 3 GCGAGTCA-----GGGTATTAGC----- 21
 Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 38
 QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
 Db 38 eGlyTrrpValArgInMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 58
 QY 48 TGACTCTGATACCATACAGCCCGTCTTCCAGGC 84
 Db 58 yAspSerAspThrArgTyrSerProSerPheGlnGly 70
 RESULT 8
 PH1279
 Ig heavy chain V region (clones CLL11, CORD3, CORD4, CORD8, CORD9, CD+1, CD+3, CD+4, CD
 C:Species: Homo sapiens (man)
 C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text change 16-Aug-1996
 C:Accession: PH1279
 R:Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
 J. Exp. Med. 176, 1073-1081, 1992
 A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chro
 A:Reference number: PH1232; MUID:93018822; PMID:1402653
 A:Accession: PH1279
 A:Molecule type: DNA
 A:Residues: 1-102 <CAI>
 A:Experimental source: adult PBL
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:19-102/Domain: immunoglobulin homology <IMM>
 Alignment Scores:
 Pred. No.: 0.000145 Length: 102
 Score: 103.40 Matches: 23
 Percent Similarity: 45.28% Conservative: 1
 Best Local Similarity: 43.40% Mismatches: 3
 Query Match: 69.86% Indels: 26
 DB: 2 Gaps: 2
 NOLAN463-2B.SEQ (1-84) x PH1279 (1-102)
 QY 3 GCGAGTCA-----GGGTATTAGC----- 21

```
|||||
19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 38
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 38 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 58
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAAGGC 84
Db 58 yAspSerAspThrArgTyrSerProSerPheGlnGly 70

RESULT 9
PH1281
Ig heavy chain V region (clone PBL12) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1281
R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1281
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1281 (1-102)
QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 38
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 38 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 58

RESULT 10
PH1244
Ig heavy chain V region (clone CORD2) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1244
R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1244
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: cord blood B cell
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
```

```
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1244 (1-102)
QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI1 38
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 38 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 58

RESULT 11
PH1272
Ig heavy chain V region (clone PBL3) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1272
R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1272
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1272 (1-102)
QY 3 GCGGAGTCA-----GGGTATTAGC----- 21
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrThrTyrTrpI1 38
QY 22 -----AGCTGGTTAGCCATCATCTATCCTGG 47
Db 38 eAlaTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProG1 58

RESULT 12
PH1282
Ig heavy chain V region (clone PBL13) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C:Accession: PH1282
R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.
J. Exp. Med. 176, 1073-1081, 1992
A:Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chrom
A:Reference number: PH1232; MUID:93018822; PMID:1402653
A:Accession: PH1282
A:Molecule type: DNA
A:Residues: 1-102 <CAI>
A:Experimental source: adult PBL
C:Superfamily: immunoglobulin V region; immunoglobulin homology
```


C:Keywords: heterotetramer; immunoglobulin
F:19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1282 (1-102)

```
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
  |||||
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 38
  |||||
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
  |||||
Db 38 eGlyTrpValArgGlnThrProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGI 58
  |||||
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
  |||||
Db 58 yAspSerAspThrArgTyrSerProSerPheGlnGly 70
  |||||
```

RESULT 13

PH1258

Ig heavy chain V region (clone CD-2) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996

C:Accession: PH1258

R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.

J. Exp. Med. 176, 1073-1081, 1992

A: Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chro

A: Reference number: PH1232; MUID: 93018822; PMID: 1402653

A: Accession: PH1258

A: Molecule type: DNA

A: Residues: 1-102 <CAI>

A: Experimental source: cord blood B cell

C: Superfamily: immunoglobulin V region; immunoglobulin homology

C: Keywords: heterotetramer; immunoglobulin

F: 19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:

Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1258 (1-102)

```
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
  |||||
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheIleAsnTyrTrpI 38
  |||||
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
  |||||
Db 38 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGI 58
  |||||
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
  |||||
Db 58 yAspSerAspThrArgTyrSerProSerPheGlnGly 70
  |||||
```

RESULT 14

PH1264

Ig heavy chain V region (clone VERG3) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jan-2000

C:Accession: PH1264

R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.

J. Exp. Med. 176, 1073-1081, 1992

A: Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chro
A: Reference number: PH1232; MUID: 93018822; PMID: 1402653
A: Accession: PH1264
A: Molecule type: mRNA
A: Residues: 1-102 <CAI>
A: Experimental source: EBV-transformed CD5+ B cell [from adult PBL]
C: Superfamily: immunoglobulin V region; immunoglobulin homology
C: Keywords: heterotetramer; immunoglobulin
F: 19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1264 (1-102)

```
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
  |||||
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheSerSerTyrTrpI 38
  |||||
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
  |||||
Db 38 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGI 58
  |||||
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
  |||||
Db 58 yAspSerAspThrArgTyrSerProSerPheGlnGly 70
  |||||
```

RESULT 15

PH1259

Ig heavy chain V region (clone CD-3) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996

C:Accession: PH1259

R: Cai, J.; Humphries, C.; Richardson, A.; Tucker, P.W.

J. Exp. Med. 176, 1073-1081, 1992

A: Title: Extensive and selective mutation of a rearranged VH5 gene in human B cell chro

A: Reference number: PH1232; MUID: 93018822; PMID: 1402653

A: Accession: PH1259

A: Molecule type: DNA

A: Residues: 1-102 <CAI>

A: Experimental source: cord blood B cell

C: Superfamily: immunoglobulin V region; immunoglobulin homology

C: Keywords: heterotetramer; immunoglobulin

F: 19-102/Domain: immunoglobulin homology <IMM>

Alignment Scores:

Pred. No.: 0.000145 Length: 102
Score: 103.40 Matches: 23
Percent Similarity: 45.28% Conservative: 1
Best Local Similarity: 43.40% Mismatches: 3
Query Match: 69.86% Indels: 26
DB: 2 Gaps: 2

NOLAN463-2B.SEQ (1-84) x PH1259 (1-102)

```
QY 3 GCGAGTCA-----GGGTATTAGC----- 21
  |||||
Db 19 GlyGluSerLeuLysIleSerCysLysGlySerGlyTyr-SerPheThrSerTyrTrpI 38
  |||||
QY 22 -----AGCTGGTTAGCCATCATCTATCTCTGG 47
  |||||
Db 38 eGlyTrpValArgGlnMetProGlyLysGlyLeuGluTrpMetGlyIleIleTyrProGI 58
  |||||
QY 48 TGACTCTGATACACATACAGCCGCTCTTCCAAGGC 84
  |||||
Db 58 yAspSerAspThrArgTyrSerProSerPheGlnGly 70
  |||||
```

Search completed: August 4, 2005, 19:02:37
Job time : 18.75 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 18:23:15 ; Search time 80.75 Seconds
(without alignments)
1065.378 Million cell updates/sec

Title: NOLAN463-2B.SEQ
Perfect score: 148
Sequence: 1 CGGGCGAGTCAGGGTATTAG.....ACAGCCCGCTCTTCAAGGC 84

Scoring table:
BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 3224756

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-O=/cgn2.1/USPTO.spool.p/NOLAN08728463-2/runat_04082005_123944_22581/app_query.fasta_1.5
-DB=uniprot -QFWT=fastan -SUFFIX=rup -MINMATCH=0.1 -LOOPCL=0 -DOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blomsum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THRM=scorepct -THR_MAX=100 -THR_MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFWT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN08728463-2 @CGN 1.1 305 @runat_04082005_123944_22581 -NCPU=6
-ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THRAD=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Uniprot 03.*

1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	84.7	57.2	118	Q921C4	Q921C4 mus musculus
2	77.7	52.5	474	Q8R3H6	Q8R3H6 mus musculus
3	76.7	51.8	111	Q9D9B8	Q9D9B8 mus musculus
4	75.7	51.1	614	Q7TMT6	Q7TMT6 mus musculus
5	74.7	50.5	117	HV06 MOUSE	P01750 mus musculus
6	74.7	50.5	117	HV05 MOUSE	P06327 mus musculus
7	73.7	49.8	110	Q9JL83	Q9JL83 mus musculus
8	73.7	49.8	481	Q91WT1	Q91WT1 mus musculus
9	72.7	49.1	464	Q6PF95	Q6PF95 mus musculus
10	71.7	48.4	463	Q991C4	Q991C4 mus musculus
11	68.2	46.1	125	HV1F HUMAN	P06326 homo sapien
12	67.7	45.7	117	HV05 MOUSE	P01749 mus musculus
13	66.7	45.1	143	Q91V67	Q91V67 mus musculus
14	65.5	44.3	236	Q6GMX8	Q6GMX8 homo sapien
15	64.7	43.7	136	Q7TPE3	Q7TPE3 mus musculus
16	63.8	43.1	370	Q7N4R1	Q7N4R1 photorhabdu

17	63.7	43.0	121	2	Q9UL96	Q9UL96 homo sapien
18	63.7	43.0	143	2	Q924Q0	Q924Q0 mus musculus
19	62.7	42.4	147	2	Q925S3	Q925S3 mus musculus
20	62.5	42.2	1680	2	Q9P1Z9	Q9P1Z9 homo sapien
c 21	62.3	39.0	295	2	Q8Z1R4	Q8Z1R4 salmonella
c 22	62.3	39.0	295	2	Q8ZKG0	Q8ZKG0 salmonella
23	62	41.9	98	2	Q8B6V3	Q8B6V3 oryctolagus
24	62	41.9	98	2	Q8B6W5	Q8B6W5 oryctolagus
25	62	41.9	99	2	Q8B6S4	Q8B6S4 oryctolagus
26	62	41.9	99	2	Q8B6S7	Q8B6S7 oryctolagus
27	61.7	41.7	117	1	HV1B HUMAN	P01743 homo sapien
28	61.7	41.7	124	2	Q9UL92	Q9UL92 homo sapien
c 29	61.6	38.5	302	2	Q919C3	Q919C3 anguilla an
30	61.1	41.3	4335	2	Q6NA45	Q6NA45 rhodopsu
31	60.7	41.0	143	2	Q924P9	Q924P9 mus musculus
32	60.7	41.0	330	2	Q93KW0	Q93KW0 streptomyce
33	60.7	41.0	481	2	Q91WT3	Q91WT3 mus musculus
34	60.7	41.0	1189	2	Q8NSU0	Q8NSU0 corynebacte
35	60.7	41.0	1208	2	Q6M7I4	Q6M7I4 corynebacte
36	60.6	40.9	733	2	Q6S8I3	Q6S8I3 oryza sativ
37	60.5	40.9	117	1	KV1I HUMAN	P01601 homo sapien
38	60.2	40.7	390	2	Q7S6A9	Q7S6A9 neurospora
39	60.1	40.6	763	2	Q7O5E3	Q7O5E3 anopheles g
40	60	40.5	537	2	Q6GNX4	Q6GNX4 xenopus lae
c 41	59.8	37.4	524	2	Q6XM46	Q6XM46 brachydanio
42	59.7	40.3	120	1	HV03 MOUSE	P01747 mus musculus
43	59.7	40.3	487	2	Q65ZL2	Q65ZL2 mus sp. fv/
44	59.5	40.2	107	1	KV1D HUMAN	P01596 homo sapien
45	59.5	40.2	117	1	KV1J_HUMAN	P01602 homo sapien

ALIGNMENTS

RESULT 1
Q921C4 PRELIMINARY; PRT; 118 AA.
ID Q921C4;
AC Q921C4;
DT 01-MAY-1999 (TREMBLrel. 10, Created)
DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Anti-porcine VCAM mab 3F4 heavy chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Balb/c;
RX MEDLINE=97450619; PubMed=9307060; DOI=10.1016/S0161-5890(97)00042-4;
RA Mueller J.P., Giannoni M.A., Hartman S.L., Elliott E.A., Squinto S.P.,
RA Matis L.A., Evans M.J.;
RT "Humanized porcine VCAM-specific monoclonal antibodies with chimeric
RT IgG2/G4 constant regions block human leukocyte binding to porcine
RT endothelial cells";
RL MOL. Immunol. 34:441-452(1997).
DR HSSP; P01751; INQB.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 118
SQ SEQUENCE 118 AA; 13036 MW; 90EECS59D31EC4FC CRC64;

Alignment Scores:
Pred. No.: 0.141
Score: 84.70
Percent Similarity: 63.33%
Best Local Similarity: 46.87%
Query Match: 57.23%
DB: 2
Length: 118
Matches: 14
Conservative: 5
Mismatches: 8
Indels: 3
Gaps: 0

```
NOLAN463-2B_SEQ (1-84) x Q921C4 (1-118)

QY 1 CGGGCGAGTCAGGTATTAGCAGCTGGTTAGCCATCATCTATCTCTGCTGACTCTGATACC 60
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 40 ArgProGlyGlnGlyLeu---GlutPileGlyAlaIleTyProGlyAspGlyAspThr 58
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 61 ACATACAGCCCGCTCTCCAGGC 84
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| |||||
Db 59 SerTyThrGlnLysPheArgGly 66
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 2
Q9R3H6 PRELIMINARY; PRT; 474 AA.
AC Q9R3H6;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE AU044919 protein.
GN Name=AU044919;
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CZECH II; TISSUE=Mammary tumor;
RX MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uesdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=CZECH II; TISSUE=Mammary tumor;
RA Strausberg R.;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC025447; AAH25447.1; -.
DR HSP; P01869; ICL7.
DR MGD; MGI:21444967; AU044919.
DR InterPro; IPR000345; Cytochrome_BS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 474 AA; 51748 MW; 8608B57C6CD2874A CRC64;

Alignment Scores:
Pred. No.: 1.4 Length: 474
Score: 77.70 Matches: 14
Percent Similarity: 60.00% Conservative: 4
Best Local Similarity: 46.67% Mismatches: 9
Query Match: 52.50% Indels: 3
```

```
DB: 2 Gaps: 0

NOLAN463-2B_SEQ (1-84) x Q9R3H6 (1-474)

QY 1 CGGGCGAGTCAGGTATTAGCAGCTGGTTAGCCATCATCTATCTCTGCTGACTCTGATACC 60
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| |||||
Db 59 ArgProGlyLysGlyLeu---GlutPileGlyArgIlePheProGlyAspGlyAspThr 77
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| |||||
QY 61 ACATACAGCCCGCTCTCCAGGC 84
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| |||||
Db 78 HisTySerGlyLysPheGlnGly 85
   ||| |||||:|:| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 3
Q9D9B8 PRELIMINARY; PRT; 111 AA.
AC Q9D9B8;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Mus musculus adult male testis cDNA, RIKEN full-length enriched
DE library, clone:170010101 product:immunoglobulin heavy chain 6 (heavy
DE chain of IgM), full insert sequence.
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA Carninci P., Hayashizaki Y.;
RA "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44 (1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA RIKEN FANTOM Consortium;
RA "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690 (2001).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Testis;
RA The FANTOM Consortium;
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573 (2002).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RA "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RL Genome Res. 10:1617-1630 (2000).
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwara S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Yoneda Y., Iehikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RA "RIKEN integrated sequence analysis (RISA) system-384-format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771 (2000).
RN [6]
RP SEQUENCE FROM N.A.
```

RC STRAIN=C57BL/6J; TISSUE=Testis;
RA Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,
RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,
RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,
RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,
RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,
RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,
RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,
RA Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
RA Muramatsu M., Hayashizaki Y.
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK007163; BAB24877.1; -
DR HSP; P01820; IG7J.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
SQ SEQUENCE 111 AA; 11976 MW; 874DDF7BD98BD7B2 CRC64;

Alignment Scores:
Pred. No.: 1.49 Length: 111
Score: 76.70 Matches: 13
Percent Similarity: 60.00% Conservative: 5
Best Local Similarity: 43.33% Mismatches: 9
Query Match: 51.82% Indels: 3
DB: 2 Gaps: 0

NOLAN463-2B.SEQ (1-84) x Q9D9B8 (1-111)
Qy 1 CGGCGAGTCAGGTATTAGCAGCTGTTAGCCATCATCTCTCTGTCGTCGATACC 60
Db 46 ArgProGlyLysGlyLeu---GluTrpIleGlyArgIleTyProGlyAspGlyAspThr 64
Qy 61 ACATACAGCCCGCTCTTCCCAAGGC 84
Db 65 AsnTyraenGlyLysPheLysGly 72

RESULT 4
Q7TWT6 PRELIMINARY; PRT; 614 AA.
ID Q7TWT6
AC Q7TWT6
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC60843 protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6NCR; TISSUE=Hematopoietic Stem Cell;
RX MEDLINE=22388257; PubMed=12477933; DOI=10.1073/pnas.2426038999;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raba S.S., Lequellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettner M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting J.M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human

RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6NCR; TISSUE=Hematopoietic Stem Cell;
RA Strausberg R.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC053409; AAHS3409.1; -
DR HSP; P01820; IG7J.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 614 AA; 67746 MW; 839BAF3B8D124F89 CRC64;

Alignment Scores:
Pred. No.: 2.64 Length: 614
Score: 75.70 Matches: 12
Percent Similarity: 60.00% Conservative: 6
Best Local Similarity: 40.00% Mismatches: 9
Query Match: 51.15% Indels: 3
DB: 2 Gaps: 0

NOLAN463-2B.SEQ (1-84) x Q7TWT6 (1-614)
Qy 1 CGGCGAGTCAGGTATTAGCAGCTGTTAGCCATCATCTCTCTGTCGTCGATACC 60
Db 59 ArgProGlyLysGlyLeu---GluTrpIleGlyArgValTyProGlyAspGlyAspThr 77
Qy 61 ACATACAGCCCGCTCTTCCCAAGGC 84
Db 78 AsnTyraenGlyLysPheLysGly 85

RESULT 5
HV06 MOUSE STANDARD; PRT; 117 AA.
ID HV06 MOUSE
AC P01750;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Ig heavy chain V region 102 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=81234548; PubMed=6788376; DOI=10.1016/0092-8674(81)90089-1;
RA Bothwell A.L.M., Paskind M., Reth M., Imanishi-Kari T., Rajewsky K.,
RA Baltimore D.;
RT "Heavy chain variable region contribution to the NPB family of
RL antibodies: somatic mutation evident in a gamma 2a variable region.";
RL Cell 24:625-637(1981).
CC -1- MISCELLANEOUS: This germline gene belongs to a set of closely
CC related genes that could encode V regions of NPb antibodies.
CC PTR; A02032; HVMS02.
DR PDB; 1QNZ; NMR; H=20-117.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW 3D-structure; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V region 102.
FT DOMAIN 20 49 Framework-1.
FT DOMAIN 50 54 Complementarity-determining-1.
FT DOMAIN 55 68 Framework-2.

OX		NCBI_TaxID=10090;
RN	[1]	
RP		SEQUENCE FROM N.A.
RC		STRAIN=CZECH II; TISSUE=Mammary tumor;
RC		MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA		Straussberg R.B., Feingold E.A., Grouse L.H., Derge J.G.,
RA		Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA		Altschul S.F., Zieberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA		Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA		Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA		Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA		Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Frange C.,
RA		Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA		Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA		Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA		Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA		Fabey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA		Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA		Blakesley R.C., Touchman J.W., Green E.D., Dickson M.C.,
RA		Rodriguez A.C., Greenwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA		Krzywinski M.I., Skalska U., Smalhus D.E., Schnurch A., Schein J.E.,
RA		Jones S.J., Marra M.A.;
RT		"Generation and initial analysis of more than 15,000 full-length human
RT		and mouse cDNA sequences.";
RT		Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN	[2]	
RP		SEQUENCE FROM N.A.
RC		STRAIN=CZECH II; TISSUE=Mammary tumor;
RC		Straussberg R.; to the ENBL/GenBank/DBJ databases.
RL		Submitted (SEP-2003) to the ENBL/GenBank/DBJ databases.
RL		EMBL; BC057672; AAH57672.1; -.
DR		HSSP; P01865; 1KB5.
DR		InterPro; IPR003599; IG.
DR		InterPro; IPR007110; IG-like.
DR		InterPro; IPR003597; IG.CL.
DR		InterPro; IPR003006; IG.MHC.
DR		InterPro; IPR003596; IG.V.
DR		Pfam; PF07654; Cl-set; 3.
DR		SMART; SM00409; IG; 2.
DR		SMART; SM00407; IGC1; 3.
DR		SMART; SM00406; IGV; 1.
DR		PROSITE; PS50835; IG LIKE; 4.
DR		PROSITE; PS00290; IG MHC; UNKNOWN_1.
DR		Hypothetical protein.
KS		SEQUENCE 464 AA; 51096 MW; 5B837464D85A1888 CRC64;
SY		
AL		Alignment Scores:
DP		Pred. No.: 6.12 Length: 464
SC		Score: 72.70 Matches: 13
SP		Percent Similarity: 60.00% Conservative: 5
SL		Best Local Similarity: 43.33% Mismatches: 9
SM		Query Match: 49.12% Indels: 3
DB		Gaps: 0
DB		
QY		NOLAN463-2B.SEQ (1-84) x Q6PPF95 (1-464)
QY	1	CGGGCAGCTCAGGTTATTAGCAGCTGTTAGCCATCATCTCTCTGGTACTCTGATACC 60
DB	59	ArgserGlyGInGlyLeu---GlutrpIlealaarglierPrroGlyThrGlySerthr 77
QY	61	ACATACAGCCCGTCCTCCCAAGGC 84
DB	78	TyrTyrAenGIuLysePhelysGly 85
DB		
RESULT 10		
Q99LCL4 ...		
ID Q99LCL4		PRELIMINARY; PRT; 463 AA.
AC Q99LCL4		
DT 01-JUN-2001	(TREMBLrel. 17, Created)	
DT 01-JUN-2001	(TREMBLrel. 17, Last sequence update)	
DT 01-MAR-2004	(TREMBLrel. 26, Last annotation update)	
DE	Igh-4 protein.	
GN	Name=Igh-4:	

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_taxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX STRAUSBERG R.;
RL Submitted (FEB-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC003435; AAH03435.1; -;
DR PIR; B45837; B45837.
DR HSSP; P01869; 1CL7.
DR MGD; MGI:96446; Igh-4.
DR GO; GO:0042571; C:immunoglobulin complex, circulating; IDA.
DR GO; GO:0003823; P:antigen binding; IDA.
DR GO; GO:0019733; P:antibacterial humoral response (sensu Verte. . .); IDA.
DR GO; GO:0001788; P:antibody-dependent cellular cytotoxicity; IDA.
DR GO; GO:0006958; P:complement activation, classical pathway; IDA.
DR GO; GO:0042830; P:defense response to pathogenic bacteria; IDA.
DR GO; GO:0006911; P:phagocytosis, engulfment; IDA.
DR GO; GO:0006910; P:phagocytosis, recognition; IDA.
DR GO; GO:0050778; P:positive regulation of immune response; IDA.
DR GO; GO:0050766; P:positive regulation of phagocytosis; IDA.
DR GO; GO:0001812; P:positive regulation of type I hypersensitivity; IDA.
DR GO; GO:0001798; P:positive regulation of type IIA hypersensit. . .; IDA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 463 AA; 51007 MW; EAA674C6BEC30783 CRC64;

Alignment Scores:

Pred. No.: 8.23 Length: 463
Score: 71.70 Matches: 13
Percent Similarity: 56.67% Conservative: 4
Best Local Similarity: 43.33% Mismatches: 10
Query Match: 48.45% Indels: 3
DB: 2 Gaps: 0

NOLAN463-2B_SEQ (1-84) x Q99L4 (1-463)

QY 1 CGGGGAGTCAGGGTATTAGCAGCTGGTTAGCCATCATCTATCTCTGGTACTCTGATACC 60
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_taxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX STRAUSBERG R.;
RL Submitted (FEB-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC003435; AAH03435.1; -;
DR PIR; B45837; B45837.
DR HSSP; P01869; 1CL7.
DR MGD; MGI:96446; Igh-4.
DR GO; GO:0042571; C:immunoglobulin complex, circulating; IDA.
DR GO; GO:0003823; P:antigen binding; IDA.
DR GO; GO:0019733; P:antibacterial humoral response (sensu Verte. . .); IDA.
DR GO; GO:0001788; P:antibody-dependent cellular cytotoxicity; IDA.
DR GO; GO:0006958; P:complement activation, classical pathway; IDA.
DR GO; GO:0042830; P:defense response to pathogenic bacteria; IDA.
DR GO; GO:0006911; P:phagocytosis, engulfment; IDA.
DR GO; GO:0006910; P:phagocytosis, recognition; IDA.
DR GO; GO:0050778; P:positive regulation of immune response; IDA.
DR GO; GO:0050766; P:positive regulation of phagocytosis; IDA.
DR GO; GO:0001812; P:positive regulation of type I hypersensitivity; IDA.
DR GO; GO:0001798; P:positive regulation of type IIA hypersensit. . .; IDA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 463 AA; 51007 MW; EAA674C6BEC30783 CRC64;

QY 61 ACATACAGCCCGTCCTCTTCCAAGGC 84
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_taxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX STRAUSBERG R.;
RL Submitted (FEB-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC003435; AAH03435.1; -;
DR PIR; B45837; B45837.
DR HSSP; P01869; 1CL7.
DR MGD; MGI:96446; Igh-4.
DR GO; GO:0042571; C:immunoglobulin complex, circulating; IDA.
DR GO; GO:0003823; P:antigen binding; IDA.
DR GO; GO:0019733; P:antibacterial humoral response (sensu Verte. . .); IDA.
DR GO; GO:0001788; P:antibody-dependent cellular cytotoxicity; IDA.
DR GO; GO:0006958; P:complement activation, classical pathway; IDA.
DR GO; GO:0042830; P:defense response to pathogenic bacteria; IDA.
DR GO; GO:0006911; P:phagocytosis, engulfment; IDA.
DR GO; GO:0006910; P:phagocytosis, recognition; IDA.
DR GO; GO:0050778; P:positive regulation of immune response; IDA.
DR GO; GO:0050766; P:positive regulation of phagocytosis; IDA.
DR GO; GO:0001812; P:positive regulation of type I hypersensitivity; IDA.
DR GO; GO:0001798; P:positive regulation of type IIA hypersensit. . .; IDA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 463 AA; 51007 MW; EAA674C6BEC30783 CRC64;

RESULT 11

HV1F HUMAN
ID HV1F HUMAN STANDARD; PRT; 125 AA.
AC P06326;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Ig heavy chain V-I region Mot.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_taxID=9606;
RN [1]
RP SEQUENCE.

RX MEDLINE=86203277; PubMed=3084950; DOI=10.1016/0161-5890(86)90039-8;
RA Kojima M., Koide T., Odani S., Ono T.;
RT "Amino acid sequence of the variable region of heavy chain in
immunoglobulin (Mot) having unusual papain cleavage sites.";
RL Mol. Immunol. 23:169-174 (1986).
DR PIR; A02025; HVHUM0.
DR HSSP; P01751; IAgW.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin V region.
FT DOMAIN 1 98 V segment.
FT DOMAIN 99 107 D segment.
FT DOMAIN 108 125 J segment.
FT DISULFID 22 96 By similarity.
FT NON_TER 125 125
SQ SEQUENCE 125 AA; 13579 MW; F4C4285D6DF0C8EA CRC64;

Alignment Scores:

Pred. No.: 18.7 Length: 125
Score: 68.20 Matches: 12
Percent Similarity: 53.12% Conservative: 5
Best Local Similarity: 37.50% Mismatches: 7
Query Match: 46.08% Indels: 8
DB: 1 Gaps: 0

NOLAN463-2B_SEQ (1-84) x HV1F_HUMAN (1-125)

QY 2 GGGGAGTCAGGGTATTAGCAGCTGGTTAGCCATCATCTATCTCTGGTACTCTGATACC 61
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_taxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX STRAUSBERG R.;
RL Submitted (FEB-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC003435; AAH03435.1; -;
DR PIR; B45837; B45837.
DR HSSP; P01869; 1CL7.
DR MGD; MGI:96446; Igh-4.
DR GO; GO:0042571; C:immunoglobulin complex, circulating; IDA.
DR GO; GO:0003823; P:antigen binding; IDA.
DR GO; GO:0019733; P:antibacterial humoral response (sensu Verte. . .); IDA.
DR GO; GO:0001788; P:antibody-dependent cellular cytotoxicity; IDA.
DR GO; GO:0006958; P:complement activation, classical pathway; IDA.
DR GO; GO:0042830; P:defense response to pathogenic bacteria; IDA.
DR GO; GO:0006911; P:phagocytosis, engulfment; IDA.
DR GO; GO:0006910; P:phagocytosis, recognition; IDA.
DR GO; GO:0050778; P:positive regulation of immune response; IDA.
DR GO; GO:0050766; P:positive regulation of phagocytosis; IDA.
DR GO; GO:0001812; P:positive regulation of type I hypersensitivity; IDA.
DR GO; GO:0001798; P:positive regulation of type IIA hypersensit. . .; IDA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 463 AA; 51007 MW; EAA674C6BEC30783 CRC64;

QY 42 GlyArg-----GlyLeu---GlutrpMetAlaValHisProSerAspArgThr 59

QY 62 CATACAGCCCGTCCTCTTCCAAGGC 81

QY 59 hrtyGlyProArgSerGln 65

RESULT 12

HV05 MOUSE
ID HV05 MOUSE STANDARD; PRT; 117 AA.
AC P01749;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Ig heavy chain V region 3 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_taxID=10090;
RN [1]
RP SEQUENCE.

RX MEDLINE=86203277; PubMed=3084950; DOI=10.1016/0161-5890(86)90039-8;
RA Kojima M., Koide T., Odani S., Ono T.;
RT "Amino acid sequence of the variable region of heavy chain in
immunoglobulin (Mot) having unusual papain cleavage sites.";
RL Mol. Immunol. 23:169-174 (1986).
DR PIR; A02025; HVHUM0.
DR HSSP; P01751; IAgW.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin V region.
FT DOMAIN 1 98 V segment.
FT DOMAIN 99 107 D segment.
FT DOMAIN 108 125 J segment.
FT DISULFID 22 96 By similarity.
FT NON_TER 125 125
SQ SEQUENCE 125 AA; 13579 MW; F4C4285D6DF0C8EA CRC64;

NOLAN463-2B_SEQ (1-84) x HV1F_HUMAN (1-125)

QY 2 GGGGAGTCAGGGTATTAGCAGCTGGTTAGCCATCATCTATCTCTGGTACTCTGATACC 61
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_taxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=FVB/N; TISSUE=Mammary tumor;
RX STRAUSBERG R.;
RL Submitted (FEB-2001) to the ENBL/GenBank/DBJ databases.
DR EMBL; BC003435; AAH03435.1; -;
DR PIR; B45837; B45837.
DR HSSP; P01869; 1CL7.
DR MGD; MGI:96446; Igh-4.
DR GO; GO:0042571; C:immunoglobulin complex, circulating; IDA.
DR GO; GO:0003823; P:antigen binding; IDA.
DR GO; GO:0019733; P:antibacterial humoral response (sensu Verte. . .); IDA.
DR GO; GO:0001788; P:antibody-dependent cellular cytotoxicity; IDA.
DR GO; GO:0006958; P:complement activation, classical pathway; IDA.
DR GO; GO:0042830; P:defense response to pathogenic bacteria; IDA.
DR GO; GO:0006911; P:phagocytosis, engulfment; IDA.
DR GO; GO:0006910; P:phagocytosis, recognition; IDA.
DR GO; GO:0050778; P:positive regulation of immune response; IDA.
DR GO; GO:0050766; P:positive regulation of phagocytosis; IDA.
DR GO; GO:0001812; P:positive regulation of type I hypersensitivity; IDA.
DR GO; GO:0001798; P:positive regulation of type IIA hypersensit. . .; IDA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 463 AA; 51007 MW; EAA674C6BEC30783 CRC64;

RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RX MEDLINE=81234548; PubMed=6788376; DOI=10.1016/0092-8674(81)90089-1;
RA Bothwell A.L.M., Paskind M., Reth M., Imanishi-Kari T., Rajewsky K.,
RA Baltimore D.;
RT "Heavy chain variable region contribution to the NPb family of
RT antibodies: somatic mutation evident in a gamma 2a variable region.";
RL Cell 24:625-637(1981).
CC -1- MISCELLANEOUS: This germline gene belongs to a set of closely
CC related genes that could encode V regions of NPb antibodies.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; J00536; AAA38605.1; -;
DR PIR; A02031; HVMS3.
DR HSP; P01810; 2FBJ.
DR MGD; MGI:96486; Igh-VJ558.
DR InterPro; IPR007110; Igh-like.
DR InterPro; IPR003596; Igh_V.
DR Pfam; PF00047; Igh; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V region 3.
FT DOMAIN 20 49 Framework-1.
FT DOMAIN 50 54 Complementarity-determining-1.
FT DOMAIN 55 68 Framework-2.
FT DOMAIN 69 85 Complementarity-determining-2.
FT DOMAIN 86 117 Framework-3.
FT DISULFID 41 115 By similarity.
FT NON TER 117 117
SQ SEQUENCE 117 AA; 13016 MW; 427C861C53975EDC CRC64;

Alignment Scores:
Pred. No.: 21.5 Length: 117
Score: 67.70 Matches: 12
Percent Similarity: 58.62% Conservative: 5
Best Local Similarity: 41.38% Mismatches: 9
Query Match: 45.74% Indels: 3
DB: 1 Gaps: 0

NOLAN463-2B-SEQ (1-84) x HV05_MOUSE (1-117)
QY 1 CGGGCGAGTCAGGCTATTAGCAGCTGGTATGCCATCATCTATCTGTGCTGATACC 60
Db 59 ArgProGlyGlnGlyLeu---GluTrpIleGlyAsnIleTyProSerAspSerGluThr 77
QY 61 ACATACAGCCGCTCTCCAA 81
Db 78 HisTyAsnGlnLysPheLys 84

RESULT 13
QY1V67 PRELIMINARY; PRT; 143 AA.
AC QY1V67;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE VH186.2-D-J-C mu protein (V304-D-J-C mu protein) (fragment).
GN Name=VH186.2-D-J-C mu; Synonyms=V304-D-J-C mu;
OS Mus musculus (Mouse).
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB069912; BAB63928.1; -;
DR EMBL; AB069914; BAB63930.1; -;
DR PIR; S26744; S26744.
DR HSP; P01751; IAGW.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 1.
FT NON TER 1 1
FT NON TER 143 143
SQ SEQUENCE 143 AA; 15775 MW; 91BC6012B4BFEFB CRC64;

Alignment Scores:
Pred. No.: 29.8 Length: 143
Score: 66.70 Matches: 12
Percent Similarity: 56.67% Conservative: 5
Best Local Similarity: 40.00% Mismatches: 10
Query Match: 45.07% Indels: 3
DB: 2 Gaps: 0

NOLAN463-2B-SEQ (1-84) x QY1V67 (1-143)
QY 1 CGGGCGAGTCAGGCTATTAGCAGCTGGTATGCCATCATCTATCTGTGCTGATACC 60
Db 40 ArgProGlyGlnGlyLeu---GluTrpIleGlyValIleAspProSerAspSerTyThr 58
QY 61 ACATACAGCCGCTCTCCAAAGC 84
Db 59 AsnTyAsnGlnLysPheLysGly 66

RESULT 14
QY6MX8 PRELIMINARY; PRT; 236 AA.
AC QY6MX8;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
EX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Frange C.,
RA Raha S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.B., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073764; AAH73764.1; -;

DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.CL.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; CI-set; 1.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00409; Ig; 2.
DR SMART; SM00407; IGC1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 236 AA; 25707 MW; 4FC8E14B6559EFC9 CRC64;

Alignment Scores:

Pred. No.:	46.1	Length:	236
Score:	65.50	Matches:	14
Percent Similarity:	36.36%	Conservative:	2
Best Local Similarity:	31.82%	Mismatches:	3
Query Match:	44.26%	Indels:	25
DB:	2	Gaps:	0

NOLAN463-2B.SEQ (1-84) x Q6GMX8 (1-236)

QY 1 CGGGCGAGTCAGGGTATTAGCAGCTGTTAGCCATCATCTATCTCTGGTGACTCTGATACC 60

Db 46 ArgAlaSerGlnGlyIleSerSerTrpLeuAla-----Trp----- 57

QY 61 ACATACAGCCGCTCTCCCAAG 82

Db 58 -TyrGlnGlnLysProGlyLys 64

RESULT 15

Q7TPE3
ID Q7TPE3 PRELIMINARY; PRT; 136 AA.
AC Q7TPE3;
DT 01-OCT-2003 (TRENBLrel. 25, Created)
DT 01-OCT-2003 (TRENBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE V23-D-J-IgG1 protein (Fragment).
GN Name=V23-D-J-IgG1;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
OX NCBI_taxid=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Kozono Y., Kozono H., Azuma T.;
RT "The higher density hapten Ag stimulates strong signal to B cells.";
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB069864; BACS4573.1; -.
DR HSSP; P01751; 1A6V.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 136
SQ SEQUENCE 136 AA; 14882 MW; 99392B1A31F663AF CRC64;

Alignment Scores:

Pred. No.:	53.5	Length:	136
Score:	64.70	Matches:	11
Percent Similarity:	55.17%	Conservative:	5
Best Local Similarity:	37.93%	Mismatches:	10
Query Match:	43.72%	Indels:	3
DB:	2	Gaps:	0

NOLAN463-2B.SEQ (1-84) x Q7TPE3 (1-136)

QY 1 CGGGCGAGTCAGGGTATTAGCAGCTGTTAGCCATCATCTATCTCTGGTGACTCTGATACC 60

Db	37	ArgProGlyGlnGlyLeu---GluTrpIleGlyAsnIleTyrProSerAsnGlyAspThr	55
Qy	61	ACATACAGCCGCTCTCCCAA	81
Db	56	AsnTyrAsnGluLysPheLys	62

Search completed: August 4, 2005, 19:01:29
Job time : 85.75 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:02:48 ; Search time 114 Seconds
(without alignments)
549.607 Million cell updates/sec

Title: DELETED1

Perfect score: 140

Sequence: 1 GAATCAATCATACTGGAAG.....ATATTAGCAGCTGTTAGCC 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 4211384

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-O=/cgn2_1/USPTO_spool_p/NOLAN463-3A/runat_04082005_120124_18790/app_query.fasta_1.263
-DB=A-Geneseq -QFMT=fastan -SUFFIX=rag -MINMATCH=0.1 -LOOPEXT=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3A @CGN 1.1 224 @runat_04082005_120124_18790 -NCPU=6 -ICPU=3
-NO MMAP -LARGQUERY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

A-Geneseq 16Dec04:*
1: Geneseq1980s:*
2: Geneseq1990s:*
3: Geneseq2000s:*
4: Geneseq2001s:*
5: Geneseq2002s:*
6: Geneseq2003as:*
7: Geneseq2003bs:*
8: Geneseq2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	113.1	80.8	249	5	ABP45310 Human Bly
2	113.1	80.8	249	5	ADG96137 Single ch
3	93.8	67.0	250	5	ADP44982 Human Bly
4	93.8	67.0	250	5	ADG95809 Single ch
5	93.8	67.0	253	5	ADP44943 Human Bly
6	93.8	67.0	253	5	ADG95770 Single ch
7	92.4	66.0	80	2	AAW62794 Amino aci
8	92.4	66.0	97	2	AAV05694 Multiple
9	92.4	66.0	97	5	ABG78212 Human Fv
10	92.4	66.0	97	5	ABG91903 Human ant

11	92.4	66.0	97	6	ABO27107	AbO27107 Human ger
12	92.4	66.0	97	7	ADB75646	ADB75646 Human pro
13	92.4	66.0	97	7	ADD28104	ADD28104 Lymphoma
14	92.4	66.0	97	7	ADF10048	ADF10048 VEGF anti
15	92.4	66.0	97	7	ADP10150	ADP10150 Antibody
16	92.4	66.0	97	7	ADP09942	ADP09942 Antibody
17	92.4	66.0	97	7	ADJ80323	ADJ80323 VH gene 1
18	92.4	66.0	114	3	AAO01949	AAO01949 Anti-Id1
19	92.4	66.0	114	3	RAO01950	RAO01950 Anti-Id1
20	92.4	66.0	114	3	RAO01953	RAO01953 Anti-Id1
21	92.4	66.0	114	3	RAO01959	RAO01959 High affi
22	92.4	66.0	114	3	RAO01952	RAO01952 Anti-Id1
23	92.4	66.0	114	3	RAO01955	RAO01955 Streptativ
24	92.4	66.0	114	3	RAO01956	RAO01956 Streptativ
25	92.4	66.0	114	3	RAO01948	RAO01948 Wild-type
26	92.4	66.0	114	7	ADG70086	ADG70086 Diversifi
27	92.4	66.0	114	7	ADG70013	ADG70013 Diversifi
28	92.4	66.0	116	2	RAE66324	RAE66324 Human imm
29	92.4	66.0	117	4	AAW60904	AAW60904 Human bra
30	92.4	66.0	117	5	ABG55317	ABG55317 Human liv
31	92.4	66.0	117	5	ABG43454	ABG43454 Human pep
32	92.4	66.0	118	6	ADA89246	ADA89246 Human ant
33	92.4	66.0	122	7	ADK17418	ADK17418 Anti-huma
34	92.4	66.0	122	8	ADG42840	ADG42840 scFv Ab12
35	92.4	66.0	123	2	AAW03757	AAW03757 Anti-rhes
36	92.4	66.0	125	6	ADA89266	ADA89266 Human ant
37	92.4	66.0	125	6	ADA89274	ADA89274 Human ant
38	92.4	66.0	139	5	AAV99556	AAV99556 Human LH1
39	92.4	66.0	139	6	ABR42859	ABR42859 Tumour-ep
40	92.4	66.0	139	7	ABW02445	ABW02445 Human mon
41	92.4	66.0	142	6	ABP96287	ABP96287 Anti-hTNF
42	92.4	66.0	154	6	ABP96293	ABP96293 Human ant
43	92.4	66.0	190	2	AAV34304	AAV34304 IGM antib
44	92.4	66.0	202	2	AAV34303	AAV34303 IGM antib
45	92.4	66.0	205	2	AAV34299	AAV34299 IGM antib

ALIGNMENTS

RESULT 1

ABP45310
ID ABP45310 standard; protein; 249 AA.

XX AC ABP45310;

XX AC (first entry)

DT 19-AUG-2002 (first entry)

XX Human BLYS binding scFv SEQ ID 1321.

BLYS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
tumour necrosis factor; B cell proliferation; B cell differentiation;
immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
common variable immunodeficiency; acquired immunodeficiency syndrome.

XX Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US019110.

XX 16-JUN-2000; 2000US-0212210P.

PR 17-OCT-2000; 2000US-0240816P.

PR 16-MAR-2001; 2001US-0276248P.

PR 21-MAR-2001; 2001US-0277379P.

PR 25-MAY-2001; 2001US-0293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

FA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX

Db 70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
 Qy 48 -----
 Db 90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
 Qy 48 -----
 Db 110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGlyGly 129
 Qy 48 -----
 Db 130 GlySerGlyGlyGlySerGlyGlyGlyGlyGlySerAspIleValMetThrGlnSerPro 149
 Qy 49 -----CGGGCCGAGTCAGGAT 63
 Db 150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
 Qy 64 ATTACGACGCTGGTTAGCC 81
 Db 170 IleSerSerTrpLeuAla 175

RESULT 3

ABP44982

ID ABP44982 standard; protein; 250 AA.

XX AC ABP44982;

XX AC

DT 19-AUG-2002 (first entry)

DE Human Blys binding scFv SEQ ID 993.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 XX tumour necrosis factor; B cell proliferation; B cell differentiation;
 XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 XX common variable immunodeficiency; acquired immunodeficiency syndrome.

OS Homo sapiens.

XX WO200202641-A1.

XX 10-JAN-2002.

XX 15-JUN-2001; 2001WO-US019110.

XX 16-JUN-2000; 2000US-0212210P.

XX 17-OCT-2000; 2000US-0240816P.

XX 16-MAR-2001; 2001US-0276248P.

XX 21-MAR-2001; 2001US-0277379P.

XX 25-MAY-2001; 2001US-0293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;

XX WPI; 2002-114799/15.

XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the diagnosis and treatment of cancers and immune disorders.

XX Claim 1; Page 1586-1587; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys

CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention

XX SQ Sequence 250 AA;

Alignment Scores:

Pred. No.: 0.00327 Length: 250
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 5 Gaps: 1

DELETED1 (1-81) x ABP44982 (1-250)

Qy 1 GAATCATCATAGTGGAGCAGCACCACTACACCGCTCTCTCAAGATCGGCGG----- 54
 Db 50 GluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
 Qy 55 AGTCAGGATATTAGCAGC 72
 Db 70 SerGlnAspThrSerAsn 75

RESULT 4

ADG95809

ID ADG95809 standard; protein; 250 AA.

XX AC ADG95809;

XX 11-MAR-2004 (first entry)

XX Single chain antibody that immunospecifically binds Blys SeqID 993.

XX antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiallergic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

XX Example 1; SEQ ID NO 993; 394pp; English.

XX This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour

CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX
 SQ Sequence 250 AA;

Alignment Scores:
 Pred. No.: 0.00327 Length: 250
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 7 Gaps: 1

DELETED1 (1-81) x ADG95809 (1-250)

QY 1 GAATCATCATAGTGGAGCACCACCTACAAACCGTCTCTCAAGATCGGGCG----- 54
 DB 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
 QY 55 AGTCAGGATATTAGCAGC 72
 DB 70 SerGlnAspThrSerAsn 75

RESULT 5

ID ABP44943
 ID ABP44943 standard; protein; 253 AA.

XX AC ABP44943;

XX DT 19-AUG-2002 (first entry)

XX DE Human Blys binding scFv SEQ ID 954.

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX OS Homo sapiens.

XX WO200202641-A1.

XX PD 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US019110.

XX PR 16-JUN-2000; 2000US-0212210P.

XX PR 17-OCT-2000; 2000US-0240816P.

XX PR 16-MAR-2001; 2001US-0276248P.

XX PR 21-MAR-2001; 2001US-0277379P.

XX PR 25-MAY-2001; 2001US-0293499P.

XX (HUMA-) HUMAN GENOME SCI INC.

PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 XX
 PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 XX
 PS Claim 1; Page 1540-1541; 3148pp; English.

XX This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys in
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention

XX Sequence 253 AA;

Alignment Scores:
 Pred. No.: 0.00328 Length: 253
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 5 Gaps: 1

DELETED1 (1-81) x ABP44943 (1-253)

QY 1 GAATCATCATAGTGGAGCACCACCTACAAACCGTCTCTCAAGATCGGGCG----- 54
 DB 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69

QY 55 AGTCAGGATATTAGCAGC 72

DB 70 SerGlnAspThrSerAsn 75

RESULT 6

ADG95770

ID ADG95770 standard; protein; 253 AA.

XX AC ADG95770;

XX DT 11-MAR-2004 (first entry)

XX DE Single chain antibody that immunospecifically binds Blys Seqid 954.

XX antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiallergic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX OS Unidentified.

XX WO2003055979-A2.

XX PD 10-JUL-2003.

XX PF 14-NOV-2002; 2002WO-US036496.

XX PR 16-NOV-2001; 2001US-0331469P.

PR 19-DEC-2001; 2001US-0340817P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 PI WPI; 2003-505530/47.
 XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 XX (Blys), useful for detecting and treating diseases or disorders e.g.
 XX rheumatoid arthritis, asthma and leukemia.
 XX Example 1; SEQ ID NO 954; 394pp; English.
 PS This invention relates to novel antibodies that immunospecifically bind
 XX to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antisthmatic, anti-allergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 253 AA;
 Alignment Scores:
 Pred. No.: 0.00328 Length: 253
 Score: 93.80 Matches: 20
 Percent Similarity: 80.77% Conservative: 1
 Best Local Similarity: 76.92% Mismatches: 3
 Query Match: 67.00% Indels: 2
 DB: 7 Gaps: 1
 DELETED1 (1-81) x ADG95770 (1-253)
 QY 1 GAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAAGAGTCGGGCG----- 54
 DB 50 GlulleAenHisSerGlySerThrAsnTyrAsnProSerLeuAenSerArgValThrIle 69
 QY 55 AGTCAGGATATTAGCAGC 72
 DB 70 SerGlnAspThrSerAsn 75
 RESULT 7
 AAW62794
 ID AAW62794 standard; peptide; 80 AA.
 XX AAW62794;
 AC AAW62794;
 XX 23-SEP-1998 (first entry)
 DT Amino acid sequence of a human antibody fragment.
 DE Human; immunoglobulin; Ig; transgenic; non-human mammal;
 XX inactivated endogenous Ig locus; B-cell development;
 KW human heavy chain Ig locus; micro constant region; J-H; D-H; V-H gene;
 KW kappa light chain Ig locus; kappa constant region; J-kappa gene; V-kappa;
 XX production; antibody.

OS Homo sapiens.
 XX WO9824893-A2.
 XX 11-JUN-1998.
 PD 03-DEC-1997; 97WO-US023091.
 PF 03-DEC-1996; 96US-00759620.
 PR (ABGE-) ABGENIX INC.
 XX Jakobovits A, Kucherlapati R, Klapholz S, Mendez M, Green L;
 PI WPI; 1998-333314/29.
 DR New transgenic non-human mammals - having an inactivated immunoglobulin
 XX locus and a near complete human immunoglobulin locus, used for production
 XX of human antibodies.
 PS Disclosure; Page 71; 128pp; English.
 CC AAW62793-822 represent fragments of human antibodies produced by
 CC transgenic Xenomice, created using the method of the invention. The
 CC specification describes a transgenic non-human mammal which has genome
 CC modifications that comprise an inactivated endogenous immunoglobulin (Ig)
 CC locus, so that the mammal does not display normal B-cell development. The
 CC modified genome also has an inserted human heavy chain Ig locus in
 CC germline configuration, the human heavy chain Ig locus comprising a human
 CC micro constant region and regulatory and switch sequences, human J-H
 CC genes, human D-H genes, and human V-H genes and an inserted human kappa
 CC light chain Ig locus in germline configuration, the human kappa light
 CC chain Ig locus comprising a human kappa constant region, J-kappa genes,
 CC and V-kappa genes, where the number of V-H and V-kappa genes inserted are
 CC selected to restore normal B-cell development in the mammal. The
 CC transgenic animals have a near complete human Ig locus, including both a
 CC human heavy chain locus and a human kappa light chain locus. They can be
 CC used for the production of human antibodies when exposed to particular
 CC antigens e.g. when exposed to human IL-8, EGFR or TNF- alpha the mice
 CC will produce antibodies to IL-8, EGFR or TNF- alpha respectively
 XX
 SQ Sequence 80 AA;
 Alignment Scores:
 Pred. No.: 0.00354 Length: 80
 Score: 92.40 Matches: 19
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 2 Gaps: 0
 DELETED1 (1-81) x AAW62794 (1-80)
 QY 1 GAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAAGAGTCGGGCGAGTCAG 60
 DB 33 GlulleAenHisSerGlySerThrAsnTyrAsnProSerLeuAenSerArgValThr--- 51
 QY 61 GATATTAGC 69
 DB 52 ---Ileser 53
 RESULT 8
 AAY05694
 ID AAY05694 standard; protein; 97 AA.
 XX AAY05694;
 AC AAY05694;
 XX 19-JUL-1999 (first entry)
 DT Multiple sclerosis patient CSF B-cell VH region (clone 4d76).
 XX Multiple sclerosis; cerebrospinal fluid; CSF; B-cell;
 KW heavy chain variable region; VH gene; somatic hypermutation;
 KW

B-cell clonality; RA gene; diagnosis; human.

Homo sapiens.

Key Location/Qualifiers

Region 1..30

/label= FR1

Misc-difference 8

/note= "encoded by GGC"

Misc-difference 13

/note= "replaces Glu of RA"

Misc-difference 14

/note= "encoded by CCT"

Misc-difference 23

/note= "replaces Gly of RA"

Misc-difference 25

/note= "replaces Phe of RA"

Misc-difference 30

/note= "replaces Gly of RA"

Region 31..36

/label= CDR1

Misc-difference 31

/note= "replaces Gly of RA"

Misc-difference 32

/note= "replaces Phe of RA"

Region 37..50

/label= FR2

Region 51..66

/label= CDR2

Misc-difference 56

/note= "replaces Asn of RA"

Misc-difference 57

/note= "replaces Ser of RA"

Misc-difference 58

/note= "replaces Lys of RA"

Region 67..97

/label= FR3

Misc-difference 71

/note= "replaces Leu of RA"

Misc-difference 81

/note= "replaces Arg of RA"

WO9915696-A1.

01-APR-1999.

17-SEP-1998; 98WO-CA000873.

19-SEP-1997; 97CA-02216595.

04-NOV-1997; 97CA-02220245.

(QINY/) QIN Y.

Qin Y;

WPI; 1999-276985/23.

N-PSDB; AAX25318.

Determination of B-cell clonality by amplification or enzymatic digestion.

Disclosure; Fig 9D; 67pp; English.

This sequence represents a heavy chain variable region (VH) as predicted from DNA of dominant clone 4d76 of B-cells taken from the cerebrospinal fluid (CSF) of a multiple sclerosis (MS) patient. Sequences of VH of CSF B-cells were obtained from 4 MS patients (see AAX25316-19). Differences in nucleotide and predicted amino acid (see AAY05691-94) sequences were compared with the closest known germline VH genes; for 4d76, this was RA.

The results provided direct evidence that intrathecal clonally expanded B-cells from the CSF of MS patients are hypermutated postgerminal centre antibody-forming or memory lymphocytes that have undergone antigen selection. This finding implicates an important pathogenic pathway for

the development of demyelination in CNS of MS. The invention provides assay kits for determining B-cell or T-cell clonality. This technology allows the establishment of clonal specific RNA library from pathogenic cells in the CNS of patients, which is important for further understanding of the role of antigen(s) in the cause of B-cell clonal expansion, and towards developing antigen specific therapeutic strategy

SQ Sequence 97 AA;

Alignment Scores:

Pred. NO.: 0.00375 Length: 97

Score: 92.40 Matches: 19

Percent Similarity: 74.07% Conservative: 1

Best Local Similarity: 70.37% Mismatches: 1

Query Match: 66.00% Indels: 6

DB: 2 Gaps: 0

DELETED1 (1-81) x AAY05694 (1-97)

QY 1 GAATCAATCATAGTGAAGCAACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60

Db 50 GlulleAenHisserGlySerThrAsnTrpAsnProSerLeuLysSerArgValThr--- 68

QY 61 GATATTAGC 69

Db 69 ---ileSer 70

RESULT 9

ABG78212

ID ABG78212 standard; protein; 97 AA.

XX AC ABG78212;

XX DT 15-NOV-2002 (first entry)

XX DE Human Fv molecule hypervariable region related peptide #87.

XX KW Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;

XX KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;

XX KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.

XX OS Homo sapiens.

XX WO200259264-A2.

XX PD 01-AUG-2002.

XX XX 31-DEC-2001; 2001WO-US049440.

XX PR 29-DEC-2000; 2000US-00751181.

XX PA (BIOT-) BIO-TECHNOLOGY GEN CORP.

XX PI Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;

XX PI Plaksin D, Peretz T;

XX DR WPI; 2002-619166/66.

XX PT Novel peptide/polypeptide for cancer therapy has Fv molecule, construct

PT or fragment, or construct of fragment with enhanced binding

PT characteristics so as to selectively bind target cell in favor of other

PT cells.

XX PS Claim 13; Page 193; 232pp; English.

XX CC The invention relates to a peptide or polypeptide comprising an Fv

CC molecule, a construct or fragments or a construct of a fragment with

CC enhanced binding characteristics which selectively and/or specifically

CC binds to a target cell in favour of other cells, where binding is

CC primarily determined by a first hypervariable region and Fv is a single

CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in

CC association with or attached, coupled, combined, linked or fused to a

CC pharmaceutical agent, is useful in the manufacture of a medicament, where

CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 CC related peptide of the invention

XX Sequence 97 AA;

Alignment Scores: Length: 97
 Pred. No.: 0.00375 Matches: 19
 Score: 92.40
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 5 Gaps: 0

DELETED1 (1-81) x ABG78212 (1-97)

Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCGCTCTCTCAAGAGTCGGCGAGTCAG 60
 Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
 Qy 61 GATATTAGC 69
 Db 69 ---IleSer 70

RESULT 10
 ABG91903

ID ABG91903 standard; protein; 97 AA.

XX AC ABG91903;

DT 04-DEC-2002 (first entry)

XX Human antibody fragment #87.

XX Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
 KW metastasis; hypervariable region; autoimmune disease; thrombosis;
 KW restenosis; leukaemia; inflammatory disease; cardiovascular disease;
 KW myocardial infarction; retinopathic disease; abnormal platelet function;
 KW sulphated tyrosine-dependent protein-protein interaction.

XX Homo sapiens.

XX WO200253700-A2.

XX 11-JUL-2002.

XX 31-DEC-2001; 2001WO-US049442.

XX 29-DEC-2000; 2000US-00751181.

XX 29-DEC-2000; 2000US-0256948P.

XX (BIOT-) BIO-TECHNOLOGY GEN CORP.

XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
 PI Sznathon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;

XX WPI; 2002-674776/72.

XX Novel isolated epitope present on cancer cells and important in
 PT physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.

XX Disclosure; Page 269; Opp; English.

XX The invention relates to an isolated epitope present on cancer cells and
 CC important in physiological phenomena such as cell rolling, metastasis and
 CC inflammation, where the epitope is capable of being bound by an antibody,
 CC its antigen-binding fragment or its complex comprising at least one

CC antibody or its binding fragment having a first hypervariable region. The
 CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
 CC tumour or leukaemia cells, increase in number of tumour or leukaemia
 CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 CC platelet and/or cell-platelet adhesion or aggregation, for increasing
 CC mortality of tumour or leukaemia cells, for increasing the susceptibility
 CC of diseased cells to damage by anti-disease, anti-cancer or anti-
 CC leukaemia agents, or for decreasing the number of tumour or leukaemia
 CC cells in a patient, or in the manufacture of a medicament for the above
 CC mentioned purposes. The epitopes are useful for diagnosing and treating
 CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 CC diseases, cardiovascular diseases such as myocardial infarction,
 CC retinopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention

XX Sequence 97 AA;

Alignment Scores: Length: 97
 Pred. No.: 0.00375 Matches: 19
 Score: 92.40
 Percent Similarity: 74.07% Conservative: 1
 Best Local Similarity: 70.37% Mismatches: 1
 Query Match: 66.00% Indels: 6
 DB: 5 Gaps: 0

DELETED1 (1-81) x ABG91903 (1-97)

Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCGCTCTCTCAAGAGTCGGCGAGTCAG 60
 Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68

Qy 61 GATATTAGC 69

Db 69 ---IleSer 70

RESULT 11

ABO27107

ID ABO27107 standard; protein; 97 AA.

XX AC ABO27107;

XX 10-SEP-2003 (first entry)

XX Human germline heavy chain variable region gene segment #40.

XX Human; heavy chain variable region; VH; humanised antibody;
 KW chimeric antibody; complementarity determining region; CDR;
 KW canonical CDR structure type.

XX Homo sapiens.

XX US2003039649-A1.

XX 27-FEB-2003.

XX 12-JUL-2002; 2002US-00194975.

XX 12-JUL-2001; 2001US-0305111P.

XX (FOOT/) FOOTE J.

XX Foote J;

XX WPI; 2003-492151/46.

XX Making humanized antibody for converting antibody, by making chimeric
 PT antibodies containing complementarity determining region from non-human
 PT antibody and appropriate framework sequences of human antibodies.

XX Example 1; Fig 1; 31pp; English.

XX The invention describes a method of making a humanised antibody,
 CC comprising making chimeric antibodies containing a complementarity
 CC determining region (CDR) from a non-human antibody and appropriate
 CC framework sequences (I) of human antibodies. (I) is selected by using
 CC canonical CDR structure types of non-human antibody in comparison to
 CC germline canonical CDR structure types of human antibodies as the basis
 CC for selection, for humanisation. The method is useful for making a
 CC humanised antibody or a converted antibody. The method is applicable for
 CC converting a subject antibody sequence of any subject species to a less
 CC immunogenic form suitable for use in an object species. The method is
 CC reliable for identifying suitable human framework sequences to support
 CC non-human CDR regions and to provide humanised antibodies that retain
 CC high antigen binding with low immunogenicity in humans, without the need
 CC for direct comparison of framework sequences, without the need for
 CC determining critically important amino acid residues in the framework,
 CC and without the need for multiple iteration and construction to obtain
 CC humanised antibodies with suitable therapeutic properties. The antibody
 CC has high affinity and low immunogenicity without need for comparing
 CC framework sequences between non-human and human antibodies. This sequence
 CC represents a human heavy chain variable region gene segment used in the
 CC creation of humanised antibodies

XX Sequence 97 AA;

Alignment Scores:

Pred. No.:	0.00375	Length:	97
Score:	92.40	Matches:	19
Percent Similarity:	74.07%	Conservative:	1
Best Local Similarity:	70.37%	Mismatches:	1
Query Match:	66.00%	Indels:	6
DB:	6	Gaps:	0

DELETED1 (1-81) x ABO27107 (1-97)

Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCCGCTCTCTCAAGAGTCGGCGAGTCAG 60
 |||||
 50 GlulleAenHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
 : : :

Db 61 GATATTAGC 69
 |||||
 69 ---IleSer 70

RESULT 12

ADB75646

ID ADB75646 standard; protein; 97 AA.

XX ADB75646;

AC

XX 04-DEC-2003 (first entry)

DE Human protein relating to the invention SEQ ID NO:55.

DE antibody library; CD1 region; CD2 region; VH region; VL region;
 KW immunoglobulin; CD3 region; TW1 scFv; human.

XX Homo sapiens.

OS

XX WO2003044198-A1.

PN

XX 30-MAY-2003.

PD

XX 22-NOV-2002; 2002WO-JP012236.

PF

XX 22-NOV-2001; 2001JP-00358602.

PR

XX (UYKE-) UNIV KEIO.

PA

XX Shimizu N, Takayanagi A, Okui M;

PI

XX WPI; 2003-449818/42.

DR

XX Highly stable artificial antibody libraries with super-repository and

PT little contamination from unexpressible ones, useful as tool in
 PT proteomics and e.g. for diagnosis and treating various diseases.

XX Disclosure; Page 101; 108pp; Japanese.

PS

XX The invention relates to a novel artificial single-stranded antibody
 CC library with superior-repository. The library is created by using a cDNA
 CC library as template for amplifying a fragment containing the CD1 and CD2
 CC regions of the VH or VL region of immunoglobulin gene and a fragment
 CC containing the CD3 region by PCR, respectively, producing VH and VL
 CC libraries, transferring into a host, and displaying the single-stranded
 CC antibody on a phage surface. An antibody library of the invention is
 CC useful as a tool in proteomics and antibody chips and filters, for
 CC screening ligands for antigens, and for studying protein-DNA interaction,
 CC diagnosis and treating various diseases. The present sequence represents
 CC a protein of the invention.

XX Sequence 97 AA;

Alignment Scores:

Pred. No.:	0.00375	Length:	97
Score:	92.40	Matches:	19
Percent Similarity:	74.07%	Conservative:	1
Best Local Similarity:	70.37%	Mismatches:	1
Query Match:	66.00%	Indels:	6
DB:	7	Gaps:	0

DELETED1 (1-81) x ADB75646 (1-97)

Qy 1 GAATCAATCATAGTGGAGCACCACCACTACACCCGCTCTCTCAAGAGTCGGCGAGTCAG 60
 |||||
 50 GlulleAenHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
 : : :

Db 61 GATATTAGC 69
 |||||
 69 ---IleSer 70

RESULT 13

ADD28104

ID ADD28104 standard; protein; 97 AA.

XX ADD28104;

AC

XX 15-JAN-2004 (first entry)

DE Lymphoma related immunoglobulin variable region F5.

DE B-cell; malignant; immunoglobulin; immunoglobulin variable region;
 KW IG variable region; glycosylation site; lymphoma; B cell receptor;
 KW cytostatic; gene therapy; glycosylation inhibitor;
 KW non-Hodgkin's lymphoma.

XX Synthetic.

OS

XX Homo sapiens.

PN WO2003074059-A2.

XX

PD 12-SEP-2003.

XX

XX 24-FEB-2003; 2003WO-GB000783.

PF

XX 07-MAR-2002; 2002GB-00005395.

PR

XX (CANC-) CANCER RES TECHNOLOGY LTD.

PA

XX Zhu D, Stevenson F;

PI

XX WPI; 2003-902720/82.

DR

XX Classifying a B-cell as malignant or normal by isolating a sequence
 PT representing an Ig variable region from the B cell, detecting the
 PT presence of a glycosylation site and classifying the cell as malignant or
 PT normal.

Disclosure; Fig 4; 6ipp; English.

The present invention describes a method for classifying a B-cell as malignant or normal comprising: (a) isolating a sequence representing an immunoglobulin (Ig) variable region from the B cell; (b) detecting the presence of a glycosylation site; and (c) classifying the cell as malignant or normal on the basis of the presence or absence of a glycosylation site. Also described: (1) treating a patient suffering from or at risk of having lymphoma; (2) screening for substances capable of inhibiting glycosylation of the Ig variable region of the B cell receptor; and (3) screening for substances (S) capable of inhibiting the interaction between lectins of the type found in the germinal centre and N-glycans found on the surface of Ig of lymphoma cells. (S) has glycosylating activity, and can be used in gene therapy, and as a glycosylation inhibitor. The method is useful in classifying a B-cell as malignant or normal. The glycosylation inhibitor is useful in preparing a medicament for treating non-Hodgkin's lymphoma. The present sequence represents an Ig variable region sequence which is used in the exemplification of the present invention.

positions.

Example 6; Fig 16a; 135pp; English.

The present invention relates to a method for optimizing at least one physico-chemical property of an antibody by a computational screening method. The method comprises: receiving a template antibody structure; selecting at least one variable position belonging to the antibody structure; selecting at least one amino acid to be considered at the variable position(s); analyzing the interaction of each selected amino acid at each variable position with at least part of the remainder of the antibody, including the selected amino acids at other variable positions; and identifying a set of at least one antibody sequence with at least one optimized physico-chemical property. The method is useful for optimizing the physico-chemical properties of an antibody, especially the stability, solubility, or antigen binding affinity. The optimized antibody may be useful for treating a patient. The present sequence is an antibody variable region sequence used to illustrate the invention.

Sequence 97 AA:

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:25:09 ; Search time 30 Seconds

(without alignments)

403.105 Million cell updates/sec

Title: DELETED1

Perfect score: 140

Sequence: 1 GAATCAATCATAGTGGAG.....ATATTAGCAGCTGGTTAGCC 81

Scoring table:

BLOSUM62	Xgapop 10.0	Xgapext 0.1
	Ygapop 10.0	Ygapext 0.1
	Fgapop 6.0	Fgapext 0.1
	Delop 6.0	Delext 0.1

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 1027090

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO.spool.p/NOLAN463-3A/runat_04082005.120126.18820/app.query.fasta.1.263
-DB=Issued Patents AA -QFWT=fastan -SUFFIX=ra1 -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOLALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFWT=pct -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3A @CGN 1.1 46 @runat_04082005.120126.18820 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEX=0.1

Database :

Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/5A.COMB.pgp:*
2: /cgn2_6/ptodata/1/iaa/5B.COMB.pgp:*
3: /cgn2_6/ptodata/1/iaa/6A.COMB.pgp:*
4: /cgn2_6/ptodata/1/iaa/6B.COMB.pgp:*
5: /cgn2_6/ptodata/1/iaa/PTCUS.COMB.pgp:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pgp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	92.4	66.0	116	3	US-08-545-809A-118
2	92.4	66.0	123	3	US-08-793-450-4
3	92.4	66.0	139	4	US-09-203-768A-2
4	92.4	66.0	472	3	US-08-793-450-8
5	87.4	62.4	429	4	US-09-372-425A-6
6	84.4	60.3	118	3	US-09-025-769B-25
7	84.4	60.3	118	4	US-09-490-070A-25
8	84.4	60.3	118	4	US-09-490-153-25
9	84.4	60.3	118	4	US-09-490-324-25
10	81	57.9	120	3	US-08-545-809A-137
11	80.7	57.6	130	3	US-08-466-151-5
12	80.7	57.6	130	3	US-08-466-163B-5

13	80.7	57.6	130	4	US-09-802-096-5	Sequence 5, Appli
14	80.7	57.6	130	4	US-09-802-077-5	Sequence 5, Appli
15	79.4	56.7	147	4	US-09-471-276-835	Sequence 835, App
16	79.4	56.7	447	4	US-09-372-425A-2	Sequence 2, Appli
17	77	55.0	119	2	US-08-428-197-16	Sequence 16, Appl
18	77	55.0	119	5	PCT-US93-10555-16	Sequence 16, Appl
19	76.4	54.6	112	3	US-09-344-587-14	Sequence 14, Appl
20	75.9	54.6	118	2	US-08-652-816A-13	Sequence 13, Appl
21	74.4	53.1	120	4	US-09-424-840B-20	Sequence 20, Appl
22	73.4	52.4	21	3	US-08-918-148-45	Sequence 45, Appl
23	73.4	52.4	21	4	US-09-138-091A-45	Sequence 45, Appl
24	73.4	52.4	76	3	US-08-851-362D-22	Sequence 22, Appl
25	73.4	52.4	96	3	US-08-851-362D-35	Sequence 35, Appl
26	73.4	52.4	116	3	US-08-545-809A-140	Sequence 140, App
27	73.4	52.4	117	3	US-08-851-362D-48	Sequence 48, Appl
28	73.4	52.4	118	3	US-08-545-809A-142	Sequence 142, App
29	73.4	52.4	119	3	US-09-025-769B-39	Sequence 39, Appl
30	73.4	52.4	119	3	US-09-025-769B-65	Sequence 65, Appl
31	73.4	52.4	119	4	US-09-490-070A-39	Sequence 39, Appl
32	73.4	52.4	119	4	US-09-490-070A-65	Sequence 65, Appl
33	73.4	52.4	119	4	US-09-490-153-39	Sequence 39, Appl
34	73.4	52.4	119	4	US-09-490-153-65	Sequence 65, Appl
35	73.4	52.4	119	4	US-09-490-324-39	Sequence 39, Appl
36	73.4	52.4	119	4	US-09-490-324-65	Sequence 65, Appl
37	73.4	52.4	139	4	US-09-471-276-837	Sequence 837, App
38	73.4	52.4	244	3	US-08-918-148-79	Sequence 79, Appl
39	73.4	52.4	244	4	US-09-138-091A-77	Sequence 77, Appl
40	73	52.1	100	4	US-09-726-219A-169	Sequence 169, App
41	72.4	51.7	140	4	US-09-471-276-850	Sequence 850, App
42	72.4	51.7	240	2	US-07-956-399-2	Sequence 2, Appli
43	72	51.4	95	4	US-09-471-276-882	Sequence 882, App
44	72	51.4	116	3	US-08-545-809A-92	Sequence 92, Appl
45	72	51.4	119	3	US-08-767-128-18	Sequence 18, Appl

ALIGNMENTS

RESULT 1

US-08-545-809A-118
; Sequence 118, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545.809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154

```
; INFORMATION FOR SEQ ID NO: 118:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-118

Alignment Scores:
Pred. No.: 0.000397 Length: 116
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 3 Gaps: 0

DELETED1 (1-81) x US-08-545-809A-118 (1-116)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTCTCTCAAGAGTCGGCGAGTCAG 60
Db 69 GlulleasnHisSerGlySerThrAsnTyraSnProSerLeuLysSerArgValThr --- 87

Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 2
US-08-793-450-4
; Sequence 4, Application US/08793450
; Patent No. 6312690
; GENERAL INFORMATION:
; APPLICANT: EDELMAN, LENA
; APPLICANT: MARGARITE, CHRISTEL
; APPLICANT: KACZOREK, MICHEL
; APPLICANT: CHAABIHI, HASSAN
; TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
; TITLE OF INVENTION: of Use
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/793.450
; FILING DATE: 03-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 94/10566
; FILING DATE: 02-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 660-118-0 PCT
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-793-450-4
```

```
Alignment Scores:
Pred. No.: 0.000405 Length: 123
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 3 Gaps: 0

DELETED1 (1-81) x US-08-793-450-4 (1-123)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleasnHisSerGlySerThrAsnTyraSnProSerLeuLysSerArgValThr --- 68

Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 3
US-09-203-768A-2
; Sequence 2, Application US/09203768A
; Patent No. 6787638
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; TITLE OF INVENTION: of Use
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/09/203.768A
; CURRENT FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 2
; LENGTH: 139
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-203-768A-2

Alignment Scores:
Pred. No.: 0.000423 Length: 139
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 4 Gaps: 0

DELETED1 (1-81) x US-09-203-768A-2 (1-139)

Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTCTCTCAAGAGTCGGCGAGTCAG 60
Db 69 GlulleasnHisSerGlySerThrAsnTyraSnProSerLeuLysSerArgValThr --- 87

Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 4
US-08-793-450-8
; Sequence 8, Application US/08793450
; Patent No. 6312690
; GENERAL INFORMATION:
; APPLICANT: EDELMAN, LENA
; APPLICANT: MARGARITE, CHRISTEL
; APPLICANT: KACZOREK, MICHEL
; APPLICANT: CHAABIHI, HASSAN
; TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
```



```
;
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-25

Alignment Scores:
Pred. No.: 0.0049 Length: 118
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 3 Gaps: 0

DELETED1 (1-81) x US-09-025-769B-25 (1-118)
Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileTyHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 7
US-09-490-070A-25
; Sequence 25, Application US/09490070A
; Patent No. 6596248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
```

```
;
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-070A-25

Alignment Scores:
Pred. No.: 0.0049 Length: 118
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 4 Gaps: 0

DELETED1 (1-81) x US-09-490-070A-25 (1-118)
Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluileTyHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 8
US-09-490-153-25
; Sequence 25, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-153-25
```


Alignment Scores:
Pred. No.: 0.0049 Length: 118
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 4 Gaps: 0

DELETED1 (1-81) x US-09-490-153-25 (1-118)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 50 GlulleTyHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
|||

Qy 61 GATATTAGC 69
|||||
Db 69 ---lleSer 70
|||

RESULT 9

US-09-490-324-25
; Sequence 25, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-324-25

Alignment Scores:
Pred. No.: 0.0049 Length: 118
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2

Query Match: 60.29% Indels: 6
DB: 4 Gaps: 0

DELETED1 (1-81) x US-09-490-324-25 (1-118)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 50 GlulleTyHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
|||

Qy 61 GATATTAGC 69
|||||
Db 69 ---lleSer 70
|||

RESULT 10

US-08-545-809A-137
; Sequence 137, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 137:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-545-809A-137

Alignment Scores:
Pred. No.: 0.0143 Length: 120
Score: 81.00 Matches: 15
Percent Similarity: 79.17% Conservative: 4
Best Local Similarity: 62.50% Mismatches: 5
Query Match: 57.86% Indels: 0
DB: 3 Gaps: 0

DELETED1 (1-81) x US-08-545-809A-137 (1-120)

Qy 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
|||||
Db 69 GlulleHisSerGlySerThrTyrrAsnProSerLeuLysSerArglleThrMet 88
|||

Qy 61 GATATTAGC 72
|||

Db 89 SerValAspThr 92

RESULT 11

US-08-466-151-5

; Sequence 5, Application US/08466151

; Patent No. 6037453

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Immunoglobulin Variants

; NUMBER OF SEQUENCES: 65

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 1 DNA Way

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatIn (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/466.151

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/466163

; FILING DATE: 06-Jun-1995

; APPLICATION NUMBER: 08/405617

; FILING DATE: 15-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/185899

; FILING DATE: 26-JAN-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/879495

; FILING DATE: 07-MAY-1992

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/744768

; FILING DATE: 14-AUG-1991

; ATTORNEY/AGENT INFORMATION:

; NAME: Svoboda, Craig G.

; REGISTRATION NUMBER: 39,044

; REFERENCE/DOCKET NUMBER: P0718P2C1D1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650/225-1489

; TELEFAX: 650/952-9881

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 130 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

US-08-466-151-5

Alignment Scores:

Pred. No.:	0.0162	Length:	130
Score:	80.70	Matches:	18
Percent Similarity:	47.92%	Conservative:	5
Best Local Similarity:	37.50%	Mismatches:	2
Query Match:	57.64%	Indels:	23
DB:	3	Gaps:	2

DELETED1 (1-81) x US-08-466-151-5 (1-130)

Qy 4 ATCAATCATAGTGGAGACCACTACACCGTCTCTCAAGAGTCGGCGAGT----- 57

Db 52 IleAsnHisSerGlyThrSerTyAsnProSerLeuLysSerArgIleSerIleThr 71

Qy 58 CAGGATATTAGC----- 69

Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91

Qy 70 -----AGCTGGTTA 78

Db 92 AlaThrTyrtYrCysAlaTrpVal 99

RESULT 12

US-08-466-163B-5

; Sequence 5, Application US/08466163B

; Patent No. 6329509

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Immunoglobulin Variants

; FILE REFERENCE: P0718P2C1D1

; CURRENT APPLICATION NUMBER: US/08/466.163B

; CURRENT FILING DATE: 1995-06-06

; PRIOR APPLICATION NUMBER: US 08/405,617

; PRIOR FILING DATE: 1995-03-15

; PRIOR APPLICATION NUMBER: US 08/185,899

; PRIOR FILING DATE: 1994-01-26

; PRIOR APPLICATION NUMBER: US 07/879,495

; PRIOR FILING DATE: 1992-05-07

; PRIOR APPLICATION NUMBER: US 07/744,768

; PRIOR FILING DATE: 1991-08-14

; NUMBER OF SEQ ID NOS: 64

; SEQ ID NO 5

; LENGTH: 130

; TYPE: PRT

; ORGANISM: Mus musculus

US-08-466-163B-5

Alignment Scores:

Pred. No.:	0.0162	Length:	130
Score:	80.70	Matches:	18
Percent Similarity:	47.92%	Conservative:	5
Best Local Similarity:	37.50%	Mismatches:	2
Query Match:	57.64%	Indels:	23
DB:	3	Gaps:	2

DELETED1 (1-81) x US-08-466-163B-5 (1-130)

Qy 4 ATCAATCATAGTGGAGACCACTACACCGTCTCTCAAGAGTCGGCGAGT----- 57

Db 52 IleAsnHisSerGlyThrSerTyAsnProSerLeuLysSerArgIleSerIleThr 71

Qy 58 CAGGATATTAGC----- 69

Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAsnSerValThrThrGluAspThr 91

Qy 70 -----AGCTGGTTA 78

Db 92 AlaThrTyrtYrCysAlaTrpVal 99

RESULT 13

US-09-802-096-5

; Sequence 5, Application US/09802096

; Patent No. 6685939

; GENERAL INFORMATION:

; APPLICANT: Jardieu, Paula M.

; APPLICANT: Presta, Leonard G.

; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)

; FILE REFERENCE: P0718P2C3US

; CURRENT APPLICATION NUMBER: US/09/802,096

; CURRENT FILING DATE: 2001-03-08

; PRIOR APPLICATION NUMBER: US 08/405,617

; PRIOR FILING DATE: 1995-03-15

; PRIOR APPLICATION NUMBER: US 08/185,899

; PRIOR FILING DATE: 1994-01-26

; PRIOR APPLICATION NUMBER: PCT/US92/06860

; PRIOR FILING DATE: 1992-08-14

; PRIOR APPLICATION NUMBER: US 07/879,495

; PRIOR FILING DATE: 1992-05-07

; PRIOR APPLICATION NUMBER: US 07/744,768

; PRIOR FILING DATE: 1991-08-14

```
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.0162 Length: 130
Score: 80.70 Matches: 18
Percent Similarity: 47.92% Conservative: 5
Best Local Similarity: 37.50% Mismatches: 2
Query Match: 57.64% Indels: 23
DB: 4 Gaps: 2

DELETED1 (1-81) x US-09-802-096-5 (1-130)
QY 4 ATCAATCATAGTGGAGCACCACCACTACACCGGTCTCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrSerTyrAsnProSerLeuLysSerArgIleSerIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAenSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyrTyrCysAlaTrpVal 99

RESULT 14
US-09-802-077-5
; Sequence 5, Application US/09802077
; Patent No. 6699472
; GENERAL INFORMATION:
; APPLICANT: Jardiou, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Treating Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C2US
; CURRENT APPLICATION NUMBER: US/09/802,077
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-077-5

Alignment Scores:
Pred. No.: 0.0162 Length: 130
Score: 80.70 Matches: 18
Percent Similarity: 47.92% Conservative: 5
Best Local Similarity: 37.50% Mismatches: 2
Query Match: 57.64% Indels: 23
DB: 4 Gaps: 2

DELETED1 (1-81) x US-09-802-077-5 (1-130)
QY 4 ATCAATCATAGTGGAGCACCACCACTACACCGGTCTCTCAAGAGTCGGCGAGT----- 57
Db 52 IleAsnHisSerGlyThrSerTyrAsnProSerLeuLysSerArgIleSerIleThr 71
QY 58 CAGGATATTAGC----- 69
Db 72 ArgAspThrSerLysAsnGlnPhePheLeuGlnLeuAenSerValThrThrGluAspThr 91
QY 70 -----AGCTGGTTA 78
Db 92 AlaThrTyrTyrCysAlaTrpVal 99

RESULT 15
US-09-471-276-835
; Sequence 835, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CPI
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 835
; LENGTH: 147
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -26...-1
US-09-471-276-835

Alignment Scores:
Pred. No.: 0.0254 Length: 147
Score: 79.40 Matches: 16
Percent Similarity: 66.67% Conservative: 2
Best Local Similarity: 59.26% Mismatches: 3
Query Match: 56.71% Indels: 6
DB: 4 Gaps: 0

DELETED1 (1-81) x US-09-471-276-835 (1-147)
QY 1 GAATCATCATAGTGGAGCACCACCACTACACCGGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 77 GlutAspHisGlyGlyAsnThrAsnTyrAsnProSerLeuLysSerArgVal****- 95
QY 61 GATATTAGC 69
Db 96 ---IleSer 97

Search completed: August 4, 2005, 19:39:59
Job time : 32 secs
```

THIS PAGE BLANK (USE)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model
Run on: August 4, 2005, 19:38:05 ; Search time 105 Seconds
(without alignments)
602.328 Million cell updates/sec

Title: DELETED1
Perfect score: 140
Sequence: 1 GAAATCAATCATAGTGAAG.....ATATTAGCAGCTGTTAGCC 81

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 3505720

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/NOLAN463-3A/runat_04082005_120128_18886/app_query.fasta_1.263
-DB=Published_Applications_AA -GPM=fastan -SUFFIX=rapb -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=Dblowm62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100
-THR MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0
-MAXLEN=200000000 -USER=NOLAN463-3A @CGN 1.1.199 @runat_04082005_120128_18886
-NCPU=6 -ICPU=3 -NO MAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100
-LONGLOG -DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1
-FGAPOP=6 -FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Published Applications AA:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	113.1	80.8	249	10	US-09-880-748-1321 Sequence 1321, Ap
2	113.1	80.8	249	15	US-10-293-418-1321 Sequence 1321, Ap
3	96.4	68.9	115	17	US-10-898-408-12 Sequence 12, Appl
4	93.8	67.0	250	10	US-09-880-748-993 Sequence 993, App
5	93.8	67.0	250	15	US-10-293-418-993 Sequence 993, App
6	93.8	67.0	253	10	US-09-880-748-954 Sequence 954, App
7	93.8	67.0	253	15	US-10-293-418-954 Sequence 954, App
8	92.4	66.0	80	14	US-10-078-958-2 Sequence 2, Appli
9	92.4	66.0	97	14	US-10-194-375-40 Sequence 40, Appl
10	92.4	66.0	97	15	US-10-308-817-83 Sequence 83, Appl
11	92.4	66.0	97	15	US-10-032-037B-87 Sequence 87, Appl
12	92.4	66.0	97	15	US-10-029-988B-87 Sequence 87, Appl
13	92.4	66.0	97	15	US-10-032-423A-87 Sequence 87, Appl
14	92.4	66.0	97	15	US-10-453-698-83 Sequence 83, Appl
15	92.4	66.0	97	15	US-10-029-926B-87 Sequence 87, Appl
16	92.4	66.0	97	16	US-10-379-392-47 Sequence 47, Appl
17	92.4	66.0	114	17	US-10-733-532-128 Sequence 128, App
18	92.4	66.0	117	9	US-09-864-761-44315 Sequence 44315, A
19	92.4	66.0	118	15	US-10-371-942-90 Sequence 90, Appl
20	92.4	66.0	118	17	US-10-893-576-192 Sequence 192, App
21	92.4	66.0	122	15	US-10-360-828-63 Sequence 63, Appl
22	92.4	66.0	125	15	US-10-371-942-110 Sequence 110, App
23	92.4	66.0	125	15	US-10-371-942-118 Sequence 118, App
24	92.4	66.0	139	14	US-10-300-675-2 Sequence 2, Appli
25	92.4	66.0	139	17	US-10-910-124-2 Sequence 2, Appli
26	92.4	66.0	139	17	US-10-893-576-43 Sequence 43, Appl
27	92.4	66.0	142	17	US-10-484-790A-10 Sequence 10, Appl
28	92.4	66.0	223	10	US-09-972-656-66 Sequence 66, Appl
29	92.4	66.0	229	10	US-09-972-656-82 Sequence 82, Appl
30	92.4	66.0	230	10	US-09-972-656-72 Sequence 72, Appl
31	92.4	66.0	249	10	US-09-880-748-957 Sequence 957, App
32	92.4	66.0	249	15	US-10-293-418-957 Sequence 957, App
33	92.4	66.0	250	10	US-09-880-748-1413 Sequence 1413, Ap
34	92.4	66.0	253	15	US-10-293-418-1413 Sequence 1413, Ap
35	92.4	66.0	253	10	US-09-880-748-1333 Sequence 1333, Ap
36	92.4	66.0	253	15	US-10-293-418-1333 Sequence 1333, Ap
37	92.4	66.0	254	10	US-09-880-748-1659 Sequence 1659, Ap
38	92.4	66.0	254	15	US-10-293-418-1659 Sequence 1659, Ap
39	92.4	66.0	450	17	US-10-484-790A-17 Sequence 17, Appl
40	92.4	66.0	453	17	US-10-484-790A-18 Sequence 18, Appl
41	90.4	64.6	246	10	US-09-880-748-1847 Sequence 1847, Ap
42	90.4	64.6	246	15	US-10-293-418-1847 Sequence 1847, Ap
43	90.3	64.5	123	14	US-10-269-805-31 Sequence 31, Appl
44	90.3	64.5	123	14	US-10-269-805-55 Sequence 55, Appl
45	88.4	63.1	255	10	US-09-880-748-1642 Sequence 1642, Ap

ALIGNMENTS

RESULT 1
US-09-880-748-1321
; Sequence 1321, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25

```
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1321
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1321

Alignment Scores:
Pred. No.:      2.81e-05      Length:      249
Score:          113.10      Matches:      26
Percent Similarity: 20.63%      Conservative: 0
Best Local Similarity: 20.63%      Mismatches: 1
Query Match:      80.79%      Indels:      99
DB:              15          Gaps:      1

DELETED1 (1-81) x US-09-880-748-1321 (1-249)
Qy  1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGCTCTCTCAAGAGT----- 48
Db  50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrIle 69
Qy  48 ----- 48
Db  70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
Qy  48 ----- 48
Db  90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
Qy  48 ----- 48
Db  110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGly 129
Qy  48 ----- 48
Db  130 GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerAspIleValMetThrGlnSerPro 149
Qy  49 -----CGGGCGAGTCAGGAT 63
Db  150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
Qy  64 ATTAGCAGCTGGTTAGCC 81
Db  170 IleSerSerTrpLeuAla 175

RESULT 2
US-10-293-418-1321
; Sequence 1321, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunoespecifically Bind Blys
; FILE REFERENCE: PFS23P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247

; SEQ ID NO 1321
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1321

Alignment Scores:
Pred. No.:      2.81e-05      Length:      249
Score:          113.10      Matches:      26
Percent Similarity: 20.63%      Conservative: 0
Best Local Similarity: 20.63%      Mismatches: 1
Query Match:      80.79%      Indels:      99
DB:              15          Gaps:      1

DELETED1 (1-81) x US-10-293-418-1321 (1-249)
Qy  1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGCTCTCTCAAGAGT----- 48
Db  50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrIle 69
Qy  48 ----- 48
Db  70 SerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAsp 89
Qy  48 ----- 48
Db  90 ThrAlaValTyrTyrCysAlaArgGlyProArgTyrTyrAspIleLeuThrGlyTyrArg 109
Qy  48 ----- 48
Db  110 TyrAsnTrpPheAspProTrpGlyArgGlyThrLeuValThrValSerSerGlyGly 129
Qy  48 ----- 48
Db  130 GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerAspIleValMetThrGlnSerPro 149
Qy  49 -----CGGGCGAGTCAGGAT 63
Db  150 SerThrLeuSerAlaSerValGlyAspArgValThrIleThrCysArgAlaSerGlnGly 169
Qy  64 ATTAGCAGCTGGTTAGCC 81
Db  170 IleSerSerTrpLeuAla 175

RESULT 3
US-10-898-408-12
; Sequence 12, Application US/10898408
; Publication No. US20050058642A1
; GENERAL INFORMATION:
; APPLICANT: GALIBERT, Laurent J.
; APPLICANT: YAN, Wei
; TITLE OF INVENTION: ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE
; FILE REFERENCE: 3467-A
; CURRENT APPLICATION NUMBER: US/10/898,408
; CURRENT FILING DATE: 2004-07-23
; PRIOR APPLICATION NUMBER: 60/490,027
; PRIOR FILING DATE: 2003-07-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 115
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-898-408-12

Alignment Scores:
Pred. No.:      0.00314      Length:      115
Score:          96.40      Matches:      19
Percent Similarity: 41.18%      Conservative: 2
Best Local Similarity: 37.25%      Mismatches: 4
Query Match:      68.86%      Indels:      26
DB:              17          Gaps:      1
```

```

DELETED1 (1-81) x US-10-898-408-12 (1-115)

Qy 1 GAAATCAATCATAGTGGAGCACCACCGTCTCTCAAGAGTCGGCGAGTCAG 60
    |||||
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrMet 69
    |||||
Qy 61 GATATTAGC----- 69
    |||||
Db 70 SerValAspThrSerLysAsnGlnPheSerLeuArgLeuAsnSerValThrAlaAlaAsp 89
    |||||
Qy 70 -----AGCTGG 75
    |||||
Db 90 ThrAlaValTyrTyrCysAlaArgValSerTrp 100
    |||||

RESULT 4
US-09-880-748-993
; Sequence 993, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 993
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-993

Alignment Scores:
Pred. No.: 0.00772 Length: 250
Score: 93.80 Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00% Indels: 2
DB: 10 Gaps: 1

DELETED1 (1-81) x US-09-880-748-993 (1-250)

Qy 1 GAAATCAATCATAGTGGAGCACCACCGTCTCTCAAGAGTCGGCG----- 54
    |||||
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrile 69
    |||||
Qy 55 AGTCAGGATATTAGCAGC 72
    |||||
Db 70 SerGlnAspThrSerAsn 75
    |||||

RESULT 5
US-09-880-748-954
; Sequence 954, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 954
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-954

Alignment Scores:
Pred. No.: 0.00774 Length: 253
Score: 93.80 Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00% Indels: 2
DB: 10 Gaps: 1

DELETED1 (1-81) x US-10-293-418-993 (1-250)

Qy 1 GAAATCAATCATAGTGGAGCACCACCGTCTCTCAAGAGTCGGCG----- 54
    |||||
Db 50 GluileAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThrile 69
    |||||
Qy 55 AGTCAGGATATTAGCAGC 72
    |||||
Db 70 SerGlnAspThrSerAsn 75
    |||||

RESULT 5
US-10-293-418-993
; Sequence 993, Application US/10293418
; Publication No. US2003023396A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817

```

```
DELETED1 (1-81) x US-09-880-748-954 (1-253)
Qy 1 GAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGGCG----- 54
Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
Qy 55 AGTCAGGATATTAGCAGC 72
Db 70 SerGlnAspThrSerAsn 75

RESULT 7
US-10-293-418-954
; Sequence 954, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 954
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-954

Alignment Scores:
Pred. No.: 0.00774 Length: 253
Score: 93.80 Matches: 20
Percent Similarity: 80.77% Conservative: 1
Best Local Similarity: 76.92% Mismatches: 3
Query Match: 67.00% Indels: 2
DB: 15 Gaps: 1

DELETED1 (1-81) x US-10-293-418-954 (1-253)
Qy 1 GAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGGCG----- 54
Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThrIle 69
Qy 55 AGTCAGGATATTAGCAGC 72
Db 70 SerGlnAspThrSerAsn 75

RESULT 8
US-10-078-958-2
; Sequence 2, Application US/10078958
; Publication No. US20030070185A1
; GENERAL INFORMATION:
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: KLAPHOLZ, SUSAN
; APPLICANT: MENDEZ, MICHAEL J.
; APPLICANT: GREEN, LARRY
; TITLE OF INVENTION: TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING
```

```
; TITLE OF INVENTION: PLURAL Vh AND Vk REGIONS AND ANTIBODIES PRODUCED
; TITLE OF INVENTION: THEREFROM
; FILE REFERENCE: CELL 4.18 CON
; CURRENT APPLICATION NUMBER: US/10/078,958
; CURRENT FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: 08/759,620
; PRIOR FILING DATE: 1996-12-03
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-078-958-2

Alignment Scores:
Pred. No.: 0.0094 Length: 80
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 14 Gaps: 0

DELETED1 (1-81) x US-10-078-958-2 (1-80)
Qy 1 GAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGGCGAGTCAG 60
Db 33 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThr--- 51
Qy 61 GATATTAGC 69
Db 52 ---IleSer 53

RESULT 9
US-10-194-975-40
; Sequence 40, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-40

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 14 Gaps: 0

DELETED1 (1-81) x US-10-194-975-40 (1-97)
Qy 1 GAATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuAsnSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 10
US-10-308-817-83
```


; Sequence 83, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-308-817-83

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

DELETED1 (1-81) x US-10-308-817-83 (1-97)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGCTCTCTCAAGAGTCGGCGGAGTCAG 60
|||||
Db 50 GlulleAsnHisSerGlySerThrAsnTyraProSerLeuLysSerArgValThr--- 68
:::

QY 61 GATATTAGC 69

Db 69 ---lleSer 70

RESULT 11

US-10-032-037B-87

; Sequence 87, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-87

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

DELETED1 (1-81) x US-10-032-037B-87 (1-97)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGCTCTCTCAAGAGTCGGCGGAGTCAG 60
|||||
Db 50 GlulleAsnHisSerGlySerThrAsnTyraProSerLeuLysSerArgValThr--- 68
:::

QY 61 GATATTAGC 69

Db 69 ---lleSer 70

RESULT 12

US-10-029-988B-87
; Sequence 87, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-87

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

DELETED1 (1-81) x US-10-029-988B-87 (1-97)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGCTCTCTCAAGAGTCGGCGGAGTCAG 60
|||||

Db 50 GlulleAsnHisSerGlySerThrAsnTyraProSerLeuLysSerArgValThr--- 68
:::

QY 61 GATATTAGC 69

Db 69 ---lleSer 70

RESULT 13

US-10-032-423A-87

; Sequence 87, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-87

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

DELETED1 (1-81) x US-10-032-423A-87 (1-97)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACAAACCGCTCTCTCAAGAGTCGGCGGAGTCAG 60
|||||

Db 50 GluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 14

US-10-453-698-83
; Sequence 83, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-453-698-83

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

DELETED1 (1-81) x US-10-453-698-83 (1-97)

Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 15

US-10-029-926B-87
; Sequence 87, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-87

Alignment Scores:
Pred. No.: 0.00974 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 15 Gaps: 0

DELETED1 (1-81) x US-10-029-926B-87 (1-97)

Qy 1 GAAATCAATCATAGTGAAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGTCAG 60

Db 50 GluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

Search completed: August 4, 2005, 19:56:40
Job time : 107 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:22:55 ; Search time 26 Seconds
(without alignments)
599.504 Million cell updates/sec

Title: DELETED1
Perfect score: 140
Sequence: 1 GAATCAATCATAGTGGAG.....ATATTAGCAGCTGTTAGCC 81

Scoring table: BLOSUM62
Xgapop 10.0, Xgapext 0.1
Ygapop 10.0, Ygapext 0.1
Fgapop 6.0, Fgapext 0.1
Delop 6.0, Delext 0.1

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 566832

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+n2p.model -DEV=xlp
-Q=/csm2_1/USPTO spool_p/NOLAN463-3A/runat_04082005_120125_18808/app_query.fasta_1.263
-DB=PIR -QFMT=FASTA -SUFFIX=rpr -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORES=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3A @CGN 1 1 63 @runat_04082005_120125_18808 -NCPU=6 -ICPU=3
-NO.MMAP -LARGQUERY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : PIR 79:.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES			
Result No.	Score	Query Match Length DB ID	Description
1	94	67.1 97 2	S26806 Ig heavy chain V r
2	93.9	67.1 140 2	S78052 Ig heavy chain pre
3	92.4	66.0 97 2	S26898 Ig heavy chain V r
4	92.4	66.0 97 2	S26805 Ig heavy chain V r
5	92.4	66.0 106 2	S37454 Ig mu chain - huma
6	92.4	66.0 122 2	J10047 Ig heavy chain V r
7	92.4	66.0 126 2	S47010 Ig heavy chain V4
8	92.4	66.0 133 2	P80341 Ig heavy chain V-D
9	92.4	66.0 140 2	A49045 Ig heavy chain V r
10	92.4	66.0 143 2	B49028 Ig heavy chain V-I
11	92.4	66.0 231 2	B23746 Ig Fab region IV-J
12	88.4	63.1 97 2	G34964 Ig heavy chain V-I
13	84.4	60.3 98 2	S26905 Ig heavy chain V r
14	83.4	59.6 97 2	S14474 Ig heavy chain V r

15	81.4	58.1	129	2	S44114	Ig heavy chain V r
16	80.4	57.4	134	2	S54906	Ig heavy chain V r
17	80	57.1	123	2	S30529	Ig heavy chain V r
18	79.1	56.5	140	2	I37782	Ig variable region
19	78.4	56.0	98	2	S26904	Ig heavy chain V r
20	78.4	56.0	145	2	S78055	Ig heavy chain pre
21	78.4	56.0	146	1	GIHUH2	Ig heavy chain pre
22	77.4	55.3	114	2	I72667	cold agglutinin FS
23	77.3	55.2	130	2	S31673	Ig heavy chain V r
24	77	55.0	134	2	B24672	Ig heavy chain pre
25	75.4	53.9	97	2	JH0428	Ig gamma chain V r
26	74.4	53.1	106	2	S26464	Ig heavy chain V r
27	74	52.9	116	2	S38718	Ig heavy chain V r
28	73.4	52.4	97	2	S26906	Ig heavy chain V r
29	73.4	52.4	97	2	S12416	Ig heavy chain V r
30	73.4	52.4	99	2	S12412	Ig heavy chain V r
31	73.4	52.4	105	2	S44125	Ig lambda chain V
32	73.4	52.4	116	2	B26340	Ig heavy chain pre
33	73.4	52.4	118	2	A26340	Ig heavy chain pre
34	73.4	52.4	130	2	S31690	Ig heavy chain V r
35	73.1	52.2	127	2	S19668	Ig heavy chain V r
36	72	51.4	97	2	S26804	Ig heavy chain V r
37	72	51.4	97	2	S26808	Ig heavy chain V r
38	72	51.4	116	2	S18557	Ig heavy chain V r
39	72	51.4	137	2	S31676	Ig heavy chain V r
40	72	51.4	139	2	S31696	Ig heavy chain V r
41	72	51.4	139	2	S31586	Ig heavy chain V r
42	71.5	51.1	109	2	PH1673	Ig heavy chain V r
43	71.4	51.0	97	2	PL0118	Ig heavy chain V-I
44	71.4	51.0	98	2	S26902	Ig heavy chain V r
45	71.4	51.0	98	2	S12421	Ig heavy chain V r

ALIGNMENTS

RESULT 1

S26806
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26806
R:Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A:Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A:Reference number: S26800; MUID:92201299; PMID:1348029
A:Accession: S26806
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-97 <WEN>
A:Cross-references: EMBL:Z14242; NID:G37716; PIDN:CAA78611.1; PID:G1335377
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
P:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000731 Length: 97
Score: 94.00 Matches: 17
Percent Similarity: 83.33% Conservative: 3
Best Local Similarity: 70.83% Mismatches: 4
Query Match: 67.14% Indels: 0
DB: 2 Gaps: 0

DELETED1 (1-81) x S26806 (1-97)

Qy	1	GAATCAATCATAGTGGAGCCCACTACACCCGCTCTCAAGAGTCGGCGAGTCAG 60
Db	50	GlulileAsnHisSerGlySerThrAsnTyAsnProSerLeuIysSerArgIleThrMet 69
Qy	61	GATATTAGCAGC 72
Db	70	SerValAspThr 73

RESULT 2

S78052
Ig heavy chain precursor V-D-J region (clone mAB 63VH) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78052; S23717
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78052
A:Molecule type: mRNA
A:Residues: 1-140 <HAW>
A:Cross-references: EMBL:X5441; NID:G37815; PIDN:CAA38308.1; PID:G930118
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Burastero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and H
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23717
A:Molecule type: mRNA
A:Residues: 15-111 <HAW>
A:Cross-references: EMBL:X5441
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F:15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:29-111/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000771 Length: 140
Score: 93.90 Matches: 21
Percent Similarity: 33.85% Conservative: 1
Best Local Similarity: 32.31% Mismatches: 2
Query Match: 67.07% Indels: 41
DB: 2 Gaps: 1

DELETED1 (1-81) x S78052 (1-140)

Qy 1 GAATCATCATAGTGGAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 64 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 82
:::
Qy 61 GATATTAGC----- 69
Db 83 ---lleSerValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAla 101
Qy 70 -----AGCTGG 75
|||
Db 102 AlaaSpThrAlaValTyrTyrCysAlaArgGlyGlySerValLeuArgPheLeuGluTrp 121
Qy 76 TTA 78
|||
Db 122 Leu 122

RESULT 3
S26898
Ig heavy chain V region (clone DP-63, V(H)4.2) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S26898; S12420
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26898
A:Molecule type: DNA
A:Residues: 1-97 <TOM>
A:Cross-references: EMBL:Z12363; NID:G32944; PIDN:CAA78233.1; PID:G32945
R:Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A:Title: The smaller human V(H) gene families display remarkably little polymorphism.
A:Reference number: S09421; MUID:90059975; PMID:2511001
A:Accession: S12420

A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-97 <SAN>
A:Cross-references: EMBL:X56364
C:Experimental source: V(H)4.2
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00119 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S26898 (1-97)

Qy 1 GAATCATCATAGTGGAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
:::
Qy 61 GATATTAGC 69
Db 69 ---lleSer 70

RESULT 4
S26805
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26805
R:Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A:Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A:Reference number: S26800; MUID:92201299; PMID:1348029
A:Accession: S26805
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-97 <WEN>
A:Cross-references: EMBL:Z14241; NID:G37714; PIDN:CAA78610.1; PID:G1335376
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00119 Length: 97
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S26805 (1-97)

Qy 1 GAATCATCATAGTGGAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
:::
Qy 61 GATATTAGC 69
Db 69 ---lleSer 70

RESULT 5
S37454
Ig mu chain - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
C:Accession: S37454
R:McIntosh, R.S.; Tandon, N.; Weetman, A.P.
submitted to the EMBL Data Library, September 1993
A:Description: Cloning and analysis of human IgM anti-Thyroglobulin autoantibodies from

A:Reference number: S37453
A:Accession: S37454
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-106 <NC1>
A:Cross-references: EMBL:X75022; NID:G404311; PIDN:CAA52930.1; PID:G758093
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin

Alignment Scores:
Pred. No.: 0.0012 Length: 106
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S37454 (1-106)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACACCCGCTCTCTCAAGAGTCGGCGAGTCAG 60
Db 28 GlulleAenHisSerGlySerThrAsnTyraenProSerLeuLysSerArgValThr--- 46
:::

QY 61 GATATTAGC 69

Db 47 ---IleSer 48

RESULT 6

JL0047
Ig heavy chain V region precursor (clone cR18) - human
C:Species: Homo sapiens (man)
C:Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 16-Aug-1996
C:Accession: JL0047
R:Baer, R.; Forster, A.; Laveniz, I.; Rabbitts, T.H.
J. Exp. Med. 167, 2011-2016, 1988
A:Title: Immunoglobulin V-H genes are transcribed by T cells in association with a new 5
A:Reference number: JL0047; MUID:88258392; PMID:3133445
A:Accession: JL0047
A:Molecule type: mRNA
A:Residues: 1-122 <BAE>
A:Experimental source: T-cell line RPMI 8402
A>Note: the authors translated the reading frame which extends to the stop codon; the se
A>Note: this sequence belongs to the VH II subgroup
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:23-105/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00121 Length: 122
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x JL0047 (1-122)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACACCCGCTCTCTCAAGAGTCGGCGAGTCAG 60
Db 58 GlulleAenHisSerGlySerThrAsnTyraenProSerLeuLysSerArgValThr--- 76
:::

QY 61 GATATTAGC 69

Db 77 ---IleSer 78

RESULT 7

S47010
Ig heavy chain V4.21-UniqueD-J5 region - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S47010
R:Mahmoudi, M.; Gasyana, E.; Denomme, G.; Edwards, J.; Bell, D.; Cairns, E.
submitted to the EMBL Data Library, July 1994

A:Description: The role of the immunoglobulin heavy chain in human anti-DNA antibody bir
A:Reference number: S47009
A:Accession: S47010
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-126 <MAH>
A:Cross-references: EMBL:Z35492; NID:G517254; PIDN:CAA84625.1; PID:G517255
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00121 Length: 126
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S47010 (1-126)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACACCCGCTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAenHisSerGlySerThrAsnTyraenProSerLeuLysSerArgValThr--- 68
:::

QY 61 GATATTAGC 69

Db 69 ---IleSer 70

RESULT 8

PS0341
Ig heavy chain V-D-J region (RAMOS) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-May-1997
C:Accession: PS0341
R:Rothen, H.
Biochem. Biophys. Res. Commun. 182, 1260-1263, 1992
A:Title: Rapid cloning of rearranged immunoglobulin heavy chain genes from human B-cell

A:Reference number: PS0341; MUID:92171937; PMID:1540170

A:Accession: PS0341

A:Molecule type: mRNA

A:Residues: 1-133 <RAI>

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:9-38/Region: framework 1

F:39-43/Region: complementarity-determining 1

F:44-57/Region: framework 2

F:58-74/Region: complementarity-determining 2

F:75-106/Region: framework 3

Alignment Scores:
Pred. No.: 0.00121 Length: 133
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x PS0341 (1-133)

QY 1 GAAATCAATCATAGTGGAGCACCACCACTACACCCGCTCTCTCAAGAGTCGGCGAGTCAG 60
Db 58 GlulleAenHisSerGlySerThrAsnTyraenProSerLeuLysSerArgValThr--- 76
:::

QY 61 GATATTAGC 69

Db 77 ---IleSer 78

RESULT 9

A49045

Ig heavy chain V region (anti-B cell autoantibody) - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999

```
C;Accession: A49045
R;Grillot-Courvalin, C.; Brouet, J.-C.; Piller, F.; Rassenti, L.Z.; Labaume, S.; Silverma
Eur. J. Immunol. 22, 1781-1788, 1992
A;Title: An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i bl
A;Reference number: A49045; MUID:92324290; PMID:1623923
A;Accession: A49045
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-140 <R>
A;Cross-references: GB:S39381; NID:g250899; PIDN:AAB22441.1; PID:g250900
A;Note: sequence extracted from NCBI backbone (NCBIN:108088, NCBIp:108089)
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-116/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00122 Length: 140
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x A49045 (1-140)
Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 69 GlulleAsnHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 87
Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 10
B49028
Ig heavy chain V-IV region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999
C;Accession: B49028
R;Timmers, E.; Kenter, M.; Thompson, A.; Kraakman, M.E.; Berman, J.E.; Alt, F.W.; Schuur
Eur. J. Immunol. 21, 2355-2363, 1991
A;Title: Diversity of immunoglobulin heavy chain gene segment rearrangement in B lymphob
A;Reference number: A49028; MUID:92008140; PMID:1915549
A;Accession: B49028
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-143 <TM>
A;Cross-references: GB:S64473; NID:g236906; PIDN:AAB20012.1; PID:g236907
A;Experimental source: X-linked agammaglobulinemia patients, B lymphoblastoid cell lines
A;Note: sequence extracted from NCBI backbone (NCBIN:64473, NCBIp:64472)
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00122 Length: 143
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x B49028 (1-143)
Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 11
```

```
B23746
Ig Fab region IV-J(H4)-C (KAU cold agglutinin) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 21-Jan-2000
C;Accession: B23746
R;Leon, J.; Ghiso, J.; Goni, F.; Frangione, B.
J. Biol. Chem. 266, 2836-2842, 1991
A;Title: The primary structure of the Fab fragment of protein KAU, a monoclonal immunogl
A;Reference number: A23746; MUID:91131575; PMID:1993660
A;Accession: B23746
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-231 <LEO>
C;Superfamily: immunoglobulin C region; immunoglobulin homology
F;140-209/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00125 Length: 231
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x B23746 (1-231)
Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 49 GlulleAsnHisSerGlySerThrAsnTyAsnProSerLeuLysSerArgValThr--- 67
Qy 61 GATATTAGC 69
Db 68 ---IleSer 69

RESULT 12
G34964
Ig heavy chain V-IV region (Ab44) - human
C;Species: Homo sapiens (man)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
C;Accession: G34964
R;Sanz, I.; Casali, P.; Thomas, J.W.; Notkins, A.L.; Capra, J.D.
J. Immunol. 142, 4054-4061, 1989
A;Title: Nucleotide sequences of eight human natural autoantibody V-H regions reveals ap
A;Reference number: A92830; MUID:89235232; PMID:2497188
A;Accession: G34964
A;Molecule type: mRNA
A;Residues: 1-97 <SAN>
A;Cross-references: UNIPROT:Q8WUX4; GB:M26998
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00404 Length: 97
Score: 88.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 63.14% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x G34964 (1-97)
Qy 1 GAAATCAATCATAGTGGGAAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 50 GlulleAsnHisSerGlyThrAsnTyAsnProSerLeuLysSerArgValThr--- 68
Qy 61 GATATTAGC 69
Db 69 ---IleSer 70

RESULT 13
S26905
Ig heavy chain V region (DP-70 / 4.19) - human (fragment)
```

```
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26905; PID:149
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26905
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: EMBL:Z12370; NID:g32960; PIDN:CAA78240.1; PID:g32961
A;Note: designated DP-70
R;Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A;Title: The smaller human V(H) gene families display remarkably little polymorphism.
A;Reference number: S09421; MUID:90059975; PMID:2511001
A;Accession: S12419
A;Status: preliminary; translation not shown
A;Molecule type: DNA
A;Residues: 1-98 <SAN>
A;Cross-references: EMBL:X56363
A;Note: designated 4.19
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0137 Length: 98
Score: 84.40 Matches: 18
Percent Similarity: 70.3% Conservative: 1
Best Local Similarity: 66.6% Mismatches: 2
Query Match: 60.2% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S26905 (1-98)

QY 1 GAAATCAATCATAGTGGAGGACCAACTACACCGGTCTCTCAAGAGTCGGCGAGTCAG 60
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
51 GluileTyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 69
QY 61 GATATTAGC 69
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
70 ---IleSer 71

RESULT 14
S14474
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C;Accession: S14474
R;van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derksen, R.H.
submitted to the EMBL Data Library, November 1990
A;Reference number: S14474
A;Accession: S14474
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <ESJ>
A;Cross-references: EMBL:X56591; NID:g37235; PIDN:CAA39929.1; PID:g1335354
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0186 Length: 97
Score: 83.40 Matches: 18
Percent Similarity: 70.3% Conservative: 1
Best Local Similarity: 66.6% Mismatches: 2
Query Match: 59.5% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S14474 (1-97)

C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26905; PID:149
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26905
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: EMBL:Z12370; NID:g32960; PIDN:CAA78240.1; PID:g32961
A;Note: designated DP-70
R;Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A;Title: The smaller human V(H) gene families display remarkably little polymorphism.
A;Reference number: S09421; MUID:90059975; PMID:2511001
A;Accession: S12419
A;Status: preliminary; translation not shown
A;Molecule type: DNA
A;Residues: 1-98 <SAN>
A;Cross-references: EMBL:X56363
A;Note: designated 4.19
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0137 Length: 98
Score: 84.40 Matches: 18
Percent Similarity: 70.3% Conservative: 1
Best Local Similarity: 66.6% Mismatches: 2
Query Match: 60.2% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S26905 (1-98)

QY 1 GAAATCAATCATAGTGGAGGACCAACTACACCGGTCTCTCAAGAGTCGGCGAGTCAG 60
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
51 GluileTyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 69
QY 61 GATATTAGC 69
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
70 ---IleSer 71

RESULT 14
S14474
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C;Accession: S14474
R;van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derksen, R.H.
submitted to the EMBL Data Library, November 1990
A;Reference number: S14474
A;Accession: S14474
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-97 <ESJ>
A;Cross-references: EMBL:X56591; NID:g37235; PIDN:CAA39929.1; PID:g1335354
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0186 Length: 97
Score: 83.40 Matches: 18
Percent Similarity: 70.3% Conservative: 1
Best Local Similarity: 66.6% Mismatches: 2
Query Match: 59.5% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S14474 (1-97)
```

```
QY 1 GAAATCAATCATAGTGGAGGACCAACTACACCGGTCTCTCAAGAGTCGGCGAGTCAG 60
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
50 GluileIleHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr--- 68
QY 61 GATATTAGC 69
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
69 ---IleSer 70

RESULT 15
S44114
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C;Accession: S44114
R;Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A;Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable r
A;Reference number: S44105
A;Accession: S44114
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-129 <HAW>
A;Cross-references: EMBL:Z31579; NID:g472968; PIDN:CAA83451.1; PID:g940525
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.0348 Length: 129
Score: 81.40 Matches: 17
Percent Similarity: 67.86% Conservative: 2
Best Local Similarity: 60.71% Mismatches: 3
Query Match: 58.14% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x S44114 (1-129)

QY 1 GAAATCAATCATAGTGGAGGACCAACTACACCGGTCTCTCAAGAGTCGGCGAGTCAG 60
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
51 GluileTyrHisSerGlySerThrAsnTyrAsnProSerPheLysSerArgValThr--- 69
QY 61 GATATTAGCAGC 72
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
70 ---IleSerAla 72

Search completed: August 4, 2005, 19:38:53
Job time : 28 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:04:23 ; Search time 108 Seconds
(without alignments)
768.119 Million cell updates/sec

Title: DELETED1

Perfect score: 140

Sequence: 1 GAAATCAATCATAGTGGAG.....ATATTAGCAGCTGTTAGCC 81

Scoring table:

```
BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1
```

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 3224756

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

```
-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/NOLAN463-3A/runat_04082005_120125_18797/app_query.fasta_1.263
-DB=UniProt -OPWT=fastan -SUFFIX=rup -MINMATCH=0.1 -LOOPCL=0 -LOPEXT=0
-UNITS=bits -START=1 -END=1 -MATTRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALLIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HSPSIZ=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN463-3A @CGN 1.1 244 @runat_04082005_120125_18797 -NCPU=6 -ICPU=3
-NO.MWAP -LARGQUERY -NEG SCORES=0 -WAIT -DSPELOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1
```

Database : UniProt_03.*

1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	92.4	66.0	116	Q7Z3Y6	Q7z3y6 homo sapien
2	92.4	66.0	595	Q8WUX4	Q8wux4 homo sapien
3	92.4	66.0	597	Q6GMX5	Q6gmx5 homo sapien
4	92.4	66.0	597	Q9BU10	Q9bu10 homo sapien
5	92.4	66.0	625	Q96AA6	Q96aa6 homo sapien
6	86.4	61.7	597	Q9BQB8	Q9bqb8 homo sapien
7	84.4	60.3	576	Q6P4I8	Q6p4i8 homo sapien
8	81.3	58.1	477	Q6GMX7	Q6gmx7 homo sapien
9	78.4	56.0	146	1 HV21 HUMAN	P06331 homo sapien
10	73.7	52.6	139	2 Q86SX2	P06331 homo sapien
11	72.6	51.9	479	2 Q99M22	Q99m22 mus musculus
12	72	51.4	465	2 Q6GMX6	Q6gmx6 homo sapien
13	72	51.4	620	2 Q96EY0	Q96ey0 homo sapien
14	70.6	50.4	262	2 Q65Z11	Q65z11 mus musculus
15	69.3	49.5	119	2 Q9UL73	Q9ul73 homo sapien
16	69.1	49.4	113	1 HV47_MOUSE	P01823 mus musculus

17	69	49.3	116	1 HV61_MOUSE	P18532 mus musculus
18	67.4	48.1	2348	2 Q8Z0Z7	Q8z0z7 anabaena sp
19	66.9	47.8	476	2 Q6GMX1	Q6gmx1 homo sapien
20	65	46.4	116	1 HV60_MOUSE	P18531 mus musculus
21	65	46.4	478	2 Q6NYH3	Q6nyh3 homo sapien
22	64	45.7	478	2 Q7Z379	Q7z379 homo sapien
23	60.8	43.4	3118	2 Q17575	O17575 caenorhabdi
24	59.4	42.4	150	2 Q95973	Q95973 homo sapien
25	59	42.1	136	2 Q6LBQ5	Q6lbq5 mus musculus
26	59	42.1	137	1 HV46_MOUSE	P01822 mus musculus
27	58.7	41.9	209	2 Q8XWU0	Q8xwu0 ralestonia s
28	57.5	41.1	963	2 Q8PSM2	Q8psm2 xanthomonas
29	57.5	41.1	1160	1 TF53_YEAST	P34111 saccharomyc
30	57.4	41.0	496	2 Q96KX8	Q96kx8 homo sapien
31	57.1	40.8	163	2 Q84F35	Q84f35 streptomyce
32	56.7	40.5	212	2 Q926K5	Q926k5 listeria in
33	56.6	40.4	408	1 YBX0_ARATH	Ybx034 arabidopsis
34	56.4	40.3	390	2 Q6HH60	Q6hh60 bacillus th
35	56.4	40.3	545	2 Q6HH58	Q6hh58 bacillus th
36	56.4	40.3	588	2 Q813F9	Q813f9 bacillus ce
37	56.3	40.2	1177	2 Q82B26	Q82b26 yersinia ps
38	56.3	40.2	1177	2 Q82B26	Q82b26 yersinia ps
39	56	37.8	589	2 Q9K7H7	Q9k7h7 bacillus ha
40	55.9	39.9	421	2 Q88115	Q88115 pseudomonas
41	55.8	39.9	877	1 SEU_ARATH	Q88234 arabidopsis
42	55.7	39.8	193	2 Q63FQ9	Q63fq9 bacillus ce
43	55.7	39.8	193	2 Q73DA2	Q73da2 bacillus ce
44	55.7	39.8	193	2 Q81HP9	Q81hp9 bacillus ce
45	55.7	39.8	193	2 Q81UW5	Q81uw5 bacillus an

ALIGNMENTS

RESULT 1

```
Q7Z3Y6
ID Q7Z3Y6 PRELIMINARY; PRT; 116 AA.
AC Q7Z3Y6;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Rearranged VH4-34 V gene segment (Fragment).
GN Name=VH4-34;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hodgkin lymphoma;
RA Tinguely M., Rosenquist R., Sundstroem C., Amini R.M., Kuppers R.,
RA Hansmann M.L., Brauning A.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ564425; CAD92032.1; -.
DR HSSP; P18532; 1KCV.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
SQ SEQUENCE 116 AA; 12902 MW; CE3DBA846616C908 CRC64;
```

Alignment Scores:
Pred. No.: 0.00232 Length: 116
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x Q7Z3Y6 (1-116)

Qy 1 GAAATCAATCATAGTGGAGCAACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60

```
Db 50 GlulieAenHisSerGlySerThrAsnTyraenProSerLeuLysSerArgValThr---- 68
|||
Qy 61 GATATTAGC 69
|||
Db 69 ---IleSer 70
|||

RESULT 2
Q8WUX4 PRELIMINARY; PRT; 595 AA.
AC Q8WUX4
DT 01-MAR-2004 (TrEMBLrel. 20, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A.
RP TISSUE=Lymph;
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC019235; AAH19235.2; -.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF07654; CI-set; 4.
DR Pfam; PF00047; IG; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 4.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG-LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Hypothetical protein.
SQ SEQUENCE 595 AA; 65290 MW; 0D4B50776545714E CRC64;

Alignment Scores:
Pred. No.: 0.00292 Length: 595
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x Q8WUX4 (1-595)

Qy 1 GAAATCAATCATAGTGGGAAGCAACCACTACACCCGCTCTCTCAAGAGTGGCGGAGTCAG 60
|||
Db 76 GlulieAenHisSerGlySerThrAsnTyraenProSerLeuLysSerArgValThr--- 94
|||
```

```
Qy 61 GATATTAGC 69
|||
Db 95 ---IleSer 96
|||

RESULT 3
Q6GMX5 PRELIMINARY; PRT; 597 AA.
AC Q6GMX5
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A.
RP TISSUE=Lymph;
RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073767; AAH73767.1; -.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF07654; CI-set; 4.
DR Pfam; PF00047; IG; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 4.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG-LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Hypothetical protein.
SQ SEQUENCE 597 AA; 65304 MW; 2A1E75F6AED85230 CRC64;

Alignment Scores:
Pred. No.: 0.00292 Length: 597
Score: 92.40 Matches: 19
Percent Similarity: 74.07% Conservative: 1
Best Local Similarity: 70.37% Mismatches: 1
Query Match: 66.00% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x Q6GMX5 (1-597)

Qy 1 GAAATCAATCATAGTGGGAAGCAACCACTACACCCGCTCTCTCAAGAGTGGCGGAGTCAG 60
```

Qy 1 GAATCAATCATAGTGAAGACCAACTACAACCGCTCTCTCAAGAGTCGGGCGAGTCAG 60
|||||
Db 69 GlulleAsnHissSerGlySerThrAsnProSerLeuLysSerArgValThr--- 87
||||| :||| :|||

DELETED1 (1-81) x Q96AA6 (1-625)

```
Db 76 GlulleAenHisSerGlySerThrAsnTyranProSerLeuLysSerArgValThr----- 94
Qy 61 GATATTAGC 69
Db 95 ---IleSer 96

RESULT 6
Q9BQ88 PRELIMINARY; PRT; 597 AA.
AC Q9BQ88
DT 01-JUN-2001 (TREMBLrel. 17, Created)
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE IGIM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raba S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC006180; AAH06180.1; -.
DR HSSP; P01861; 1ADQ.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 5.
DR PROSITE; PS00290; IG-MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65300 MW; 2DAFAD50A6375851 CRC64;

Alignment Scores:
Pred. No.: 0.0197 Length: 597
Score: 86.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 61.71% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x Q9BQ88 (1-597)

Qy 1 GAAATCAATCATAGTGGAGCAACCACTACACCGCTCTCTCAAGAGTGGCGGAGTCAG 60
Db 69 GlulleAenHisSerGlyIleThrAsnTyranProSerLeuLysSerArgValThr--- 87
```

```
Qy 61 GATATTAGC 69
Db 88 ---IleSer 89

RESULT 7
Q6P418 PRELIMINARY; PRT; 576 AA.
AC Q6P418
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE IGHD protein.
CN Name=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raba S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC063384; AAH63384.1; -.
DR HSSP; P01820; 1A7N.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; C1-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00409; IGV; 1.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 4.
DR PROSITE; PS00290; IG-MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63363 MW; FBB97C949D720F1E CRC64;

Alignment Scores:
Pred. No.: 0.0371 Length: 576
Score: 84.40 Matches: 18
Percent Similarity: 70.37% Conservative: 1
Best Local Similarity: 66.67% Mismatches: 2
Query Match: 60.29% Indels: 6
DB: 2 Gaps: 0

DELETED1 (1-81) x Q6P418 (1-576)
```

```

Qy 1 GAATCATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 77 GllullefyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr 95
Qy 61 GATATTAGC 69
Db 96 ---lleSer 97

RESULT 8
Q6GMX7
ID Q6GMX7 PRELIMINARY; PRT; 477 AA.
AC Q6GMX7;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettner M., Madan A., Rodrigues S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073765; AAH73765.1; -.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG-MHC.
DR Pfam; PF07654; C1-set; 2.
DR Pfam; PF00047; IG; 3.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 477 AA; 51631 MW; 9PF59C0C50CFF85 CRC64;

Alignment Scores:
Pred. No.: 0.0971 Length: 477
Score: 81.30 Matches: 17
Percent Similarity: 39.22% Conservative: 3
Best Local Similarity: 33.33% Mismatches: 4
Query Match: 58.07% Indels: 27
DB: 2

DELETED1 (1-81) x Q6GMX7 (1-477)
Qy 4 ATCAATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 63
Db 77 GllullefyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr 95
Qy 61 GATATTAGC 69
Db 96 ---lleSer 97

RESULT 9
HV2I_HUMAN
ID HV2I_HUMAN STANDARD; PRT; 146 AA.
AC P06331.
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE IG heavy chain V-II region ARH-77 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85205332; PubMed=3922855; DOI=10.1016/0378-1119(85)90092-7;
RA Kudo A., Ishihara T., Nishimura Y., Watanabe T.;
RT "A cloned human immunoglobulin heavy chain gene with a novel direct-
RT repeat sequence in 5' flanking region.";
RL Gene 33:181-189(1985).
DR PIR; A02101; G1HUH2.
DR HSSP; P01825; 7FAB.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 146 Ig heavy chain V-II region ARH-77.
FT DOMAIN 20 117 V segment.
FT DOMAIN 118 127 D segment.
FT DOMAIN 128 146 J segment.
FT DISULFID 42 115 By similarity.
FT NON_TER 146 146
SQ SEQUENCE 146 AA; 16228 MW; 8D7FD52BB218171F CRC64;

Alignment Scores:
Pred. No.: 0.207 Length: 146
Score: 78.40 Matches: 17
Percent Similarity: 66.67% Conservative: 1
Best Local Similarity: 62.96% Mismatches: 3
Query Match: 56.00% Indels: 6
DB: 1

DELETED1 (1-81) x HV2I_HUMAN (1-146)
Qy 1 GAATCATCATAGTGGAGCACCACCACTACAAACCGTCTCTCAAGAGTCGGCGAGTCAG 60
Db 70 GllullefyrHisSerGlySerThrAsnTyrAsnProSerLeuLysSerArgValThr 88
Qy 61 GATATTAGC 69
Db 89 ---lleSer 90

RESULT 10
Q6GSX2

```

```

ID Q86SX2 PRELIMINARY; PRT; 139 AA.
AC Q86SX2;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Full-length cDNA clone CS0DL004YM19 of B cells (Ramos cell line) of
DE Homo sapiens (human) (Fragment).
DE Homo sapiens (human).
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=B cells;
RA Li W.B., Gruber C., Jessee J., Polayes D.;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=B cells;
RA Genoscope;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX248300; CAD62627.1; -.
DR HSSP; P01820; 1G7J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON TER 1
SQ SEQUENCE 139 AA; 15573 MW; 7D1E2302410B4F8C CRC64;

Alignment Scores:
Pred. No.: 0.92 Length: 139
Score: 73.70 Matches: 17
Percent Similarity: 35.71% Conservative: 3
Best Local Similarity: 30.36% Mismatches: 33
Query Match: 52.64% Indels: 1
Gaps: 2
DB: 1

DELETED1 (1-81) x Q86SX2 (1-139)
Qy 4 ATCAATCATAGTGAAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGT----- 57
Db 83 IletyTyTySerGlySerThrAsnTyAsnProSerLeuLysSerArgValThrIleSer 102
Qy 57 ----- 57
Db 103 ValAspThrSerLysAsnGlnPheSerLeuLysLeuSerSerValThrAlaAlaAspThr 122
Qy 58 -----CAGGATATTAGCAGC 72
Db 123 AlaValTyTyTyCysAlaArgAspThrValArgGlyAspValSerSer 138

RESULT 11
Q99M22 PRELIMINARY; PRT; 479 AA.
ID Q99M22;
AC Q99M22;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Mus musculus (mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=mix FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=2388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
Brownstein M.J., Ustin T.B., Tohiyuki S., Carninci P., Prange C.,
Raha S.S., Ioquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
Krzywinski M.I., Skalska U., Smutius D.E., Schnerch A., Schein J.E.,
Jones S.J., Marra M.A.;
"Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RP SEQUENCE FROM N.A.
RC STRAIN=mix FVB/N; TISSUE=Mammary tumor;
RA Strausberg R.;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002091; AAH02091.1; -.
DR HSSP; P01820; 1G7J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig ci.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Ci-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
KW Hypothetical protein_
SQ SEQUENCE 479 AA; 51992 MW; 768E39A138918892 CRC64;

Alignment Scores:
Pred. No.: 1.55 Length: 479
Score: 72.60 Matches: 17
Percent Similarity: 33.93% Conservative: 2
Best Local Similarity: 30.36% Mismatches: 4
Query Match: 51.86% Indels: 34
Gaps: 1
DB: 2

DELETED1 (1-81) x Q99M22 (1-479)
Qy 4 ATCAATCATAGTGAAGCACCACCACTACACCGTCTCTCAAGAGTCGGCGAGTCA---- 59
Db 70 IleAsnTyTySerGlySerAsnAsnTyAsnProSerLeuLysAsnArgIleSerIleThr 89
Qy 59 ----- 59
Db 90 ArgAspThrSerLysAsnGlnPhePheLeuLysLeuAsnSerValThrThrGluAspThr 109
Qy 60 -----GGATATTAGCAGCTGG 75
Db 110 AlaThrTyTyTyCysAlaSerArgGlyTyTy-----SerTrp 121

RESULT 12
Q6GMX6 PRELIMINARY; PRT; 465 AA.
ID Q6GMX6;
AC Q6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
```

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RA Strausberg R.;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL: BC073766; AAH73766.1; --
 DR InterPro: IPR003599; IG.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003597; IG cl.
 DR InterPro: IPR003006; IG MHC.
 DR InterPro: IPR003596; IG v.
 DR Pfam: PF07654; Cl-set; 3.
 DR Pfam: PF00047; IG; 4.
 DR SMART: SM00409; IG; 2.
 DR SMART: SM00407; IGcl; 3.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG LIKE; 4.
 DR PROSITE: PS00290; IG MHC; UNKNOWN 2.
 KW Hypothetical protein.
 SQ SEQUENCE 465 AA; 51083 MW; B3A9B7D0FD81386E CRC64;
 Alignment Scores:
 Pred. No.: 1-87 Length: 465
 Score: 72.00 Matches: 13
 Percent Similarity: 80.00% Conservative: 3
 Best Local Similarity: 65.00% Mismatches: 4
 Query Match: 51.43% Indels: 0
 DB: Gaps: 0
 DELETED1 (1-81) x Q6GMX6 (1-465)
 QY 13 AGTGAAGCACCACCACTACACCGCTCTCTCAAGAGTCGGCGAGTCAGGATATTAGCAGC 72
 Db 73 SerGlySerThrAsnTyAsnProSerLeuLysSerArgValThrMetSerValAspThr 92
 RESULT 13
 Q96EY0 PRELIMINARY; PRT; 620 AA.
 AC Q96EY0;
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE IGHM protein.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Primary B-Cells;
 RA Strausberg R.;
 RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: BC011857; AAH11857.2; --
 DR PIR: S15590; S15590.
 DR HSP: P01820; IGTJ.
 DR InterPro: IPR003599; IG.
 DR InterPro: IPR007110; IG-like.
 DR InterPro: IPR003597; IG cl.
 DR InterPro: IPR003006; IG MHC.
 DR InterPro: IPR003596; IG v.
 DR Pfam: PF07654; Cl-set; 4.
 DR SMART: SM00409; IG; 2.
 DR SMART: SM00407; IGcl; 4.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE: PS50835; IG LIKE; 5.
 DR PROSITE: PS00290; IG MHC; UNKNOWN 3.
 SQ SEQUENCE 620 AA; 68125 MW; 990A1A4A6E8FF27B CRC64;
 Alignment Scores:
 Pred. No.: 1-95 Length: 620
 Score: 72.00 Matches: 13
 Percent Similarity: 80.00% Conservative: 3
 Best Local Similarity: 65.00% Mismatches: 4
 Query Match: 51.43% Indels: 0
 DB: Gaps: 0
 DELETED1 (1-81) x Q96EY0 (1-620)
 QY 13 AGTGAAGCACCACCACTACACCGCTCTCTCAAGAGTCGGCGAGTCAGGATATTAGCAGC 72
 Db 80 SerGlySerThrAsnTyAsnProSerLeuLysSerArgValThrMetSerValAspThr 99
 RESULT 14
 Q65Z11 PRELIMINARY; PRT; 262 AA.
 ID Q65Z11;
 AC Q65Z11;
 DT 25-OCT-2004 (TrEMBLrel. 28, Created)
 DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
 DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
 DE Anti-HIV-1 reverse transcriptase single-chain variable.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Hybridoma;
 RX MEDLINE=96211469; PubMed=8648670;
 RA Shaheen F., Duan L., Zhu M., Bagasra O., Pomerantz R.J.;
 RT "Targeting human immunodeficiency virus type 1 reverse transcriptase
 RT by intracellular expression of single-chain variable fragments to
 RT inhibit early stages of the viral life cycle.";
 RL J. Virol. 70:3392-3400(1996).
 DR EMBL: U48716; AAB64342.1; --

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:39:01 ; Search time 119 Seconds
(without alignments)
526.514 Million cell updates/sec

Title:

DELETED2

Perfect score: 140

Sequence: 1 CGGCGAGTACGATATTAG.....ACAACCCCTCTCTCAAGAGT 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 4211384

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-O=/cgn2_1/USPTO_spool_p/NOLAN463-3B/runat_04082005_120453_19604/app_query.fasta_1.263
-DB=A_Geneseq -OFMT=fastan -SUFFIX=rag -MINMATCH=0.1 -LOOPEL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3B @CGN 1.1 224 @runat_04082005_120453_19604 -NCPU=6 -ICPU=3
-NO_MMAP -LARGQUERY -NEG_SCORES=0 -WAIT_DSBLCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREDS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : A_Geneseq 16Dec04:*

1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004as:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	100.1	71.5	253	5	ABP45322 Human Bly
2	100.1	71.5	253	7	ADG96149 Single ch
3	99.9	71.4	125	6	ADA89274 Human ant
4	98.2	70.1	80	2	AAW62794 Amino aci
5	98.2	70.1	97	2	AAV05694 Multiple
6	98.2	70.1	97	5	ABG78212 Human Fv
7	98.2	70.1	97	5	ABG91903 Human ant
8	98.2	70.1	97	6	ABO27107 Human ger
9	98.2	70.1	97	7	ABD75646 Human pro
10	98.2	70.1	97	7	ADD28104 Lymphoma

11	98.2	70.1	97	7	ADF10048	Adf10048 VEGF anti
12	98.2	70.1	97	7	ADF10150	Adf10150 Antibody
13	98.2	70.1	97	7	ADF09942	Adf09942 Antibody
14	98.2	70.1	97	7	ADJ80323	ADJ80323 VH gene 1
15	98.2	70.1	114	3	RAA01949	RAA01949 Anti-Id1
16	98.2	70.1	114	3	RAA01950	RAA01950 Anti-Id1
17	98.2	70.1	114	3	RAA01953	RAA01953 Anti-Id1
18	98.2	70.1	114	3	RAA01959	RAA01959 High affi
19	98.2	70.1	114	3	RAA01952	RAA01952 Anti-Id1
20	98.2	70.1	114	3	RAA01955	RAA01955 Streptativ
21	98.2	70.1	114	3	RAA01956	RAA01956 Streptativ
22	98.2	70.1	114	3	RAA01948	RAA01948 Wild-type
23	98.2	70.1	114	3	RAA01954	RAA01954 Anti-Id1
24	98.2	70.1	114	7	ADG70086	ADG70086 Diversifi
25	98.2	70.1	114	7	ADG70013	ADG70013 Diversifi
26	98.2	70.1	116	2	RAA66324	RAA66324 Human imm
27	98.2	70.1	117	4	RAA60904	RAA60904 Human bra
28	98.2	70.1	117	4	ABG55317	ABG55317 Human liv
29	98.2	70.1	117	5	ABG43454	ABG43454 Human pep
30	98.2	70.1	118	6	ADA89246	ADA89246 Human ant
31	98.2	70.1	122	7	ADK17418	ADK17418 Anti-huma
32	98.2	70.1	122	8	ADG42840	ADG42840 scFv Abl2
33	98.2	70.1	123	2	RAW03757	RAW03757 Anti-rhes
34	98.2	70.1	125	6	ADA89266	ADA89266 Human ant
35	98.2	70.1	139	3	RAY99556	RAY99556 Human LHL
36	98.2	70.1	139	6	ABR42859	ABR42859 Tumour-sp
37	98.2	70.1	139	7	ABW02445	ABW02445 Human mon
38	98.2	70.1	142	6	ABP96287	ABP96287 Anti-hTNF
39	98.2	70.1	154	6	ABP96293	ABP96293 Human ant
40	98.2	70.1	190	2	RAY34304	RAY34304 IGM antib
41	98.2	70.1	202	2	RAY34303	RAY34303 IGM antib
42	98.2	70.1	205	2	RAY34299	RAY34299 IGM antib
43	98.2	70.1	218	7	ADG70090	ADG70090 Diversifi
44	98.2	70.1	223	7	ADJ32112	ADJ32112 Human int
45	98.2	70.1	224	7	ADG70088	ADG70088 Diversifi

ALIGNMENTS

RESULT 1

ABP45322
ID ABP45322 standard; protein; 253 AA.

XX AC ABP45322;

XX DT 19-AUG-2002 (first entry)

XX DE Human Blys binding scFv SEQ ID 1333.

XX KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

XX KW tumour necrosis factor; B cell proliferation; B cell differentiation;

XX KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;

XX KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;

XX KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

XX KW common variable immunodeficiency; acquired immunodeficiency syndrome.

XX OS Homo sapiens.

XX FN WO200202641-A1.

XX PD 10-JAN-2002.

XX PF 15-JUN-2001; 2001WO-US019110.

XX PR 16-JUN-2000; 2000US-0212210P.

XX PR 17-OCT-2000; 2000US-0240816P.

XX PR 16-MAR-2001; 2001US-0276248P.

XX PR 21-MAR-2001; 2001US-0277379P.

XX PR 25-MAY-2001; 2001US-0293499P.

XX XX (HUMA-) HUMAN GENOME SCI INC.

XX PA (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX XX

PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 DR WPI; 2002-114799/15.
 XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 XX Claim 1; Page 1993-1994; 3148pp; English.
 PS This invention describes novel antibodies that immunospecifically bind to
 XX B lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
 CC and so may be used to detect and quantitate the presence of BlyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BlyS. They may also be
 CC administered to treat diseases associated with aberrant BlyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 XX the invention
 SQ Sequence 253 AA;
 Alignment Scores:
 Pred. No.: 0.000258 Length: 253
 Score: 100.10 Matches: 21
 Percent Similarity: 50.00% Conservative: 1
 Best Local Similarity: 47.73% Mismatches: 3
 Query Match: 71.50% Indels: 19
 DB: 5 Gaps: 1
 DELETED2 (1-81) x ABP45322 (1-253)
 QY 3 GCGGAGTCA-----GGATAT 17
 DB 26 GlyGluSerPheSerGlyTyrTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
 QY 18 TAGCAGCTGGTTAGCGAAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAA 77
 DB 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeu 64
 QY 78 GAGT 81
 DB 64 sSer 65
 RESULT 2
 ID ADG96149
 AC ADG96149 standard; protein; 253 AA.
 XX ADG96149;
 XX 11-MAR-2004 (first entry)
 XX Single chain antibody that immunospecifically binds BlyS SeqID 1333.
 KW antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiallergic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
 XX Unidentified.
 OS
 XX WO2003055979-A2.
 PN
 XX 10-JUL-2003.
 PD
 XX

PF 14-NOV-2002; 2002WO-US036496.
 XX 16-NOV-2001; 2001US-0331469P.
 PR 19-DEC-2001; 2001US-0340817P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 XX WPI; 2003-505530/47.
 DR Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 XX (BlyS), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.
 PT Example 1; SEQ ID NO 1333; 394pp; English.
 PS This invention relates to novel antibodies that immunospecifically bind
 XX to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey BlyS. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of BlyS or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiallergic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds BlyS of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 253 AA;
 Alignment Scores:
 Pred. No.: 0.000258 Length: 253
 Score: 100.10 Matches: 21
 Percent Similarity: 50.00% Conservative: 1
 Best Local Similarity: 47.73% Mismatches: 3
 Query Match: 71.50% Indels: 19
 DB: 7 Gaps: 1
 DELETED2 (1-81) x ADG96149 (1-253)
 QY 3 GCGGAGTCA-----GGATAT 17
 DB 26 GlyGluSerPheSerGlyTyrTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
 QY 18 TAGCAGCTGGTTAGCGAAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAA 77
 DB 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeu 64
 QY 78 GAGT 81
 DB 64 sSer 65
 RESULT 3
 ID ADA89274
 AC ADA89274 standard; protein; 125 AA.
 XX ADA89274;
 XX 20-NOV-2003 (first entry)
 DT Human antibody 3H2 heavy chain amino acid sequence SEQ ID NO:118.
 DE

XX immunoglobulin; Ig; heavy chain variable domain;
KW light chain variable domain; major histocompatibility complex; MHC;
KW gp100; MUC1; TAX; hTERT; cytostatic; gene therapy; cancerous disorder;
KW cancer.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO2003070752-A2.
XX
XX PD 28-AUG-2003.
XX
XX PF 20-FEB-2003; 2003WO-US005128.
XX
XX PR 20-FEB-2002; 2002US-0358994P.
XX
XX PA (DVAX-) DVAX CORP.
XX (TECR) TECHNION RES & DEV FOUND LTD.
XX
XX PI Hoogenboom HRJM, Reiter Y;
XX
XX DR WPI; 2003-663847/62.
XX N-PSDB; ADA89273.
XX
XX New protein comprising an immunoglobulin heavy chain variable (VH) domain
PT and an immunoglobulin light chain variable (VL) domain, useful for
PT preparing a composition for treating or preventing a cancerous disorder.
XX
XX Disclosure; Fig 28B; 22app; English.
XX
XX The present invention describes a protein comprising an immunoglobulin
CC (Ig) heavy chain variable (VH) domain and an Ig light chain variable (VL)
CC domain. The protein binds a complex comprising a major histocompatibility
CC complex (MHC) and a peptide, does not substantially bind the MHC in the
CC absence of the bound peptide, and does not substantially bind the peptide
CC in the absence of the MHC. The peptide is a peptide fragment of gp100,
CC MUC1, TAX or hTERT. Also described: (1) a pharmaceutical composition
CC comprising one or more nucleic acids for expressing the Ig that binds a
CC complex having an MHC and a peptide, does not substantially bind the MHC
CC in the absence of the bound peptide, and does not substantially bind the
CC peptide in the absence of the MHC; (3) an isolated nucleic acid
CC comprising a first segment that encodes the Ig variable domain; (4) a
CC host cell comprising heterologous nucleic acid sequences that encodes the
CC novel protein; (5) a transgenic animal whose genome includes heterologous
CC nucleic acid sequences that encode the protein; (6) identifying the
CC protein that specifically binds the MHC-peptide complex; (7) expressing
CC an antigen-binding protein; (8) ablating or killing a target cell that
CC displays a peptide on a surface MHC molecule; (9) treating or preventing
CC a cancerous disorder in a subject; and (10) detecting an MHC-peptide
CC complex in a sample. A protein of the invention has cytostatic activity,
CC and can be used in gene therapy. The protein is useful for preparing a
CC composition for treating or preventing a cancerous disorder. The present
CC sequence represents the heavy chain of an antibody which binds to an MHC-
CC peptide complex where the peptide component in as peptide fragment of
CC hTERT.
XX
XX SQ Sequence 125 AA;
Alignment Scores:
Pred. No.: 0.000224 Length: 125
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 6 Gaps: 1
DELETED2 (1-81) x ADA89274 (1-125)
QY 3 GCGAGTACAGTATATACAGC----- 24
Db 26 GlyGlySer-----IleSerSerSerTyrTrpAlaTrpIleArgGlnProG1 44

QY 25 -----TGTTAGCCGAATCAATCATAGTCGAGCACTACAAACCCGTC 71
Db 44 yLyseGlyLeuGluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSe 64
QY 72 TCTCAAGAGT 81
Db 64 rLeuLyseSer 67
RESULT 4
AAW62794
ID AAW62794 standard; peptide; 80 AA.
XX
XX AC AAW62794;
XX
XX DT 23-SEP-1998 (first entry)
XX Amino acid sequence of a human antibody fragment.
XX Human; immunoglobulin; Ig; transgenic; non-human mammal;
KW inactivated endogenous Ig locus; B-cell development;
KW human heavy chain Ig locus; micro constant region; J-H; D-H; V-H gene;
KW kappa light chain Ig locus; kappa constant region; J-kappa gene; V-kappa;
KW production; antibody.
XX
XX Homo sapiens.
XX OS
XX PN WO9824893-A2.
XX
XX PD 11-JUN-1998.
XX
XX PF 03-DEC-1997; 97WO-US023091.
XX
XX PR 03-DEC-1996; 96US-00759620.
XX
XX PA (ABGE-) ABGENIX INC.
XX
XX PI Jakobovits A, Kucherlapati R, Klapholz S, Mendez M, Green L;
XX WPI; 1998-333314/29.
XX
XX New transgenic non-human mammals - having an inactivated immunoglobulin
PT locus and a near complete human immunoglobulin locus, used for production
PT of human antibodies.
XX
XX PS Disclosure; Page 71; 128pp; English.
XX
XX CC AAW62793-822 represent fragments of human antibodies produced by
CC transgenic Xenomice, created using the method of the invention. The
CC specification describes a transgenic non-human mammal which has genome
CC modifications that comprise an inactivated endogenous immunoglobulin (Ig)
CC locus, so that the mammal does not display normal B-cell development. The
CC modified genome also has an inserted human heavy chain Ig locus in
CC germline configuration, the human heavy chain Ig locus comprising a human
CC micro constant region and regulatory and switch sequences, human J-H
CC genes, human D-H genes, and human V-H genes and an inserted human kappa
CC light chain Ig locus in germline configuration, the human kappa light
CC chain Ig locus comprising a human kappa constant region, J-kappa genes,
CC and V-kappa genes, where the number of V-H and V-kappa genes inserted are
CC selected to restore normal B-cell development in the mammal. The
CC transgenic animals have a near complete human Ig locus, including both a
CC human heavy chain locus and a human kappa light chain locus. They can be
CC used for the production of human antibodies when exposed to particular
CC antigens e.g. when exposed to human IL-8, EGFR or TNF- alpha the mice
CC will produce antibodies to IL-8, EGFR or TNF- alpha respectively
XX
XX SQ Sequence 80 AA;
Alignment Scores:
Pred. No.: 0.000334 Length: 80
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3

```
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x AAW62794 (1-80)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGGAGCACCACCACT 61
   |||::: ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 25 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 42
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Qy 62 AACACCGCTCTCTCAAGAGT 81
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 42 YrAsnProSerLeuLysSer 48
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 5
AAV05694
ID AAV05694 standard; protein; 97 AA.
XX AC AAV05694;
XX 19-JUL-1999 (first entry)
XX Multiple sclerosis patient CSF B-cell VH region (clone 4d76).
DE Multiple sclerosis; cerebrospinal fluid; CSF; B-cell;
KW heavy chain variable region; VH gene; somatic hypermutation;
KW B-cell clonality; RA gene; diagnosis; human.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Region 1..30 /label= FR1
FT Misc-difference 8 /note= "encoded by GGC"
FT Misc-difference 13 /note= "replaces Glu of RA"
FT Misc-difference 14 /note= "encoded by CCT"
FT Misc-difference 23 /note= "replaces Gly of RA"
FT Misc-difference 25 /note= "replaces Phe of RA"
FT Misc-difference 30 /note= "replaces Gly of RA"
FT Region 31..36 /label= CDR1
FT Misc-difference 31 /note= "replaces Gly of RA"
FT Misc-difference 32 /note= "replaces Phe of RA"
FT Region 37..50 /note= "replaces Asn of RA"
FT Region 51..66 /label= FR2
FT Misc-difference 56 /note= "replaces Ser of RA"
FT Misc-difference 57 /note= "replaces Lys of RA"
FT Region 67..97 /label= FR3
FT Misc-difference 71 /note= "replaces Leu of RA"
FT Misc-difference 81 /note= "replaces Arg of RA"
XX WO9915696-A1.
XX 01-APR-1999.
XX 17-SEP-1998; 98WO-CA000873.
XX
```

```
PR 19-SEP-1997; 97CA-02216595.
PR 04-NOV-1997; 97CA-02220245.
XX (QINY/) QIN Y.
XX Qin Y;
XX WPI; 1999-276985/23.
XX N-PSDB; AAX25318.
XX Determination of B-cell clonality by amplification or enzymatic
XX digestion.
XX Disclosure; Fig 9D; 67pp; English.
XX This sequence represents a heavy chain variable region (VH) as predicted
XX from DNA of dominant clone 4d76 of B-cells taken from the cerebrospinal
XX fluid (CSF) of a multiple sclerosis (MS) patient. Sequences of VH of CSF
XX B-cells were obtained from 4 MS patients (see AAX25316-19). Differences
XX in nucleotide and predicted amino acid (see AAY05691-94) sequences were
XX compared with the closest known germline VH genes; for 4d76, this was RA.
XX The results provided direct evidence that intrathecal clonally expanded B
XX -cells from the CSF of MS patients are hypermutated postgerminal centre
XX antibody-forming or memory lymphocytes that have undergone antigen
XX selection. This finding implicates an important pathogenic pathway for
XX the development of demyelination in CNS of MS. The invention provides
XX assay kits for determining B-cell or T-cell clonality. This technology
XX allows the establishment of clonal specific RNA library from pathogenic
XX cells in the CNS of patients, which is important for further
XX understanding of the role of antigen(s) in the cause of B-cell clonal
XX expansion, and towards developing antigen specific therapeutic strategy
XX SQ Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.000353 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x AAY05694 (1-97)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGGAGCACCACCACT 61
   |||::: ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Qy 62 AACACCGCTCTCTCAAGAGT 81
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 59 YrAsnProSerLeuLysSer 65
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 6
ABG78212
ID ABG78212 standard; protein; 97 AA.
XX AC ABG78212;
XX 15-NOV-2002 (first entry)
XX Human Fv molecule hypervariable region related peptide #87.
XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX Homo sapiens.
XX WO200259264-A2.
XX 01-AUG-2002.
XX 31-DEC-2001; 2001WO-US049440.
XX
```


KW Human; heavy chain variable region; VH; humanised antibody;
 KW chimeric antibody; complementarity determining region; CDR;
 KW canonical CDR structure type.

XX Homo sapiens.

XX US2003039649-A1.

XX 27-FEB-2003.

XX 12-JUL-2002; 2002US-00194975.

XX 12-JUL-2001; 2001US-0305111P.

XX (FOOT/) FOOTE J.

XX Foote J;

XX WPI; 2003-492151/46.

XX Making humanized antibody for converting antibody, by making chimeric
 PT antibodies containing complementarity determining region from non-human
 PT antibody and appropriate framework sequences of human antibodies.

XX Example 1; Fig 1; 31pp; English.

XX The invention describes a method of making a humanised antibody,
 CC comprising making chimeric antibodies containing a complementarity
 CC determining region (CDR) from a non-human antibody and appropriate
 CC framework sequences (I) of human antibodies. (I) is selected by using
 CC canonical CDR structure types of non-human antibody in comparison to
 CC germline canonical CDR structure types of human antibodies as the basis
 CC for selection, for humanisation. The method is useful for making a
 CC humanised antibody or a converted antibody. The method is applicable for
 CC converting a subject antibody sequence of any subject species to a less
 CC immunogenic form suitable for use in an object species. The method is
 CC reliable for identifying suitable human framework sequences to support
 CC non-human CDR regions and to provide humanised antibodies that retain
 CC high antigen binding with low immunogenicity in humans, without the need
 CC for direct comparison of framework sequences, without the need for
 CC determining critically important amino acid residues in the framework,
 CC and without the need for multiple iteration and construction to obtain
 CC humanised antibodies with suitable therapeutic properties. The antibody
 CC has high affinity and low immunogenicity without need for comparing
 CC framework sequences between non-human and human antibodies. This sequence
 CC represents a human heavy chain variable region gene segment used in the
 CC creation of humanised antibodies

XX Sequence 97 AA;

Alignment Scores:
 Pred. No.: 0.000353 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 6 Gaps: 0

DELETED2 (1-81) x ABO27107 (1-97)

Qy 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCGGAATCAATCATAGTGGAGACCAACT 61
 Db 42 Glylys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
 Qy 62 ACAACCCGTCCTCTCAAGAGT 81
 Db 59 yrAsnProSerLeuLysSer 65

RESULT 9

ADB75646

ID ADB75646 standard; protein; 97 AA.

XX

AC ADB75646;

XX

04-DEC-2003 (first entry)

Human protein relating to the invention SEQ ID NO:55.

antibody library; CD1 region; CD2 region; VH region; VL region;
 immunoglobulin; CD3 region; TM1 scFv; human.

Homo sapiens.

WO2003044198-A1.

30-MAY-2003.

22-NOV-2002; 2002WO-JP012236.

22-NOV-2001; 2001JP-00358602.

(UYKE-) UNIV KEIO.

Shimizu N, Takayanagi A, Okui M;

WPI; 2003-449818/42.

Highly stable artificial antibody libraries with super-repository and
 little contamination from unexpressible ones, useful as tool in
 proteomics and e.g. for diagnosis and treating various diseases.

Disclosure; Page 101; 108pp; Japanese.

The invention relates to a novel artificial single-stranded antibody
 library with superior-repository. The library is created by using a cDNA
 library as template for amplifying a fragment containing the CD1 and CD2
 regions of the VH or VL region of immunoglobulin gene and a fragment
 containing the CD3 region by PCR, respectively, producing VH and VL
 libraries, transferring into a host, and displaying the single-stranded
 antibody on a phage surface. An antibody library of the invention is
 useful as a tool in proteomics and antibody chips and filters, for
 screening ligands for antigens, and for studying protein-DNA interaction,
 diagnosis and treating various diseases. The present sequence represents
 a protein of the invention.

Sequence 97 AA;

Alignment Scores:
 Pred. No.: 0.000353 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 7 Gaps: 0

DELETED2 (1-81) x ADB75646 (1-97)

Qy 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCGGAATCAATCATAGTGGAGACCAACT 61
 Db 42 Glylys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
 Qy 62 ACAACCCGTCCTCTCAAGAGT 81
 Db 59 yrAsnProSerLeuLysSer 65

RESULT 10

ADD28104

ID ADD28104 standard; protein; 97 AA.

XX

AC ADD28104;

DT 15-JAN-2004 (first entry)

XX

Lymphoma related immunoglobulin variable region F5.

XX

B-cell; malignant; immunoglobulin; immunoglobulin variable region;

KW Ig variable region; glycosylation site; lymphoma; B cell receptor;
 KW cyclostatic; gene therapy; glycosylation inhibitor;
 KW non-Hodgkin's lymphoma.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2003074059-A2.
 XX
 PD 12-SEP-2003.
 XX
 XX
 XX 24-FEB-2003; 2003WO-GB000783.
 XX
 PR 07-MAR-2002; 2002GB-00005395.
 XX
 XX (CANC-) CANCER RES TECHNOLOGY LTD.
 XX
 XX Zhu D, Stevenson F;
 PI
 XX WPI; 2003-902720/82.
 DR
 XX
 XX
 PT Classifying a B-cell as malignant or normal by isolating a sequence
 PT representing an Ig variable region from the B cell, detecting the
 PT presence of a glycosylation site and classifying the cell as malignant or
 PT normal.
 XX
 XX Disclosure; Fig 4; 61pp; English.
 PS
 XX
 CC The present invention describes a method for classifying a B-cell as
 CC malignant or normal comprising: (a) isolating a sequence representing an
 CC immunoglobulin (Ig) variable region from the B cell; (b) detecting the
 CC presence of a glycosylation site; and (c) classifying the cell as
 CC malignant or normal on the basis of the presence or absence of a
 CC glycosylation site. Also described: (1) treating a patient suffering from
 CC or at risk of having lymphoma; (2) screening for substances capable of
 CC inhibiting glycosylation of the Ig variable region of the B cell receptor
 CC ; and (3) screening for substances (S) capable of inhibiting the
 CC interaction between lectins of the type found in the germinal centre and
 CC N-glycans found on the surface of Ig of lymphoma cells. (S) has
 CC cytosolic activity, and can be used in gene therapy, and as a
 CC glycosylation inhibitor. The method is useful in classifying a B-cell as
 CC malignant or normal. The glycosylation inhibitor is useful in preparing a
 CC medicament for treating non-Hodgkin's lymphoma. The present sequence
 CC represents an Ig variable region sequence which is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 97 AA;

Alignment Scores:
 Pred. No.: 0.000353 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 7 Gaps: 0

DELETED2 (1-81) x ADD28104 (1-97)

Oy 2 GGCGAGTCAGATATTAGCAGCTGGTTAGCGGAAATCAATCATAGTCGAGCACCACACT 61
 |||||
 Db 42 Glylys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsn 59
 |||||

Oy 62 ACAACCCGCTCTCTCAAGAGT 81
 |||||
 Db 59 yrAsnProSerLeuLysSer 65
 |||||

RESULT 11
 ADF10048
 ID ADF10048 standard; protein; 97 AA.
 XX
 XX
 AC ADF10048;
 XX
 DT 12-FEB-2004 (first entry)

XX VEGF antibody heavy chain variable region VH_4-34.
 DE
 XX Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human; VEGF.
 KW
 XX Homo sapiens.
 OS
 XX WO2003074679-A2.
 PN
 XX 12-SEP-2003.
 PD
 XX
 XX 03-MAR-2003; 2003WO-US006598.
 PF
 XX 01-MAR-2002; 2002US-0360843P.
 PR
 PR 29-MAY-2002; 2002US-0384197P.
 XX
 XX (XENC-) XENCOR.
 PA
 XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 PI
 XX WPI; 2003-722066/68.
 DR
 XX
 XX Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.
 XX
 XX Example 6; Fig 16a; 135pp; English.
 PS
 XX
 CC The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.
 XX
 SQ Sequence 97 AA;

Alignment Scores:
 Pred. No.: 0.000353 Length: 97
 Score: 98.20 Matches: 19
 Percent Similarity: 65.62% Conservative: 2
 Best Local Similarity: 59.38% Mismatches: 3
 Query Match: 70.14% Indels: 8
 DB: 7 Gaps: 0

DELETED2 (1-81) x ADF10048 (1-97)

Oy 2 GGCGAGTCAGATATTAGCAGCTGGTTAGCGGAAATCAATCATAGTCGAGCACCACACT 61
 |||||
 Db 42 Glylys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsn 59
 |||||

Oy 62 ACAACCCGCTCTCTCAAGAGT 81
 |||||
 Db 59 yrAsnProSerLeuLysSer 65
 |||||

RESULT 12
 ADF10150
 ID ADF10150 standard; protein; 97 AA.
 XX
 XX
 AC ADF10150;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Antibody heavy chain variable region VH_4-34.

XX Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX Homo sapiens.

OS WO2003074679-A2.

PN 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.

XX Example 16; Fig 40a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.

XX Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.000353 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 7 Gaps: 0

DELETED2 (1-81) x ADF10150 (1-97)

QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGGAATCAATCATATGTAAGCACCACACT 61

Db 42 GlyLys-----GlyLeu-----GlutrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59

QY 62 ACAACCCGCTCTCTCAAGAGT 81

Db 59 yrAsnProSerLeuLysSer 65

RESULT 13

ADF09942

ID ADF09942 standard; protein; 97 AA.

XX ADF09942;

XX 12-FEB-2004 (first entry)

XX Antibody heavy chain variable region VH_4-34.

XX Antibody; stability; solubility; antigen binding affinity;

KW variable region; human.

XX Homo sapiens.

OS WO2003074679-A2.

PN 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.

XX Disclosure; Fig 2a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.

XX Sequence 97 AA;

Alignment Scores:
Pred. No.: 0.000353 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 7 Gaps: 0

DELETED2 (1-81) x ADF09942 (1-97)

QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGGAATCAATCATATGTAAGCACCACACT 61

Db 42 GlyLys-----GlyLeu-----GlutrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59

QY 62 ACAACCCGCTCTCTCAAGAGT 81

Db 59 yrAsnProSerLeuLysSer 65

RESULT 14

ADJ80323

ID ADJ80323 standard; protein; 97 AA.

XX ADJ80323;

XX 06-MAY-2004 (first entry)

XX VH gene locus antibody amino acid sequence #43.

XX hybrid antibody; antibody; framework region; homology; immunogenicity.

XX Homo sapiens.

Score:	98.20	Matches:	19
Percent Similarity:	65.62%	Conservative:	2
Best Local Similarity:	59.38%	Mismatches:	3
Query Match:	70.14%	Indels:	8
DB:	3	Gaps:	0

DELETED2 (1-81) x AAB01949 (1-114)

Qy	2	GGCGGAGTCAGGATATTAGCAGCTGCTTACCGCGAATCAATCATATAGTCGAGACCAACT	61
		::	
Db	36	GIYLS----GIYLeu----GlutripiledylcylulleasnHisserGlyserThrAent	53
Qy	62	ACAACCCGCTCTCTCAAGAGT	81
Db	53	yrAenProSerLeuLYsser	59

Search completed: August 4, 2005, 20:00:48
Job time : 123 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:53:13 ; Search time 29.5 Seconds
(without alignments)
409.937 Million cell updates/sec

Title: DELETED2
Perfect score: 140
Sequence: 1 CGGCGGAGTCAGGATATTAG.....ACAACCCGTCCTCTCAAGAGT 81

Scoring table: BLOSUM62

Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 513545 segs, 74649064 residues

Total number of hits satisfying chosen parameters: 1027090

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/NOLAN463-3B/runat_04082005_120454_19634/app_query.fasta_1.263
-DB=Issued Patents AA -QFWT=faetan -SUFFIX=xai -MINWATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pco -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3B @CGN 1.1.46 @runat_04082005_120454_19634 -NCPU=6 -ICPU=3
-NO MMAP -LARGQUERY -NEG SCORES=0 -WAIT -DSBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : Issued Patents AA:*

1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PTCUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	98.2	70.1	116	3	US-08-545-809A-118
2	98.2	70.1	123	3	US-08-793-450-4
3	98.2	70.1	139	4	US-09-203-768A-2
4	98.2	70.1	472	3	US-08-793-450-8
5	93.2	66.6	429	4	US-09-372-425A-6
6	92.1	65.8	118	3	US-09-025-769B-25
7	92.1	65.8	118	4	US-09-490-070A-25
8	92.1	65.8	118	4	US-09-490-153-25
9	92.1	65.8	118	4	US-09-490-324-25
10	91.1	65.1	120	3	US-08-545-809A-137
11	87.2	62.3	147	4	US-09-471-276-835
12	86.3	61.6	130	3	US-08-466-151-5

13	86.3	61.6	130	3	US-08-466-163B-5	Sequence 5, Appli
14	86.3	61.6	130	4	US-09-802-096-5	Sequence 5, Appli
15	86.3	61.6	130	4	US-09-802-077-5	Sequence 5, Appli
16	85.2	60.9	447	4	US-09-372-425A-2	Sequence 2, Appli
17	83.1	59.4	118	2	US-08-652-816A-13	Sequence 13, Appli
18	83.1	59.4	139	4	US-09-471-276-837	Sequence 837, App
19	83.1	59.4	139	4	US-08-918-148-79	Sequence 77, Appli
20	83.1	59.4	244	3	US-08-138-091A-77	Sequence 16, Appli
21	81.2	58.0	119	5	PCT-US93-10555-16	Sequence 16, Appli
22	80.1	57.2	100	4	US-09-726-219A-169	Sequence 169, App
23	80.1	57.2	117	4	US-09-720-493-2	Sequence 2, Appli
24	79.3	56.6	100	2	US-08-273-146-69	Sequence 69, Appli
25	79.3	56.6	137	3	US-08-466-163B-7	Sequence 7, Appli
26	79.3	56.6	137	3	US-08-466-163B-7	Sequence 7, Appli
27	79.3	56.6	137	4	US-09-802-096-7	Sequence 7, Appli
28	79.3	56.6	137	4	US-09-802-077-7	Sequence 7, Appli
29	79.1	56.5	119	3	US-09-025-769B-39	Sequence 39, Appli
30	79.1	56.5	119	3	US-09-025-769B-65	Sequence 65, Appli
31	79.1	56.5	119	3	US-09-490-070A-39	Sequence 39, Appli
32	79.1	56.5	119	4	US-09-490-070A-65	Sequence 65, Appli
33	79.1	56.5	119	4	US-09-490-153-39	Sequence 39, Appli
34	79.1	56.5	119	4	US-09-490-153-65	Sequence 65, Appli
35	79.1	56.5	119	4	US-09-490-324-39	Sequence 39, Appli
36	79.1	56.5	119	4	US-09-490-324-65	Sequence 65, Appli
37	79.1	56.5	119	4	US-09-343-698-6	Sequence 6, Appli
38	78.3	55.9	118	4	US-08-325-955-6	Sequence 6, Appli
39	78.3	55.9	118	4	US-08-325-955-6	Sequence 18, Appli
40	78.3	55.9	213	4	US-09-170-769A-2	Sequence 2, Appli
41	78.3	55.9	213	4	US-09-170-769A-2	Sequence 7, Appli
42	78.3	55.9	832	3	US-08-630-820-7	Sequence 7, Appli
43	78.3	55.9	832	4	US-09-273-453-7	Sequence 140, App
44	78.1	55.8	116	3	US-08-545-809A-140	Sequence 22, Appli
45	77.9	55.6	76	3	US-08-851-362D-22	

ALIGNMENTS

RESULT 1

US-08-545-809A-118
; Sequence 118, Application US/08545809A
; Patent No. 6096878

; GENERAL INFORMATION:

; APPLICANT: Honjo, Tasuku

; APPLICANT: Matsuda, Fumihiko

; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE

; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME

; NUMBER OF SEQUENCES: 145

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson, P.C.

; STREET: 225 Franklin Street

; CITY: Boston

; STATE: MA

; COUNTRY: US

; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: Windows95

; SOFTWARE: FastSeq for Windows Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/545,809A

; FILING DATE: 27-MAR-1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/JP93/00603

; FILING DATE: 10-MAY-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Freeman, John W.

; REGISTRATION NUMBER: 29,065

; REFERENCE/DOCKET NUMBER: 06501/004001

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 617-542-5070

; TELEFAX: 617-542-8906

; TELEX: 200154

```
; INFORMATION FOR SEQ ID NO: 118:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 116 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-118

Alignment Scores:
Pred. No.: 4.16e-05 Length: 116
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 3 Gaps: 0

DELETED2 (1-81) x US-08-545-809A-118 (1-116)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACAACT 61
Db 61 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78
Qy 62 ACAACCCGCTCTCTCAAGAGT 81
Db 78 yrAsnProSerLeuLysSer 84

RESULT 2
US-08-793-450-4
; Sequence 4, Application US/08793450
; Patent No. 6312690
; GENERAL INFORMATION:
; APPLICANT: EDELMAN, LENA
; APPLICANT: MARGARITTE, CHRISTEL
; APPLICANT: KACZOREK, MICHEL
; APPLICANT: CHAABIHI, HASSAN
; TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/793.450
; FILING DATE: 03-MAR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 94/10566
; FILING DATE: 02-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 660-118-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-793-450-4
```

```
Alignment Scores:
Pred. No.: 4.25e-05 Length: 123
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 3 Gaps: 0

DELETED2 (1-81) x US-08-793-450-4 (1-123)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACAACT 61
Db 42 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGCTCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 3
US-09-203-768A-2
; Sequence 2, Application US/09203768A
; Patent No. 6787638
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; TITLE OF INVENTION: of Use
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/09/203.768A
; CURRENT FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 139
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-203-768A-2

Alignment Scores:
Pred. No.: 4.45e-05 Length: 139
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 4 Gaps: 0

DELETED2 (1-81) x US-09-203-768A-2 (1-139)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACAACT 61
Db 61 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78
Qy 62 ACAACCCGCTCTCTCAAGAGT 81
Db 78 yrAsnProSerLeuLysSer 84

RESULT 4
US-08-793-450-8
; Sequence 8, Application US/08793450
; Patent No. 6312690
; GENERAL INFORMATION:
; APPLICANT: EDELMAN, LENA
; APPLICANT: MARGARITTE, CHRISTEL
; APPLICANT: KACZOREK, MICHEL
; APPLICANT: CHAABIHI, HASSAN
; TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
; TITLE OF INVENTION:
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
```

STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/793,450
FILING DATE: 03-MAR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 94/10566
FILING DATE: 02-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 660-118-0 PCT
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 472 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-793-450-8

Alignment Scores:
Pred. No.: 6,986-05 Length: 472
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 3 Gaps: 0

DELETED2 (1-81) x US-08-793-450-8 (1-472)

QY 2 GGGCGAGTCAGATATTAGCAGCTGGTTCAGCGAAATCAATCATAGTCGAGCACCACACT 61
Db 61 GlyLeys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnt 78
QY 62 ACAACCCGCTCTCTCAAGAGT 81
Db 78 yRAsnProSerLeuLySer 84

RESULT 5

US-09-372-425A-6
Sequence 6, Application US/09372425A
Patent No. 6475749
GENERAL INFORMATION:
APPLICANT: Sherie L. Morrison
APPLICANT: Ramon Montano
TITLE OF INVENTION: Improved Rh Antibody
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Oppenheimer Wolff & Donnelly LLP
STREET: 2029 Century Park East, Suite 3800
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90067
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 98
SOFTWARE: MS Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/372,425A
FILING DATE: August 11, 1999
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Oldenakmp, David J.
REGISTRATION NUMBER: 29,421
REFERENCE/DOCKET NUMBER: 510015-223
TELEPHONE: (310) 788-5000
TELEFAX: (310) 788-5100
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 429 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Heavy chain without Tailpiece - AA
US-09-372-425A-6

Alignment Scores:
Pred. No.: 0.00033 Length: 429
Score: 93.20 Matches: 18
Percent Similarity: 65.62% Conservative: 3
Best Local Similarity: 56.25% Mismatches: 3
Query Match: 66.57% Indels: 8
DB: 4 Gaps: 0

DELETED2 (1-81) x US-09-372-425A-6 (1-429)

QY 2 GGGCGAGTCAGATATTAGCAGCTGGTTCAGCGAAATCAATCATAGTCGAGCACCACACT 61
Db 61 GlyLeys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnt 78
QY 62 ACAACCCGCTCTCTCAAGAGT 81
Db 78 yRAsnProSerLeuLySer 84

RESULT 6

US-09-025-769B-25
Sequence 25, Application US/09025769B
Patent No. 630064
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
APPLICANT: Pack, Peter
APPLICANT: Ilag, Vic
APPLICANT: Ge, Liming
APPLICANT: Moroney, Simon
APPLICANT: Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:

```
;
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: linear
; MOLECULE TYPE: protein
; TOPOLOGY: linear
; US-09-025-769B-25
;
; Alignment Scores:
; Pred. No.: 0.000291 Length: 118
; Score: 92.10 Matches: 21
; Percent Similarity: 50.00% Conservative: 1
; Best Local Similarity: 47.73% Mismatches: 3
; Query Match: 65.79% Indels: 19
; DB: Gaps: 1
;
; DELETED2 (1-81) x US-09-025-769B-25 (1-118)
;
; Qy 3 GCGAGTCAGATATTAGCAGC----- 24
; Db 26 GlyGlySer-----IleSerSerTyrTyrTrpSerTrpIleArgGlnProProGlyLysG1 44
; Qy 25 -----TGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACAACTCTCTCAA 77
; Db 44 yLeuGluTrpIleGlyGluIleTyrHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
;
; Qy 78 GAGT 81
; Db 64 sSer 65
;
; RESULT 7
; US-09-490-070A-25
; Sequence 25, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 25:
;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: linear
; MOLECULE TYPE: protein
; TOPOLOGY: linear
; US-09-490-070A-25
;
; Alignment Scores:
; Pred. No.: 0.000291 Length: 118
; Score: 92.10 Matches: 21
; Percent Similarity: 50.00% Conservative: 1
; Best Local Similarity: 47.73% Mismatches: 3
; Query Match: 65.79% Indels: 19
; DB: Gaps: 1
;
; DELETED2 (1-81) x US-09-490-070A-25 (1-118)
;
; Qy 3 GCGAGTCAGATATTAGCAGC----- 24
; Db 26 GlyGlySer-----IleSerSerTyrTyrTrpSerTrpIleArgGlnProProGlyLysG1 44
; Qy 25 -----TGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACAACTCTCTCAA 77
; Db 44 yLeuGluTrpIleGlyGluIleTyrHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
;
; Qy 78 GAGT 81
; Db 64 sSer 65
;
; RESULT 8
; US-09-490-153-25
; Sequence 25, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
;
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 118 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-153-25

Alignment Scores:
Pred. No.: 0.000291 Length: 118
Score: 92.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 65.79% Indels: 19
DB: 4 Gaps: 1

DELETED2 (1-81) x US-09-490-153-25 (1-118)

QY 3 GCGAGTCAGGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerTyTrpSerTrpIleArgGlnProProGlyLysG1 44
QY 25 -----TGGTTAGCGGAAATCAATCATAGTGGAGACCAACTACAACCGTCTCTCAA 77
Db 44 YleuGlutrpIleGlyGluIleTyHisSerGlySerThrAsnTyAsnProSerLeuY 64
QY 78 GAGT 81
Db 64 sSer 65

RESULT 9
US-09-490-324-25
; Sequence 25, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
```

```
;
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-490-324-25

Alignment Scores:
Pred. No.: 0.000291 Length: 118
Score: 92.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 65.79% Indels: 19
DB: 4 Gaps: 1

DELETED2 (1-81) x US-09-490-324-25 (1-118)

QY 3 GCGAGTCAGGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerTyTrpSerTrpIleArgGlnProProGlyLysG1 44
QY 25 -----TGGTTAGCGGAAATCAATCATAGTGGAGACCAACTACAACCGTCTCTCAA 77
Db 44 YleuGlutrpIleGlyGluIleTyHisSerGlySerThrAsnTyAsnProSerLeuY 64
QY 78 GAGT 81
Db 64 sSer 65

RESULT 10
US-08-545-809A-137
; Sequence 137, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Humihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 137:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-137
```

```
Alignment Scores:
Pred. No.: 0.000402 Length: 120
Score: 91.10 Matches: 20
Percent Similarity: 52.27% Conservative: 3
Best Local Similarity: 45.45% Mismatches: 2
Query Match: 65.07% Indels: 19
DB: 3 Gaps: 1

DELETED2 (1-81) x US-08-545-809A-137 (1-120)
Qy 3 GCGGAGTCAGGATATTAGCAGC----- 24
Db 45 GlyAspSer-----lleSerSerGlyAsnTrpValArgGlnProProGlyLysG1 63
Qy 25 -----TGGTTAGCCGAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAA 77
Db 63 yLeuGluTrpIleGlyGluIleHisHisSerGlySerThrTrpTrpAsnProSerLeuLy 83
Qy 78 GAGT 81
Db 83 sser 84

RESULT 11
US-09-471-276-835
; Sequence 835 Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CPI
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 835
; LENGTH: 147
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: 26...-1
US-09-471-276-835

Alignment Scores:
Pred. No.: 0.0015 Length: 147
Score: 87.20 Matches: 16
Percent Similarity: 65.62% Conservative: 5
Best Local Similarity: 50.00% Mismatches: 3
Query Match: 62.29% Indels: 8
DB: 4 Gaps: 0

DELETED2 (1-81) x US-09-471-276-835 (1-147)
Qy 2 GCGGAGTCAGGATATTAGCAGCTGGTAGCCGAATCAATCATAGTGGAGCACCACCACT 61
Db 69 GlyLys---GlyLeu---GluTrpIleSerGluIleAspHisGlyGlyAsnThrAsnT 86
Qy 62 ACAACCGCTCTCTCAAGAGT 81
Db 86 yAsnProSerLeuLysSer 92

RESULT 12
US-08-466-151-5
; Sequence 5, Application US/08466151
```

```
; Patent No. 6037453
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,151
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466163
; FILING DATE: 06-Jun-1995
; APPLICATION NUMBER: 08/405617
; FILING DATE: 15-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/185899
; FILING DATE: 26-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/879495
; FILING DATE: 07-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/744768
; FILING DATE: 14-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Svoboda, Craig G.
; REGISTRATION NUMBER: 39,044
; REFERENCE/DOCKET NUMBER: P0718P2C1D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1489
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 130 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; US-08-466-151-5

Alignment Scores:
Pred. No.: 0.0019 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: 3 Gaps: 1

DELETED2 (1-81) x US-08-466-151-5 (1-130)
Qy 1 CCGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuSerLeuThrCysThrValThrGlyTyrThrIleThrSerAsp 32
Qy 22 -----AGCTGGTTAGCCGAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrIle 52
Qy 40 AATCATAGTGGAGCACCACCACTACACCGTCTCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSeryTrpAsnProSerLeuLysSer 66

RESULT 13
```



```
US-08-466-163B-5
; Sequence 5, Application US/08466163B
; Patent No. 6329509
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Immunoglobulin Variants
; FILE REFERENCE: P0718P2C1D1
; CURRENT APPLICATION NUMBER: US/08/466,163B
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-08-466-163B-5

Alignment Scores:
Pred. No.: 0.0019 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: Gaps: 1

DELETED2 (1-81) x US-08-466-163B-5 (1-130)
Qy 1 CGGGCGAGTCTAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuSerLeuThrCysThrValThrGlyThrIleThrSerAsp 32
Qy 22 -----AGCTGGTTAGCCGAAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrlle 52
Qy 40 AATCATAGTGAAGACCACTACAAACCGCTCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyAsnProSerLeuLysSer 66

RESULT 14
US-08-802-096-5
; Sequence 5, Application US/09802096
; Patent No. 6685939
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C3US
; CURRENT APPLICATION NUMBER: US/09/802,096
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-08-802-096-5

Alignment Scores:
Pred. No.: 0.0019 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: Gaps: 1

DELETED2 (1-81) x US-08-466-163B-5 (1-130)
Qy 1 CGGGCGAGTCTAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuSerLeuThrCysThrValThrGlyThrIleThrSerAsp 32
Qy 22 -----AGCTGGTTAGCCGAAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrlle 52
Qy 40 AATCATAGTGAAGACCACTACAAACCGCTCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyAsnProSerLeuLysSer 66

RESULT 14
US-09-802-096-5
; Sequence 5, Application US/09802096
; Patent No. 6685939
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Preventing the Onset of Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C3US
; CURRENT APPLICATION NUMBER: US/09/802,096
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-096-5

Alignment Scores:
Pred. No.: 0.0019 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: Gaps: 1

DELETED2 (1-81) x US-09-802-096-5 (1-130)
Qy 1 CGGGCGAGTCTAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuSerLeuThrCysThrValThrGlyThrIleThrSerAsp 32
Qy 22 -----AGCTGGTTAGCCGAAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrlle 52
Qy 40 AATCATAGTGAAGACCACTACAAACCGCTCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyAsnProSerLeuLysSer 66

RESULT 15
US-09-802-077-5
; Sequence 5, Application US/09802077
; Patent No. 6699472
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Method of Treating Allergic Disorders (as amended)
; FILE REFERENCE: P0718P2C2US
; CURRENT APPLICATION NUMBER: US/09/802,077
; CURRENT FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 64
; SEQ ID NO 5
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-802-077-5

Alignment Scores:
Pred. No.: 0.0019 Length: 130
Score: 86.30 Matches: 17
Percent Similarity: 40.74% Conservative: 5
Best Local Similarity: 31.48% Mismatches: 5
Query Match: 61.64% Indels: 27
DB: Gaps: 1

DELETED2 (1-81) x US-09-802-077-5 (1-130)
Qy 1 CGGGCGAGTCTAGGATATTAGC----- 21
Db 13 LysProSerGlnSerLeuSerLeuThrCysThrValThrGlyThrIleThrSerAsp 32
Qy 22 -----AGCTGGTTAGCCGAAATC 39
Db 33 AsnAlaTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrlle 52
Qy 40 AATCATAGTGAAGACCACTACAAACCGCTCTCAAGAGT 81
Db 53 AsnHisSerGlyThrThrSerTyAsnProSerLeuLysSer 66
```

Search completed: August 4, 2005, 20:06:46
Job time : 31.5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 20:04:58 ; Search time 105.5 Seconds
(without alignments)
599.473 Million cell updates/sec

Title:

Perfect score: 140

Sequence:

1 CGGCGAGTCAGGATATTAG.....ACAACCCGTCCTCTCAAGAGT 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 3505720

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool/p/NOLAN463-3B/runat_04082005_120456_19700/app query.fasta_1.263
-DB=Published Applications AA -QPM=fastan -SUFFIX=rapb -MINMATCH=0.1
-LOOPCU=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blom62
-TRANS=human40.cdi -LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100
-THR_MIN=0 -ALIGN=15 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0
-MAXLEN=200000000 -MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100
-NCPU=6 -ICPU=3 -NO_WARP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSPBLOCK=100
-LONGLOG -DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1
-FGAPOP=6 -FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

1: /cgn2_6/ptodata/1/pubaa/US07_PUBCOMB.pcp.*
2: /cgn2_6/ptodata/1/pubaa/PCT_NEW_PUB.pcp.*
3: /cgn2_6/ptodata/1/pubaa/US06_NEW_PUB.pcp.*
4: /cgn2_6/ptodata/1/pubaa/US06_PUBCOMB.pcp.*
5: /cgn2_6/ptodata/1/pubaa/US07_NEW_PUB.pcp.*
6: /cgn2_6/ptodata/1/pubaa/PCTUS_PUBCOMB.pcp.*
7: /cgn2_6/ptodata/1/pubaa/US08_NEW_PUB.pcp.*
8: /cgn2_6/ptodata/1/pubaa/US08_PUBCOMB.pcp.*
9: /cgn2_6/ptodata/1/pubaa/US09A_PUBCOMB.pcp.*
10: /cgn2_6/ptodata/1/pubaa/US09B_PUBCOMB.pcp.*
11: /cgn2_6/ptodata/1/pubaa/US09C_PUBCOMB.pcp.*
12: /cgn2_6/ptodata/1/pubaa/US09_NEW_PUB.pcp.*
13: /cgn2_6/ptodata/1/pubaa/US10A_PUBCOMB.pcp.*
14: /cgn2_6/ptodata/1/pubaa/US10B_PUBCOMB.pcp.*
15: /cgn2_6/ptodata/1/pubaa/US10C_PUBCOMB.pcp.*
16: /cgn2_6/ptodata/1/pubaa/US10D_PUBCOMB.pcp.*
17: /cgn2_6/ptodata/1/pubaa/US10E_PUBCOMB.pcp.*
18: /cgn2_6/ptodata/1/pubaa/US10_NEW_PUB.pcp.*
19: /cgn2_6/ptodata/1/pubaa/US11A_PUBCOMB.pcp.*
20: /cgn2_6/ptodata/1/pubaa/US11_NEW_PUB.pcp.*
21: /cgn2_6/ptodata/1/pubaa/US60_NEW_PUB.pcp.*
22: /cgn2_6/ptodata/1/pubaa/US60_PUBCOMB.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	100.1	71.5	253	10	US-09-880-748-1333
2	100.1	71.5	253	15	US-10-293-418-1333
3	99.9	71.4	125	15	US-10-371-942-118
4	98.2	70.1	80	14	US-10-078-958-2
5	98.2	70.1	97	14	US-10-194-975-40
6	98.2	70.1	97	15	US-10-308-817-83
7	98.2	70.1	97	15	US-10-032-037B-87
8	98.2	70.1	97	15	US-10-029-988B-87
9	98.2	70.1	97	15	US-10-032-423A-87
10	98.2	70.1	97	15	US-10-453-698-83
11	98.2	70.1	97	15	US-10-029-926B-87
12	98.2	70.1	97	16	US-10-379-392-47
13	98.2	70.1	114	17	US-10-733-532-128
14	98.2	70.1	115	17	US-10-898-408-12
15	98.2	70.1	117	9	US-09-884-761-44315
16	98.2	70.1	118	15	US-10-371-942-90
17	98.2	70.1	118	17	US-10-893-576-192
18	98.2	70.1	122	15	US-10-360-828-63
19	98.2	70.1	125	15	US-10-371-942-110
20	98.2	70.1	139	14	US-10-300-675-2
21	98.2	70.1	139	17	US-10-310-124-2
22	98.2	70.1	139	17	US-10-893-576-43
23	98.2	70.1	142	17	US-10-484-790A-10
24	98.2	70.1	223	10	US-09-972-656-66
25	98.2	70.1	229	10	US-09-972-656-82
26	98.2	70.1	230	10	US-09-972-656-72
27	98.2	70.1	249	10	US-09-880-748-1321
28	98.2	70.1	249	15	US-10-293-418-1321
29	98.2	70.1	250	15	US-09-880-748-1413
30	98.2	70.1	250	15	US-10-293-418-1413
31	98.2	70.1	254	10	US-09-880-748-1659
32	98.2	70.1	254	15	US-10-293-418-1659
33	98.2	70.1	450	17	US-10-484-790A-17
34	98.2	70.1	453	17	US-10-484-790A-18
35	97.2	69.4	249	15	US-09-880-748-957
36	97.2	69.4	249	15	US-10-293-418-957
37	95	67.9	246	10	US-09-880-748-1847
38	95	67.9	246	15	US-10-293-418-1847
39	94.2	67.3	123	14	US-10-269-805-31
40	94.2	67.3	123	14	US-10-269-805-55
41	94.2	67.3	255	10	US-09-880-748-1642
42	94.2	67.3	255	15	US-10-293-418-1642
43	93.7	66.9	116	15	US-10-308-817-189
44	93.7	66.9	116	15	US-10-453-698-189
45	93.2	66.6	250	10	US-09-880-748-993

ALIGNMENTS

RESULT 1
US-09-880-748-1333
; Sequence 1333, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25

```
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1333
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1333

Alignment Scores:
Pred. No.: 0.000755 Length: 253
Score: 100.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 71.50% Indels: 19
DB: 1 Gaps: 1

DELETED2 (1-81) x US-09-880-748-1333 (1-253)

Qy 3 GCGAGTCA-----GGATAT 17
Db 26 GlycylserPheSerGlyTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
Qy 18 TAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAA 77
Db 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLy 64

Qy 78 GAGT 81
Db 64 sSer 65

RESULT 2
US-10-293-418-1333
; Sequence 1333, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1333
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1333

Alignment Scores:
Pred. No.: 0.000755 Length: 253
Score: 100.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 71.50% Indels: 19
DB: 1 Gaps: 1

DELETED2 (1-81) x US-10-293-418-1333 (1-253)
```

```
Qy 3 GCGAGTCA-----GGATAT 17
Db 26 GlycylserPheSerGlyTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
Qy 18 TAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAA 77
Db 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLy 64

Qy 78 GAGT 81
Db 64 sSer 65

RESULT 3
US-10-371-942-118
; Sequence 118, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-118

Alignment Scores:
Pred. No.: 0.000704 Length: 125
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 1 Gaps: 1

DELETED2 (1-81) x US-10-371-942-118 (1-125)

Qy 3 GCGAGTCAAGTATTAGCAGC----- 24
Db 26 GlycylSer-----IleSerSerSerSerTyrTyrTrpAlaTrpIleArgGlnProGly 44
Qy 25 -----TGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACACCGTC 71
Db 44 YLysGlyLeuGluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSe 64

Qy 72 TCTCAAGAT 81
Db 64 rLeuLysSer 67

RESULT 4
US-10-078-958-2
; Sequence 2, Application US/10078958
; Publication No. US20030070185A1
; GENERAL INFORMATION:
; APPLICANT: JAKOBOVITS, AVA
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: KLAPHOLZ, SUSAN
; APPLICANT: MENDEZ, MICHAEL J.
; APPLICANT: GREEN, LARRY
; TITLE OF INVENTION: TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING
; TITLE OF INVENTION: PLURAL Vh AND Vk REGIONS AND ANTIBODIES PRODUCED
; FILE REFERENCE: CELL 4.18 CON
; CURRENT APPLICATION NUMBER: US/10/078,958
; CURRENT FILING DATE: 2002-02-19
; PRIOR APPLICATION NUMBER: 08/759,620
; PRIOR FILING DATE: 1996-12-03
```

```
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-078-958-2

Alignment Scores:
Pred. No.: 0.00107 Length: 80
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 14 Gaps: 0

DELETED2 (1-81) x US-10-078-958-2 (1-80)

QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAAGCACCACCAACT 61
Db 25 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 42
QY 62 ACAACCCGCTCTCTCAAGAGT 81
Db 42 yRAsnProSerLeuLysSer 48

RESULT 5
US-10-194-975-40
; Sequence 40, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-40

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 14 Gaps: 0

DELETED2 (1-81) x US-10-194-975-40 (1-97)

QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAAGCACCACCAACT 61
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59

RESULT 6
US-10-308-817-83
; Sequence 83, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37

; NUMBER OF SEQ ID NOS: 195
; CURRENT FILING DATE: 2002-12-03
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-308-817-83

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-308-817-83 (1-97)

QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAAGCACCACCAACT 61
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
QY 62 ACAACCCGCTCTCTCAAGAGT 81
Db 59 yRAsnProSerLeuLysSer 65

RESULT 7
US-10-032-037B-87
; Sequence 87, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-87

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-032-037B-87 (1-97)

QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAAGCACCACCAACT 61
Db 42 GlyLys---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
QY 62 ACAACCCGCTCTCTCAAGAGT 81
Db 59 yRAsnProSerLeuLysSer 65

RESULT 8
US-10-029-988B-87
; Sequence 87, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
```

```
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-87

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-029-988B-87 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAGACCAACT 61
Db 42 GlyLys----GlyLeu-----GlutPrIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGTCCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 9
US-10-032-423A-87
; Sequence 87, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-87

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-032-423A-87 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAGACCAACT 61
Db 42 GlyLys----GlyLeu-----GlutPrIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGTCCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 10
US-10-032-423A-87
; Sequence 87, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-87

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-032-423A-87 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAGACCAACT 61
Db 42 GlyLys----GlyLeu-----GlutPrIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGTCCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65
```

```
US-10-453-698-83
; Sequence 83, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
; LENGTH: 97
; TYPE: PRT
; ORGANISM: human
US-10-453-698-83

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-453-698-83 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAGACCAACT 61
Db 42 GlyLys----GlyLeu-----GlutPrIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGTCCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65

RESULT 11
US-10-029-926B-87
; Sequence 87, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-87

Alignment Scores:
Pred. No.: 0.00111 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 15 Gaps: 0

DELETED2 (1-81) x US-10-029-926B-87 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTCGAGACCAACT 61
Db 42 GlyLys----GlyLeu-----GlutPrIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGTCCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLysSer 65
```



```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 4315
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AB019439.1
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.54
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.57
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 0.56
; OTHER INFORMATION: EST HUMAN HIT: BE672445.1, EVALUE 2.00e-57
; OTHER INFORMATION: SWISSPROT HIT: P06331, EVALUE 1.00e-53
US-09-864-761-44315
```

```
Alignment Scores:
Pred. No.: 0.00115 Length: 117
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 9 Gaps: 0
```

```
DELETED2 (1-81) x US-09-864-761-44315 (1-117)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAATCAATCATAGTGGAGCACCACACT 61
Db 45 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 62
Qy 62 ACAACCCCGCTCTCTCAAGAGT 81
Db 62 yAsnProSerLeuLysSer 68
```

Search completed: August 4, 2005, 20:23:29
Job time : 106.5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:56:53 ; Search time 341.5 Seconds
(without alignments)
554.076 Million cell updates/sec

Title: DELETED2

Perfect score: 140

Sequence: 1 CGGGCGAGTCAGGATATTAG.....ACACCCGCTCTCAAGAGT 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 6959266 seqs, 116806243 residues

Total number of hits satisfying chosen parameters: 13918532

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+n2p.model -DEV=xlp
-O=/cgn2_1/USPTO_spool_p/NOLAN463-3b/runat_04082005_120455_19651/app_query.fasta_1.263
-DB=Pending_Patents_AA_Main -QFMT=fastan -SUFFIX=rapm -MINMATCH=0.1 -LOOPCPU=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.cdi
-LIST=45 -DOALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pct -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3B @CGN 1 1 804 @runat_04082005_120455_19651 -NCPU=6 -ICPU=3
-NO MWAP -LARGQUERY -NEG SCORES=0 -WALT -DSPLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database :

Pending Patents AA Main:
1: /cgn2_6/ptodata/1/paa/PCTUS_COMB.pep.*
2: /cgn2_6/ptodata/1/paa/US06_COMB.pep.*
3: /cgn2_6/ptodata/1/paa/US07_COMB.pep.*
4: /cgn2_6/ptodata/1/paa/US08_COMB.pep.*
5: /cgn2_6/ptodata/1/paa/US081_COMB.pep.*
6: /cgn2_6/ptodata/1/paa/US082_COMB.pep.*
7: /cgn2_6/ptodata/1/paa/US083_COMB.pep.*
8: /cgn2_6/ptodata/1/paa/US084_COMB.pep.*
9: /cgn2_6/ptodata/1/paa/US085_COMB.pep.*
10: /cgn2_6/ptodata/1/paa/US086_COMB.pep.*
11: /cgn2_6/ptodata/1/paa/US087_COMB.pep.*
12: /cgn2_6/ptodata/1/paa/US088_COMB.pep.*
13: /cgn2_6/ptodata/1/paa/US089_COMB.pep.*
14: /cgn2_6/ptodata/1/paa/US090_COMB.pep.*
15: /cgn2_6/ptodata/1/paa/US091_COMB.pep.*
16: /cgn2_6/ptodata/1/paa/US092_COMB.pep.*
17: /cgn2_6/ptodata/1/paa/US093_COMB.pep.*
18: /cgn2_6/ptodata/1/paa/US094_COMB.pep.*
19: /cgn2_6/ptodata/1/paa/US095_COMB.pep.*
20: /cgn2_6/ptodata/1/paa/US096_COMB.pep.*
21: /cgn2_6/ptodata/1/paa/US097A_COMB.pep.*
22: /cgn2_6/ptodata/1/paa/US097B_COMB.pep.*
23: /cgn2_6/ptodata/1/paa/US098_COMB.pep.*
24: /cgn2_6/ptodata/1/paa/US099A_COMB.pep.*
25: /cgn2_6/ptodata/1/paa/US099B_COMB.pep.*
26: /cgn2_6/ptodata/1/paa/US100_COMB.pep.*
27: /cgn2_6/ptodata/1/paa/US101_COMB.pep.*
28: /cgn2_6/ptodata/1/paa/US102_COMB.pep.*

29: /cgn2_6/ptodata/1/paa/US103_COMB.pep.*
30: /cgn2_6/ptodata/1/paa/US104_COMB.pep.*
31: /cgn2_6/ptodata/1/paa/US105_COMB.pep.*
32: /cgn2_6/ptodata/1/paa/US106_COMB.pep.*
33: /cgn2_6/ptodata/1/paa/US107_COMB.pep.*
34: /cgn2_6/ptodata/1/paa/US108_COMB.pep.*
35: /cgn2_6/ptodata/1/paa/US109_COMB.pep.*
36: /cgn2_6/ptodata/1/paa/US110_COMB.pep.*
37: /cgn2_6/ptodata/1/paa/US60_COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	104.4	74.6	124	22	US-09-791-537-89288	Sequence 89288, A
2	102.1	72.9	125	22	US-09-791-537-111128	Sequence 111128,
3	101.7	72.6	87	22	US-09-791-537-144795	Sequence 144795,
4	101.7	72.6	125	22	US-09-791-537-111072	Sequence 111072,
5	101.6	72.6	119	22	US-09-791-537-716	Sequence 716, App
6	101.6	72.6	143	22	US-09-791-537-36503	Sequence 36503, A
7	100.4	71.7	97	22	US-09-791-537-78283	Sequence 78283, A
8	100.2	71.6	105	22	US-09-791-537-22691	Sequence 22691, A
9	100.1	71.5	253	1	PCT-US01-19110-1333	Sequence 1333, Ap
10	100.1	71.5	253	23	US-09-880-748-1333	Sequence 1333, Ap
11	100.1	71.5	253	23	US-09-880-748-1333	Sequence 1333, Ap
12	100.1	71.5	253	28	US-10-293-418-1333	Sequence 1333, Ap
13	99.9	71.4	121	22	US-09-791-537-110576	Sequence 110576,
14	99.9	71.4	125	1	PCT-US03-05128-118	Sequence 118, App
15	99.9	71.4	125	29	US-10-371-942-118	Sequence 118, App
16	98.7	70.5	119	22	US-09-791-537-110532	Sequence 110532, A
17	98.7	70.5	130	22	US-09-791-537-68863	Sequence 68863, A
18	98.2	70.1	67	22	US-09-791-537-122614	Sequence 122614,
19	98.2	70.1	73	22	US-09-791-537-134695	Sequence 134695,
20	98.2	70.1	80	26	US-10-078-958-2	Sequence 2, Appl
21	98.2	70.1	88	22	US-09-791-537-111396	Sequence 111396,
22	98.2	70.1	90	22	US-09-791-537-130857	Sequence 130857,
23	98.2	70.1	91	22	US-09-791-537-130896	Sequence 130896,
24	98.2	70.1	92	22	US-09-791-537-130953	Sequence 130953,
25	98.2	70.1	92	22	US-09-791-537-130969	Sequence 130969,
26	98.2	70.1	93	22	US-09-791-537-151700	Sequence 151700,
27	98.2	70.1	93	22	US-09-791-537-152140	Sequence 152140,
28	98.2	70.1	96	22	US-09-791-537-152186	Sequence 152186,
29	98.2	70.1	97	1	PCT-US02-22011-40	Sequence 40, Appl
30	98.2	70.1	97	1	PCT-US02-38450-83	Sequence 83, Appl
31	98.2	70.1	97	1	PCT-US03-06598-47	Sequence 47, Appl
32	98.2	70.1	97	12	US-08-896-535-76	Sequence 76, Appl
33	98.2	70.1	97	19	US-09-508-110-69	Sequence 69, Appl
34	98.2	70.1	97	22	US-09-751-181-87	Sequence 87, Appl
35	98.2	70.1	97	22	US-09-791-537-78284	Sequence 78284, A
36	98.2	70.1	97	22	US-09-791-537-80274	Sequence 80274, A
37	98.2	70.1	97	22	US-09-791-537-111367	Sequence 111367,
38	98.2	70.1	97	22	US-09-791-537-126333	Sequence 126333,
39	98.2	70.1	97	22	US-09-791-537-130951	Sequence 130951,
40	98.2	70.1	97	26	US-10-029-3268-87	Sequence 87, Appl
41	98.2	70.1	97	26	US-10-029-9888-87	Sequence 87, Appl
42	98.2	70.1	97	26	US-10-032-0378-87	Sequence 87, Appl
43	98.2	70.1	97	26	US-10-032-423A-87	Sequence 87, Appl
44	98.2	70.1	97	27	US-10-189-258A-87	Sequence 87, Appl
45	98.2	70.1	97	27	US-10-194-375-40	Sequence 40, Appl

ALIGNMENTS

RESULT 1
US-09-791-537-89288
; Sequence 89288, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Biocomix, Inc.

```

; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBERS
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 89288
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-791-537-89288

Alignment Scores:
Pred. No.: 0.000343 Length: 124
Score: 104.40 Matches: 20
Percent Similarity: 45.28% Conservative: 4
Best Local Similarity: 37.74% Mismatches: 3
Query Match: 74.57% Indels: 26
DB: Gaps: 1

DELETED2 (1-81) x US-09-791-537-89288 (1-124)

QY 1 CGGGCGAGTCAGGATATTAGC----- 21
   :: |||:::|||::|||
Db 13 LysLeuSerGluAspLeuSerLeuThrCysAlaValTyrGlyGlySerPheSerGlyTyr 32
QY 22 -----AGCTGGTTAGCCGAAATCAAT 42
   |||:: |||::|||
Db 33 TyrTrpSerTrpIleArgArgProGlyLysGlyLeuGluTrpIleGlyGluIleAsn 52
QY 43 CATAGTGGAGCACCACACTACACCCGCTCTCTCAAGAGT 81
   |||::|||::|||::|||::|||::|||
Db 53 HisSerGlySerThrAsnTyrAsnProSerLeuLysSer 65

RESULT 2
US-09-791-537-111128
; Sequence 111128, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Blonomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBERS
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 111128
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-791-537-111128

Alignment Scores:
Pred. No.: 0.000691 Length: 125
Score: 102.10 Matches: 21
Percent Similarity: 52.27% Conservative: 2
Best Local Similarity: 47.73% Mismatches: 2
Query Match: 72.93% Indels: 19
DB: Gaps: 1

DELETED2 (1-81) x US-09-791-537-111128 (1-125)

QY 3 GGGCGAGTCAGGATATTAGC----- 21
   |||::|||::|||::|||
Db 26 GlyGluSer----ValSerGlyTyrTyrTrpTrpIleArgGlnProProGlyLysG 44
QY 22 -----AGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACAACCCGCTCTCAA 77
   |||::|||::|||::|||

```

QY 9 TCAGATATTAGC-----AGCTGTTAGC 32
Db 30 SerGlyTyr-SerTrpSerTrpIleArgGlnProProGlyLysGlyLeuGluTrpIleG1 49
QY 33 CGAATCATCATAGTGAAGCACCAACTACAAACCGTCTCTCAAGAGT 81
Db 49 yGluIleAenHisSerGlySerThrAsnTyrAsnProSerLeuLysSer 65

RESULT 5
US-09-791-537-716
; Sequence 716, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBERS
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 716
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-537-716

Alignment Scores:
Pred. No.: 0.000794 Length: 119
Score: 101.60 Matches: 19
Percent Similarity: 71.43% Conservative: 1
Best Local Similarity: 67.86% Mismatches: 4
Query Match: 72.57% Indels: 4
DB: 22 Gaps: 0

DELETED2 (1-81) x US-09-791-537-716 (1-119)
QY 6 GAGTCAGCATATTAGCAGCTGGTTCAGCCCAATCAATCATAGTGAAGCACCAACTACAA 65
Db 42 GluLysGlyLeu---GluTrpIleGlyGluIleAenHisSerGlySerThrAsnTyrAs 60

QY 66 CCCGTCCTCAAGAGT 81
Db 60 nProSerLeuLysSer 65

RESULT 6
US-09-791-537-36503
; Sequence 36503, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBERS
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 36503
; LENGTH: 143
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-537-36503

Alignment Scores:
Pred. No.: 0.000831 Length: 143
Score: 101.60 Matches: 19
Percent Similarity: 55.56% Conservative: 1
Best Local Similarity: 52.78% Mismatches: 2
Query Match: 72.57% Indels: 14

DB: 22 Gaps: 0
DELETED2 (1-81) x US-09-791-537-36503 (1-143)
QY 2 GGGCGAGTCAGGATATTAGCAGCTGGTTCAGCCGAATCAATCATAGTGAAGCACCAACT 61
Db 44 GlyArg-----GluTrpIleGlyGluIleAenHisSerGlySerThrAsnT 59
QY 62 ACAACCCGCTCTCTCAAGAGT 81
Db 59 yTrpSerLeuLysSer 65

RESULT 7
US-09-791-537-78283
; Sequence 78283, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBERS
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 78283
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-537-78283

Alignment Scores:
Pred. No.: 0.00109 Length: 97
Score: 100.40 Matches: 20
Percent Similarity: 43.40% Conservative: 3
Best Local Similarity: 37.74% Mismatches: 4
Query Match: 71.71% Indels: 26
DB: 22 Gaps: 1

DELETED2 (1-81) x US-09-791-537-78283 (1-97)
QY 1 CGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnThrLeuSerLeuThrCysAlaValTyrGlyGlySerPheSerGlyTyr 32
QY 22 -----AGCTGTTAGCCGAATCAAT 42
Db 33 TyrTrpSerTrpIleArgGlnProProGlyLysGlyLeuGluTrpIleGlyGluIleAen 52
QY 43 CATAGTGAAGCACCAACTACAAACCGTCTCTCAAGAGT 81
Db 53 HisSerGlySerThrAsnTyrAsnProSerLeuLysSer 65

RESULT 8
US-09-791-537-22691
; Sequence 22691, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Bionomix, Inc.
; APPLICANT: Debe, Derek
; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBERS
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22691
; LENGTH: 105
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-537-22691


```

Qy 3 GCGAGTCA-----CGATAT 17
Db 26 GlyGluSerPheSerGlyTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
Qy 18 TAGCAGCTGGTTAGCGCAATCAATCATAGTGGAGACCACTACAAACCGCTCTCTCAA 77
Db 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
Qy 78 GAGT 81
Db 64 sSer 65

RESULT 12
US-10-293-418-1333
; Sequence 1333, Application US/10293418
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1333
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1333

Alignment Scores:
Pred. No.: 0.00151 Length: 253
Score: 100.10 Matches: 21
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.73% Mismatches: 3
Query Match: 71.50% Indels: 19
DB: 28 Gaps: 1

DELETED2 (1-81) x US-10-293-418-1333 (1-253)
Qy 3 GCGAGTCA-----CGATAT 17
Db 26 GlyGluSerPheSerGlyTyrTrpSerTrpIleArgGlnProProGlyLysGlyLeu 45
Qy 18 TAGCAGCTGGTTAGCGCAATCAATCATAGTGGAGACCACTACAAACCGCTCTCTCAA 77
Db 46 ----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSerLeuLy 64
Qy 78 GAGT 81
Db 64 sSer 65

RESULT 13
US-09-791-537-110576
; Sequence 110576, Application US/09791537
; GENERAL INFORMATION:
; APPLICANT: Biocomix, Inc.
; APPLICANT: Debe, Derek

```

```

; APPLICANT: Danzer, Joseph
; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMB
; FILE REFERENCE: 261/210
; CURRENT APPLICATION NUMBER: US/09/791,537
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 153055
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 110576
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-537-110576

Alignment Scores:
Pred. No.: 0.00134 Length: 121
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 22 Gaps: 1

DELETED2 (1-81) x US-09-791-537-110576 (1-121)
Qy 3 GCGAGTCAGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerSerSerTyrTyrTrpGlyTrpIleArgGlnProProGl 44
Qy 25 -----TGGTTAGCGCAATCAATCATAGTGGAGACCACTACAAACCGCTC 71
Db 44 YLysGlyLeuGluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSe 64
Qy 72 TCTCAAGAGT 81
Db 64 rLeuLysSer 67

RESULT 14
PCT-US03-05128-118
; Sequence 118, Application PC/TUS0305128
; GENERAL INFORMATION:
; APPLICANT: Dyax Corporation, et al
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034WO1
; CURRENT APPLICATION NUMBER: PCT/US03/05128
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US03-05128-118

Alignment Scores:
Pred. No.: 0.00135 Length: 125
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 1 Gaps: 1

DELETED2 (1-81) x PCT-US03-05128-118 (1-125)
Qy 3 GCGAGTCAGATATTAGCAGC----- 24
Db 26 GlyGlySer-----IleSerSerSerSerTyrTyrTrpAlaTrpIleArgGlnProProGl 44
Qy 25 -----TGGTTAGCGCAATCAATCATAGTGGAGACCACTACAAACCGCTC 71
Db 44 YLysGlyLeuGluTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSe 64

```

Qy 72 TCTCAAGAGT 81
Db 64 rLeuLysSer 67

RESULT 15

US-10-371-942-118
; Sequence 118, Application US/10371942
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-118

Alignment Scores:
Pred. No.: 0.00135 Length: 125
Score: 99.90 Matches: 22
Percent Similarity: 50.00% Conservative: 1
Best Local Similarity: 47.83% Mismatches: 2
Query Match: 71.36% Indels: 21
DB: 29 Gaps: 1

DELETED2 (1-81) x US-10-371-942-118 (1-125)

Qy 3 GCGGAGTCAGGATATTAGCAGC----- 24
Db 26 GlyGlySer-----lleSerSerSerSerTyrTrpAlaTrpIleArgGlnProG1 44
Qy 25 -----TGGTTAGCGGAAATCATCATAGTGGAGGACCACTACACCGTC 71
Db 44 yLysGlyLeuGlutTrpIleGlyGluIleAsnHisSerGlySerThrAsnTyrAsnProSe 64
Qy 72 TCTCAAGAGT 81
Db 64 rLeuLysSer 67

Search completed: August 4, 2005, 20:18:16
Job time : 343.5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:51:37 ; Search time 25 Seconds
(without alignments)
623.485 Million cell updates/sec

Title: DELETED2
Perfect score: 140
Sequence: 1 CGGCGAGTCAGGATATTAG.....ACAACCCGTCTCTCAAGAGT 81

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 566832

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:
-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cgn2_1/USPO_spool_p/NOLAN463-3B/runat_04082005_120454_19622/app_query.fasta_1.263
-DB=PIR -QWTF=fastcan -SUFFIX=rpr -MINMATCH=0.1 -LOOPECL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=-1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=NOLAN463-3B@cgn 1.1.63 @runat_04082005_120454_19622 -NCPUS=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : PIR 79:.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	101.6	72.6	143	2	B49028
2	100.4	71.7	97	2	S26805
3	98.2	70.1	97	2	S26898
4	98.2	70.1	97	2	S26806
5	98.2	70.1	106	2	S37454
6	98.2	70.1	122	2	JU0047
7	98.2	70.1	126	2	S47010
8	98.2	70.1	140	2	S78052
9	98.2	70.1	140	2	A49045
10	98.2	70.1	231	2	B23746
11	98	70.0	133	2	P50341
12	94.2	67.3	97	2	G34964
13	92	65.7	98	2	S26905
14	92	65.7	145	2	S78055

15	89.2	63.7	97	2	S14474	Ig heavy chain V r
16	88	62.9	129	2	S44114	Ig heavy chain V r
17	87.2	62.3	146	1	G1HUH2	Ig heavy chain pre
18	86.2	61.6	134	2	S54906	Ig heavy chain V r
19	86	61.4	98	2	S26904	Ig heavy chain V r
20	83.7	59.8	134	2	B24672	Ig heavy chain pre
21	83.2	59.4	114	2	I72667	cold agglutinin FS
22	83	59.3	123	2	S30529	Ig heavy chain V r
23	81.2	58.0	97	2	JH0428	Ig gamma chain V r
24	80.3	57.4	116	2	S38718	Ig heavy chain V r
25	80.1	57.2	98	2	S26902	Ig heavy chain V r
26	80.1	57.2	98	2	S12421	Ig heavy chain V r
27	80.1	57.2	130	2	S31673	Ig heavy chain V r
28	80.1	57.2	140	2	A24770	hypothetical hybri
29	79.9	57.1	127	2	S19668	Ig heavy chain V r
30	79.1	56.5	97	2	S26906	Ig heavy chain V r
31	79.1	56.5	97	2	S12416	Ig heavy chain V r
32	79.1	56.5	105	2	S44125	Ig lambda chain V
33	79.1	56.5	130	2	S31690	Ig heavy chain V r
34	79.1	56.5	140	2	I37782	Ig variable region
35	78.9	56.4	99	2	S12412	Ig heavy chain V r
36	78.3	55.9	106	2	S26464	Ig heavy chain V r
37	78.1	55.8	116	2	B26340	Ig heavy chain pre
38	77.9	55.6	118	2	A26340	Ig heavy chain pre
39	77.6	55.4	109	2	PH1673	Ig heavy chain V r
40	77.2	55.1	97	2	FL0118	Ig heavy chain V-I
41	77.2	55.1	99	2	S26899	Ig heavy chain V r
42	77.2	55.1	130	2	S30534	Ig heavy chain V r
43	77.1	55.1	97	2	S26804	Ig heavy chain V r
44	77.1	55.1	97	2	S26808	Ig heavy chain V r
45	77.1	55.1	116	2	S18557	Ig heavy chain V r

ALIGNMENTS

RESULT 1

B49028

Ig heavy chain V-IV region - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999

C:Accession: B49028

R:TimmerB, E.; Kenter, M.; Thompson, A.; Kraakman, M.E.; Berman, J.E.; Alt, F.W.; Schuur

Eur. J. Immunol. 21, 2355-2363, 1991

A:Title: Diversity of immunoglobulin heavy chain gene segment rearrangement in B lymphob

A:Reference number: A49028; MUID:92008140; PMID:1915549

A:Accession: B49028

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-143 <TIM>

A:Cross-references: GB:S64473; NID:g236906; PIDN:AAB20012.1; PID:g236907

A:Experimental source: X-linked agammaglobulinemia patients, B lymphoblastoid cell lines

A>Note: sequence extracted from NCBI backbone (NCBIN:64473, NCBI:64472)

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotrimer; immunoglobulin

F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:				
Pred. No.:	8.29e-05	Length:	143	
Score:	101.60	Matches:	19	
Percent Similarity:	55.56%	Conservative:	1	
Best Local Similarity:	52.78%	Mismatches:	2	
Query Match:	72.57%	Indels:	14	
DB:	2	Gaps:	0	

DELETED2 (1-81) x B49028 (1-143)

Qy 2 GGGCGAGTCAGGATATTAGCTGGTACCGGAAATCAATCATAGTGGAGCACTACT 61

Db 44 GlyArg-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGTCTCTCAAGAGT 81

Db 59 yrAnProSerLeuLysSer 65

```
RESULT 2
S26805
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26805
R:Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A:Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A:Reference number: S26800; MUID:92201299; PMID:1348029
A:Accession: S26805
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-97 <WEN>
A:Cross-references: EMBL:Z14241; NID:g37714; PIDN:CAA78610.1; PID:g1335376
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000117 Length: 97
Score: 100.40 Matches: 20
Percent Similarity: 43.40% Conservativeness: 3
Best Local Similarity: 37.74% Mismatches: 4
Query Match: 71.71% Indels: 26
DB: 2 Gaps: 1

DELETED2 (1-81) x S26805 (1-97)
Qy 1 CGGCGAGTCAGGATATTAGC----- 21
Db 13 LysProSerGlnThrLeuSerLeuThrCysAlaValTyrGlyGlySerPheSerGlyTyr 32
Qy 22 -----ACGCTGGTAGCCGAAATCAAT 42
Db 33 TyrTrpSerTrpIleArgGlnProProGlyLysGlyLeuGluTrpIleGlyGluIleAsn 52
Qy 43 CATAGTCGAGCACCACCTACTCAACCGCTCTCTCAAGAGT 81
Db 53 HisSerGlySerThrAsnTyrAsnProSerLeuLysSer 65

RESULT 3
S26898
Ig heavy chain V region (clone DP-63, V(H)4.2) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S26898; S12420
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26898
A:Molecule type: DNA
A:Residues: 1-97 <TOM>
A:Cross-references: EMBL:Z12363; NID:g32944; PIDN:CAA78233.1; PID:g32945
A:Experimental source: clone DP-63
R:Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A:Title: The smaller human V(H) gene families display remarkably little polymorphism.
A:Reference number: S09421; MUID:90059975; PMID:2511001
A:Accession: S12420
A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-97 <SAN>
A:Cross-references: EMBL:X56364
A:Experimental source: V(H)4.2
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000228 Length: 97
```

```
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservativeness: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x S26898 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACACT 61
Db 42 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGCTCTCTCAAGAGT 81
Db 59 YrAsnProSerLeuLysSer 65

RESULT 4
S26806
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26806
R:Wang, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Eur. J. Immunol. 22, 1075-1082, 1992
A:Title: Polymorphism of human immunoglobulin V(H)4 germ-line genes.
A:Reference number: S26800; MUID:92201299; PMID:1348029
A:Accession: S26806
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-97 <WEN>
A:Cross-references: EMBL:Z14242; NID:g37716; PIDN:CAA78611.1; PID:g1335377
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000228 Length: 97
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservativeness: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x S26806 (1-97)
Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGCACCACACT 61
Db 42 GlyLys----GlyLeu----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 59
Qy 62 ACAACCCGCTCTCTCAAGAGT 81
Db 59 YrAsnProSerLeuLysSer 65

RESULT 5
S37454
Ig mu chain - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
C:Accession: S37454
R:McIntosh, R.S.; Tandon, N.; Weetman, A.P.
Submitted to the EMBL Data Library, September 1993
A:Description: Cloning and analysis of human IGM anti-Thyroglobulin autoantibodies from
A:Reference number: S37453
A:Accession: S37454
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-106 <MCI>
A:Cross-references: EMBL:X75022; NID:g404311; PIDN:CAA52930.1; PID:g758093
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
```



```
Score: 98.20      Matches: 19
Percent Similarity: 65.62%      Conservative: 2
Best Local Similarity: 59.38%      Mismatches: 3
Query Match: 70.14%      Indels: 8
DB: 2      Gaps: 0

DELETED2 (1-81) x S37454 (1-106)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGAAGCACCACCAACT 61
   |||:|:|
Db 20 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAeNT 37
   |||:|:|

Qy 62 ACAACCCGTCCTCTCAAGAGT 81
   |||:|:|
Db 37 yrAsnProSerLeuLysSer 43
   |||:|:|

RESULT 6
JL0047
Ig heavy chain V region precursor (clone cr18) - human
C:Species: Homo sapiens (man)
C:Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 16-Aug-1996
C:Accession: JL0047
R:Baer, R.; Forster, A.; Lavenit, I.; Rabbitts, T.H.
J. Exp. Med. 167, 2011-2016, 1988
A:Title: Immunoglobulin V-H genes are transcribed by T cells in association with a new S
A:Reference number: JL0047; MUID:88258392; PMID:3133445
A:Accession: JL0047
A:Molecule type: mRNA
A:Residues: 1-122 <BAE>
A:Experimental source: T-cell line RPMI 8402
A:Note: the authors translated the reading frame which extends to the stop codon; the se
A:Note: this sequence belongs to the VH II subgroup
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:23-105/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00023      Length: 122
Score: 98.20      Matches: 19
Percent Similarity: 65.62%      Conservative: 2
Best Local Similarity: 59.38%      Mismatches: 3
Query Match: 70.14%      Indels: 8
DB: 2      Gaps: 0

DELETED2 (1-81) x JL0047 (1-122)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGAAGCACCACCAACT 61
   |||:|:|
Db 50 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAeNT 67
   |||:|:|

Qy 62 ACAACCCGTCCTCTCAAGAGT 81
   |||:|:|
Db 67 yrAsnProSerLeuLysSer 73
   |||:|:|

RESULT 7
S47010
Ig heavy chain V4.21-UniqueD-J5 region - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C:Accession: S47010
R:Mahmoudi, M.; Gasyna, E.; Denomme, G.; Edwards, J.; Bell, D.; Cairns, E.
submitted to the EMBL Data Library, July 1994
A:Description: The role of the immunoglobulin heavy chain in human anti-DNA antibody bin
A:Reference number: S47009
A:Accession: S47010
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-126 <MAH>
A:Cross-references: EMBL:Z35492; NID:G517254; PIDN:CAA84625.1; PID:G517255
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>
```

```
Alignment Scores:
Pred. No.: 0.00023      Length: 126
Score: 98.20      Matches: 19
Percent Similarity: 65.62%      Conservative: 2
Best Local Similarity: 59.38%      Mismatches: 3
Query Match: 70.14%      Indels: 8
DB: 2      Gaps: 0

DELETED2 (1-81) x S47010 (1-126)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGAAGCACCACCAACT 61
   |||:|:|
Db 42 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAeNT 59
   |||:|:|

Qy 62 ACAACCCGTCCTCTCAAGAGT 81
   |||:|:|
Db 59 yrAsnProSerLeuLysSer 65
   |||:|:|

RESULT 8
S78052
Ig heavy chain precursor V-D-J region (clone mAB 63VH) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78052; S23717
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78052
A:Molecule type: mRNA
A:Residues: 1-140 <HAR>
A:Cross-references: EMBL:X54441; NID:G37815; PIDN:CAA38308.1; PID:G930118
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Buraetero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and i
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23717
A:Molecule type: mRNA
A:Residues: 15-111 <HAW>
A:Cross-references: EMBL:X54441
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-14/Domain: signal sequence (fragment) #status predicted <SIG>
F:15-140/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:29-111/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.000231      Length: 140
Score: 98.20      Matches: 19
Percent Similarity: 65.62%      Conservative: 2
Best Local Similarity: 59.38%      Mismatches: 3
Query Match: 70.14%      Indels: 8
DB: 2      Gaps: 0

DELETED2 (1-81) x S78052 (1-140)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGAAGCACCACCAACT 61
   |||:|:|
Db 56 GlyLys-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAeNT 73
   |||:|:|

Qy 62 ACAACCCGTCCTCTCAAGAGT 81
   |||:|:|
Db 73 yrAsnProSerLeuLysSer 79
   |||:|:|

RESULT 9
A49045
Ig heavy chain V region (anti-B cell autoantibody) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999
C:Accession: A49045
R:Grillot-Courvalin, C.; Brouet, J.C.; Piller, F.; Rasseenti, L.Z.; Labaume, S.; Silverma
Eur. J. Immunol. 22, 1781-1788, 1992
A:Title: An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i b1
```

A;Reference number: A49045; MUID:92324290; PMID:1623923

A;Accession: A49045

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-140 <GR>

A;Cross-references: GB:S39381; NID:g250899; PIDN:AAB22441.1; PID:g250900

A;Note: sequence extracted from NCBI backbone (NCBIN:108088, NCBI:P:108089)

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;34-116/Domain: immunoglobulin homology <IM>

Alignment Scores:
Pred. No.: 0.000231 Length: 140
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x A49045 (1-140)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61

Db 61 GlyLys----GlyLeu----GlutrpIleGlyGluileAsnHisSerGlySerThrAsnT 78

Qy 62 ACAACCCGCTCTCTCAAGAGT 81

Db 78 yrAsnProSerLeuLysSer 84

RESULT 10

B23746 Ig Fab region IV-J(H4)-C (KAU cold agglutinin) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Dec-1991 #sequence_revision 30-Dec-1991 #text_change 21-Jan-2000

C;Accession: B23746

R;Leoni, J.; Ghiso, J.; Coni, F.; Frangione, B.

J. Biol. Chem. 266, 2836-2842, 1991

A;Title: The primary structure of the Fab fragment of protein KAU, a monoclonal immunoglobulin

A;Reference number: A23746; MUID:91131575; PMID:1993660

A;Accession: B23746

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-231 <LEO>

C;Superfamily: immunoglobulin C region; immunoglobulin homology

F;140-209/Domain: immunoglobulin homology <IM>

Alignment Scores:
Pred. No.: 0.000236 Length: 231
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x B23746 (1-231)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61

Db 41 GlyLys----GlyLeu----GlutrpIleGlyGluileAsnHisSerGlySerThrAsnT 58

Qy 62 ACAACCCGCTCTCTCAAGAGT 81

Db 58 yrAsnProSerLeuLysSer 64

RESULT 11

PS0341 Ig heavy chain V-D-J region (RAMOS) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-May-1997

C;Accession: PS0341

F;Ratetch, H.

Biochem. Biophys. Res. Commun. 182, 1260-1263, 1992

A;Title: Rapid cloning of rearranged immunoglobulin heavy chain genes from human B-cell

A;Reference number: PS0341; MUID:92171937; PMID:1540170

A;Accession: PS0341

A;Molecule type: mRNA

A;Residues: 1-133 <RAT>

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;9-38/Region: framework 1

F;39-43/Region: complementarity-determining 1

F;44-57/Region: framework 2

F;58-74/Region: complementarity-determining 2

F;75-106/Region: framework 3

Alignment Scores:
Pred. No.: 0.000245 Length: 133
Score: 98.00 Matches: 17
Percent Similarity: 94.74% Conservative: 1
Best Local Similarity: 89.47% Mismatches: 1
Query Match: 70.00% Indels: 0
DB: 2 Gaps: 0

DELETED2 (1-81) x PS0341 (1-133)

Qy 25 TGGTTAGCCGAAATCAATCATAGTGGAGGACCAACTACACCGTCTCTCAAGAGT 81

Db 55 TrpIleGlyGluileAsnHisSerGlySerThrAsnTyraenProSerLeuLysSer 73

RESULT 12

G34964

Ig heavy chain V-IV region (Ab44) - human

C;Species: Homo sapiens (man)

C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004

C;Accession: G34964

R;Sanz, I.; Casali, P.; Thomas, J.W.; Nokinis, A.L.; Capra, J.D.

J. Immunol. 142, 4054-4061, 1989

A;Title: Nucleotide sequences of eight human natural autoantibody V-H regions reveals ap

A;Reference number: A92830; MUID:89235232; PMID:2497188

A;Accession: G34964

A;Molecule type: mRNA

A;Residues: 1-97 <SAN>

A;Cross-references: UNIPROT:Q8WUX4; GB:M26998

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;15-97/Domain: immunoglobulin homology <IM>

Alignment Scores:

Pred. No.: 0.000763 Length: 97
Score: 94.20 Matches: 18
Percent Similarity: 62.50% Conservative: 2
Best Local Similarity: 56.25% Mismatches: 4
Query Match: 67.29% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x G34964 (1-97)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGGACCAACT 61

Db 42 GlyLys----GlyLeu----GlutrpIleGlyGluileAsnHisSerGlySerThrAsnT 59

Qy 62 ACAACCCGCTCTCTCAAGAGT 81

Db 59 yrAsnProSerLeuLysSer 65

RESULT 13

S26905

Ig heavy chain V region (DP-70 / 4.19) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Accession: S26905; S12419

R;Tomlinson, I.M.; Walford, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V

A;Reference number: S26885; MUID:93021117; PMID:1404388

A;Accession: S26905

A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-98 <ROM>
A:Cross-references: EMBL:Z12370; NID:G32960; PIDN:CAA78240.1; PID:G32961
A:Note: designated DP-70
R:Sanz, I.; Kelly, P.; Williams, C.; Scholl, S.; Tucker, P.; Capra, J.D.
EMBO J. 8, 3741-3748, 1989
A:Title: The smaller human V(H) gene families display remarkably little polymorphism.
A:Reference number: S09421; MUID:90059975; PMID:2511001
A:Accession: S12419
A:Status: preliminary; translation not shown
A:Molecule type: DNA
A:Residues: 1-98 <SAN>
A:Cross-references: EMBL:X56363
A:Note: designated 4.19
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00148 Length: 98
Score: 92.00 Matches: 21
Percent Similarity: 48.89% Conservativity: 1
Best Local Similarity: 46.67% Mismatches: 3
Query Match: 65.71% Indels: 20
DB: Gaps: 1

DELETED2 (1-81) x S26905 (1-98)
QY 3 GGCGAGTCAGGATATTAGCAGC----- 24
Db 26 GlyGlySer-----lleSerSerSerAsnTrpSerTrpValArgGlnProProGlyLy 44
QY 25 -----TGTTAGCGCGAAATCAATCATAGTGGAGACCACTACAAACCGCTCTCT 74
Db 44 sGlyLeuGlutTrpIleGlyGluIleTyRHisSerGlySerThrAsnTyRAsnProSerLe 64
QY 75 CAAGAGT 81
Db 64 uLySer 66

RESULT 14
S78055
Ig heavy chain precursor V-D-J region (clone mAb 67VH) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 19-Nov-1997 #sequence_revision 05-Dec-1997 #text_change 23-Jul-1999
C:Accession: S78055; S23720
R:Harindranath, N.
submitted to the EMBL Data Library, August 1990
A:Reference number: S78051
A:Accession: S78055
A:Molecule type: mRNA
A:Residues: 1-145 <HAR>
A:Cross-references: EMBL:X54445; NID:G37817; PIDN:CAA38312.1; PID:G37818
R:Harindranath, N.; Goldfarb, I.S.; Ikematsu, H.; Buraetero, S.E.; Wilder, R.L.; Notkins
Int. Immunol. 3, 865-875, 1991
A:Title: Complete sequence of the genes encoding the V(H) and V(L) regions of low- and H
patient.
A:Reference number: S23716; MUID:92031262; PMID:1718404
A:Accession: S23720
A:Molecule type: mRNA
A:Residues: 18-115 <HAW>
A:Cross-references: EMBL:X54445
A:Note: the authors translated the codon GCA for residue 67 as Arg
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F:1-17/Domain: signal sequence (fragment) #status predicted <SIG>
F:18-145/Product: Ig heavy chain (fragment) #status predicted <MAT>
F:32-115/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00151 Length: 145
Score: 92.00 Matches: 21

Percent Similarity: 48.89% Conservativity: 1
Best Local Similarity: 46.67% Mismatches: 3
Query Match: 65.71% Indels: 20
DB: Gaps: 1

DELETED2 (1-81) x S78055 (1-145)
QY 3 GGCGAGTCAGGATATTAGCAGC----- 24
Db 43 GlyGlySer-----lleSerSerSerAsnTrpSerTrpValArgGlnProProGlyLy 61
QY 25 -----TGTTAGCGCGAAATCAATCATAGTGGAGACCACTACAAACCGCTCTCT 74
Db 61 sGlyLeuGlutTrpIleGlyGluIleTyRHisSerGlySerThrAsnTyRAsnProSerLe 81
QY 75 CAAGAGT 81
Db 81 uLySer 83

RESULT 15
S14474
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C:Accession: S14474
R:van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derksen, R.H.
submitted to the EMBL Data Library, November 1990
A:Reference number: S14474
A:Accession: S14474
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-97 <ESJ>
A:Cross-references: EMBL:X56591; NID:G37235; PIDN:CAA39929.1; PID:G1335354
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Alignment Scores:
Pred. No.: 0.00345 Length: 97
Score: 89.20 Matches: 18
Percent Similarity: 62.50% Conservativity: 2
Best Local Similarity: 56.25% Mismatches: 4
Query Match: 63.71% Indels: 8
DB: Gaps: 0

DELETED2 (1-81) x S14474 (1-97)
QY 2 GGCGAGTCAGGATATTAGCAGCTGGTTAGCCGAAATCAATCATAGTGGAGACCACT 61
Db 42 GlyLys-----GlyLeu----GlutTrpIleGlyGluIlelleHisSerGlySerThrAsn 59
QY 62 ACAACCGCTCTCTCAAGAGT 81
Db 59 yrAsnProSerLeuLySer 65

Search completed: August 4, 2005, 20:05:40
Job time : 27 secs

THIS PAGE BLANK (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 4, 2005, 19:40:06 ; Search time 116 Seconds
(without alignments)
715.145 Million cell updates/sec

Title: DELETED2

Perfect score: 140

Sequence: 1 CGGCGAGTCAGGATATTAG.....ACAACCCGCTCTCTCAAGAGT 81

Scoring table:

BLOSUM62
Xgapop 10.0 , Xgapext 0.1
Ygapop 10.0 , Ygapext 0.1
Fgapop 6.0 , Fgapext 0.1
Delop 6.0 , Delext 0.1

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 3224756

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ n2p.model -DEV=xlp
-Q=/cgn2.1/USPTO spool p/NOLAN463-3B/runat 04082005 120453 19612/app query.fasta_1.263
-DB=UniProt -QFMT=fastan -SUFFIX=rup -MINMATCH=0.1 -LOOPCL=0 -LOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=BLOSUM62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
-USER=NOLAN463-3B @CGN 1.1 244 @runat 04082005 120453 19612 -NCPU=6 -ICPU=3
-NO.MMAP -LARGQUERY -NEG SCORES=0 -WAIT -DSPLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.1 -FGAPOP=6
-FGAPEXT=0.1 -YGAPOP=10 -YGAPEXT=0.1 -DELOP=6 -DELEXT=0.1

Database : UniProt 03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	98.2	70.1	116	2 Q7Z3Y6	Q7Z3Y6 homo sapien
2	98.2	70.1	595	2 Q8WUX4	Q8WUX4 homo sapien
3	98.2	70.1	597	2 Q6GMX5	Q6GMX5 homo sapien
4	98.2	70.1	597	2 Q9BU10	Q9BU10 homo sapien
5	98.2	70.1	625	2 Q96AA6	Q96AA6 homo sapien
6	92.2	65.9	597	2 Q9BQB8	Q9BQB8 homo sapien
7	92	65.7	576	2 Q5P4I8	Q5P4I8 homo sapien
8	87.2	62.3	146	1 HV2I1 HUMAN	P06331 homo sapien
9	82.1	58.6	477	2 Q6GMX7	Q6GMX7 homo sapien
10	79.1	56.5	139	2 Q86SX2	Q86SX2 homo sapien
11	77.1	55.1	620	2 Q96EY0	Q96EY0 homo sapien
12	76.3	54.5	479	2 Q99M22	Q99M22 mus musculus
13	75.7	54.1	116	1 HV6I1 MOUSE	P18532 mus musculus
14	75.2	53.7	465	2 Q6GMX6	Q6GMX6 homo sapien
15	72.8	52.0	262	2 Q5Z11	Q5Z11 mus musculus
16	71.3	50.9	116	1 HV60 MOUSE	P18531 mus musculus

17	71.2	50.9	119	2 Q9UL73	Q9UL73 homo sapien
18	71.2	50.9	476	2 Q6GMX1	Q6GMX1 homo sapien
19	69.1	49.4	478	2 Q6NYH3	Q6NYH3 homo sapien
20	68.6	49.0	150	2 Q95973	Q95973 homo sapien
21	68.2	48.7	478	2 Q7Z379	Q7Z379 homo sapien
22	67.4	48.1	113	1 HV47 MOUSE	P01823 mus musculus
23	66.4	47.4	104	2 Q99CA9	Q99CA9 human immun
24	66.4	47.4	106	2 Q6TJQ4	Q6TJQ4 human immun
25	66.4	47.4	133	2 Q90QV6	Q90QV6 human immun
26	65.9	47.1	496	2 Q96KX8	Q96KX8 homo sapien
27	65.5	46.8	523	2 Q6QJ60	Q6QJ60 paraphlegop
28	65.5	46.8	523	2 Q6QJ62	Q6QJ62 paraphlegop
29	65.4	46.7	104	2 Q99CH3	Q99CH3 human immun
30	65.4	46.7	130	2 Q9QL43	Q9QL43 human immun
31	65.4	46.7	202	2 Q9IUP1	Q9IUP1 human immun
32	65.4	46.7	202	2 Q9IUR6	Q9IUR6 human immun
33	65.4	46.7	206	2 Q7ZN97	Q7ZN97 human immun
34	65.4	46.7	207	2 Q9IU05	Q9IU05 human immun
35	65.4	46.7	212	2 Q9J783	Q9J783 human immun
36	65.4	46.7	220	2 Q9IUT6	Q9IUT6 human immun
37	65.4	46.7	231	2 Q9IQS9	Q9IQS9 human immun
38	65.4	46.7	489	2 Q80632	Q80632 human immun
39	65.3	46.6	136	2 Q6LBO5	Q6LBO5 mus musculus
40	65.3	46.6	137	1 HV46 MOUSE	P01822 mus musculus
41	64.4	46.0	130	2 Q7ZB82	Q7ZB82 human immun
42	64.4	46.0	131	2 Q90QT5	Q90QT5 human immun
43	64.4	46.0	131	2 Q9QKY2	Q9QKY2 human immun
44	64.4	46.0	131	2 Q9QKY3	Q9QKY3 human immun
45	64.4	46.0	140	2 Q698Z8	Q698Z8 human immun

ALIGNMENTS

RESULT 1

Q7Z3Y6 PRELIMINARY; PRT; 116 AA.
ID Q7Z3Y6;
AC Q7Z3Y6;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Rearranged VH4-34 V gene segment (Fragment).
GN Name=VH4-34;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Hodgkin lymphoma;
RA Tinguely M., Rosenquist R., Sundstroem C., Amini R.M., Kuppers R.,
RA Hansmann M.L., Brauninger A.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DBAJ databases.
DR EMBL; AJ564425; CAD92032.1; -
DR HSSP; P18532; 1KCV.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
SQ SEQUENCE 116 AA; 12902 MW; CE3D8A846616C908 CRC64;

Alignment Scores:

Pred. No.: 0.000436 Length: 116
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x Q7Z3Y6 (1-116)

Oy 2 GGGCGAGTCAGGATATTAGCAGCTGTTAGCCGAATCAATCATAGTGGAGACCAACT 61

```
||||:| 42 Glylys---GlyLeu---GluTrpIleGlyGluIleAenHisSerGlySerThrAsnT 59
||||:| 62 ACAACCCGTCCTCAAGAGT 81
||||:| 59 YrAsnProSerLeuLysSer 65

RESULT 2
Q8WUX4 PRELIMINARY; PRT; 595 AA.
ID Q8WUX4
AC Q8WUX4
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RA and mouse cDNA sequences.";
RA Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RA Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC019235; AAH19235.2; -.
DR InterPro; IPR003599; IG.
DR PIR; G34964; G34964.
DR HSP; P01861; IADQ.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00407; IGC1; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Hypothetical protein.
SQ SEQUENCE 595 AA; 65290 MW; 0D4B50776545714E CRC64;

Alignment Scores:
Pred. No.: 0.000538 Length: 595
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x Q8WUX4 (1-595)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCGGAAATCAATCATAGTCGAAGCACCACACT 61
Db ||||:| 68 Glylys---GlyLeu---GluTrpIleGlyGluIleAenHisSerGlySerThrAsnT 85
```

```
62 ACAACCCGTCCTCAAGAGT 81
||||:| 85 YrAsnProSerLeuLysSer 91

RESULT 3
Q6GMX5 PRELIMINARY; PRT; 597 AA.
ID Q6GMX5
AC Q6GMX5
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RA and mouse cDNA sequences.";
RA Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RA Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC073767; AAH73767.1; -.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 4.
DR Pfam; PF00047; IG; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Hypothetical protein.
SQ SEQUENCE 597 AA; 65304 MW; 2A1E75F6AED85230 CRC64;

Alignment Scores:
Pred. No.: 0.000538 Length: 597
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x Q6GMX5 (1-597)

Qy 2 GGGCGAGTCAGATATTAGCAGCTGGTTAGCGGAAATCAATCATAGTCGAAGCACCACACT 61
```

```
Db 61 GlyLeu-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78
Qy 62 AACACCCCGTCTCTCAAGAGT 81
Db 78 yRanProSerLeuLysSer 84

RESULT 4
ID Q9BU10 PRELIMINARY; PRT; 597 AA.
AC Q9BU10;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzyzanski M.I., Skalska U., Smalusz D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC002963; AAH02963.1; -.
DR HSSP; P01861; IADQ.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65274 MW; 2DAFA8FB7E055851 CRC64;

Alignment Scores:
Pred. No.: 0.000538 Length: 597
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x Q9BU10 (1-597)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGGAATCAATCATAGTGGAGCACCACACT 61
Db 61 GlyLeu-----GlyLeu-----GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 78
```

```
Qy 62 AACACCCCGTCTCTCAAGAGT 81
Db 78 yRanProSerLeuLysSer 84

RESULT 5
ID Q96AA6 PRELIMINARY; PRT; 625 AA.
AC Q96AA6;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzyzanski M.I., Skalska U., Smalusz D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph;
RA Strausberg R.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC017356; AAH17356.2; -.
DR PIR; S15590; S15590.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 625 AA; 68610 MW; FG2FAB3ADE7ECBFE CRC64;

Alignment Scores:
Pred. No.: 0.000541 Length: 625
Score: 98.20 Matches: 19
Percent Similarity: 65.62% Conservative: 2
Best Local Similarity: 59.38% Mismatches: 3
Query Match: 70.14% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x Q96AA6 (1-625)

Qy 2 GGGCGAGTCAGGATATTAGCAGCTGGTTAGCCGGAATCAATCATAGTGGAGCACCACACT 61
```

```
||||:|
68 Glylys----GlyLeu----GlutrpIleGlyGluIleAsnHisSerGlySerThrAent 85
||||:|
62 ACAACCGTCTCTCAAGAGT 81
||||:|
85 yRAenProSerLeuLySer 91
||||:|

RESULT 6
Q9BQB8 PRELIMINARY; PRT; 597 AA.
ID Q9BQB8
AC Q9BQB8;
DT 01-JUN-2001 (TReMBLrel. 17, Created)
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE IGHM protein.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC006180; AA06180.1; -.
DR HSSP; P01861; 1AQO.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 597 AA; 65300 MW; 2DAFAD50A6375851 CRC64;

Alignment Scores:
Pred. No.: 0.00355 Length: 597
Score: 92.20 Matches: 18
Percent Similarity: 62.50% Conservative: 2
Best Local Similarity: 56.25% Mismatches: 4
Query Match: 65.86% Indels: 8
DB: 2 Gaps: 0

DELETED2 (1-81) x Q9BQB8 (1-597)

Qy 2 GCGCGAGTCAGATATTAGCAGCTGGTTAGCGCAATCAATCATAGTGGAGACCAACT 61
Db 61 Glylys----GlyLeu----GlutrpIleGlyGluIleAsnHisSerGlySerThrAent 78
||||:|
```

```
62 ACAACCGTCTCTCAAGAGT 81
||||:|
78 yRAenProSerLeuLySer 84
||||:|

RESULT 7
Q6P4I8 PRELIMINARY; PRT; 576 AA.
ID Q6P4I8
AC Q6P4I8;
DT 05-JUL-2004 (TReMBLrel. 27, Created)
DT 05-JUL-2004 (TReMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TReMBLrel. 27, Last annotation update)
DE IGHM protein.
CN Name=IGHD;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (DEC-2003) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC063384; AAH63384.1; -.
DR HSSP; P01820; 1A7N.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig.MHC.
DR InterPro; IPR003596; Ig.v.
DR Pfam; PF07654; Cl-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 576 AA; 63363 MW; FBB97C949D720F1E CRC64;

Alignment Scores:
Pred. No.: 0.00377 Length: 576
Score: 92.00 Matches: 21
Percent Similarity: 48.89% Conservative: 1
Best Local Similarity: 46.67% Mismatches: 3
Query Match: 65.71% Indels: 20
DB: 2 Gaps: 1

DELETED2 (1-81) x Q6P4I8 (1-576)
```



```

QY 3 GCGGAGTCAGGATATTAGCAGC----- 24
D 52 GlySer-----IleSerSerSerSerTrpValArgInProProGlyLy 70
QY 25 -----TGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACACCGTCTCT 74
D 70 sGlyLeuGlutTrpIleGlyGluIleTyrHisSerGlySerThrAsnTyrAsnProSerLe 90
QY 75 CAAGAGT 81
D 90 uLysSer 92

RESULT 8
HV21 HUMAN STANDARD; PRT; 146 AA.
AC P06331;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Ig heavy chain V-II region ARH-77 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85205332; PubMed=3922855; DOI=10.1016/0378-1119(85)90092-7;
RA Kudo A., Ishihara T., Nishimura Y., Watanabe T.;
RT "A cloned human immunoglobulin heavy chain gene with a novel direct-
RT repeat sequence in 5' flanking region.";
RL Gene 33:181-189(1985).
DR PIR; A02101; GI1042.
DR HSSP; P01825; 7FAB.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1
FT CHAIN 19
FT DOMAIN 20 146 Ig heavy chain V-II region ARH-77.
FT DOMAIN 118 127 V segment.
FT DOMAIN 128 146 D segment.
FT DISULFID 42 115 J segment.
FT NON_TER 146 146 By similarity.
SQ SEQUENCE 146 AA; 16228 MW; 8D7FD52B5218171F CRC64;

Alignment Scores:
Pred. No.: 0.0143 Length: 146
Score: 87.20 Matches: 18
Percent Similarity: 59.38% Conservative: 1
Best Local Similarity: 56.25% Mismatches: 5
Query Match: 62.29% Indels: 8
DB: 1 Gaps: 0

DELETED2 (1-81) x HV21_HUMAN (1-146)

QY 2 GCGGAGTCAGGATATTAGCAGTCGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACT 61
D 62 GlyArg---GlyLeu---GluTrpIleGlyGluIleAsnHisSerGlySerThrAsnT 79
QY 62 ACAACCCGTCCTCTCAAGAGT 81
D 79 yrLysThrSerLeuLysSer 85

RESULT 9
Q6GMX7 PRELIMINARY; PRT; 477 AA.
ID Q6GMX7
AC Q6GMX7;

```

```

DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci F., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RX TISSUE=Primary B-Cells;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073765; AAH73765.1; -.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG ci.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; CI-set; 2.
DR SMART; SM00407; IG; 3.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 477 AA; 51631 MW; 9FE59C09C50CFF85 CRC64;

Alignment Scores:
Pred. No.: 0.0828 Length: 477
Score: 82.10 Matches: 19
Percent Similarity: 47.73% Conservative: 2
Best Local Similarity: 43.18% Mismatches: 4
Query Match: 58.64% Indels: 19
DB: 2 Gaps: 1

DELETED2 (1-81) x Q6GMX7 (1-477)

QY 3 GCGGAGTCAGGATATTAGCAGC----- 24
D 45 GlyGlySer----IleSerSerTyrTyrTrpSerTyrIleArgGlnThrAlaGlyLysG 63
QY 25 -----TGGTTAGCCGAAATCAATCATAGTGGAGCACCACCACTACACCGTCTCTCAA 77
D 63 yLeuGlutTrpIleGlyTyrIleSerHisSerGlySerThrTyrAsnProSerLeu 83
QY 78 GAGT 81

```


OX NCBI_TaxID=10090;
RN SEQUENCE FROM N.A.
RC STRAIN=mix FVB/N; TISSUE=Mammary tumor;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Sherman C.F., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raba S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
RN SEQUENCE FROM N.A.
RC STRAIN=mix FVB/N; TISSUE=Mammary tumor;
RA Strausberg R.;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC02091; AA02091.1; -;
DR HSSP; P01820; 1G7J.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 4.
DR PROSITE; PS0290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 479 AA; 5192 MW; 768E39A138918892 CRC64;

Alignment Scores:
Pred. No.: 0.513 Length: 479
Score: 76.30 Matches: 15
Percent Similarity: 37.04% Conservative: 5
Best Local Similarity: 27.78% Mismatches: 7
Query Match: 54.50% Indels: 27
DB: 2 Gaps: 1

DELETED2 (1-81) x Q99M22 (1-479)
Qy 1 CGGGCGATCAGGATATTAGC----- 21
Db 31 LysProSerGlnSerLeuSerLeuThrCysSerValThrGlyTyrSerIleThrSerGly 50
Qy 22 -----AGCTGGTACCGAATC 39
Db 51 TyrTyrTrpAsnTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetGlyTyrIle 70
Qy 40 AATCATAGTGAAGACCACTACAAACCGCTCTCTCAAGAGT 81
Db 71 AsnTyrAspGlySerAsnAsnTyrAsnProSerLeuLysAsn 84

RESULT 13
ID HV61 MOUSE
AC P18532; STANDARD; PRT; 116 AA.
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Ig heavy chain V region 1B43 precursor.

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN SEQUENCE FROM N.A.
RC STRAIN=HALB/CJ;
RX MEDLINE=89279149; PubMed=2499654;
RA Levy N.S., Malipiero U.V., Lebecque S.G., Gearhart P.J.;
RT "Early onset of somatic mutation in immunoglobulin VH genes during the
RT primary immune response.";
RL J. Exp. Med. 169:2007-2019 (1989).
CC -1- MSCCELLANE05: This sequence belongs to the VH3660 subfamily.
DR FIR; J0508; HVMS1B.
DR PDB; IKCS; X-ray; H=19-116.
DR PDB; IKCV; X-ray; H=19-116.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW 3D-structure; Immunoglobulin V region; Signal.
FT SIGNAL 1 18
FT CHAIN 19 116 Ig heavy chain V region 1B43.
FT DOMAIN 19 48 Framework-1.
FT DOMAIN 49 53 Complementarity-determining-1.
FT DOMAIN 54 67 Framework-2.
FT DOMAIN 68 84 Complementarity-determining-2.
FT DOMAIN 85 116 Framework-3.
FT DISULFID 40 114 By similarity.
FT STRAND 21 25
FT STRAND 29 30
FT TURN 32 33
FT STRAND 36 43
FT TURN 47 49
FT TURN 52 58
FT TURN 60 61
FT TURN 64 71
FT TURN 72 73
FT STRAND 76 78
FT TURN 80 85
FT STRAND 86 91
FT TURN 92 95
FT STRAND 96 101
FT HELIX 106 108
FT STRAND 110 116
FT NON_TER 116 116
SQ SEQUENCE 116 AA; 13158 MW; 1CB547253681FF74 CRC64;

Alignment Scores:
Pred. No.: 0.517 Length: 116
Score: 75.70 Matches: 16
Percent Similarity: 56.76% Conservative: 5
Best Local Similarity: 43.24% Mismatches: 3
Query Match: 54.07% Indels: 13
DB: 1 Gaps: 1

DELETED2 (1-81) x HV61_MOUSE (1-116)
Qy 9 TCAGGATATTAGC-----AGCTGGTATTAGC 32
Db 49 SerGlyTyr-SerTrpHisTrpIleArgGlnPheProGlyAsnLysLeuGluTrpMetG1 68
Qy 33 CGAATCAATCATAGTGAAGCACCACTACAAACCGCTCTCTCAAGAGT 81
Db 68 yTyrIleHisTyrSerGlyAsnThrSerTyrAsnProSerLeuLysSer 84

RESULT 14
ID Q6GMX6 PRELIMINARY; PRT; 465 AA.
AC Q6GMX6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)

Search completed: August 4, 2005, 20:04:46
Job time : 120 secs